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About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) is one of the European Union’s decentralised 
agencies. Established in 1993 and based in Lisbon, it is the 
central source of comprehensive information on drugs and 
drug addiction in Europe.
The EMCDDA collects, analyses and disseminates factual, 
objective, reliable and comparable information on drugs and 
drug addiction. In doing so, it provides its audiences with an 
evidence-based picture of the drug phenomenon at European 
level.
The Centre’s publications are a prime source of information 
for a wide range of audiences including policy-makers and 
their advisers; professionals and researchers working in the 
drugs field; and, more broadly, the media and general public.
EMCDDA monographs are comprehensive scientific 
publications containing thematic papers prepared in the 
context of the Centre’s activities. Topics cover a wide range 
of issues relating to science, policy, epidemiology and best 
practice.
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Introduction
Smoked, eaten, imbibed — or just talked about — it seems the world has a strong 
appetite for cannabis. An estimated one in five European adults have tried it. Thirteen 
million Europeans have consumed it in the past month. Nearly 50 000 tonnes of 
cannabis herb or resin is produced for consumption each year. Little wonder, then, that 
cannabis has become a controversial cultural and commercial phenomenon. Today, 
cannabis has a unique ability to divide opinion among policymakers, scientists, law 
enforcers, drugs professionals and consumers.
This EMCDDA cannabis monograph addresses one basic question. How can I find 
quality information on cannabis, amid all the bias and opinion? During the editing of 
this monograph it soon became clear that the EMCDDA was entering an area crowded 
with general guides, even competing cannabis monographs. This is where the idea of 
a cannabis ‘reader’ emerged. Our audience — researchers, parliamentarians, drugs 
professionals, students, European citizens — is currently faced with an overload of 
professional publications. Added to this is the daily flood of information on the Internet, 
often crusading in nature, and sometimes misleading. This threatens to obscure the 
genuine progress made in cannabis research during the past two decades.
The EMCDDA cannabis reader underlines the point that cannabis is not just a static, 
unchanging plant, but a dynamic product that is subject to gradual evolution in potency, 
prevalence, cultivation, legislative and public health concerns. In this monograph, 
leading experts provide short, sharp insights on a range of cannabis topics while 
offering advice on further reading for each topic. Brief editorial notes provide concise 
introductions to each topic, occasionally drawing attention to political sensitivities and 
the need for a ‘critical eye’. So this cannabis reader has a value both as a shortcut to 
researchers entering the area and a synthesis for experts.
You will find a wide range of views expressed in the chapters in this monograph, not 
all of them in agreement. The arguments, tone and conclusion of each chapter is the 
responsibility of the author alone, and is not necessarily endorsed or supported by the 
EMCDDA. This reflects the wider discourse on cannabis where different positions and 
perspectives often lead to different conclusions being drawn from the same evidence. 
We believe each chapter represents a useful contribution to the overall debate, even if 
their individual perspectives differ.
Introduction
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Two volumes, multiple audiences: policymakers, 
enforcers, researchers, professionals
The monograph is divided into two volumes, each comprising three sections. There are 
a number of reasons for the two-volume approach. While complementary, each has a 
slightly different audience. The first volume centres on political, legislative, commercial 
and social developments relating to cannabis. Its core audience thus comprises 
policymakers, sociologists, historians, journalists and those involved in enforcement. 
The second volume is very much centred on drugs professionals working in the fields of 
treatment, prevention and healthcare.
Volume 1
Cannabis in the pastt
Policies, legislation and control strategiest
Supply and production issuest
Volume 2
Epidemiologyt
Health effects of cannabis uset
Prevention and treatmentt
Changing perspectives: from global issues to local 
experiences
What unites both volumes is an attempt to fuse general chapters with specific case 
studies. Within each section, you will encounter a progression from a ‘top level’ to a 
‘close-up’ view of the subject. So each section begins with chapters providing a general 
introduction to a single cannabis issue, often of an encyclopaedic nature, together with a 
summary of the current state of scientific research. The monograph then ‘zooms in’ with 
a case study about a specific aspect of cannabis.
In Volume 2 ...
In Volume 2 we can read general overviews of impact of cannabis use on health, from 
an individual perspective (the Witton chapter) and public health perspective (the Hall 
and Room chapters); descriptions of current European patterns of cannabis use, from 
a general population perspective (EMCDDA analysis) and in terms of adolescent use 
(results from the ESPAD surveys and from Dutch schools); and descriptions of treatment 
demand for cannabis use disorders in Europe. Case study articles look at the way 
cannabis users perceive their use in Finland, the specific effects of cannabis use on 
driving and the rise in cannabis treatment demand in Germany.
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Foreword
The first volume of the EMCDDA’s cannabis reader reviewed the history of the drug 
and its social impact, and also explored legislative issues. In this second volume, the 
focus moves to describing contemporary patterns of use, reviewing what is known about 
the potential health effects of the drug and highlighting how Europe is responding to 
cannabis use in terms of prevention and treatment.
The cannabis reader would not have been possible without the input of many European 
and international experts and the EMCDDA is indebted to all the scientists and 
researchers who have contributed original papers to this publication. We would also 
especially acknowledge the excellent work carried out by the Centre for Social Research 
on Alcohol and Drugs (SoRAD) in Sweden, which was the main contractor on this 
project. We also thank the reviewers from the EMCDDA’s Scientific Committee, and John 
Witton and Wendy Swift, independent scientific editors.
Epidemiology, and the need to focus on ‘at-risk’ 
populations
The epidemiology of illicit drug use has seen marked improvements in the last two 
decades, with standard indicators having been set up and more reliable surveying 
methods introduced in many European countries. However, while surveys now allow us 
to chart the changing prevalence of cannabis use, they currently remain a weak vehicle 
for identifying those who may be using the drug intensively or experiencing problems. 
Measuring problematic cannabis use at the population level is methodologically 
challenging, but progress is being made.
This volume includes a chapter on screening instruments for identifying cannabis use 
problems, together with a Dutch schools study, which explores how cannabis use can be 
part of a broader pattern of polydrug consumption.
Cannabis consumption in the European population, particularly among adolescents and 
young adults, has been increasing since the 1960s. The most recent EMCDDA figures 
estimate that 13 million of the nearly 500 million Europeans in the EU Member States 
have consumed cannabis in the past month. Yet despite its being the most commonly 
consumed drug, cannabis use is far from ‘standard behaviour’. The number of people 
who have not smoked cannabis in Europe in the last month is clearly far higher than 
the number of those who have, by a factor of around 40 to 1. Cannabis is a drug 
associated with the young. Yet even in high-prevalence countries, among those aged 
between 15 and 34 years, at most only one in five are estimated to have used cannabis 
Foreword
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in the past month. And a more typical representative estimate across Europe is that only 
one in eight young people have smoked cannabis in the last month, whilst in the lower 
prevalence countries such as Greece, Bulgaria and Sweden, as few as 1 in 20 young 
people report last-month use of the drug.
Moreover, much cannabis use can be described as experimental behaviour which does 
not result in regular consumption patterns becoming established. Some surveys have 
sought to identify intensive use, defined as ‘daily’ or ‘near-daily’ use. Among the EU 
Member States for which data are available, the proportion of last-month cannabis users 
reporting daily or near-daily use ranges from 1 in 20 (Latvia) to 1 in 3 (Spain). Other 
reporting countries state that around one-quarter to one-fifth of last-month cannabis 
users report ‘daily or near-daily use’. While data are insufficient to indicate an accurate 
estimate of intensive cannabis users across Europe, a rough figure would place the 
number of daily or near-daily cannabis users in Europe at around 3 million.
Most last-month cannabis users are young, with males generally more likely to have 
used cannabis in the last month. Data from the ESPAD series of school surveys provides 
us with an interesting window on consumption patterns among 15–16 year olds. Among 
this group, young males are generally more likely to have used cannabis on a frequent 
basis (defined as having used cannabis on 40 or more occasions). Reported frequent 
use by male students is twice, three times or even, in one country, four times higher than 
among female students.
Even among those who establish regular cannabis use patterns in their youth, many will 
stop using the drug as they grow older. Cannabis prevalence rates tend to peak among 
younger adults (aged 15–24 years), suggesting that the majority of cannabis users quit 
as they get older and assume more responsibilities. However, whilst most cannabis users 
will have stopped consuming the substance by their mid- to late 30s, there is some 
evidence to suggest that more people are now continuing to smoke the drug into middle 
age. If this is true, it could have important implications for assessing the likely longer-
term public health impact of cannabis consumption.
More positively, recent studies suggest that in many high-prevalence countries, cannabis 
use is now showing signs of a stabilisation, or even a moderate decrease. Interestingly, 
this finding may be particularly evident in younger age cohorts. Nonetheless, cannabis 
use in Europe remains at a historically high level, and it remains unclear if we are 
seeing any stabilisation or fall in the numbers of those using the drug intensively and 
chronically — a group who are likely to be at particular risk of experiencing adverse 
consequences.
Foreword
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Cannabis and health
Historically, the cannabis health debate has often appeared poorly grounded in science 
with the possible adverse health effects of use being either trivialised or exaggerated. 
In this volume, a number of commentaries address cannabis and health issues. This is 
an area of emerging science where the evidence base is developing rapidly. A clear 
message emerges from this discourse: when discussing the health impact of cannabis 
use, it is vital to understand that different consumption patterns are likely to be 
associated with different risk profiles, and that risks may vary according to individual 
susceptibilities.
Cannabis has been associated with a number of adverse physical and psychological 
health effects, especially if used regularly. Recently, considerable concern has been 
expressed regarding cannabis’s relationship with mental health problems, including 
a possible association with schizophrenia. Studies on the physical effects of cannabis 
use have also appeared regularly in the research literature. Amongst others, they have 
examined cannabis and respiratory problems, potential genetic vulnerabilities linked to 
cannabis-related problems, the effects of cannabinoids on the body’s endocannabinoid 
system and cannabis’s potential to impair driving skills.
A chapter in this volume by John Witton summarises the predominant recent studies of 
cannabis’s adverse health effects. An appendix also offers a guide to help students to 
navigate the research base, with advice on how to approach the many claims made 
for and against cannabis use with a critical eye. Witton’s chapter argues that, although 
cannabis use has been linked to psychological problems, and an association clearly 
exists between cannabis use and some forms of mental illness, determining with certainty 
a direct causal relationship still remains a more difficult question.
Although few people today regard cannabis as a harm-free substance, there is debate 
as to the relative public health impact of the substance, particularly in comparison with 
tobacco, alcohol and other illicit drugs. This volume of the monograph includes analysis 
by Wayne Hall and Robin Room of the global burden of cannabis use disorders in 
comparison with other drugs. While cannabis appears to have lower intrinsic risks than 
drugs such as heroin and other opiates — for example in terms of overdose risk, degree 
of intoxication and risk of dependence — cannabis use is far more widespread than the 
use of other illicit drugs, and so relatively low risks at the individual level can still result 
in a significant problem for public health at the population level. 
Beyond the direct risk that cannabis use may pose to health, a number of broader public 
health issues exist. Among these are the secondary health risks posed by the drug, for 
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example the extent to which the drug is associated with road traffic accidents. Some 
work has been done in this area, particularly with respect to cannabis use and driving. 
This topic is reviewed here in a chapter that suggests that a minority of cannabis users 
drive under the influence of cannabis, with an adverse effect on road safety.
Although reports of drug treatment attendance by cannabis users have been growing, 
it is difficult to interpret what this means regarding the extent to which users experience 
difficulties. There are a number of reasons for this, including the fact that this data 
reflects both direct referrals from criminal justice and other agencies, as well as 
individuals spontaneously seeking help. Additionally, treatment services specifically 
targeted to cannabis users are still relatively rare in Europe. This may be beginning to 
change, but it is still worth noting that few evaluation studies of the efficacy of different 
cannabis treatment approaches have been carried out. More research is necessary to 
identify the best practices in this area. At the current time, no ‘gold standard’ exists 
for treating cannabis-related disorders, although structured psychosocial interventions 
appear to offer some promise in this area.
Prevention: a shift towards standard programmes and 
measuring effectiveness
In the field of prevention, considerable progress has been made in identifying factors 
which may influence cannabis use (age of initiation, peer influence, risk perception) 
and organisation of prevention intervention (universal, selective, indicated prevention). 
A number of countries have standardised prevention practice in schools by introducing 
manuals, although there is considerable variation in prevention programmes across 
Europe. Some evaluation of outcomes of specific prevention projects (e.g. EU-Dap) 
has showed that prevention, according to the predefined objectives, can contribute to 
a decrease in cannabis use. However, little is still known about the cost-effectiveness 
of interventions in this area. Moreover, the evidence base for some specific types of 
intervention, in particular mass media campaigns, remains weak.
The cannabis reader . . . one more addition to a growing 
evidence base
Drawing the various strands of cannabis in Europe together, this monograph 
demonstrates that cannabis is a complex subject, in which we see considerable changes 
over time. The dynamic nature of this topic is evident not just in developments in the 
way the drug is used but also in attitudes, legislation and societal responses. Our 
understanding of this complex phenomenon is, however, growing and new material of 
all types is becoming ever more available.
Foreword
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There may be cause for muted optimism. Prevention practice is increasingly responding 
to the evidence base for what works. In terms of science, the workings of the 
endocannabinoid system are gradually being unravelled, with developments in the 
medicinal use of cannabis encouraging research scientists to identify the neurological 
and biological mechanisms that have a bearing on behaviour. In terms of mental health, 
there is increased understanding of the risk factors that accompany cannabis-associated 
psychological problems. Perhaps the most positive development is that, increasingly, 
drug policy in Europe reflects the evidence base drawn from the fields of epidemiology 
and drug treatment. This evidence base is growing ever stronger, with surveys, medical 
studies and statistical data all contributing to a sharper, more multidirectional focus on 
the subject.
The growing volume of new data in this area will naturally need regular review and 
synthesis. If anything is certain in this field, it is that this will not be the last monograph 
to published on cannabis in Europe, nor should it be considered as ‘the final word’ 
on this topic. However, it is clear that, in 2008, our understanding of cannabis use in 
Europe and its probable implications has improved substantially. Cannabis, a substance 
used in Europe for millennia, still remains worthy of our attention, concern and 
vigilance.
1BVM(SJGGJUIT
Head of Epidemiology, crime and markets unit, EMCDDA
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Overview of Volume 2
Part I: Epidemiology
 1 Prevalence, patterns and trends of cannabis use among adults in Europe 
Julian Vicente, Deborah Olszewski and João Matias
 2 Measuring cannabis-related problems and dependence at the population level 
François Beck and Stéphane Legleye
 3 Patterns of cannabis use among students in Europe 
Björn Hibell and Barbro Andersson
 4 Cannabis in the context of polydrug use: results from the Dutch National School 
Survey 
Karin Monshouwer, Filip Smit and Jacqueline Verdurmen
 5 Cannabis users and their relation to Finnish society 
Taru Kekoni
Historically, the focus for much work in the area of drug epidemiology has been 
treatment demand data. However, in recent years we have increasingly seen the parallel 
development of survey data sets, relating both to the general population and selected 
population groups. This shift in focus has important implications for our understanding 
of patterns of cannabis use, particularly as in the past the drug has been less associated 
with problematic patterns of use, while most cannabis users will never come into 
contact with drug treatment services. In Europe, the EMCDDA has helped coordinate, 
standardise and collate national drug surveys since it was set up in 1993. Important 
supranational surveys such as the European School Survey Project on Alcohol and 
Other Drugs (ESPAD) also offer insight into drug use among adolescents. Monitoring 
cannabis use trends across countries and over time is now possible in Europe, although 
methodological differences still exist between countries which mean that data in this area 
require appropriate technical scrutiny.
The EMCDDA’s key indicator on drug use in the general population is represented in 
this volume in Chapter 1, by Vicente, Olszewski and Matias. The chapter describes 
cannabis use in the adult population, and the state of play in data collection on 
cannabis use today. Picking up on one of the conclusions of the EMCDDA chapter — the 
need for increased knowledge of frequent and intensive patterns of use — the next 
chapter, by Beck and Legleye, from the French focal point OFDT, provides an overview 
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of instruments that have been developed to screen populations for intensive cannabis 
use. These screening instruments vary in length, nature and content, yet some consensus 
is forming about common ways to measure the incidence of cannabis use disorders, and 
to identify at-risk populations.
The section proceeds to look at cannabis use among adolescents. Björn Hibell of the 
ESPAD survey describes cannabis use trends in the school student population, focusing 
on ESPAD’s methodology and its measures of a common age group (15–16 year olds) 
across Europe. Cannabis use among adolescents is also examined in the following 
chapter by Monshouwer, who uses data from Dutch school surveys. In particular, this 
chapter looks at the issue of polydrug use and how cannabis fits alongside alcohol, 
tobacco and other drug use.
While statistics can tell us much about drug use, there are stories behind numbers and 
percentages that can provide an additional perspective on this issue. This section ends 
with a chapter from Finland that uses a qualitative, interview-based approach. Kekoni 
describes how cannabis users view the substances in terms of their lives, lifestyles and 
political outlooks. While the chapter makes no claim to be representative of Finnish 
cannabis users as a whole, it does serve to underline the fact that cannabis use has a 
social dimension and that the meanings, rationales and experience of cannabis users in 
different Member States are likely to be important for informing our understating of why 
consumption patterns differ.
Part II: Health effects of cannabis use 
 6 Cannabis use and physical and mental health 
John Witton
 7 The public health significance of cannabis in the spectrum of psychoactive substances 
Robin Room
 8 Assessing the population health impact of cannabis use 
Wayne Hall
 9 Cannabis use and driving: implications for public health and transport policy 
Robert E. Mann, Gina Stoduto, Scott Macdonald and Bruna Brands
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Considerable research effort has been, and continues to be, devoted to the investigation 
of adverse health effects of cannabis use. Although the current state of research does 
not provide a clearcut understanding of the issues, some conclusions are beginning 
to emerge from the current evidence base. This section begins with a chapter by John 
Witton, summarising what we know about the health effects of cannabis today. He 
highlights that the issue of the extent of comorbidity of substance-specific and non-
substance-specific disorders is crucial when discussing cannabis use, and especially 
frequent and harmful use.
The topic of health effects to the individual naturally has a bearing on the health 
of entire populations. The chapter by Room looks at the issue of the public health 
‘footprint’ of cannabis. It provides some insight into the significance of cannabis-related 
health issues in comparison with tobacco, alcohol and other illicit drugs such as heroin. 
Room takes on the controversial task of comparing cannabis with other substances, 
legal as well as illegal. In so doing he provides the reader with a sense of perspective, 
from which the relative adverse health and social effects of cannabis may be better 
understood.
In the following chapter, Hall notes that one problem in the debate concerning health 
effects of cannabis use has been an ‘inflationary–deflationary dialectic’, in which a 
demand for unreasonably high standards of proof is often made by both sides of the 
debate. There are those who argue that there are few or no adverse health effects 
of cannabis use, and there are those who argue that effects are serious and grave. 
Hall discusses the problems that arise from conducting research on cannabis use and 
potential social and health outcomes, and proposes some guidelines for improved 
research in the future.
Beyond somatic and psychological effects of cannabis, there are other health 
consequences of cannabis use as it relates to behaviour. One of the areas of cannabis’s 
effect on behaviour that has received strong attention is driving under the influence 
of cannabis (DUIC). Mann et al. discuss the specific issue of cannabis and driving. 
The authors have reviewed the scientific literature concerning the effects of cannabis 
on psychomotor skills, as well as the evidence of the combined effect of alcohol and 
cannabis on driving skills. They also address the issue of how society might be able to 
detect and protect itself from cannabis-impaired drivers. As drug-driving tests are being 
introduced in many European countries, the chapter looks at how countries have sought 
to quantify the impact of cannabis on road safety.
Thomas and Rödner Sznitman
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Part III: Prevention and treatment
 10 Treating cannabis use disorders: perspectives and best practices 
Anders Bergmark
 11 Cannabis prevention in the EU 
Gregor Burkhart
 12 Moving towards evidence-based practice: school-based prevention of substance use 
in the USA 
Zili Sloboda
 13 Cannabis users in drug treatment in Europe: an analysis from treatment demand 
data 
Linda Montanari, Colin Taylor and Paul Griffiths
 14 Cannabis treatment in Europe: a survey of services 
Sharon Rödner Sznitman
 15 Has treatment demand for cannabis-related disorders increased in Germany?  
Roland Simon and Ludwig Kraus
 16 Risk factors for cannabis use 
Niall Coggans
Cannabis prevention and treatment are areas filled with complexity and contradictions. 
The issue of what constitutes effective treatment remains relatively open in comparison to 
many other types of drug, and considerable debate exists on whether prevention efforts 
are effective in this area. Nonetheless, in recent decades a large number of interventions 
have been developed in Western countries in order to prevent and treat the use of 
cannabis and other drugs, and the knowledge base in this area is steadily growing.
This section begins with an introduction to cannabis treatment. As the first chapter by 
Bergmark shows, there is considerable research regarding evidence-based cannabis 
treatment, yet this does not necessarily mean that the data provide adequate information 
as to which approach is the most appropriate and effective. For instance, studies do 
not allow us to determine guidelines for type, duration or intensity of treatment. We 
also do not know if it is the treatment as such which provides the effect, as it might 
be the decision to come to treatment in itself that determines the outcome. From this 
perspective, as Bergmark points out, it is clear that, despite an expanded pool of 
treatment effect research, the literature does not necessarily provide clearcut answers 
and guidelines on the issue of best practice in cannabis treatment.
Overview of Volume 2
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Chapter 11, by Burkhart, provides an overview of prevention relating to cannabis in 
Europe, categorised according to the typology of universal, selective and indicated 
prevention. A number of EU Member States have begun to standardise universal 
school prevention programmes, yet have also placed emphasis on selective prevention 
linked to risk factor research. Nonetheless, the knowledge base on prevention is based 
strongly around research in the USA. The third chapter in this section, by Zili Sloboda, 
an American prevention expert and former Director of the Division of Epidemiology 
and Prevention Research of the National Institute on Drug Abuse (NIDA), provides an 
overview of school prevention programmes in the USA, together with some explanation 
of their rationale.
The section then looks at the issue of the treatment of cannabis use disorders. In recent 
years, there has been an apparent increase in demand for treatment related to cannabis 
use. Montanari et al. of the EMCDDA provide an analysis of cannabis treatment demand 
in Europe, based on data from the EMCDDA treatment demand indicator. The data 
used are gathered for the purpose of cross-national comparisons, and thereby provide a 
fruitful starting point for analysing the current situation in Europe. A chapter by Rödner 
Sznitman then provides an analysis of fresh data gathered in order to reach a better 
understanding of the current treatment system available to cannabis cases in Europe 
today. This overview provides relatively up-to-date information about the treatment 
facilities that see cannabis cases in Europe and what kind of treatment is offered, as 
well as information about client characteristics. A more in-depth analysis of treatment 
demand follows in the chapter by Simon and Kraus. This chapter focuses solely on 
Germany, and analyses what may lie behind the increase in treatment demand related 
to cannabis use in Germany.
The final chapter looks at risk factors relating to cannabis use. Coggans summarises 
the literature on the subject of risk factors for cannabis use, and discusses how these 
might be used to help us target populations at risk. Risk factors are, naturally, important 
aspects of both prevention and treatment. The chapter thus provides a useful resource 
for practitioners to understand the needs of their clients, and to target interventions 
accordingly.
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Setting the context
A total of 71 million European adults (22 %) have tried cannabis: 23 million European 
adults (7 %) have used it in the last year while 13–14 million European adults (4 %) have 
used the drug in the last 30 days. A crude estimate suggests that 3 million European 
adults (around 1 %) are ‘daily’ or ‘almost daily’ cannabis users.
Such headline figures provide neat, newspaper-friendly estimates of the number of 
cannabis users in Europe. Yet it is important to differentiate between the numbers. There 
is a vast difference between those who admit having tried cannabis and those whose use 
appears to be intensive. Beyond this basic distinction there are myriad other variations: 
growth and decay in perceived risk of use; intensity and setting of use; generational or 
demographic acceptance and disapproval; country-by-country and region-by-region 
variation; and ethnicity and gender differences. In short, while cannabis use may be 
perceived as common in one subgroup, it might be considered outright deviance in 
another.
Reliable statistics are crucial for defining evidence-based drugs policy. For example, 
knowing that there is a large difference in lifetime use between 15- to 16-year-olds and 
17- to 18-year-olds (1) demonstrates that much experimentation with the drug clusters in 
the late teens. Targeted prevention should, thus, take into account the fact that late-teen 
initiation is commonplace. Moreover, early indications that use is growing among forty-
somethings should be monitored. Middle-age concerns, such as careers, parenthood, 
rent and mortgages, have traditionally counteracted regular drug use — is something 
changing today?
 (1) http://stats06.emcdda.europa.eu/en/elements/eyefig01a-en.html
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Information on cannabis use in Europe has improved substantially in recent years, and 
is subject to a standard reporting cycle. Each year, for over a decade, the EMCDDA has 
published analysis and information on the prevalence of cannabis and other illicit drugs 
in its Annual report (2) (currently covering 29 countries). Since 2004, the Annual report 
has also included a companion publication, the Statistical bulletin (3), that provides 
further information on the underlying data, information sources and methodology. On a 
less strict yet still frequent cycle — dependent upon implementation of the questionnaire 
— the ESPAD (4) school survey (37 countries) provides a key transnational source for 
cannabis use patterns among adolescents. Beyond Europe, the standard transnational 
source for epidemiological data on cannabis is the United Nations Office on Drugs and 
Crime (UNODC)’s annual World drugs report. In addition to this, at a domestic level, 
many countries publish prevalence surveys in the context of focused national surveys 
on drugs (e.g. Australia’s National drug strategy household survey and the SAMHSA 
National survey on drug use and health in the USA).
In addition to these statistical publications, the EMCDDA’s National reports (5) include 
discursive analysis of cannabis trends in different European countries. Grey literature 
(governmental, NGO, think tank) publications on cannabis typically appear several times 
per year (see the Appendix to Volume 1 of this monograph). Such publications play an 
important qualitative role, providing explanations for trends and nuanced information at 
regional level (6).
There remains work to be done. With the EU growing — the recent entry of Bulgaria 
and Romania having brought the total number of EU citizens close to 500 million — the 
scope for generalisation is getting smaller. One of the challenges of adding complexity 
to any sample is that the lists of exceptions grows. There are also possibilities for mining 
the rich seams of data in the grey literature and ad hoc surveys. As the reporting cycle 
matures to cover not simply years but decades of data, longitudinal analysis will become 
possible. For example, it is perhaps premature to speak about generational shifts in 
cannabis use in 2007.
 (2) http://annualreport.emcdda.europa.eu
 (3) http://stats07.emcdda.europa.eu
 (4) www.espad.org/
 (5) www.emcdda.europa.eu/index.cfm?nNodeID=435
 (6) See also EMCDDA (2000), Understanding and responding to drug use: the role of qualitative 
research, EMCDDA Monograph Series 4, European Monitoring Centre for Drugs and Drug 
Addiction, Lisbon.
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Cannabis epidemiology: key websites
Bibliography of European nationwide drug surveys: Table GPS-0 
www.emcdda.europa.eu/stats07/gpstab00/
EMCDDA Annual report 
http://annualreport.emcdda.europa.eu
EMCDDA Handbook for surveys about drug use among the general population 
http://www.emcdda.europa.eu/?nnodeid=1380
UNODC World drug report 
www.unodc.org/unodc/world_drug_report.html
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Prevalence, patterns and trends 
of cannabis use among adults in 
Europe
Julian Vicente, Deborah Olszewski and João Matias
This chapter presents an overview of prevalence and trends in cannabis use in Europe, 
based on survey data reported annually to the EMCDDA. This source of information on 
cannabis use in Europe has improved substantially in recent years. Not only have most 
countries now conducted national surveys on drug use, but most have also adopted a 
common set of core items for measuring this behaviour. Methodological differences 
still exist in the way some surveys are conducted. Nonetheless, overall this information 
source can now be considered a relatively robust one for commenting on trends and 
levels of cannabis consumption in Europe.
Cannabis is by far the illegal substance most frequently used in Europe. It is estimated 
that roughly 71 million people have tried the substance in Europe (about 22 % of adult 
population of 15–64 years), although recent use (last 12 months) or current use (last 30 
days) is clearly lower. A rough estimation for Europe indicates 23 million recent users 
(about 7 % of adults) and 13–14 million current users (about 4 % of adults), although 
with marked differences between countries.
Levels of cannabis use are highest among young adults, and this is particularly true 
when more recent or current use is considered. For example, at the European level, on 
average among those aged 15–34, last year and last month prevalence is estimated to 
be 13 % and 7 % respectively. Use is generally discontinued in later adult life, although 
it is possible that in future years we will see an increased use of the drug among older 
people as there is some evidence to suggest that regular use of the drug is becoming 
more common. Despite increasing concerns about intensive cannabis use, very limited 
information is available in Europe on the extent of this problem. A rough estimate made 
by EMCDDA in 2004 suggested that probably around 1 % of European adults may be 
daily cannabis users, and among young adults (15–34 years) estimates range roughly 
between 1 and 3.5 %.
Use of cannabis, as with other illegal drugs, is more common among males, and 
this is particularly true for measures of more recent or current use. There are marked 
differences between countries in gender differences, although among young people 
and school children these differences tend to be smaller. Of the Europeans that have 
ever tried cannabis, it is estimated that only 18 % have used it also in the last 30 days 
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(current use), although a higher 32 % have used it during the last 12 months (recent 
use).
Cannabis use has increased substantially in most EU countries during the 1990s, in 
particular among young people. In the new Member States that have more recently 
joined the European Union, increases have also been generally notable since the 
mid-1990s. The picture may be beginning to change, however. Although increases are 
still continuing to some extent, in recent data they are generally less marked and some 
countries now report a stabilisation or even a decrease in levels of use in the most recent 
data available.
Introduction
The increasing levels of cannabis use observed during the last 10 years in most of 
Europe clearly requires close monitoring as this drug continues to generate considerable 
public and policy interest. While there is recent evidence that cannabis use may be 
decreasing in some high-prevalence countries, such as the United Kingdom and Spain, it 
remains an important topic. Monitoring patterns of cannabis use, especially the intensive 
and sustained use of the drug, has also become more important as concerns have 
grown about the possible longer-term health and social consequences of use. Overall, 
in Europe the information available on the use of this drug varies considerably and 
there is generally an absence of data on more intensive patterns of use — which may 
be most important for considering the implications of cannabis use for public health 
(see Beck and Legleye, this monograph). A comprehensive review of the European data 
can therefore provide a more robust platform for facilitating a debate on cannabis 
and identifying information needs. This chapter offers a basic descriptive overview of 
cannabis prevalence in the different EU countries. In addition, crude European averages 
have been computed for basic patterns of cannabis use: lifetime experience, last year 
prevalence, last month prevalence and, with more difficulties, more intensive forms of 
use such as daily use. The method to estimate these European figures has been relatively 
simple (weighted averages) and results should be taken as a first but informative 
approximation, which will require improvement in the future as further data become 
available.
Measuring cannabis use in the population
Cannabis use in the general population can be measured through representative surveys 
among adults and school children, which provide estimations of the proportion of the 
population having used drugs during standard timeframes: any use in the lifetime (also 
sometimes referred to as ‘experimentation’), any use in the previous 12 months (also 
sometimes referred to as ‘recent use’) and any use in the previous 30 days (also referred 
Prevalence, patterns and trends of cannabis use among adults in Europe
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to as ‘current use’). Although response and non-reporting biases can have an impact on 
any survey exercise, population surveys — if well conducted — are generally considered 
to produce reasonable estimations of cannabis use. This is particularly true of cannabis 
use: compared with other drugs, cannabis smoking is a relatively less stigmatised 
behaviour, and it is also more common than use of other drugs.
‘Lifetime use’ as a measure has limited value in describing current levels of drug use, 
although it may be useful for exploring broader questions, for example, the difference 
between users and non-users in attitudes and perceptions, or charting cannabis over 
time to analyse ‘use careers’. Use in the previous 12 months and the previous 30 days 
give better indicators of actual drug use. The latter can be used to indicate regularity of 
use, although clearly this is an imperfect measure in this respect.
Information presented here is based on national surveys among adults (7), but the reader 
should note that school surveys are addressed in detail elsewhere in this monograph. 
Analysis is presented here that is predominantly based on surveys conducted by EU 
Member States, between 2003 and 2006 (8). The results of these surveys are reported 
annually by Member States to the EMCDDA through a standardised form. Detailed 
information on those datasets included here can be found in the EMCDDA annual 
reports and the accompanying Statistical Bulletin.
The EMCDDA has developed guidelines for surveys that include a set of common core 
items (‘European Model Questionnaire’ (EMQ)) (9). These questions are now used in 
most adult surveys conducted in the EU Member States. Although, overall, the quality, 
reliability and comparability of European survey data have improved considerably, 
some methodological differences still exist between countries in they way surveys are 
conducted. This means that caution is still required in interpreting differences, especially 
where they are small.
In this chapter we will restrict our attention to the issue of prevalence. However, it 
is worth noting that survey work in Europe is increasingly addressing a wider set of 
questions in this area. Among these are: the identification of risk and protective factors 
for initiation of cannabis use or for progression to more intensive forms of use (see 
Coggans, this monograph); and the assessment of levels of problems and dependence 
found with different patterns of use. Readers interested in these issues are directed to 
recent reviews by Hall et al. (2001), INSERM (2001), Rodin Foundation (2002) and 
Simon (2004).
 (7) The term ‘adults’ is used in this paper to refer to the group of 16–64 years of age. Most surveys 
target this population, although the reporting may address other specific subgroups selected by 
age.
 (8) Malta 2001, Portugal 2001 — new survey conducted in 2007 — and Poland 2002.
 (9) See EMCDDA (2002), Handbook for surveys about drug use among the general population: 
www.emcdda.eu.int/?nnodeid=1380
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Prevalence of cannabis use in Europe
Lifetime prevalence (ever use)
Cannabis is by far the most commonly used illegal substance in Europe (10). Recent 
surveys indicate that between 2 and 37 % of adults (15–64 years) have tried the 
substance at least once. The lowest lifetime prevalence estimates were found in Romania 
(1.7 %), Malta (3.5 %) and Bulgaria (4.4 %) and the highest in the United Kingdom 
(29.8 %), France (30.6 %) and Denmark (36.5 %). In most countries (12 of the 26 
countries from which information was available) lifetime prevalence was estimated to be 
between 10 and 25 % of the adult population.
A crude estimation, computed as an average from national prevalence data and 
weighted to reflect population size, suggests that over 70 million adults (15–64 years) 
have tried cannabis in Europe as a whole, representing about 22 % of the adult 
population. Perhaps unsurprisingly, cannabis use is concentrated among young adults 
(15–34 years), who consistently report higher rates of lifetime use than the population 
average. Between 3 and 49.5 % of young Europeans report having tried the drug, with 
the lowest prevalence estimates found in Romania, Malta and Bulgaria and the highest 
in Denmark (49.5 %), France (43.6 %) and the United Kingdom (41.5 %). In general, 
the prevalence levels are found to be greatest among young people aged 15–24 years, 
with most countries reporting that somewhere in the range of 20–40 % of this age group 
have tried the drug at least once.
Last 12 months prevalence (‘last year’, recent use)
Overall in the EU, an estimated one-third (32 %) of people who have ever tried cannabis 
have also used it in the last 12 months. Put another way, around two-thirds of those 
who have ever used cannabis have not done so in the last year. Interestingly, among 
those who have used cannabis in the last year, about 60 % have also done so in the last 
month, suggesting some regularity of use.
Depending on the country surveyed, between 1 and 11.2 % of adults report having used 
cannabis in the last 12 months, with Malta, Bulgaria and Greece presenting the lowest 
prevalence estimates and Italy (11.2 %), Spain (11.2 %), the Czech Republic (9.3 %) and 
the United Kingdom (8.7 %) the highest. Most countries (13 out of 25) reported figures in 
the range of 4–9 %.
 (10) Estimates for the EU presented in this paper relate to the European Member States and Norway, 
which participates in EMCDDA activities by special agreement.
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A crude estimate would suggest that over 23 million adults, around 7 %, have used 
cannabis in the last 12 months in the European Union as a whole. Most of those who 
had used the drug in the previous 12 months were young, with 18 of the 23 million 
estimated users falling into the age range of 15–34 years. In other words, about 13 % 
of all those aged 15–34 had used the drug, a rate nearly five times higher than that 
found among those aged 35–64 years, among whom, at the European level, last year 
prevalence is estimated to be about 2.5 %.
European averages are naturally most influenced by patterns of use in the countries with 
larger populations. They can therefore obscure heterogeneity at the Member State level. 
Depending on the country surveyed, between 2 and 20 % of young adults (15–34 years) 
report having used cannabis, with the lowest figures found in Malta, Greece, Cyprus and 
Bulgaria, and the highest in Spain (20.3 %), the Czech Republic (19.3 %), France (16.7 %) 
and Italy (16.5 %). Overall, 11 countries reported prevalence estimates for this age 
group in the range of 7–15 %.
If attention is restricted to young adults, last year prevalence rates rise considerably. 
Among Europeans aged 15–24 years, estimates of use in the last year range from 4 
to 28 %, with most countries falling between 10 and 25 %. This means that, depending 
on the country, somewhere between 1 in 10 and 1 in 4 young Europeans have used 
cannabis in the previous year, with the figure rising to nearly one out of every two males 
between 15 and 24 in some countries (Figure 1).
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Last 30 days prevalence (current use)
In recent European surveys, current use (last month prevalence) was reported somewhere 
between 0.5 and 8.7 % of all adults. The highest figures were found in Spain (8.7 %), 
Italy (5.8 %) and the United Kingdom (5.2 %) and the lowest in Malta, Sweden and 
Lithuania. Thirteen out of 26 countries for which information was available reported 
figures in the range 2–6 %. These data can be used to produce an EU population 
estimate that around 13.5 million adults (aged 15–64 years) have used cannabis in 
the last 30 days, representing nearly 4 % of all adults. This figure should be considered 
as a minimum estimate. The majority of those who had used in the last month were 
young, with about 10 million out of the total 13.5 million falling in the 16–34 years 
age group, suggesting that around 7 % of young adult Europeans can be considered 
current cannabis users. These figures vary considerably depending on the country, from 
less than 2 % (1.5 %) to over 15 %, with the highest figures in Spain (15.5 %) and France 
(9.8 %). Sixteen out of 25 countries for which information was available reported figures 
in the range of 3–10 %. By restricting the analysis to an even younger age group (15–24 
years), even higher levels of last month use were generally reported. For this age cohort, 
last month prevalence varied between 1.2 and 18.6 %, with most countries typically 
falling in a range of between 5 and 10 %.
‘Use in the last 30 days’ can be taken as an indicator of ‘current use’ and will include 
people who use cannabis regularly, although clearly not all will fall into this category. 
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It is also unclear what proportion of those reporting use in the last month will be 
consuming the drug on a daily or near-daily basis. A clue is provided by a recent 
estimate conducted by the EMCDDA, based on more detailed analysis of data available 
from seven countries. In this exercise, it was found that between 19 and 33 % of those 
reporting use in the last 30 days were daily or near-daily users (EMCDDA, 2004a) 
(Figure 2). As those using cannabis on a regular and intensive basis are an important 
group for developing a better understanding of the public health impact of cannabis 
consumption, improving the information available on this kind of consumption pattern 
is, therefore, an important task for the future (see Beck and Legleye, this monograph).
Comparing figures from Europe and other parts of the 
world
When considering cannabis consumption in Europe, one question that often arises is 
how it compares with patterns of use elsewhere. Cannabis consumption is estimated to 
be common in both parts of Africa and Asia, but data to allow meaningful comparisons 
with European patterns are not available. A contrasting point of reference can be found 
in data from the USA, Canada and Australia, all of which have undertaken surveys of 
cannabis use that are broadly similar to European studies. In 2005, the US national 
household survey on drugs (11) reported that 40.1 % of adults (12 years and older) 
reported lifetime use of cannabis. This can be compared with an EU average of about 
22 %. Even taking into account the slightly different age range covered, the US figure 
is clearly higher than the European average, although some European countries come 
close. For example, both Denmark and the United Kingdom report lifetime prevalence 
estimates slightly in excess of 30 %.
To some extent, differences in lifetime prevalence between America and Europe can 
be seen to reflect a historically earlier — that is, generational — experience with 
widespread drug use. This is illustrated by looking at last year prevalence estimates, 
which are more similar, at 10.4 % and 7 % respectively, with a number of European 
countries (Italy, Spain and the Czech Republic) reporting similar figures that approach 
the higher US estimate. Further points of comparison are provided by Canadian 
data (2004) (12), with lifetime adult prevalence (defined as 15 years and above) being 
estimated at 44.5 % and last year prevalence at 14.1 %, higher than the figures for 
 (11) Source: SAMHSA, Office of Applied Studies, National Survey on Drug use and Health, 2005 — see 
www.samhsa.gov and http://oas.samhsa.gov/nhsda.htm#NHSDAinfo. Note that the age range 
for ‘all adults’ in the US survey (‘12 years and over’) is wider than the age standard range for 
European surveys (15–64), implying that these will present relatively higher figures.
 (12) Source: Adlaf, E.M., Begin, P. and Sawka, E. (eds) (2005), Canadian Addiction Survey (CAS): A 
national survey of Canadians’ use of alcohol and other drugs — prevalence of use and related 
harms, detailed report. Canadian Centre on Substance Abuse, Ottawa. Note that the age range 
for ‘all adults’ in the Canadian survey (‘15 years and over’) is wider than the age standard range 
for European surveys. See Note 4.
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both Europe and the USA. Similarly, Australian data (2004) (13) suggest that one-third 
(33.6 %, or 5.5 million people) of adults (defined as 14 years and older) have ever used 
cannabis; 11.3 % have used cannabis in the last year; and 6.7 % are estimated to have 
used the drug in the last 30 days.
A similar picture is found when prevalence rates among younger adults are compared 
(Figure 3). In Europe, lifetime prevalence is overall around 30 % for the 15–34 years age 
group. This can be compared with estimates of nearly half (49.1 %) of 16- to 34-year-
olds in the USA, and a similar figure of 48 % for Australians, although the available 
age breakdown is slightly wider in Australia (14–39 years). In Canada, the estimate 
for lifetime prevalence among young adults (aged 15–34) is higher still, at 58.6 %. For 
these same age groups, last year prevalence estimates report some divergence: Europe 
at 13 %, the USA at 21.6 %, Australia at 20 % and Canada at 28.1 %. Again, it should 
be noted that at national level some of the higher-prevalence European countries — the 
Czech Republic, France, Spain and the United Kingdom — reported estimates that were 
broadly similar to those found in the USA, Australia and Canada.
 (13) Source: Australian Institute of Health and Welfare, 2005. 2004 National drug strategy household 
survey: detailed findings. AIHW cat. no. PHE 66. Canberra: AIHW (Drug Statistics Series No. 16). 
Note that the age range for ‘all adults’ in the Australian survey (‘14 years and over’) is wider 
than the age standard range for European surveys.
Ro
m
an
ia
M
al
ta
Bu
lg
ar
ia
C
yp
ru
s
G
re
ec
e
Po
rtu
ga
l
Lit
hu
an
ia
Po
la
nd
Lu
xe
m
bo
ur
g
H
un
ga
ry
Sw
ed
en
La
tvi
a
Fin
la
nd
Be
lg
iu
m
Ire
la
nd
N
or
w
ay
Au
str
ia
Sl
ov
ak
ia
EU
 a
ve
ra
ge
N
et
he
rla
nd
s
Ita
ly
G
er
m
an
y
C
ze
ch
 R
ep
ub
lic
Sp
ai
n
UK
 (E
&W
)
Fr
an
ce
Au
str
al
ia
US
A
De
nm
ar
k
C
an
ad
a
Pe
rc
en
ta
ge
70
60
50
40
30
20
10
0
Note: In the USA the age range for all adults is 12 years and over.
'JHVSF Lifetime prevalence and previous 12-month prevalence of cannabis use among 
young adults, in the EU Member States, in the EU as an average and in third 
countries (USA, Canada, Australia)
Prevalence, patterns and trends of cannabis use among adults in Europe
14
Prevalence of more intensive forms of cannabis use
There is an increasing concern about prevalence of intensive cannabis use and its 
potential health consequences (14). Unfortunately, very little information is available 
that might allow some assessment of either levels or trends in this pattern of cannabis 
use. Where information sources do exist, they are usually difficult to compare across 
studies. Even the concepts in this area lack standardisation, with different researchers 
using terms such as ‘regular’, ‘repeated’ or ‘intensive’ use with differing operational 
definitions. Some population surveys have started to include scales to assess 
‘problematic use’ or ‘dependence/abuse’, although this work remains very much in its 
infancy, and harmonisation at the European level is needed (see Beck and Legleye, this 
monograph).
Last 30 days use
Given the lack of alternatives, last 30 days cannabis prevalence (current use) could 
be used as a very rough proxy indicator for estimating regularity of use. However, it 
should be stressed that this indicator does not imply problematic use or dependence. 
Information about prevalence of last 30 days use is presented in Figure 4. However, 
it should be noted that trends over time in this pattern of use are difficult to assess at 
the European level. Very few countries have data series with more than two measured 
points, and no clear picture emerges from the data that are available: in many countries 
no marked changes are observed. In the United Kingdom, a decreasing trend has been 
observed since 2004, whereas increases of different magnitude are reported in Spain, 
Belgium, Italy and Finland.
Daily use of cannabis
‘Daily use’ or ‘almost daily use’ (use on 20 days or more during the previous 30 days) 
may be considered a better indicator of ‘intensive use’ of cannabis and is included as 
a topic in a number of different studies and the EMQ. Although it is in need of update, 
the EMCDDA included an analysis on the available data in this area for the 2004 
EMCDDA Annual report (EMCDDA, 2004a). Eight countries (15) provided data, and, with 
the exception of Latvia, where the figure was lower (4 %), approximately one-quarter 
(19–33 %) of those who had used cannabis in the last 30 days were reported to be daily 
or near-daily users (Figure 5). In terms of overall prevalence rates, daily use estimates 
 (14) For further discussion of the public health effects of cannabis, see chapters by Hall and Room, this 
monograph, and also dedicated publications by Hall et al. (2001), INSERM (2001), the Rodin 
Foundation (2002) and Simon (2004).
 (15) France, Greece, Ireland, Italy, Latvia, the Netherlands, Portugal and Spain. Finland decided not 
to report due to the small number of last month users in their survey. See more details in 2004 
Annual report (http://ar2004.emcdda.europa.eu).
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Spain (2001;
15–64 n = 14 113;
15–34 n = 6 915)
Greece (1998;
15–64 n = 3 398;
15–34 n = 2 014)
France (2000;
15–64 n = 11 317;
15–34 n = 4 749)
Ireland (2002/03;
15–64 n = 4 925;
15–34 n = n.a.)
Latvia (2003;
15–64 n = 4 534;
15–34 n = n.a.)
Netherlands (2000/01;
15–64 n = 14 045;
15–34 n = 6 687)
Italy (2001;
15–64 n = 6 032;
15–34 n = 3 689)
Portugal (2001;
15–64 n = 14 184;
15–34 n = 6 406)
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ranged between 0.5 % and 2.3 % of all adults (15–64 years) and between 0.9 % and 
3.7 % of young adults (15–34 years). Extrapolation of these data would give a rough 
estimation that there may be around 3 million daily cannabis users in the EU, or about 
1 % of the adult population.
Almost all daily users concentrate in the age range 15–34 years, and the vast majority 
are male. At present, it is difficult to assess trends in daily use, as information reported 
here was based on an ad hoc data collection exercise. However, this exercise is currently 
being repeated. Moreover, the data currently available are simply a behavioural 
measure of drug use. No supplementary information is available that allows informed 
comment on the extent to which daily users are likely to be experiencing problems or 
dependence. It would, nonetheless, be reasonable to assume that daily use would be 
associated with both. A study conducted in 1992 in the USA (Kandel and Davis, 1992) 
reported that one in three daily users met DSM-III criteria for dependence. The extent to 
which this estimate is likely to be valid for patterns of cannabis use in Europe today is 
unclear.
Estimations of cannabis dependence or problematic use
Frequency of use is relatively easy to measure in questionnaires, although additional 
information on dependence or problems would add insight into the implications and 
correlates of substance use. Despite the difficulties, it can be argued that surveys have 
the potential to better estimate cannabis use disorders. At present, there is limited 
information on prevalence of cannabis dependence or problematic use in Europe. A 
recent review of surveys carried out in European countries from 1990 until 2002 found 
that 0.3–2.9 % of adults met the criteria for ‘drug dependence’ (including all illicit drugs) 
in the previous 12 months, and in addition similar or higher numbers were classified as 
using the drug in a manner that could be defined as ‘abuse/harmful use’. The highest 
estimates were found among young people aged 18–25 years (Rehm et al., 2005).
Figures from the US survey may provide a useful point of reference, although they 
cannot be assumed to translate directly to the European situation. In the 2003 National 
Survey on Drug Use and Health (SAMHSA, 2004a) 1.8 % of people aged 12 or over 
fulfilled DSM-IV criteria for cannabis dependence or abuse during the previous year, or 
around 4.2 million Americans. The proportion among 18- to 25-year-olds was higher, 
at 5.9 %. Data from this survey suggested that 16.6 % of those who had used cannabis 
in the last year met the criteria for either dependence or abuse of the substance.
Patterns of use: continuation rates of cannabis use
In general, cannabis use tends to be occasional or discontinued some time after its 
initiation in adolescence or during a user’s early 20s. Thus, prevalence rates become 
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lower with increasing age, in particular for measures of last year or last month use. 
‘Continuation rates’ can be considered as the proportion of people that, having used 
a drug for a longer period of time (e.g. during their lifetime), have also used it in a 
more recent period (e.g. during the last 12 months or last 30 days). As a European 
average, only 18 % of those that have ever tried cannabis have used it also in the last 
30 days (Figure 6). National figures range from 10 % or less in Denmark, Lithuania, 
Romania and Sweden to over 20 % in Belgium, the Czech Republic, Spain, Italy, Cyprus 
and Portugal. In addition, on average in Europe, about one-third of those who have 
ever used the substance have used it in the last 12 months. It is worth noting that, in 
most countries a relatively high proportion, averaging almost 60 %, of those who have 
used cannabis in the last 12 months have also done so in the last 30 days, suggesting 
a certain regularity of use, although not necessarily frequent or intensive use. However, 
there is a wide variation between countries (30–78 %).
Continuation rates are relatively stable in those few EU countries where this rate can be 
computed over a number of years. A similar finding is observed in the USA. This may 
suggest that there is not an intensification of use patterns among most users, although 
this may not apply to the more intensive or problematic forms of use. Furthermore, this 
statement must be made with the caveat that the overall European dataset in which this 
question can be explored is limited.
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Gender differences in cannabis use
In Europe, most young people who have tried an illicit drug have used cannabis, and 
males are generally more likely to have done so than females. Adult and school survey 
data suggest that there has been only limited convergence in cannabis use between 
males and females, and increases in cannabis use have tended to occur largely in 
parallel. Some patterns are, nonetheless, detectable. For example, female and male use 
tends to become more equal as prevalence of cannabis use increases, and this gender 
gap is generally wider for use of other illegal drugs and for recent or frequent patterns 
of drug use.
Male to female ratios (16) tend to be consistently higher among surveys of adults than 
among school students. Among students aged 15–16 years, lifetime experience of 
cannabis is slightly higher among males in all but three countries (Ireland, Finland and 
Norway). School student male/female differences are fairly consistent and small across 
most countries in the European Union, ranging from equal ratios in Ireland, Finland 
and Norway to 1.8 in Portugal. However, among adults (aged 15–64 years) gender 
differences for lifetime experience of cannabis use reveal a greater gender gap and 
more variation across countries than among school students: male to female ratios 
range from 1.25 in Finland to 4.0 in Estonia.
The gender gap also becomes wider if one progresses from lifetime use through recent 
(last 12 months) to current use (last 30 days) (Figure 7). Recent use (last year prevalence) 
male–female ratios range from 1.5 in Finland to 4.3 in Hungary. In the case of current 
use, male–female ratios are even larger, ranging from 1.8 in Norway to 5.9 in Portugal. 
Among school students, gender ratio differences are considerably greater for ‘frequent 
use’ of cannabis (defined as ‘used 40+ times during a lifetime’) than for lifetime 
prevalence or last year prevalence. Nonetheless, some caution is needed in interpreting 
results for current or frequent use because of the relatively small numbers involved. In 
European Union countries with relatively high prevalence rates, the difference between 
male and female adults tends to be less marked than in countries with low prevalence 
rates. Sweden, Norway and Finland are exceptions, as prevalence is relatively low and 
male/female differences are minimal.
From 1995 to 2003, although increases generally occurred in parallel among both 
male and female school students, the trend in countries with relative high prevalence 
has generally been towards equality between males and females. Among adults, there is 
 (16) Differences between males and females are presented here as ratios of prevalence of use among 
males over prevalence of use among females. Ratios higher than 1 indicate more males than 
females; for example, a ratio of 2 indicates twice as many males as females (diagrams are 
drawn with logarithmic scaling).
Chapter 1
19
little evidence of gender convergence in countries with trend data. It is not clear to what 
extent male predominance at low prevalence levels is determined by persistent cultural 
factors that make males disproportionately prone to illicit drug experimentation and to 
what extent it arises from the fact that in many of these countries drug use is a relatively 
recent historical phenomenon, developing first within the male population. The gender 
ratios for school students aged 15–16 years reporting that they had drunk five or more 
drinks in one session during the past 30 days and for lifetime prevalence of cannabis 
use are broadly similar among different countries (a log scale correlation of 0.46). This 
may suggest a common association of drug use with an outgoing lifestyle related to 
gender or age.
Evolution of cannabis use in Europe — long-term and 
recent trends
Only a few European countries have a series of drug surveys that allow long-term 
trends to be identified with any precision. Most countries do not have a set of historical 
data that can reasonably be considered to represent a time series in any strict sense, 
although sporadic surveys are sometimes available that give some indication of the 
historical situation. Moreover, even in those countries where data are the strongest, it 
is only possible to extend the observational window with any confidence to the early or 
mid-1990s.
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Initial expansion of cannabis use in European countries
In the USA the widespread expansion of cannabis use began in the first half of the 
1960s (Kandel et al., 2001). It is generally considered that this cannabis use began 
to spread to parts of Europe at this time as part of a growing counterculture (see 
Olsson and Abrams chapters, this monograph). Where it had become established, the 
popularity of the drug continued to grow through the 1970s and 1980s. However, both 
within and between countries there was considerable heterogeneity in levels of use, and 
the drug was probably more clearly linked with particular subgroups than it is today.
Some indication of patterns of use over time can be gained by looking at the dates 
given for when a cross-section of cannabis users report their first use of the drug. An 
analysis on initiation of cannabis use (age of first use) found, for example, that cannabis 
use expanded markedly in Spain during the 1970s, in the former West Germany during 
the 1980s and in Greece during the 1990s. In addition, it was observed that the more 
recent young generations had reported higher levels of cannabis experience than any 
previous generation in these countries (Kraus and Agustin, 2002). Surveys conducted 
between 2000 and 2003 indicate significant levels of lifetime experience (12–24 %) 
among the 45- to 54-year-olds in Denmark, France, Germany, the Netherlands, Spain 
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(Figure 8), Sweden and the United Kingdom, suggesting that the number of cannabis 
users was probably not trivial in these countries 25–30 years ago.
Recent trends in European countries (1990s to present)
Different types of surveys (national or local household surveys, conscript and school 
surveys) have shown that cannabis use increased markedly during the 1990s in almost 
all EU countries, particularly among young people (Hibell et al., 2004; EMCDDA, 
2005a) (Figure 9). In most European countries, cannabis use has continued to increase 
until recent years, although different paces of growth have been observed between 
countries. Nonetheless, it is worth noting that several countries are reporting a recent 
stabilisation in levels of use in different settings (EMCDDA, 2005a).
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Differences by countries
In the United Kingdom (England and Wales) (17), which since the early 1990s has 
reported among the highest figures in Europe, cannabis use among young adults 
(16–34 years) remained stable from the mid-1990s until 2003 (19–20 %) and then fell 
between 2003 and 2006 (20–16.3 %). It is worth noting that levels of reported use fell 
more in a time comparison of the age group 16–24 years, while continuing to increase 
among 25- to 34-year-old males (from 9.4 % in 1994 to 14.8 % in 2003–2004), 
although a slight decrease is seen here in the most recent data (12 % in 2005–2006). 
These UK data suggest a ‘generational effect’ in which those who started using the drug 
10 or 15 years ago may be more likely to be continuing to use the drug into adulthood, 
and that the popularity of cannabis may be waning slightly among younger age cohorts 
(Figure 10).
 (17) In this section the information for the United Kingdom is based on British Crime Survey data (for 
England and Wales). The first BCS (E&W) for which information on drugs is available at the 
EMCDDA is from 1994.
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Prevalence figures among young adults in France, Spain and Italy have reached 
the levels of the United Kingdom in recent years (2002 or 2003), after a markedly 
increasing trend for several years. However, some stabilisation is also becoming 
apparent in these countries. France reported a decrease in 2005, and Spain a clear 
moderation in the increasing rate in the more recent data (2006). Figures from the 
Czech Republic (2002) were similar to those from these high-prevalence countries, 
although more recent information (2004) suggests stabilisation or a slight decrease in 
prevalence levels.
It is worth noting that, in contrast to the United Kingdom, increases in France and Spain 
among 15- to 24-year-olds have continued until very recently, with a decrease in France 
only in its most recent survey. Among 25- to 34-year-olds, a marked increase has been 
observed in Spain since 1999, with only a slight decrease in 2006. It is, thus, likely that 
trends among younger people anticipate trends in the broader population, and should 
therefore be monitored with particular attention.
Denmark and Germany also reported increases in cannabis use until recent years 
(reaching 12–15 % of last 12 months use among young adults), although not reaching 
the levels of the high-prevalence countries above. The most recent information for these 
countries indicates stabilisation or small decreases. In the Netherlands, prevalence 
figures have remained stable, at around 10 %, in the period 1998–2005.
Finland and Sweden have presented comparatively low prevalence estimates of cannabis 
use since the early 1990s. Although some increases have been observed, their figures 
remain low compared with other countries, without apparent signs of likely convergence 
with high-prevalence countries. The increase observed in Sweden between 2000 (1.3 %) 
and 2004 (5.3 %) may be related to methodological changes. Prevalence estimates for 
Sweden in the 2004, 2005 and 2006 surveys suggest a stable situation.
Among new Member States, the available information, mainly from school surveys within 
the ESPAD project (Hibell et al., 2004; EMCDDA, 2004a), suggests that there has been 
a substantial increase in cannabis use in recent years, in particular since the mid-1990s. 
Consecutive surveys among adults in Estonia (1998, 4 %; 2003, 10 %) and Hungary 
(2001, 5.4 %; 2003, 7.7 %) have also revealed increases of cannabis use among young 
adults.
It can be noticed in several new Member States that last 12 months prevalence among 
15- to 24-year-olds is in the same range as other EU countries. By contrast, prevalence 
estimates drop considerably among the immediately older age groups (25–34 or 
35–44 years), suggesting a generational effect that could be related to lifestyle changes 
occurring during political and social changes that took place in these countries during 
the 1990s, and that were possibly adopted initially by the younger generations (see 
Moskalewicz et al., this monograph).
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Finally, from different sources (adult surveys, youth or conscripts surveys and school 
surveys, etc.) it can be noted that a number of countries are now reporting recent 
stabilisation or even a decrease in levels of cannabis use. In some cases, different 
surveys may signal opposite trends in a country, possibly due to the different age 
ranges or social milieu covered. Among countries reporting stabilisations are the Czech 
Republic, Denmark, Germany, France, the Netherlands, Finland, the United Kingdom 
and Norway. These findings may indicate that the overall increase in cannabis use 
observed during the 1990s and early 2000s may be starting to stabilise, at least in some 
countries, and in particular among younger people.
The present situation and future information needs
Information on prevalence of cannabis use and patterns has increased substantially 
in recent years in the European Union. Most European Union countries are now 
conducting harmonised school surveys at regular intervals within the ESPAD project, 
although sample sizes are sometimes relatively small. Almost all EU countries have 
conducted general population surveys on drugs, with overall strong compatibility with 
the EMQ. However, clear limitations still do exist on information at EU level. There are 
still differences in methodology (e.g. data collection, sampling). Only very few countries 
have a series of repeated surveys with consistent methodology. Harmonisation beyond 
the basic items of the EMQ is often limited, including questions that would allow better 
assessment of more intensive forms of use.
Added value is accrued from surveys if they are repeated over time using comparable 
methods. It is, therefore, important to consolidate national series of household surveys 
to generate robust time series. This would greatly increase the analytical value of the 
data and permit more complex and detailed analyses. There is a need to educate 
policymakers and those commissioning surveys that this is, by necessity, a long-term 
investment, with the value of information progressively increasing as survey series 
become longer.
Data from population surveys form one of the EMCDDA key indicators and there is a 
political commitment to implementing the indicators in the current EU action plan on 
drugs. However, although almost all European countries have made progress in this 
area, there is a clear need to stimulate more regular data collection exercises and a 
greater adoption of common standards of good practice.
As concern increases about the possible public health implications of cannabis use, it 
is imperative to improve existing methods and capacity to assess intensive patterns of 
use, and to analyse their correlates, and potential health and social consequences. This 
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approach may also need to be extended to embrace other substances (e.g. stimulants, 
psychoactive medicines, problematic and combined use of alcohol with drugs).
Finally, survey data need to be complemented with longitudinal and more focused 
studies to describe the specific behaviour of vulnerable subgroups, or to explore 
important temporal issues, such as drug use initiation and cessation rates. In particular, 
qualitative studies of users can contribute valuable information that can illuminate the 
drier statistics. These help to understand the associations found within the statistics, by 
placing them in the context of an understanding of the individual user’s experiences, 
rationale and motivation.
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Chapter 2
Measuring cannabis-related 
problems and dependence at the 
population level
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Setting the context
While there is evidence of stabilisation or slight decline in use in some high-prevalence 
countries, cannabis use has, on the whole, increased in most European countries over 
the last 15 years, especially among adolescents and young adults.
Despite strong public health interest, the commonly used indicators of cannabis use — 
lifetime and last year prevalence — aim to assess not problematic use but broader use 
patterns. Indicators of current use — last month prevalence and frequency of use in the 
past month — provide indirect indications of the extent of more intensive forms of use 
and problematic use of drugs. Yet frequent use of cannabis does not necessarily imply 
that users will experience problems, so a more detailed picture is required. As Europe 
becomes increasingly sensitive to the health risks of cannabis use, particularly among 
high-prevalence populations, distinguishing between various kinds of use is vital to 
ensure that interventions are targeted to those most at risk.
Nearly all EU countries now collect information on how many days cannabis has 
been used in the month prior to interview. However, standardisation remains far 
from complete: some collect number of days, others number of times smoked or less 
well-defined measures. The EMCDDA, in collaboration with several national experts, 
is currently developing the methodological and conceptual framework necessary for 
monitoring ‘intensive forms of drug use’ to better identify those experiencing problems. 
Several projects to test psychometric instruments are under way in Germany, France, 
the Netherlands, Poland, Portugal, the United Kingdom and, most recently, Spain 
(EMCDDA, 2007).
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This chapter, written by experts based at the OFDT (the National focal point for 
France), presents the main concepts for diagnosing harmful cannabis use, abuse and 
dependence as well as tolerance and withdrawal symptoms from cannabis. It also 
touches on wider difficulties in abstaining and controlling use, together with other factors 
linked to problematic use (family disapproval, financial impacts, etc.). The authors have 
collected the existing screening tests for cannabis-related disorders. They review the 
screening processes and comment on their reliability. They then present and discuss 
the main available cannabis tests and how they may be used in general population 
surveys. While they suggest that even if the concepts and tools are somewhat arbitrary 
and vary according to cultural background, such screening instruments remain useful in 
increasing research into cannabis-related disorders.
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Measuring cannabis-related 
problems and dependence at the 
population level
François Beck and Stéphane Legleye
Introduction
Although common perceptions of the ‘harmlessness’ of cannabis have often been 
countered in recent years, the fact remains that a majority of cannabis users do not 
encounter any clinical or social problems. So epidemiologists have sought ways to 
distinguish — among the many people who report lifetime, last year or last month 
cannabis use — the profiles of cannabis users who suffer from a cannabis use disorder 
or who manifest patterns of cannabis use that may require a timely intervention.
The definition of an acceptable level of cannabis use, i.e. the establishment of a 
threshold beyond which the use becomes problematic, is beset with ethical issues. 
First, cannabis is an illegal drug and so establishing use guidelines may be perceived 
as condoning its use (see Bennett, this monograph). Second, as with legal drugs such 
as alcohol or tobacco, problematic use can emerge from what some groups — peers, 
specific generations and subcultures — might perceive as moderate or normative 
consumption. Indeed, in the light of increasing treatment demand for cannabis 
(Montanari, 2004; Simon and Kraus, this monograph), there is considerable demand to 
operationalise concepts of dependence into measurable criteria, and to inform people of 
cannabis-related health risks.
Problematic use can be defined as use leading to negative consequences on a social 
or health level, both for the individual user and for the larger community. From this 
definition of problematic use, various other concepts can be defined, such as misuse, 
abuse and dependence, together with difficulties faced in abstaining or controlling use. 
Harms are either directly linked to the substance itself, for example loss of concentration 
in the short term or lung damage in the long term (see Witton, this monograph, Vol. 
2), or are secondarily harms linked to polydrug use (principally, alcohol and tobacco) 
or risky behaviour (drug driving, binge patterns). Such risk situations should ideally 
be detected early by practitioners. By identifying problems early, drugs workers have 
a window of opportunity to minimise cannabis-induced problems, for instance by 
referring users to treatment or by taking actions aimed at preventing intensive use and 
dependence.
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Monitoring of cannabis use has been improved since the beginning of the 1990s, partly 
due to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), which 
has developed a European model questionnaire for general population surveys (Bless 
et al., 1997). Nonetheless, most studies dealing with abuse, problematic use, harmful 
use or dependence reflect a lack of standardised screening tools (1). And more study is 
needed on the links between various types of use, socio-demographic characteristics and 
socio-medical factors.
The literature provides evidence that brief rating scales are well suited for screening 
purposes, and that instruments with direct questions appear to perform better than 
scales with more subtle questions (Rost et al., 1993; Svanum and McGrew, 1995). 
Yet, there remain many different screening instruments used to measure cannabis use 
disorders (2). This heterogeneity reflects the diverse goals of researchers and practitioners 
(which types of uses are to be screened and in which contexts), and of the means they 
choose to reach them (which types of questions, how many items and what kind of 
questionnaires). Although there are a number of definitions of cannabis use disorders, 
those which operationalise specific types of drug use are relatively vague. Furthermore, 
the way such definitions are translated into questions in screening tools can be very 
different. This is partly because identifying potentially harmful drug uses is complex and 
partly because in most countries attempts to distinguish problematic cannabis use from 
other types of cannabis use are new.
In this chapter we first clarify the different concepts for defining general substance use 
disorders and how these are applied to cannabis. Second, we describe the various 
screening instruments which attempt to measure cannabis use disorders, their differences 
and similarities. Finally, we discuss the various problems with existing screening tools 
and propose a possible step forward in order to better screen cannabis-related disorders 
in the future.
Concepts and their adaptation
The basics of screening potential problematic drug use are (i) establishing criteria 
to define problem use and (ii) developing questions that can be used to diagnose 
whether a respondent meets these criteria. Screening typically takes the form of a 
clinical interview between a patient and practitioner. Nonetheless, difficulties can 
 (1) The majority of these tests are conceived for all the psychoactive substances then adapted to 
cannabis; the others were specifically conceived for this product.
 (2) Recent European screening can be summarised as follows: Germany: Severity of Dependence 
Scale (SDS); France: Cannabis Abuse Screening Test (CAST); the Netherlands: CIDI modified 
plus additional ad hoc scale; Poland: Problematic Use of Marijuana (PUM); Portugal: Diagnostic 
and Statistical Manual of Mental Disorders, 4th edition (DSM-IV scale); Spain: Estudes study, 
combining CAST, SDS and the abuse subscale of the DSM-IV.
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be encountered by the researchers, practitioners and respondents. This section does 
not focus on cannabis use or particular screening tests. Instead, it deals with three 
questions which should precede screening: ‘what is problematic use of drugs?’, ‘how 
is problematic use best screened?’ and ‘will the screening process give us relevant and 
reliable information?’.
Concepts
The concepts of drug use disorders have a history. Until the middle of the 20th century 
the clinical study of drug addiction was characterised by many different theoretical 
approaches. Theory shifted to practical definition within a number of international 
standardised grids describing the disorders associated with drug use. Since this period, 
criteria have been modified alongside evolution in research and in interpretations of 
dependence. The term ‘dependence’ was borrowed from psychopharmacology, where 
it referred to tolerance and withdrawal, and was used more generally to replace the 
term addiction by a WHO Expert Committee in 1964. Edwards et al. (1981) introduced 
cognitive and behavioural signs and symptoms to the concept, and dependence became 
both behavioural and physical. Thanks to Goodman (1990), behavioural criteria gained 
more importance and the concept of dependence could be used to describe addictions 
without a drug, for example addiction to gambling. Dependence might also include a 
physical dependence characterised by pharmacological criteria (Kaminer, 1994; Bailly, 
1997, 1998).
Today, the most widely accepted definitions of use disorders are harmful use, abuse 
and dependence. These are defined by a list of criteria. Harmful use and dependence 
are defined in the International Classification of Diseases (ICD-10), Section F10–F19 (3), 
of the World Health Organisation, a concept developed from a European perspective, 
whereas the American Psychiatric Association’s Diagnosis and Statistical Manual of 
Mental Disorders (DSM-IV) (4) defines abuse and dependence — a concept developed 
from a US perspective.
Abuse under DSM-IV and harmful use under ICD-10 can be regarded as immediate 
damaging use for the individual, and are parts of a continuum that ranges from 
abstinence to dependence. Abuse may involve legal problems resulting from use, for 
example arrests for substance-related problems, and risky behaviours, such as use 
in physically hazardous situations, which are not included in the definition of harmful 
use. Yet, despite their differences, both take into account problems linked to the wider 
environment of the user, such as reproaches from the family circle or personal or social 
 (3) www.who.int/classifications/apps/icd/icd10online
 (4) www.dsmivtr.org. DSM-IV is currently in the process of being updated to a new manual, DSM-V.
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difficulties associated with use. Still, neither definition allows us to classify cases in terms 
of staggered stages of increasing gravity, and concepts of dependence stricto sensu 
require further definition.
Two other components make up the definition of dependence according to DSM-IV: 
physiological and psychological dependence. Physiological dependence comprises 
tolerance and withdrawal. Tolerance is defined by the need for increased amounts of 
the substance to achieve the original effects of the substance, or a markedly diminished 
effect with continued use of the same amount of the substance (criterion 1). The 
withdrawal symptom (used in criterion 2) is described as a maladaptive behavioural 
change that occurs when the substance concentration declines in an individual who 
has maintained prolonged heavy use of the substance (APA, 1994). Psychological 
dependence includes compulsive use (criteria 3, 4, 7), intensity of use (criterion 5) and 
consequences of use (criterion 6). These concepts may be found in most of the existing 
drug screening tests, whether specific to cannabis or not.
In Europe, some definitions of substance use problems are not based on ICD-10 
or DSM-IV concepts, but are purely pragmatic. One is the EMCDDA’s definition of 
problematic drug use as injection or regular use of opiates, cocaine, crack and/or 
amphetamines. The EMCDDA uses its definition of problematic use as one of its key 
indicators, and the definition is helpful in establishing a link with its key indicators on 
drug-related infectious diseases and drug-related deaths and mortality.
Work is still ongoing in Europe in defining problematic use of cannabis. One approach 
used in general population surveys is to assess problematic use by measuring ‘intensive 
use’, which can be defined through indicators of intensity or frequency of use (Simon, 
2004). This notion is based on the idea that the use is problematic above a certain 
excess threshold. This makes sense, but its definition is arbitrary and not based on 
medical criteria. Furthermore, many studies have shown that a statistical link between 
problems and use appears even at very low levels of use (Ramström, 2003), although 
this link must be cautiously interpreted as it varies with other variables such as gender, 
age, socio-economic context and the illegal status of the drug. Nonetheless, intensive 
use is useful in identifying those who are more at risk of developing problems linked to 
cannabis use.
Such criteria of problematic drug use play a practical role in diagnosis, alerting 
practitioners to problem patterns and enabling immediate diagnosis of harms. 
Nonetheless, difficulties remain in shifting from abstraction to action, i.e. to develop 
practical screening instruments for cannabis use disorders:
Definitions of substance use disorders do not easily translate into screening tool t
questions.
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Problems related to consumption are not purely somatic, but embrace other aspects t
of the user’s environment — associated risks, medical, educational, social and legal 
problems.
A survey given at a specific time may not be able to gauge the risk of a user, for t
example mid- or long-term problems that have not yet transpired.
From concepts to screening tests
Screening consists of comparing substance disorder criteria — that is, the concept 
defining harmful use — against the actual pattern of use. This process can provide 
a variety of insights on the side of both the practitioner and patient or respondent, 
which are open to diverse interpretation. Thus, it is crucial to design a questionnaire 
that adequately reflects the criteria defining problematic use, and which ensures 
that responses are accurate, valid and actionable. There are basic delivery issues 
too: the context of use and population sample (adults, children, at school, at clinics, 
etc.) determines how questions are worded, how many questions are asked, how 
questionnaires can ‘fork’ to provide further details, and so on.
Harmful use criteria can differ from one population to another. Harrison et al. (1998) 
showed, for example, that DSM-IV does not completely fit adolescents. Within DSM-IV, 
criteria applicable to adolescents are often absent for concepts such as withdrawal, 
tolerance or giving up other activities providing pleasure and interest. Thus, it has 
been argued that DSM-IV concepts, when applied without adaptation to adolescents, 
do not deliver the prognostic value they have for adults (Bukstein and Kaminer, 1994). 
According to many researchers, current tools made for the screening of adults only 
deliver a late screening of youth-specific problems. So, it has become common for 
research teams working on adolescents to try to develop their own tools (Inserm, 2001).
Validation and quality measures
Measuring the quality of a screening test is not easy. As stated, a test must be theory 
based and should correctly screen users according to a harmful use concept. This 
concept must be clarified through a reference test, i.e. a ‘dry-run’ test that may or may 
not offer the kind of responses one obtains during actual use of the test. Thus, validation 
of the screening test needs to be iterative, based on comparing actual responses with the 
reference test, and tweaking the screening test accordingly. This process can be split into 
two basic tasks: first, comparing the screening test with the reference test; and, second, 
assessing the quality of the screening test (and its reference test) in a clinical situation 
in which a practitioner’s diagnosis can be compared with the result of the test. While it 
is not our aim to summarise best practices in survey validity here, validity can be tested 
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in a number of ways: completeness (Have all questions been answered? In the right 
sequence?); respondent base (Has the test been adequately prepared? Have sufficient 
respondents been used to test the practicality of the test? Have respondents answered 
sincerely and have interviewers correctly recorded responses?); and logic (Does the test 
reflect the harmful use concept? Can conclusions be generalised across the respondent 
base? And are other plausible explanations ruled out?). While preparation does not 
guarantee the ideal screening instrument, it is possible to avoid common pitfalls and to 
‘build in’ validation into clinical interviews or in general population surveys.
Existing screening tests for cannabis use disorders
Standardised early screening instruments have been used for tobacco (Fagerström and 
Schneider, 1989) and alcohol (Daeppen, 2004) for a long time. These tools are used as 
an aid in informing a diagnosis in a clinical situation, and also as an epidemiological 
tool in general population surveys among adults or adolescents in order to measure the 
levels of the different patterns of use. For alcohol, the most common instruments are the 
Alcohol Use Disorders Identification Test (AUDIT) (Saunders et al., 1993) and the CAGE 
test (Cut down, Annoyed, Guilty, Eye-opener test) (Ewing, 1984).
For other drugs, a large number of tests exist. Most have been developed for use with all 
drugs but can be adapted to a specific drug. For example, the Severity of Dependence 
Scale (SDS), was conceived for heroin and opiates (Gossop et al., 1995), and then 
adapted for cocaine and amphetamines, and recently for cannabis (Swift et al., 1998; 
Kraus et al., 2005). A literature review on screening tests and on their validation, 
describing the great diversity of what is available, has been conducted in France (Beck 
and Legleye, 2007a).
For cannabis, available screening tests are relatively recent and rarely used in general 
population surveys. In the 1990s, assessment instruments such as the Composite 
International Diagnostic Interview (CIDI) and the Schedules for Clinical Assessment in 
Neuropsychiatry (SCAN) have been used in several general population surveys, but 
their ability to measure cannabis dependence and cannabis abuse remains a matter for 
discussion (Compton et al., 1996). One difficulty is that contexts and motivation for use 
vary greatly among heavy cannabis users. Heavy use can develop both through solitary 
use, for example to manage stress or enable sleep, and in social settings, for example at 
recreational events or among peers. The same respondent can report both recreational 
use and harmful effects due to use.
A good example of adaptation of the concept of dependence into a set of questions 
can be found in aggregated data from three waves (1991 to 1993) of the US National 
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Household Survey on Drug Abuse (NHSDA) (5), with 87 915 respondents aged 12 
and over (Kandel et al., 1997). For this survey, a measure of cannabis dependence 
was developed, inspired by DSM IV (see Appendix A). The test asked questions about 
tolerance, withdrawal, loss of control, how much time spent on using cannabis, negative 
consequences for daily life, and continued use despite knowing that cannabis causes 
significant problems.
Among adolescents, problems associated with physical cannabis dependence appear 
to be rare (Beck et al., 2004), although they are reported in some studies (Dennis et 
al., 2002; Martin et al., 2005). Adolescents reporting problems seem to suffer more 
from psychological dependence, exacerbated by the fact that cannabis is almost always 
mixed with tobacco. Adolescents also appear more likely to experience risky situations, 
concentration and motivation difficulties or problems in their relationships with their 
family and friends (Obradovic, 2006). However, many of these factors might derive from 
the fact that cannabis is an illegal substance.
As dependence is considered to be the last and most harmful stage of use, screening in 
general population surveys rarely aims to detect dependence and its symptoms, although 
there are some exceptions (e.g. the OPCS Surveys of Psychiatric Morbidity in the 1980s 
and 1990s in the United Kingdom; the ESA survey in Germany; the Australian National 
Drug Strategy Household Survey). Some questions related to dependence criteria may 
be included in some tests, for example the screening carried out by the Alcohol Advisory 
Council of New Zealand (ALAC, see Appendix A). However, other tools could be used 
for this purpose, such as SDS or MINI Cannabis, or the instrument developed by Kandel 
et al. (1997), with questions from the NHSDA.
There have been several recent attempts to develop a scale measuring problematic 
cannabis use. These screening instruments intend to measure problems related to 
cannabis use in various areas:
 (i) consumption per se;
 (ii) physical dependence (withdrawal and tolerance);
 (iii) psychological dependence;
 (iv) social harm from use (legal difficulties, harm to relationships, work role harm, etc.); 
and
 (v) health harm due to use (memory loss, physical ailments, casualties, etc.).
Many of these are familiar. DSM-IV and ICD-10 include the second and third of these 
dimensions in their definition of dependence. ICD-10 includes item (v) as harmful 
use. DSM-IV includes criteria from items (iv) and (v) as abuse. Some diagnostic 
 (5) NHSDA is a household survey conducted by the federal government’s Substance Abuse and 
Mental Health Services Administration (SAMHSA).
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instruments also include these criteria, although they sometimes also include other 
harms, for example guilt or deviance from a standard context of use. Some items, like 
the reproaches of relatives, may enter many categories, such as social harm, health 
problems or dependence. Solitary smoking may indicate either dependence or social 
harm.
Screening scales used among adults
Although they seem to underestimate heroin, cocaine or amphetamine use disorders, 
general population surveys can be used to give a relevant estimate of cannabis use 
disorders (Rhem et al., 2005). The 2003 Epidemiological Survey on Substance Abuse 
(ESA) in Germany employed the Severity of Dependence Scale (SDS), as proposed by 
Gossop et al. (1995), to measure cannabis dependence (see Appendix A). This general 
population survey (self-administered questionnaires) was carried out with a sample of 
8 061 adults aged 18–59 years. The SDS was used to identify subjects who showed signs 
of cannabis dependence. A score of three or more points was taken as a cut-off point 
for cannabis-related problems. Overall, 1.1 % of the sample exceeded the threshold of 
three or more points on the SDS and were characterised as cannabis dependent (Kraus 
et al., 2005). The scale consisted of five items, with each scored on a four-point scale 
(0–3). The greater the score, the higher the degree of psychological dependence. The 
total score is obtained through the addition of the five-item ratings. The scale explores 
strictly psychological dependence and no other areas of harm.
A team from New Zealand used the Cannabis Use Disorders Identification Test 
(CUDIT, see Appendix) screening instrument (Adamson and Sellman, 2003), derived 
by modifying the AUDIT test for alcohol (Saunders et al., 1993). This 11-question scale 
aims to screen for cannabis abuse or dependence. It was used in a clinical sample 
of alcohol-dependent adults who reported some cannabis use over the preceding six 
months (n = 53). The scale was compared with the self-reported frequency of cannabis 
use in the preceding six months. The scale explores the nature of consumption per 
se, including intensity of use and compulsive use, physical dependence, psychological 
dependence, social harm from use, health harm due to use, and also guilt and 
reproaches or blame from relatives. Several queried items could be classified as linked 
to more than one harm, for example cannabis consumption in the morning.
According to the authors, on the basis of the Diagnostic Interview for Genetic Studies 
(DIGS) providing a DSM-IV diagnosis (Nurnberger et al., 1994), the CUDIT test was 
better than a frequency measure (at least 80 days using cannabis), achieved positive 
predictive power of 84.6 % and sensitivity of 73.3 % at a cut-off of 8, compared with 
positive predictive power of 81.8 % and sensitivity of 60.0 % for the frequency measure. 
Such results indicate the viability of the CUDIT measure for identifying cannabis use 
Chapter 2
39
disorder in risk populations, and its use for the general population should be assessed. 
However, one general problem of this scale is that the reference period (6 months) 
would need to be adapted to European standards (last month, or last year use), defined 
by EMCDDA.
On several French prevention websites, a cannabis-specific adaptation of the CAGE 
(Cut down, Annoyed, Guilty, Eye-opener) alcohol screening test has been tried to enable 
self-evaluation of problematic cannabis use. CAGE explores four areas of harms: 
psychological dependence, social harm, guilt and physical dependence. Two positive 
answers out of a possible four is interpreted as indicating problematic cannabis use 
(Midanik et al., 1998). The test has never been validated in its cannabis version. It 
should, however, be noted that the alcohol version has been criticised by Bisson et al. 
(1999). Moreover, CAGE is not recommended as a brief alcohol screening test among 
adolescents, as it appears to perform less well than AUDIT or CRAFFT (Knight et al., 
2003).
Some surveys focus only on one or two areas of harm; for example, a survey carried out 
in Ontario (Ferris et al., 1994) explored only health and social harm (see Appendix A). 
Alternative scales are sometimes created for self-assessment of cannabis use and its 
impact, such as the one developed by the Jellinek clinic in Amsterdam (Kerssemakers, 
2000) (6). The Know cannabis test has 16 questions, and can be filled out on a website. 
The result is accompanied by recommendations for the cannabis user. The scale 
explores multiple consequences of cannabis consumption per se, including spending 
money and compulsive use, polydrug use, motivations for use, dependence, social harm, 
guilt, health consequences and reproaches and blame from relatives. Again, some items 
may explore more than one area of harm.
Screening scales used in the youth population
Several recent studies have explored the feasibility of measuring adolescent cannabis 
use disorders in the general population. In Poland, a study in progress aims to assess 
the accuracy of a test focused on problematic herbal cannabis use in an adolescent 
population (Okulicz-Kozaryn and Sieroslawski, 2005). In France, Chabrol et al. (2000) 
conducted a study on abuse and dependence, according to the DSM-IV criteria, in 
a school survey. They used the MINI cannabis screening test, derived from the Mini 
Neuropsychiatry International Interview (Lecrubier et al., 1997; Sheehan et al., 1997; 
see Appendix A). The MINI tests for cannabis dependence as well as for cannabis abuse.
 (6) The Jellinek test can be taken at www.knowcannabis.org.uk and www.jellinek.nl/zelfhulp/
cannabis
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In France, the Cannabis Abuse Screening Test (CAST) (see Appendix) was constructed to 
be used in general population surveys. It was used in a sample of 20 000 adolescents 
in the ESCAPAD survey (Beck and Legleye, 2003). CAST explores consumption per se, 
deviance from a common standard of use, health and social harm, and reproaches from 
relatives and dependence. It aims to determine two kinds of populations: adolescents 
with no problem and adolescents who need a diagnosis on their cannabis use (Karila 
et al., 2004). Clinical validation of CAST is in progress in a partnership between the 
French monitoring centre for drug and drug addiction (OFDT) and two specialised 
centres for cannabis use prevention and treatment.
CAST is used both in general population surveys and in cannabis consultation to screen 
problematic cannabis users and to refer them to the appropriate service. Thresholds 
enable practitioners to normalise the interview with the person in consultation and 
to gauge whether the cannabis use pattern is potentially problematic. Two positive 
answers highlight the need for the person to be careful about use. Three or more 
positive answers indicates that the use may be problematic and the person should be 
offered a specialised consultation to obtain help to diminish or stop use, thereby alerting 
clinicians that a deeper assessment is warranted. Other tests are also in the process of 
clinical validation in this study, such as the French versions of the CRAFFT and of the 
ALAC tests used as self-administered evaluation instruments. The ALAC questionnaire 
(see Appendix A) for the self-evaluation of cannabis use is recommended by the Alcohol 
Advisory Council of New Zealand (1996). Two positive answers indicate a moderate 
risk of abuse, and three positive answers indicate a strong risk of abuse. The ALAC 
questionnaire has not yet been validated, but it aims to assess the harms of reproaches, 
health problems, dependence and social problems. It appears to be problematic 
compared with the other tests, as several of the questions do not mention drugs at all.
Longer screening tests
Other scales, which query a greater number of harms, have been used among specific 
populations. For example, the Cannabis Problems Questionnaire (CPQ) was very 
recently modelled (Copeland et al., 2005; Martin et al., 2006) on the 46 items of the 
Alcohol Problems Questionnaire (APQ; Williams and Drummond, 1994). The study was 
conducted among 72 adolescents smoking at least 15 days per month. It left the final 
CPQ as a 22-binary-item scale, which seems to be an efficient and reliable measure of 
cannabis-related problems for use with populations of current cannabis users, offering 
more than 80 % sensitivity and specificity, according to DSM IV criteria.
Heishman et al. (2001) have developed and validated the Marijuana Craving 
Questionnaire (MCQ), a 47-item multidimensional questionnaire on marijuana craving, 
based on the model of the Questionnaire on Smoking Urges (Tiffany and Drobes, 
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1991) and the Cocaine Craving Questionnaire (Tiffany et al., 1993). In their study, 
current marijuana smokers (n = 217) not seeking treatment completed forms assessing 
demographics, drug use history, marijuana quit attempts and current mood. The 
findings suggested that four specific constructs characterise craving for marijuana: 
compulsivity — an inability to control marijuana use; emotionality — use of marijuana 
in anticipation of relief from withdrawal or negative mood; expectancy — anticipation 
of positive outcomes from smoking marijuana; and purposefulness — intention and 
planning to use marijuana for positive outcomes. Heishman et al. (2001) found that the 
MCQ is a valid and reliable instrument for assessing marijuana craving in individuals 
not seeking drug abuse treatment, and that marijuana craving can be measured in the 
absence of withdrawal symptoms.
The Marijuana Effect Expectancy Questionnaire (MEEQ) assesses motivation to use 
marijuana (Schafer and Brown, 1991). It has 70 yes/no format items with agree/
disagree instructions similar to those of the Alcohol Expectancy Questionnaire (AEQ). 
Subjects are asked to respond according to their own beliefs and whether they have 
actually used marijuana. Although MEEQ is not designed for general clinical screening, 
it contains items with potential for screening. It has been tested in a psychometric 
evaluation on 279 adolescents from a clinical and community sample (Aarons et al., 
2001) and on 149 males from a clinical sample (Galen and Henderson, 1999).
The Marijuana Screening Inventory (MSI-X) is a 39-binary-item scale. Thirty-one of the 
items are used to calculate a simple score to classify into one of the four following 
categories: no problem; normal or experimental marijuana use; potentially problematic 
marijuana use; and problematic marijuana use. The study was conducted on a sample 
of 420 military reservists (a convenience sample). The MSI-X was found to be promising, 
especially for rapid diagnosis assessment, but a clinical validation is yet to be conducted 
(Dale, 2003).
These instruments seem, at a first glance, to be too long to apply as part of a general 
population survey. The application of such instruments requires more time than available 
in most cases in population surveys, and sometimes skilled interviewers, too. They have 
only been tested in clinical populations, which might not be sufficient to assess their 
applicability in the general population.
Discussion
This chapter presents the main tools aiming to screen different kinds of cannabis use 
and problems resulting from it. It is not an exhaustive presentation of the published 
literature, yet it provides concise discussion of the concepts and tests developed so far.
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There is evidence that cannabis use sometimes leads to problems, and these problems 
are now a major concern in the field of public health. As a consequence, many surveys 
try to evaluate the proportion of cannabis users who suffer problems resulting from 
cannabis use or the proportion of dependent users. The largest recent surveys were 
conducted in the USA and Australia. Estimations vary and depend on the instruments 
used. In Australia, the National Survey of Mental Health and Well-being conducted 
a study in 1997 among a representative sample of 10 600 people of the Australian 
population aged 18 and over, and used DSM-IV and ICD-10 diagnoses. Swift et al. 
(2001) found that 1.5 % (DSM-IV) or 1.7 % (ICD-10) of this population was cannabis 
dependent, with marked differences in symptom prevalence. The proportions among 
cannabis users during the last 12 months were 21 % (DSM-IV) and 22 % for ICD-10. In 
the USA, according to a recent NHSDA survey (SAMHSA, 2002), 2 % of people aged 
12 and over fulfilled DSM-IV criteria for cannabis dependence or abuse during the last 
12 months. The proportion among those aged 18–25 years was 6 %. According to this 
survey, 17 % of last year cannabis users fulfilled criteria for cannabis dependence or 
abuse.
The concepts and definitions used in the DSM and in the ICD are controversial, and not 
all studies support the idea that cannabis smokers develop dependence as well as abuse 
(see also Witton, this monograph, Vol. 2). In a study by Hollister (1986), for instance, 
cannabis was given to subjects for a certain period of time in order to study the effects 
of interruption of the supply. The first attempts failed, but this may be due to amounts of 
cannabis, which were too small, and a period of supply, which was too short, for ethical 
reasons. Many authors do, however, confirm that dependence can occur with long-term 
use: patients who receive significant doses over a long period of time develop symptoms 
such as occasional perspiration, slight nausea, anxiety and sleeplessness (Compton et 
al., 1990; Jones, 1996; Crowley et al., 1998; Haney et al., 1999a,b; Vandrey et al., 
2005). Despite this general agreement, Jones (1996) emphasises that frequency of 
dosing and dose interval are more important than daily dose for producing a cannabis 
withdrawal syndrome. Typical patterns of cannabis use appear to be non-optimal 
conditions to get an obvious withdrawal syndrome, though less obvious symptoms may 
be relevant when treating cannabis-dependent patients. Smith (2002) points out that 
these symptoms are not specific for cannabis (they can be observed with tobacco) and 
vary with the psychological profile of the individual. Coffey et al. (2002), argue that 
tolerance might be useless in clinical assessment of cannabis dependence.
The list of criteria used for psychological dependence for all drugs in the DSM-IV 
definition of dependence appears non-exhaustive. In addition, some of these criteria 
have been criticised for not seeming relevant for certain researchers (Soellner, 2002). 
For example, criterion 7, dealing with the continuation of use despite the recognition of 
its contributing role to some psychic or physical problems, ignores the eventuality that 
the user might have no intention of stopping use and, on the contrary, might rationally 
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choose to continue to use it because it provides greater benefits. This possibility has not 
been investigated. Indeed, the challenge of adapting a generic mental health standard, 
such as DSM-IV, to use of a specific drug is illustrated in the discrepancy between DSM-
IV’s definition of dependence for all drugs and the criteria it proposes for cannabis.
Problems with conceptualising harmful use and thresholds are compounded by the 
difficulties of developing the screening tools themselves. Measures such as MINI use 
items from the ‘problem domain’ and refer to them as criteria of dependence. It also 
seems problematic to define dependence by its consequences, for example criterion 6 
in the DSM-IV. As the definition of dependence is so strictly delimited in DSM, a link 
between dependence and its potential consequences cannot be proven (Soellner, 2002). 
‘Drift’ in the use of items from the problem domain can also be criticised as these items 
do not measure whether users intend to quit. Intention to quit is crucial, as research 
shows that cannabis users argue that they would and could quit if cannabis consumption 
led to suffering (Swift et al., 1998), and cannabis use is not necessarily viewed as a 
problem by dependent users.
Other variables are also problematic. Some of the dependence criteria, such as 
spending a great deal of time around the substance, might be confounded by the 
illegality of the drug (this is a problem for MINI and ICD-10, for instance). In CUDIT and 
CAGE there is a question about feelings of guilt after using cannabis, which could also 
be confounded by the illegality of the drug. Thus, most screening measures combine 
the dimensions of psychological dependence and harm. This is true of CUDIT, MINI 
and CAST, and thus it is not clear what they are screening for: dependence? Or abuse? 
These are concepts that DSM-IV makes a serious attempt to separate, and combining 
the two areas is problematic for an illicit substance: many of the problems have resulted 
from the fact that cannabis is illegal.
In general, analysis of diagnostic tools, such as DSM-III, DSM-IV and ICD, used as 
severity scales for drug dependence shows that diagnostic algorithms greatly influence 
the results (Langenbucher et al., 1995). A comparison between DSM-III R and DSM-IV 
emphasises the influence of the evolution of the diagnostic criteria on the screening 
results (Mikulich et al., 2001). These problems question the very nature of the concepts 
of addiction: what should be measured, why and how?
An examination of concepts used in American and European definitions of the stages of 
drug use disorders reveals some cultural differences. For example, the definition of drug 
abuse, according to the American DSM-IV, contains moral criteria and characteristics, 
either in the concepts themselves or in the wording of the concepts, whereas the 
European definition of harmful use, according to the ICD-10, seems more pragmatic. 
Law transgression or failing in social roles are included in DSM-IV’s definition of abuse, 
in addition to using despite knowledge that damage results from use. Use in hazardous 
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situations, such as driving, may be seen as risky behaviour that increases risk of being 
injured or of causing injury, yet an accident may never occur. In DSM-IV’s definition of 
dependence, criterion 7 presupposes that use itself is bad, even if it brings a benefit and 
contributes to the psychological balance of the user, who might have made a rational 
decision to continue using. In a sense, the user under DSM-IV is presupposed to have a 
social duty and responsibility: he or she must conform to social and legal norms. Users’ 
knowledge of the law and their psychological reaction both contribute to the definition 
of abuse. Such moral rationale seems less present in ICD-10’s definition of harmful use, 
although these concepts should perhaps be examined when defining drug-related harm.
Conclusion
Measuring the proportion of problematic or dependent cannabis users from among the 
wider cannabis user base is complex. It presents far more challenges than measuring 
prevalence by lifetime or last month cannabis use in general population surveys. Faced 
with an increase in cannabis use, policymakers may choose to add some tools to 
general population surveys or the monitoring instruments used by addiction treatment 
centres.
Today, a great number of concepts and tools exist to monitor problematic cannabis 
use, and they vary in terms of both quality and robust scientific validation. Nonetheless, 
these instruments do offer valuable insights into use patterns. Implementing a common 
screening tool, even if not validated, can deliver important information to inform the 
fields of prevention and treatment. Policymakers should be prepared for some criticism 
based on the lack of consensus surrounding dependence and abuse, but screening at 
least delivers a base of knowledge that can be used by specialists in defining public 
policy.
There is clearly a need to develop screening tools that are more reliable in measuring 
adverse effects of cannabis use than those presently in use. Some existing instruments, 
such as CIDI and CAST, go some way to providing a standard, practical tool, and can 
provide a basis for further work. In Europe, screening projects for cannabis are under 
way in Germany, France, the Netherlands, Poland, Portugal, the United Kingdom and, 
most recently, Spain (EMCDDA, 2007). It is hoped that such initiatives will help to 
develop a reliable and comparable indicator of problematic cannabis use in the general 
population.
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A: Measuring cannabis dependence based on DSM IV (Kandel et 
al., 1997) (the numbers refer to DSM items, the following sentences 
to the corresponding question in the NHSDA)
 1 Tolerance: during the past 12 months, for which drugs have you needed larger amounts 
to get the same effect; that is, for which drugs could you no longer get high on the 
same amount you used to?
 2 Withdrawal: for which drugs have you had withdrawal symptoms; that is, you felt sick 
because you stopped or cut down on your use of them during the past 12 months?
 3 Greater use than intended: which drugs have you felt that you needed or were 
dependent on in the past 12 months?
 4 Unsuccessful efforts to cut down or control: during the past 12 months, for which drugs 
have you consciously tried to cut down on your use? During the past 12 months, for 
which drugs have you been unable to cut down on your use, even though you tried?
 5 Great deal of time spent in using: have you used three joints or more nearly daily (three 
times or more a week) in the past 30 days; or 2 oz or more (86 joints or more or 43 g 
or more) in the past 30 days; or traded service for cannabis?
 6 Reduction in social, occupational or recreational activities: as a result of drug use, at 
any time in your life, did you, in the past 12 months, get less work done than usual 
at school or on the job?
 7 Continued using cannabis despite knowing it caused significant problems: as a result of 
drug use at any time in your life, did you in the past 12 months … (become depressed; 
have arguments/fights with family and friends; feel completely alone and isolated; 
A DSM-IV dependence adapted in National Household Survey on 
Drug Abuse
Kandel et al. (1997)
B SDS (Severity Dependence Scale) Gossop et al. (1995)
C CUDIT (Cannabis Use Disorders Identification Test) Adamson and Sellman (2003)
D CAGE-cannabis Midanik et al. (1998)
E Ontario alcohol and other drug opinion survey Ferris et al. (1994)
F Know cannabis test Kerssemakers (2000)
G MINI-cannabis Lecrubier et al. (1997), 
Sheehan et al. (1997)
H CAST (Cannabis Abuse Screening Test) Beck and Legleye (2003)
I ALAC (Alcohol Advisory Council of New Zealand) ALAC (1996)
J CPQ (Cannabis Problem Questionnaire) Copeland et al. (2005)
K MCQ (Marijuana Craving Questionnaire) Heishman et al. (2001)
L MEEQ (Marijuana Effect Expectancy Questionnaire) Schafer and Brown (1991)
M MSI-X (Marijuana Screening Inventory) Dale (2003)
Appendix A: List of tests and references
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feel very nervous and anxious; find it difficult to think clearly; have health problems; 
feel irritable and upset; feel suspicious and distrustful of people; find it harder to 
handle your problems; have to get emergency medical help; have someone suggest 
you seek treatment)?.
B: SDS (Gossop et al., 1995)
In the past year:
 A Did you think your use of cannabis was out of control?
 B Did the prospect of missing cannabis or not chasing make you anxious or worried?
 C Did you worry about your use of cannabis?
 D Did you wish you could stop?
 E How difficult did you find it to stop, or go without cannabis?
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1 How often do you use cannabis? Never Monthly
or less
2–4 
times a 
month
2–3 
times a 
week
4 times a 
week or 
more
0 1 2 3 4
2 How many hours were you ‘stoned’ on 
a typical day when you had been using 
cannabis?
1 or 2 3 or 4 5 or 6 7 to 9 10 or more
0 1 2 3 4
3 How often were you ‘stoned’ for six or 
more occasions?
Never Less than
monthly
Monthly Weekly Daily or 
almost daily
0 1 2 3 4
4 How often during the past six months did 
you find that you were not able to stop 
using cannabis once you had started?
0 1 2 3 4
5 How often during the past six months did 
you fail to do what was normally expected 
from you because of using cannabis?
0 1 2 3 4
6 How often during the past six months 
have you needed to use cannabis in the 
morning to get yourself going after a 
heavy session of using cannabis?
0 1 2 3 4
7 How often during the past six months did 
you have a feeling of guilt or remorse 
after using cannabis?
0 1 2 3 4
8 How often in the past six months have 
you had a problem with your memory or 
concentration after using cannabis?
0 1 2 3 4
9 Have you or someone else been injured as 
a result of your use of cannabis over the 
past six months?
No Yes
0 4
10 Has a relative, friend or doctor, or other 
health worker been concerned about your 
use of cannabis or suggested that you 
should cut down over the past six months?
No Yes
0 4
C: The Cannabis Use Disorders Identification Test (CUDIT) 
(Adamson and Sellman, 2003)
 A Have you used any cannabis over the past 6 months?  Yes No
If yes:
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D: CAGE (Cut down, Annoyed, Guilty, Eye-opener) questionnaire 
for cannabis smoking (Midanik et al., 1998)
 1 Have you ever tried to, or felt the need to, Cut down on your smoking?
 2 Do you ever get Annoyed when people tell you to quit smoking?
 3 Do you ever feel Guilty about smoking?
 4 Do you ever smoke within half an hour of waking up (Eye-opener)?
E: Ontario alcohol and other drug opinion survey
Was there ever (and in the last 12 months) a time that you felt your use of marijuana 
had a harmful effect on your:
 A friendship or social life?
 B physical health?
 C home life or marriage?
 D work, studies or employment opportunities?
 E financial position?
F: Know cannabis test
Source: Kerssemakers (2000). Also available at www.knowcannabis.org.uk/ and www.
jellinek.nl/zelfhulp/cannabis/
 1 How often do you smoke cannabis?
 1 a few times a year (0)
 2 once or twice a month (0)
 3 once or twice a week (1)
 4 almost every day (2)
 2 How much money do you spend on cannabis in an average week? (Base your answer 
on what you pay, or should have to pay, as a consumer.)
 1 3 euros or less (0)
 2 3 to 9 euros (1)
 3 10 to 25 euros (2)
 4 more than 25 euros (2)
 3 How often are you stoned?
 1 more than half of the day (2)
 2 a few hours every day (2)
 3 a few times a week (1)
 4 a few times a month (0)
 5 once a month or less (0)
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 4 When you smoke cannabis, how often do you light up a second joint or pipe to get extra 
stoned?
 1 never (0)
 2 sometimes (0)
 3 regularly (1)
 4 almost always (2)
 5 Do you ever smoke cannabis in combination with other drugs or alcohol?
 1 yes, often (2)
 2 yes, sometimes (1)
 3 no, never (0)
 6 When do you usually smoke cannabis? (More than one answer possible.)
 1 morning (1)
 2 afternoon (1)
 3 evening (1)
 4 night (1)
 7 What are (three of) the most important reasons why you use marijuana and/or hash?
 1 it’s more fun than drinking alcohol (0)
 2 to relieve boredom (1)
 3 to feel good (0)
 4 I’m just accustomed to taking it/it’s part of the game (1)
 5 it’s nice to smoke with friends (0)
 6 to relieve feelings of depression (1)
 7 to help me relax, like before going to sleep (0)
 8 to perform or concentrate better (1)
 9 I forget my problems for a while (2)
 10 to change the effects of other substances (drugs or alcohol) (1)
 11 I don’t know (0)
 8 When you smoke cannabis, what people do you usually smoke with?
 1 always with friends (0)
 2 usually with friends, but sometimes alone (0)
 3 usually alone, and sometimes with friends (1)
 4 always alone (2)
 9 Could you stop smoking marijuana or hash whenever you want?
 1 no, I couldn’t (2)
 2 maybe, but it would take me a lot of trouble (1)
 3 probably, but not without some trouble (0)
 4 sure, I would have no trouble at all (0)
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 10 How often have you thought to yourself in the past year, ‘I should cut down or 
stop’?
 1 never (0)
 2 a few times (0)
 3 once a month (1)
 4 once a week (2)
 5 almost every day (2)
 11 In the past year, how often has your use of cannabis affected your performance in 
your work or studies?
 1 never (0)
 2 a few times (0)
 3 once a month (1)
 4 once a week (2)
 5 almost every day (2)
 12 Do you sometimes put things off or procrastinate because you are stoned?
 1 no, never (0)
 2 yes, sometimes (0)
 3 yes, regularly (1)
 4 yes, almost always (2)
 13 Have you ever felt extremely frustrated because you couldn’t smoke cannabis when 
you wanted to?
 1 no, never (0)
 2 yes, sometimes (0)
 3 yes, quite often (1)
 4 yes, almost always (2)
 14 How often in the past year have you felt worried about your use of cannabis?
 1 never (0)
 2 a few times during the year (0)
 3 a few times a month (1)
 4 a few times a week (2)
 5 every day (2)
 15 Do you ever have trouble remembering what you said or did?
 1 no, never (0)
 2 yes, sometimes (0)
 3 yes, quite often (1)
 4 yes, almost all the time (2)
Chapter 2
51
 16 Has a friend or acquaintance of yours who also smokes cannabis ever told you that 
you really need to cut down on marijuana or hash?
 1 yes, sometimes (0)
 2 yes, regularly (1)
 3 no (0)
 4 no, because they don’t know I smoke it (2)
Score ranges:
0–5: No added risk, although taking drugs always carries risks.
6–15: Definite risk. You’re taking too many chances. Try to reduce the risks of your 
drug use.
16–36:  Serious risk. Your drug use is getting out of hand.
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G: MINI cannabis (Sheehan et al., 1997)
Considering your use of cannabis in the past 12 months:
A Have you found that you needed to use more cannabis to get the same 
effect that you did when you first started taking it?
Yes No
B When you reduced or stopped using cannabis, did you have withdrawal 
symptoms (aches, shaking, fever, weakness, diarrhoea, nausea, sweating, 
heart pounding, difficulty sleeping, or feeling agitated, anxious, irritable, 
or depressed)? Did you use any drug(s) to keep yourself from getting sick 
(withdrawal symptoms) or so that you would feel better?
Yes No
C Have you often found that when you used cannabis you ended up taking 
more than you thought you would?
Yes No
D Have you tried to reduce or stop taking cannabis but failed? Yes No
E On the days that you used cannabis, did you spend substantial time (> 2 
hours), obtaining, using or in recovering from the drug, or thinking about 
the drug?
Yes No
F Did you spend less time working, enjoying hobbies, or being with family or 
friends because of your cannabis use?
Yes No
G Have you continued to use cannabis, even though it caused you health or 
mental problems? Yes No
Considering your use of cannabis in the past 12 months:
H Have you been intoxicated, high, or hungover from cannabis more than 
once, when you had other responsibilities at school, at work, or at home? 
Did this cause any problem?
Yes No
I Have you been high or intoxicated from cannabis more than once in any 
situation where you were physically at risk (for example, driving a car, 
riding a motorbike, using machinery, boating, etc.)?
Yes No
J Did you have legal problems more than once because of your drug use, 
for example, an arrest or disorderly conduct?
Yes No
K Did you continue to use cannabis, even though it caused problems with 
your family or other people?
Yes No
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H: Cannabis abuse screening test (CAST) (Beck and Legleye, 2003)
During the last 12 months:
No Yes
1 Have you ever smoked cannabis before midday? 0 1
2 Have you ever smoked cannabis when you were alone? 0 1
3 Have you ever had memory problems when you smoke cannabis? 0 1
4 Have friends or members of your family ever told you that you ought 
to reduce your cannabis use?
0 1
5 Have you ever tried to reduce or stop your cannabis use without 
succeeding?
0 1
6 Have you ever had problems because of your use of cannabis 
(argument, fight, accident, bad result at school, etc.)? Which: 
………………………………………………………
0 1
I: ALAC (ALAC, 1996)
1 Have people close to you complained about your cannabis use? 1  Yes 2  No
2 Do you have problems with short-term memory? 1  Yes 2  No
3 Have you experienced ‘paranoid’ episodes following cannabis use? 1  Yes 2  No
4 Do you consider it difficult to go through a day without a ‘joint’? 1  Yes 2  No
5 Do you lack the energy to get things done in the way you used to? 1  Yes 2  No
6 Do you ever worry about the effects of your cannabis use? 1  Yes 2  No
7 Do you have more difficulty in understanding new information? 
(difficulty in studying)
1  Yes 2  No
8 Have you ever unsuccessfully attempted to cut down or stop your 
cannabis use?
1  Yes 2  No
9 Do you like to get ‘stoned’ in the morning? 1  Yes 2  No
10 Are you spending more and more time ‘stoned’? 1  Yes 2  No
11 Do you experience cravings, headaches, irritability or difficulty in 
concentration when you cut down or cease cannabis use?
1  Yes 2  No
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Setting the context
Cannabis is the most used illicit drug among adolescents in Europe. The European 
School Survey Project on Alcohol and Other Drugs (ESPAD) is the key transnational 
instrument for comparing adolescent cannabis consumption in Europe. This chapter 
provides a summary of recent ESPAD findings on cannabis.
Use of alcohol, illegal drugs and other substances among young people is of great 
concern in all countries. Acute consequences can be harmful for the individual and 
negatively affect the development and future well-being of an adolescent. Another 
concern is that the heavier the use in adolescence, the larger the risk an individual may 
encounter substance-related problems in the future (1).
The literature is plentiful on suggested associations between early-onset drug 
consumption and wider psychosocial problems, both in late adolescence and in later 
adulthood (2). However, cannabis is usually placed in a wider psychosocial context of risk 
factors, and direct causal links are not attributed to the drug. Still, studies among youth 
detention centres and school drop-outs, for example, highlight associations between 
delinquent behaviour and high prevalence of intensive drug or alcohol consumption (3). 
 (1) For a wider discussion of risk factors and cannabis use, see Coggans, this monograph.
 (2) A review of psychosocial correlates with ESPAD data (Bulgaria, Croatia, Greece, Romania, 
Slovenia and United Kingdom) was recently carried out (Kokkevi et al., 2007).
 (3) A study in Spain by the Centro de Estudios sobre Promoción de la Salud (CEPS, 2004) of a sample 
of youths at protection and reform centres found approximately one-third reported weekly 
cannabis use. Two Dutch studies (Korf et al., 2005; Vreugdenhil, 2003) also reported high 
prevalence of cannabis use among youths in detention centres (see Dutch National Focal Point, 
Netherlands National report, 2006).
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Moving from deviant patterns to normative behaviour, studies have suggested 
correlations between cannabis use and impaired educational performance, and (less 
strongly) occupational performance, interpersonal relationships, mental health issues 
and suicide (4).
There is also a strong economic argument for building strong epidemiological data 
to inform cannabis prevention activities (5). With school drug prevention budgets in 
the larger Member States running to tens of millions of euros, it is not surprising that 
debate in the area is lively. Points of contention include: the ‘gateway’ or ‘stepping 
stone’ theory (cannabis use as a risk factor for use of ‘harder’ drugs) (6); effects on 
adolescent neurological development (including some genetic predisposition debate); 
means to evaluate the efficacy of programmes (7); polydrug patterns in adolescents, in 
particular correlations to alcohol, tobacco and inhalant misuse; the dangers of episodic 
or ‘binge’ patterns; the role to be played by prevention actors (peers, teachers, family, 
drugs workers, police); and delivery of drug prevention in the context of general health 
programmes (smoking, alcohol, sex education, obesity, healthy lifestyles) (8).
Beyond the enormous volume and varied quality of school prevention and harm 
reduction materials (websites, brochures, films, cartoons, posters), a number of recent 
European publications have sought to distil the research literature into practical 
publications. Resources include practical guidelines for teachers and parents (9), 
screening instruments (10) and grey literature (see Appendix). On the internet, the Drugs 
 (4) A useful synthesis is given by Hall and Pacula (2003); see further reading list. Key studies include: 
Lynskey and Hall (2000); Macleod et al. (2004); the ESTUDES project (Spain, 2004); and Silva 
and de Deus (2005).
 (5) For a wider discussion of prevention in Europe, see Burkhart, this monograph.
 (6) For a concise analysis of the gateway theory, see ‘What is the current evidence for cannabis 
as a gateway drug?’ in the 2006 Australian publication Evidence-based answers to cannabis 
questions: a review of the literature (Copeland et al., 2006). Longer analysis can be found in 
Chapter 10 of Cannabis use and dependence (Hall and Pacula, 2003).
 (7) The EU-Dap study (Austria, Belgium, Germany, Greece, Italy, Spain, Sweden) has reported on 
evaluation mechanisms for school-based drug prevention programs (Faggiano et al., 2005) — 
see www.eudap.net. A strong introduction to the principles of school drug prevention evaluation 
is the Australian government’s Principles for school drug education (2004) and its series of eight 
monographs, Innovation and good practice in drug education (2003).
 (8) A long-running study in the area of general health concerns is the WHO’s Health behaviour in 
school-aged children. See www.hbsc.org/
 (9) Publications include: Unplugged, a teaching manual produced in the context of the EU-Dap 
project (www.eudap.net); in Germany, Schule und Cannabis (BZgA, 2004) and materials for the 
Bekifft in der Schule project (SuchtPräventionsZentrum Hamburg, 2004); in Switzerland, Ecoles 
et cannabis (OFSP, 2004); in France, Repérage précoce de l’usage nocif de Cannabis (INPES, 
2006); in the United Kingdom, School drug policy: a review process (Blueprint, UK Home Office, 
2004) and Advice for teachers on delivering drug education (Drug Education Forum, 2004). A 
Rowntree Foundation study of cannabis supply routes to adolescents is scheduled for 2008 (see 
www.jrf.org.uk/knowledge/wip/record.asp?ID=804400).
 (10) For a discussion of screening instruments, see Beck and Legleye, this monograph.
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Education Forum’s newsblog (11) has evolved into a strong channel for practitioner 
information and debate in the area. Cross-border cooperation training (study visits, staff 
exchange) in school drug programmes is likely to benefit from funding under a current 
European Commission programme on drugs prevention and information (12).
Further reading
Drugs in Focus No. 5: Drug prevention in EU schools (EMCDDA, 2002) — includes a short reading 
list.
Drugs in Focus No. 10: Drug use amongst vulnerable young people (EMCDDA, 2004) — includes a 
short reading list.
EMCDDA website on school-based universal prevention 
www.emcdda.europa.eu/index.cfm?nnodeid=1578
ESPAD website 
www.espad.org/
Hall, W., Pacula, R. (2003), ‘Adolescent psychosocial outcomes’, Chapter 11 in Cannabis Use and 
Dependence: Public Health and Public Policy, Cambridge University Press.
McBride, N. (2005), ‘The evidence base for School Drug Education Interventions’, in Stockwell, T., 
Gruenewald, P. J., Toumbourou, J. W., Loxley, W. (eds), Preventing harmful substance use: the 
evidence base for policy and practice, John Wiley and Sons, Chichester, 101–112.
Soole, D. W., Mazerolle, L., Rombouts, S. (2005), Monograph No. 07: School based drug prevention: 
a systematic review of the effectiveness on illicit drug use, DPMP Monograph Series, Fitzroy: 
Turning Point Alcohol and Drug Centre.
Recent focused publications
Youth detention centres
CEPS (2004), Análisis de la situación de los centros de protección y reforma en el ámbito de la 
prevención, Centro de Estudios de Promoción Social, Madrid.
Korf, D. J., Benschop, A., Rots, G. (2005), ‘Geweld, alcohol en drugs bij jeugdige gedetineerden en 
school drop-outs’, Tijdschrift voor Criminologie 47(3): 239–254.
Vreugdenhil, C., Van den Brink, W., Wouters, L. F., Doreleijers, T. A. (2003), ‘Substance use, 
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Dutch adolescents’, Journal of Nervous and Mental Disease 191(6): 372–378.
Cannabis, schools and educational performance
Faggiano, F., Vigna-Taglianti, F., Versino, E., Zambon, A., Borraccino, A., Lemma, P. (2005), 
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2005, Issue 2.
Lynskey, M., Hall, W. (2000), Educational outcomes and adolescent cannabis use, NSW Department 
of Education and Training, Sydney.
 (11) http://drugeducationforum.blogspot.com/
 (12) Ref. COD 2006/0037 Belgium;  
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:52006PC0230(02):EN:NOT
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Patterns of cannabis use among 
students in Europe
Björn Hibell and Barbro Andersson
Debate on policy and prevention for young people requires accurate data. This is the 
rationale that drives the European School Survey Project on Alcohol and Other Drugs 
(ESPAD) (13). ESPAD collects comparable data on alcohol, tobacco and drug use among 
students aged 15–16 years in European countries. It also monitors trends in alcohol 
and drug habits among students in Europe and compares trends between countries and 
groups of countries.
ESPAD began in the early 1990s. So far, data have been collected three times in 
an increasing number of countries (14). The first survey was done in 1995 with 26 
participating countries, the second in 1999 with 30 countries and the third in 2003 with 
35 countries. More than 100 000 students answered the ESPAD questionnaire in 2003. 
The surveys were carried out on nationally representative samples of school classes (15). 
However, there were three exceptions from this. One is Germany, in which the study was 
limited to 6 out of 18 Bundesländer. In Turkey, data were collected in six large cities, 
and in Russia the survey was carried out only in Moscow. In addition to the 35 countries 
that participated in the 2003 data collection, the report also included data from Spain 
(collected in 2002) and the USA (Hibell et al., 2003).
Awareness of cannabis: a well-known drug
Of all illicit drugs, marijuana and hashish (16) are the best known by students aged 
15–16. This is true for nearly all countries and among boys as well as girls: gender 
differences for cannabis awareness are small. Looking at the averages of all the 35 
ESPAD countries in the 2003 data collection, 92 % of students admitted that they had 
heard of marijuana and hashish. Equally well known are cocaine and heroin (91 % 
each). Next in terms of awareness are ecstasy (83 %) and amphetamines (66 %). In 
some countries nearly all students have heard about marijuana or hashish. This is the 
 (13) The ESPAD website is at www.espad.org
 (14) ‘Country’ here refers to a political entity, but not necessarily a national state. Such subnational 
entities as the Faroe Islands and the Isle of Man are included.
 (15) A full description of survey methodology is available on the ESPAD website at  
www.espad.org/method.asp.
 (16) ‘Marijuana and hashish’ is used together with ‘cannabis’ in this chapter as ‘marijuana and 
hashish’ are the terms used in the ESPAD questionnaire. Elsewhere in the monograph, ‘herbal 
cannabis’ and ‘cannabis resin’ are the preferred terms.
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case among 95 % or more of the students in 11 ESPAD countries. The highest figures 
(98–99 %) are found in the Czech Republic, France and Slovakia. The lowest proportion 
of students who have heard of cannabis products is found in Turkey (six cities), where 
68 % of the students reported that they were aware of cannabis. In all other countries, 
81 % or more of the students reported that they had heard of cannabis.
Availability: the most available illicit drug
To measure the perceived availability of different substances the ESPAD students were 
asked the following question: ‘How difficult do you think it would be for you to get 
each of the following?’. For each of the listed substances the response categories were: 
‘impossible’, ‘very difficult’, ‘fairly difficult’, ‘fairly easy’, ‘very easy’ and ‘don’t know’. 
Besides beer, wine and spirits, the highest proportion of students answering ‘very easy’ 
and ‘fairly easy’ is for inhalants (41 %, in ESPAD 2003).
However, if one looks only at illegal drugs, cannabis is the drug that is perceived 
as most available. On average, this was the case for a little more than one-third of 
the students in the ESPAD countries (35 %). Other substances perceived to be readily 
available are tranquillisers and sedatives (21 %), followed by ecstasy (17 %). The 
perceived availability differs widely between countries; from 7 % in Turkey (six cities) to 
60 % in Ireland. In seven countries a majority of the students answered that marijuana or 
hashish is ‘very easy’ or ‘fairly easy’ to obtain. These include the Czech Republic, Ireland 
and the United Kingdom (58–60 %), as well as Denmark, the Isle of Man, Slovenia and 
Switzerland (51–55 %). Hence, countries with high perceived availability of cannabis 
are spread throughout Europe. However, more of them are found in the north-west, 
including all the countries of the British Isles.
A high perceived availability is also found in the two non-ESPAD countries from which 
some data are available in the ESPAD report. In Spain 67 % of the students reported that 
marijuana or hashish was ‘very easy’ or ‘fairly easy’ to get, and in the USA the figure 
was even slightly higher (74 %). Turkey (six cities) showed particularly low perceived 
availability (at 7 %), and other countries reporting low perceived availability were Cyprus, 
Romania and Ukraine, at 10–13 %.
Supply channels: mainly available in discos and bars
ESPAD students were asked where they thought that they could easily buy marijuana or 
hashish if they wanted it. The proportion of students reporting places of purchase varies 
considerably between countries. In some countries many students do not know where 
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to buy cannabis. The highest figures in this respect are found in Turkey (six cities) and 
Ukraine (80–83 %), followed by Romania and Russia (69–73 %). ‘Disco, bar, etc.’ is 
the option selected by most students. The ESPAD average was 27 % in 2003, followed 
by ‘street, park, etc.’ (23 %) and ‘home of a dealer’ (21 %). In 20 countries the option 
‘discos, bar, etc.’ was recognised as the easiest place to buy cannabis. ‘Streets and 
parks’ was the most popular option in seven countries and ‘home of a dealer’ in six.
When looking at individual countries, the highest figure for ‘discos and bars’ was 
found in the Czech Republic, where 55 % gave this answer. Other countries with high 
figures (40–46 %) include Belgium, Denmark, Germany (six Bundesländer), Austria and 
Slovakia. ‘Streets and parks’ was reported mainly from Italy (45 %), followed by Belgium, 
Ireland, Norway, Slovenia and Switzerland (35–38 %). The highest figures for ‘home 
of a dealer’ were found in France, Italy and the United Kingdom (39–43 %). However, 
the highest single figure is found in the Netherlands, where 60 % of the students 
answered ‘coffee shops’ (17). This category was included only in the Dutch and Belgian 
questionnaires. In Belgium it was mentioned by a far smaller number of students than in 
the Netherlands (29 %).
The availability of drugs in schools is a sensitive issue (18). However, on average, 
‘schools’ was the least reported option for purchasing cannabis. Nonetheless, 16 % 
of ESPAD students reported availability at school. The variation between the countries 
with the smallest and highest figure is large. Among Italian students, as many as 43 % 
reported that cannabis products could easily be bought in schools. Other countries with 
high figures include Belgium, the Czech Republic, France and Ireland, where 30–36 % 
gave this answer. Countries in which only 3 % of the students reported that cannabis was 
easily available in schools include the Faroe Islands, Greenland, Turkey (six cities) and 
the Ukraine. Responses about places where marijuana and hashish can easily be bought 
are similar for both boys and girls. The most striking gender difference in the ESPAD 
averages is that more girls (30 %) than boys (24 %) answered that they can buy cannabis 
products at a disco or a bar. Among the boys there is no difference in the averages for 
the two alternatives ‘disco, bar, etc.’ (24 %) and ‘street, park, etc.’ (25 %).
 (17) ‘Coffee shop’ in this context refers to the category of shops in the Netherlands where cannabis is 
openly available to those aged 18 and above (see Korf, this monograph).
 (18) With regard to legislative approaches to cannabis possession, a number of countries include 
references to cannabis use which places minors at risk. See the ELDD map of European legislation 
on cannabis possession at: http://eldd.emcdda.europa.eu/index.cfm?nnodeid=5769
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Lifetime prevalence: the most widely used illicit drug, yet 
large differences between countries
Cannabis is the most commonly used of all the illicit drugs (19) (Figure 1). In 2003 the 
ESPAD average for lifetime cannabis prevalence was 21 %. However, the proportion of 
students who have tried cannabis varies from 3 to 44 % between countries.
 (19) Far behind cannabis comes ecstasy, which was mentioned on average by 3 % of students. The 
highest prevalence rate for any drug other than cannabis in any single country is 8 %: 8 % of 
Czech students reported use of ecstasy as well as of magic mushrooms.
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Note: Values within brackets refer to all students. Germany and Turkey — limited geographical coverage. 
Spain and USA — limited comparability.
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Students in the Czech Republic reported the highest cannabis use, at 44 %, yet high 
prevalence rates were also reported from Switzerland (40 %), Ireland and the Isle of Man 
(39 % each), France and the United Kingdom (38 % each). Other countries where more 
than a quarter of students have used cannabis include Belgium (32 %), the Netherlands 
and Slovenia (28 % each), Germany (six Bundesländer), Greenland, Italy and Slovakia 
(27 % each). The lowest levels of cannabis use are reported from Romania (3 %), Cyprus, 
Turkey (six cities) (4 % each), Greece (6 %) and Sweden (7 %). Low prevalence rates are 
also found in the Faroe Islands, Norway (9 % each) and Finland (10 %). Data from the 
non-ESPAD countries Spain and the USA reveal that 36 % of students in both countries 
had ever used cannabis (Figure 2).
0–7%
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15–25%
26–35%
36–45%
Data uncertain
or not available
Non-participating
country
'JHVSF Lifetime experience of marijuana or hashish. Percentages among all students, 
2003
Note: Germany and Turkey — limited geographical coverage. Spain and USA — limited comparability.
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Recent use of cannabis (last year and last month 
prevalence) — between 2 and 36 %
In adult populations regular drug use can be measured in different ways. One of these 
is last month prevalence (drug use in the last 30 days). In many cases this indicates not 
only recent use but also more regular consumption. However, for a 15- or 16-year-old 
student, last month prevalence may very well be identical with first use. A better way of 
defining regular use is to ask young people to declare frequency information for last 
year (use in the last 12 months) and last month prevalence. For example, to measure 
whether a student has used cannabis ‘10 times or more during the last 12 months’ and 
‘three times or more during the last 30 days’ (20).
In the current absence of explicit frequency-of-use data, one way to build a picture of 
recent use is to compare the figures for last year prevalence with those for last month 
prevalence.
As mentioned earlier, an average of 21 % of ESPAD students reported ever-in-lifetime 
use of cannabis. By comparison, 16 % of ESPAD students reported last year prevalence 
and 9 % last month prevalence. For other drugs, the highest figure for any other drug 
was 2 % for the last year prevalence for ecstasy and 1 % for last month prevalence of 
amphetamines, ecstasy and magic mushrooms. Thus, there is a broad overlap between 
average ever-in-lifetime use (21 %) and last year prevalence (16 %).
The Czech Republic reported the highest last year prevalence (36 %), while other high-
prevalence countries include the Isle of Man (34 %), France, Ireland, Switzerland and 
the United Kingdom (31 % each). Countries where very few students have used cannabis 
during the last 12 months are to a large extent the same that reported low lifetime 
prevalence rates. Thus, the smallest number of students reporting this behaviour are 
found in Romania (2 %), Cyprus, Turkey (six cities) (3 % each), the Faroe Islands (4 %), 
Greece and Sweden (5 % each). In the non-ESPAD country, Spain, 32 % of the students 
had used cannabis during the last 12 months. The corresponding value for the USA is 
28 %.
Not unexpectedly, the high- and low-prevalence countries with regard to last month 
prevalence are about the same as for last year prevalence. Countries with the highest 
last month prevalence include France (22 %), the Isle of Man (21 %), Switzerland, the 
United Kingdom (20 % each) and the Czech Republic (19 %). Other countries with 
relatively high rates are Belgium, Ireland (17 % each) and Italy (15 %). In some countries, 
however, very few report last month prevalence. The six countries with the lowest figures 
 (20) This information is available in the ESPAD national datasets, but at the time of writing it was not 
available for comparative analysis.
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are the Faroe Islands, Romania, Sweden (1 % each), Cyprus, Greece and Turkey (six 
cities) (2 % each). In Spain and the USA last month prevalence rates are 23 % and 17 % 
respectively.
Gender differences?
There is a clear gender gap in cannabis prevalence (21), with boys generally more likely 
to have tried cannabis, or to have recently used cannabis, than girls.
For lifetime prevalence, with one exception (Ireland), in no country are there more girls 
than boys who have tried cannabis. Boys are in the majority in about two-thirds of the 
ESPAD countries (see Figure 1). However, in some countries there are no strong gender 
differences. Few differences in gender can be seen in the British Isles and among the 
Nordic countries, including the Faroe Islands, Finland, Greenland, Iceland, Ireland, 
the Isle of Man, Norway and Sweden. Greece is also an exceptional southern country, 
reporting near-equal lifetime prevalence for girls and boys. In the Czech Republic, 
Denmark, Estonia, Ireland, Latvia, Poland, Slovakia and Norway the gender gap has 
narrowed in successive surveys. It may also be noted that countries with near-equal 
prevalence between genders relate to both high- and low-prevalence countries.
More boys (19 %) than girls (14 %) on average report last year use of cannabis. 
This pattern applies to the majority of reporting countries, and applies to both 
high-prevalence countries (e.g. Czech Republic, France, the United Kingdom) and 
low-prevalence countries (e.g. Cyprus and Turkey). The largest gender gap in last year 
prevalence is found in the Ukraine, with 18 % for boys and 6 % for girls. Large gender 
divides in last year prevalence are also reported by Belgium (32 % boys, 22 % girls) and 
Slovakia (24 % boys, 14 % girls).
For last month prevalence, on average 11 % of boys and 7 % of girls reported cannabis 
use in the last 30 days. The pattern is reflected in nearly half of the countries. There is 
no real geographical pattern in the gender distribution.
The typical debut drug
Cannabis is the illegal substance most commonly reported as a debut drug among both 
boys and girls. On average, 18 % of all ESPAD students report that cannabis was the 
first illegal substance they have tried, corresponding to about 80 % of all students who 
 (21) Gender issues in drug use were explored in the EMCDDA selected issue, A gender perspective 
on drug use and responding to drug problems (EMCDDA, 2006), available at: http://issues06.
emcdda.europa.eu/en/page013-en.html
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have tried any illicit drug. Cannabis is the leading debut illegal drug in all but three 
ESPAD countries. Second to cannabis, but with much lower figures, are tranquillisers or 
sedatives, reported by 2 % of all students, about 9 % of students who report having tried 
any illicit drug.
Early onset
If one excludes inhalants, which are not defined as an illicit drug, cannabis is the most 
common drug that is used at an early age. Of all ESPAD students, 4 % report that they 
were 13 years or younger when they tried cannabis for the first time (‘early onset’) (22). 
The figures for early onset vary between countries, from 0 % in Romania to 13 % in the 
United Kingdom. Examples of other countries with high early onset figures include the 
Isle of Man (12 %) and Switzerland (11 %). These figures are similar to those reported in 
the USA (10 %). Very small gender differences appear when it comes to early onset. In 
the very few cases where a gender gap exists, figures are slightly higher for boys. The 
largest gender difference is found in Belgium, where 10 % of boys and 5 % of girls report 
trying cannabis at age 13 or younger.
Increased use in many countries
Between the first ESPAD data collection in 1995 and the second in 1999, a majority 
of countries reported an increase in lifetime cannabis prevalence. Many countries also 
showed continuing increases between 1999 and 2003.
Of the ESPAD countries that participated in 1995, 21 provided comparable data 
from the second data collection. Two-thirds of these countries reported higher lifetime 
cannabis prevalence in 1999. These countries were spread geographically across 
Europe and include countries with high lifetime prevalence (e.g. the Czech Republic, 
with 35 % in 1999) and low lifetime prevalence (e.g. Finland, with 10 %, and Hungary, 
with 11 % in 1999). Three countries reported a decline in lifetime cannabis prevalence 
between 1999 and 1995. Two of these were the top countries in both 1995 and 1999: 
the United Kingdom (35 % in 1999) and Ireland (32 % in 1999). The third country was a 
low prevalence country: the Faroe Islands (7 % in 1999).
Six countries reported minor decreases in lifetime prevalence between 1999 and 2003: 
Denmark (23 % = –1 %), Greece (6 % = –3 %), Sweden (7 % = –1 %), Norway (9 % = –3 %), 
Iceland (13 % = –2 %) and Latvia (16 % = –1 %) (Figure 3). In a majority of the countries 
that participated in both surveys (18 out of 28) the figures were about the same in the 
two data collections. However, lifetime prevalence increased in absolute percentage 
 (22) For further discussion of early initiation into cannabis use in Europe, see Kokkevi et al. (2006).
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points by over 4 % in 10 countries: Czech Republic (44 % = +9 %), Ireland (39 % = +7 %), 
France (38 % = +4%), Slovakia (27 % = +8 %), Estonia (23 % = +10 %), Croatia 
(22 % = +8 %), Bulgaria (21 % = +9%), Poland (18 % = +4 %), Portugal (15 % = +6 %), 
Hungary (16 % = + 16 %).
Of the 21 countries that have comparable data from all three data collections, six show 
an increased trend through all three data collections. These are Croatia, Czech Republic, 
Estonia, Hungary, Poland and Slovakia: all Eastern European countries. In 1995 some 
of these countries were among those with lowest prevalence (e.g. Hungary with 4 % 
and Estonia with 7 %). In 2003 one of these was at the top of all participating countries 
(Czech Republic with 44 %), three others are in the upper half and two are around the 
middle (Hungary with 16 % and Poland with 18 %) (23). The number of countries which 
showed an increase in prevalence between 1999 and 2003 are about the same both for 
last year prevalence (nine countries) and for lifetime prevalence (10 countries). However, 
relatively few countries reported an increase in last month prevalence (three countries). 
In nearly all countries the trends over time have been about the same among boys and 
girls.
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 (23) For a more detailed analysis of cannabis in these countries, see Moskalewicz et al., this 
monograph.
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Increased perceived availability in many countries
Perceived availability of cannabis (24) increased strongly compared with other substances 
from 1999 to 2003, from an average of 29–35 %. Changes in perceived availability 
are also very similar for boys and girls. The number of countries in which perceived 
availability increased for other drugs is much smaller, and averages were about the 
same in 2003 as in 1999.
Increases in cannabis perceived availability were reported in nearly half of the countries 
with available information (13 out of 28). These countries were broadly concentrated in 
the eastern parts of Europe (10 out of these 13 countries). Increases were reported in 
countries with low as well as high perceived availability; for example, Romania (11 %) 
and the Czech Republic (58 %). Only three countries — Denmark (52 %), Greece (20 %) 
and Norway (26 %) — reported lower perceived availability of cannabis in 2003 than in 
1999.
In seven countries perceived availability of cannabis increased in all three data 
collections from 1995 to 2003 (Croatia, the Czech Republic, Estonia, Lithuania, Poland, 
Slovakia and Slovenia). All are Eastern European countries, and five of them are among 
the six countries in which the lifetime prevalence increased in 1995, 1999 and 2003 
(Croatia, the Czech Republic, Estonia, Poland, Slovakia).
Consumption and perceived availability — strongly 
correlated
ESPAD uses, to some extent, the same questions that are used in the Monitoring the 
Future (25) studies in the USA, where they have a long series for grade 12 students 
(17–18 years old), dating back to the 1970s (Johnston et al., 2005). In the USA, it is 
evident that there have been changes in cannabis use over time. However, during the 
whole period the perceived availability seems to have remained relatively stable among 
12th graders.
Information about students in grade 10 (15–16 years old), i.e. students of about the 
same age as the ESPAD target group, is available in the US studies only from 1991. The 
use of marijuana increased in this group between 1991 and 1997, then levelled off, 
before decreasing from 2001 onwards. For the whole period the availability trend has 
followed the use trend very closely.
 (24) Defined as the share of students reporting that marijuana or hashish were ‘very easy’ or ‘fairly 
easy’ to obtain.
 (25) The website of the Monitoring the Future Study is www.monitoringthefuture.org/
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As mentioned in the previous section, in five out of the six ESPAD countries in which 
the lifetime prevalence for cannabis increased consistently in 1995, 1999 and 2003, 
perceived availability also increased. This indicates that there is a strong relationship 
in the ESPAD countries between changes in the level of consumption in a country and 
changes in the perceived availability of cannabis. This relationship is found in 2003 
when one compares the proportion of students in different ESPAD countries who have 
ever used cannabis and the proportion of all students who perceive marijuana and 
hashish ‘very easy’ or ‘fairly easy’ to obtain (Figure 4). It is obvious that there is a strong 
positive relationship between lifetime prevalence of cannabis and perceived availability 
(rxy = 0.85, rrank = 0.85).
These results indicate that use of cannabis and perceived availability are highly 
correlated among 15- to 16-year-old students in Europe, as well as in the USA. 
However, this is not the case among 17- to 18-year-old American students. Possible 
explanations for this could include age (12th graders are about two years older than 
the ESPAD target group), degree of availability (in 2003, 87 % among the 12th graders, 
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74 % among 10th graders, compared with 35 % on average among the ESPAD students, 
with a range from 7 to 60 %); the degree of stability of perceived availability (this has 
changed among the 15- to 16-year-old students, while it has been stable among 
American 12th graders). A conclusion from this is that changes in the availability of 
cannabis are linked to changes in consumption among 15- to 16-year-old students, 
even though any direct causal link needs to take into account other psychosocial factors.
Consumption and risk perception — strongly correlated
The Monitoring the Future study in the USA has found a strong relationship between 
changes in the perceived risk of cannabis use and changes in consumption levels. This 
has been interpreted as reflecting a causal connection (Johnston et al., 2005). With 
only three data collections within ESPAD, a similar analysis of the possible influences 
of changes over time is difficult. However, a comparison between the countries in the 
2003 data collection shows a very strong relationship between the risk perception of 
cannabis and consumption level. The correlation at the country level between the lifetime 
prevalence rates of cannabis use and the proportion of students who indicated that 
there is a ‘great risk’ related to using it once or twice was strongly negative (rxy = –0.76, 
rrank = –0.79). This indicates that at the country level there is a strong negative 
relationship between risk perception and consumption levels, i.e. the lower the risk 
perception, the higher the consumption levels.
Correlates of adolescent cannabis use
The research literature offers numerous studies of psychosocial factors that correlate with 
adolescent cannabis use (26). However, findings are mixed or inconsistent, and focus on 
a single country or restricted group of countries, with different methodological aspects 
influencing the results. Moreover, such statistical associations are far from deterministic: 
there is hardly any correlate of adolescent substance use that has not been found to be 
non-significant in some study.
As ESPAD data collections in the different countries are carried out in a standardised 
way, the ESPAD project includes data that may be more suitable for cross-cultural 
comparison. One of the chapters in the latest ESPAD report includes correlates at the 
individual level from nearly all ESPAD countries (Hibell et al., 2004: 194–199). The 
summary below provides an overview of correlates for cannabis. Some caveats are 
 (26) A review of psychosocial correlates with ESPAD data from Bulgaria, Croatia, Greece, Romania, 
Slovenia and United Kingdom was recently carried out (Kokkevi et al., 2007). Another recent 
study analysed correlates of adolescent cannabis use and consumer expenditure (PCE), 
unemployment and peer factors in 31 countries (ter Bogt et al., 2006).
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required, however. ESPAD is based on a clustered not random sample (samples of 
classes, with classes as the sampling unit), which complicates statistical calculations. 
Yet, for pragmatic reasons standard t-tests have been used in this section, based on the 
understanding that these tests of statistical significance are likely to overestimate any 
correlates: the results must be interpreted as offering useful general guidelines only.
The lifetime use of cannabis was correlated with parents’ education (27) (father’s and 
mother’s education separately), family structure (single parents and one parent together 
with a step-parent) (28), economic situation (how well-off the students thought their family 
is compared with other families), perceived parental control (the students’ opinions 
concerning the extent to which their parents know where they spend Saturday nights), 
truancy (the number of days of school skipped during the last 30 days) and siblings’ use 
of cannabis (Table 1).
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Chapter 4
Cannabis in the context of 
polydrug use: results from the 
Dutch National School Survey
Keywords: adolescent prevalence – alcohol – cannabis – epidemiology – 
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Setting the context
Polydrug consumption, the consumption of more than one drug, is one of the great 
confounders of our knowledge of drug use. A vast array of psychoactive substances, 
both legal and illegal, are consumed in Europe today: alcohol, tobacco, prescription 
drugs, ecstasy, inhalants, cocaine, amphetamines, heroin, hallucinogens, not to mention 
the long list of synthetic substances monitored by the EMCDDA’s early warning system 
(GBL, TMA, 4-MTA, MDBD, etc.). This wide range of substances means that, in practice, 
drug use can come in many forms.
Despite the puzzle it represents, examination of polydrug consumption is rewarding, 
providing valuable insights into the context of drug use and complementary risk patterns. 
People who consume psychoactive substances commonly do not restrict themselves 
to a single drug (i.e. cocaine or heroin alone). Nonetheless, there are pairings and 
combinations that often go hand in hand. This is particularly the case with cannabis, 
which is very often combined with tobacco, and is commonly consumed together with 
alcohol, and, less commonly, other illicit substances. In terms of drug use among 
young people, studies looking at contexts such as schools, youth detention centres and 
recreational nightlife settings have sharpened our insight into polydrug use.
This chapter outlines two of the key concepts in defining polydrug use: ‘concurrent use’, 
i.e. use of multiple substances within a defined time period, and ‘simultaneous use’, i.e. 
use of multiple substances on the same occasion. It also looks at means of ‘clustering’, a 
technique that helps us to identify common pairings or clusters of drugs used in a given 
population, and to build a typology of different groups of drug users. Such typologies 
are useful in enabling practitioners, teachers and parents to identify ‘at-risk’ groups.
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School surveys provide a useful opportunity for examining drug use across the 
population. This chapter looks in particular at school students aged 12–16 years in the 
Netherlands. This age group encompasses younger students than in the most exhaustive 
European school survey, ESPAD, which surveys students aged 15–16 years (see Hibell, 
this monograph). Using a younger sample for drugs surveys is interesting. Teenagers 
are at a stage in life when many will encounter drugs for the first time, with some of 
them beginning to drink alcohol or smoke in their early teens. And, as with many other 
aspects of life, experiences at school, even if they do not determine or accurately predict 
later behaviour, strongly influence drug-using behaviour in adult life.
So, while this chapter provides a national case study of polydrug consumption within a 
restricted sample, its insights will have wider relevance. They are particularly valuable 
for those attempting to decipher the many complexities of polydrug use, with a view to 
informing intervention.
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Cannabis in the context of 
polydrug use: results from the 
Dutch National School Survey
Karin Monshouwer, Filip Smit and Jacqueline 
Verdurmen
Summary
A survey was conducted to describe the position of cannabis in the wider context of 
polydrug use among secondary school juniors (aged 12–16 years) in the Netherlands. 
Data were derived from the 1999 sample of the Dutch National School Survey 
on Substance Use. Studied substances were alcohol, tobacco, cannabis, ecstasy, 
amphetamines, opiates and cocaine. Among the total student population, 56.7 % use 
one or more substances, of whom 41.8 % are polydrug users in that they used more 
than one substance during the previous four weeks. Projected to a Dutch student 
population of 1 million, 237 000 are polydrug users, of whom 142 000 use only alcohol 
and tobacco, 65 000 combine alcohol or tobacco with cannabis, and 20 000 combine 
alcohol, tobacco or cannabis with at least one hard drug such as ecstasy, cocaine, 
amphetamines or heroin. The risk of polydrug use increases with age. Prevalence rates 
were highest among ethnic Dutch students, very low among Moroccan students and 
high at the lower educational levels. By comparison with girls, boys had a specific risk of 
becoming the type of polydrug user using soft or hard drugs. The position of cannabis 
use in the context of polydrug use is an ambiguous one. On the one hand, cannabis use 
is more strongly associated with drinking and smoking than with the use of hard drugs. 
On the other hand, among cannabis users, higher prevalence rates of hard drug use 
can be observed than is the case among drinkers and smokers.
Introduction
Although it has been well established that cannabis and other substance use often 
co-occur, relatively few studies have focused on polydrug use and its relation to 
cannabis use. In the Netherlands, for example, reliable epidemiological figures about 
polydrug use are rare (NDM, 2001).
Yet polydrug use is important: using combinations of drugs can have often unpredictable 
risks through additive and synergetic effects (Earlywine and Newcomb, 1997; Leccese 
et al., 2000). Studies have shown that the combined use of substances increases the 
likelihood of both physical and psychological damage (Feigelman et al., 1998). For 
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example, Stronski et al. (2000) found that cannabis users who were also using other 
illicit drugs were at higher risk for risk-related behaviour (for example, antisocial 
behaviour and accidents) than those who were not using other drugs in addition to 
cannabis. Furthermore, in 2003 in the Netherlands, 40 % of the newly registered 
individuals in addiction care had a problem with more than one addictive substance 
other than tobacco use (IVV, 2001). Of all clients reporting a cannabis use disorder 
as their primary problem, 38 % also had a secondary substance use problem, most 
commonly alcohol (reported at 18 % of all primary cannabis clients).
However, the number of people in treatment does not provide a strong picture of 
polydrug use in the general population. With regard to polydrug use, secondary school 
students form a group that warrants special interest. Most substance use is initiated 
in adolescence and students can easily be targeted with preventive interventions. In 
addition, this group can be regarded as a new generation, in which the contours of 
what lies ahead, in an epidemiological sense, start to appear. After all, polydrug use 
during the teenage years is a significant predictor of polydrug use in adult life (Galaif 
and Newcomb, 1999; Jessor, 1987).
For these reasons, in our study, we sought answers to the following:
What polydrug use patterns can be discerned among secondary school students, t
and where does cannabis fit in?
What types of user groups can be defined among students, and how many students t
can be found in each of these user groups?
What are the corresponding social and demographic risk profiles?t
This chapter is based on the work of Smit et al. (2002a), which appeared in Drugs, 
Education, Prevention and Policy (DEPP). The editorial board of DEPP kindly gave 
permission to make use of the original work.
Method
Sample, data collection and response
Data were used from the fifth wave of the National School Survey on Substance Use, 
conducted in 1999 (De Zwart et al., 2000). The school survey methodology has been 
fully described elsewhere (Smit et al., 2002b). In short, a questionnaire was administered 
in classes, which included questions on substance use during the previous four weeks. 
The non-response rate was low: on average, 4.8 % of students in each class were not 
reached due to illness, truancy or other reasons, and only 0.07 % of the students refused 
participation. Analysis was limited to secondary school students between the age of 12 
and 16 years, an age at which school attendance is compulsory (n = 6 236). In this way, 
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insight was gained into a broad group of students attending all different school types 
and we avoid overrepresentation of students older than 16, who mostly attend school 
types of a higher, pre-university level.
Polydrug use
In the literature, two forms of polydrug use are distinguished: concurrent and 
simultaneous polydrug use. Concurrent polydrug use is the use of at least two 
substances in the same time period, for instance the previous four weeks. A specific 
form of concurrent polydrug use is simultaneous polydrug use, in which a user combines 
two or more substances on the same occasion (see Earlywine and Newcomb, 1997; 
Collins et al., 1998). In this study, polydrug use was operationalised as the use of 
two or more substances by one person in the four weeks preceding the study, i.e. 
‘concurrent polydrug use’. According to this definition, polydrug users can also be 
people who use several substances on the same occasion and who therefore may be 
called ‘simultaneous polydrug users’. In this study we included the following substances: 
alcohol, tobacco, cannabis, ecstasy, amphetamines, heroin and cocaine.
Demographics
The following demographic characteristics were included: gender, age, level of 
urbanisation, school type (first class secondary school, lower vocational, lower general, 
higher general and pre-university education) and ethnicity. The five levels of urbanisation 
used by the central bureau of statistics in the Netherlands (Statistics Netherlands) were 
collapsed into two categories: the index category ‘very urbanised’, i.e. more than 
2 500 addresses per km2, and a reference category, ‘all other urbanisation levels’. This 
division was made because in a number of studies (e.g. Monshouwer et al., 2003) we 
concluded that ‘very urbanised’ living environments are significantly associated with 
substance use, and the same association has also been found by others (Abraham et al., 
1999). Ethnicity was divided into six categories: Dutch (reference category), Caribbean, 
Surinamese, Moroccan, Turkish and others. Following the rules of Statistics Netherlands, 
a person was regarded, for example, as Surinamese if he or she was born in Surinam, 
or if at least one of the parents was born in Surinam. With the aid of these demographic 
variables, the recognition of the group with an increased risk of polydrug use can be 
enhanced. This information can be useful for targeting preventative interventions.
Analysis
In order to assess the representativeness of the sample, we compared the multivariate 
distribution over the variables of school type, school year and level of urbanisation in the 
sample with the corresponding distribution in the Dutch student population, as described 
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by Statistics Netherlands. The small differences between sample and population were 
corrected by weighting, after which the distribution in the sample was exactly the same 
as in the population.
It is of note that we obtained a cluster sample, as all students from the same class 
were drawn as a single group. This method is not without consequences. Students 
from the same class share several characteristics, such as having the same teacher, or 
being exposed to the same educational system. This results in dependence between the 
observations and this, in turn, can influence the standard errors, confidence intervals 
and P-values. Therefore, robust variance-related statistics were obtained, using the first-
order Tailor-series linearisation method.
A number of substance use variables suffered from non-response to items. The item 
non-response rate was highest for alcohol, at 6.1 %, followed by cannabis, at 2.2 %. 
For the remaining substances, item non-response was less than 1 %. The missing values 
were imputed with the help of a regression model, using the demographic variables 
as predictors. Under the regression model, the most likely values were calculated 
and used to replace the missing values. Tables 1, 2 and 3 include only percentages. 
In Table 4 odds ratios (ORs) are presented, obtained by multiple logistic regression 
analysis. The interdependence between the use of the various substances was studied 
with ‘homogeneity analysis through alternating least squares’ (HOMALS; cf. Van de 
Geer, 1993; Van der Heijden et al., 1999). HOMALS is a multivariate scaling technique, 
similar to factor analysis, but applicable to nominal variables. HOMALS can be used for 
finding homogeneous clusters of substance users who resemble each other (see Figure 
1). In this chapter only, the statistics after imputation, weighing and correction for cluster 
effects are presented.
For the HOMALS analysis SPSS version 8.0 was used (SPSS Inc., 1988). For all other 
analyses, Stata version 6.0 was used (StataCorp, 1997).
Results
Demographic characteristics
Of the total student population, 76.2 % were Dutch, 1.3 % Caribbean, 4.7 % Surinamese, 
4.1 % Moroccan, 2.8 % Turkish and the remaining 10.9 % were of another, mainly 
European or Asian, origin. The average age was 14 years (range 12–16 years). Of the 
students, 30.3 % attended the first year of secondary school, 25.3 % lower vocational, 
19.6 % lower general, 12.8 % higher general and 12.1 % pre-university education. A 
minority (15.1 %) of the students lived in densely urbanised areas.
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Prevalence of substance use
Table 1 shows the four-week prevalence rates of use of the different substances, by 
gender. The prevalence rates were highest for the use of alcohol and tobacco, followed 
immediately by the use of cannabis. The prevalence rates of the use of hard drugs were 
relatively low. Cocaine ranked at a similar level to ecstasy and amphetamines. Heroin 
occupied the last place.
Table 2 shows the top 10 of the most frequently occurring patterns of use, divided 
according to non-use, mono- and polydrug use. Of the 12- to 16-year-olds, 43.3 % 
had used no substance during the previous four weeks, 28.2 % had used only alcohol 
and 14.7 % had combined alcohol with tobacco. In fourth position was the combination 
Table 1: Four-week prevalences (%) of the separate substances by gender
Substances Girls Boys Total
Alcohol 45.8 54.1 49.8
Tobacco 26.6 25.2 25.9
Cannabis 5.9 10.0 7.9
Ecstasy 0.6 1.8 1.2
Cocaine 0.4 1.7 1.1
Amphetamines 0.6 1.2 0.9
Heroin 0.2 0.4 0.3
Table 2: Top 10 of four-week prevalences (%) of no use, mono- and polyuse 
by gender
Substances Girls Boys Total
Nothing 48.0 41.5 43.3
Only alcohol 24.8 31.2 28.2
Alcohol, tobacco 15.3 12.9 14.7
Alcohol, tobacco, cannabis 4.0 6.0 5.4
Only tobacco 5.9 3.4 4.8
Alcohol, cannabis 0.5 1.4 1.0
Tobacco, cannabis 0.2 0.6 0.5
Alcohol, tobacco, cannabis, other 0.3 0.5 0.4
Alcohol, tobacco, cannabis, cocaine 0.1 0.3 0.2
Alcohol, tobacco, cannabis, amphetamine 0.2 0.2 0.2
Total 99.2 97.7 98.5
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of alcohol, tobacco and cannabis, with a prevalence of 5.4 %, followed by the group 
of students using only tobacco (4.8 %). All other patterns of substance use showed 
prevalence rates of 1 % or less. We counted 46 patterns of use, but the top 10 
accounted for 98 % of the students and, consequently, gives an accurate picture. Of the 
students who had used at least one substance during the previous month (56.7 % of 
students), 41.8 % were polydrug users.
Pairwise associations between substances
Table 3 shows how the use of one substance increased the likelihood of the use of 
another substance. For instance, the use of any other substance was about double 
for alcohol users compared with the general population. Among tobacco users, the 
likelihood of cannabis use was three times higher than among the general population. 
To use another example, cocaine use had a low prevalence among the general 
population. However, among cannabis users, the prevalence of cocaine use was almost 
10 times higher, and among ecstasy users the prevalence was 43 times higher. Heroin 
use appeared to coincide mainly with the use of amphetamines and cocaine.
Clusters
Table 3 shows the associations between pairs of substances. However, we also wanted 
to know whether clusters of three or more substances could be found. These clusters are 
depicted in Figure 1.
A homogeneity analysis (HOMALS) solution of substance use results in a graph in 
which the distances between the substances illustrates how drug use clusters. The line in 
Figure 1 runs from non-use, via alcohol, tobacco and cannabis use to ecstasy, cocaine 
and amphetamines use, and finally reaches heroin. It shows that non-use and the use 
of alcohol and tobacco are located close together. This mutual proximity points to a 
relationship which may be interpreted as the level of social acceptance of non-use 
and the use of alcohol and tobacco. The associations between alcohol, tobacco and 
cannabis use can then be regarded as a second cluster. Noticeably, a third cluster, in 
which ecstasy, cocaine and amphetamines were found close together, was located at 
some distance from the first two clusters. These ‘harder’ substances appear to be mainly 
used in recreational settings, and are, therefore, otherwise known as ‘party drugs’. 
Heroin was located the furthest from the ‘normal’ use of alcohol and tobacco.
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Typology of polydrug users
The previous analyses showed, in different ways, that a number of clusters of substances 
can be found. Closer inspection of Table 3 reveals a hierarchy which resembles Russian 
dolls, each enclosing the other: a heroin user almost certainly uses one or more of 
the party drugs, while a user of party drugs is more than likely to use alcohol, tobacco 
and cannabis. Taking these patterns into account, we tried to construe a hierarchical 
typology of polydrug users. In so doing, we strove to place in a concise typology as 
many polydrug users as possible. We came up with three types of polydrug users:
Type A: students who combined only alcohol and tobacco and used no other t
substances. We called this type the ‘ordinary’ polydrug users.
Type B: students who used cannabis in addition to alcohol or tobacco, but did not t
use hard drugs. We called this type ‘soft’ polydrug users. It should be mentioned 
here that, under Dutch law, cannabis is recognised as a ‘soft drug’ as opposed to 
a ‘hard drug’ such as ecstasy, amphetamines, cocaine or heroin, hence, our use of 
the phrase ‘soft polydrug user’.
Type C: students who used one or more hard drugs (ecstasy, cocaine, t
amphetamines, heroin) in addition to alcohol, tobacco or cannabis. We called this 
type of user a ‘hard’ polydrug user.
Type A represented 59.9 % of polydrug users, type B 27.4 % and type C 8.6 %. In all, 
95.9 % of polydrug users were described by this typology. The remaining 4.1 % must be 
classified as ‘atypical’, since they used two or more hard drugs, without combining them 
with alcohol, tobacco or cannabis. Extrapolating our findings to 1 million students in the 
Nothing
alc
tob
can
xtc
coc
amph
her
'JHVSF Clusters of three or more substances
Note: Alc, alcohol; amph, amphetamines; can, cannabis; coc, cocaine; her, heroin; tob, tobacco; 
xtc, ecstasy.
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All pupils
n = 1 000 000
Users
n = 567 000
(56.7%)
Non-users
n = 433 000
(43.3%)
Mono
n = 333 000
(58.2%)
Poly
n = 237 000
(41.8%)
Ordinary
n = 142 000
(59.9%)
Soft
n = 65 000
(27.4%)
Hard
n = 20 000
(8.6%)
Rest
n = 10 000
(4.1%)
'JHVSF Classification of adolescent drug use and prevalence rates (per 1 million)
population, we would expect to find 142 000 ‘ordinary’, 65 000 ‘soft’ polydrug users, 
20 000 ‘hard’ polydrug users and 10 000 ‘atypical polydrug users’ (Figure 2).
Risk profiles per type
Table 4 shows the associations between the demographic characteristics and the three 
types of polydrug users. The group that did not use any of the substances during the 
four weeks before the study was used as the reference group. A measure for association 
is the odds ratio (OR). An OR < 1 implies that the presence of a demographic 
characteristic is associated with a lower risk being the type of polydrug user concerned. 
A demographic characteristic with an OR > 1 implies a higher risk. All ORs were 
corrected for the influence of the other variables in Table 4.
Age was related to every group type. As the age of the student increased, the risk 
of belonging to one of the three types of polydrug users also increased. The risk of 
becoming an ‘ordinary’ polydrug user increased by a factor of 2.17 for every additional 
year. For ‘soft’ and ‘hard’ polydrug use, these factors are 3.09 and 2.58, respectively. 
Age, therefore, was a general and not a specific risk factor.
There was no statistically significant difference between boys and girls in the risk of 
becoming an ‘ordinary’ polydrug user. However, boys had a greater risk of becoming 
a type B or type C. As gender was a differentiating factor, it could be regarded as a 
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Table 4: Demographic risk profile of polydrug users compared with abstainers
Type A (alcohol and 
tobacco only)
Type B (alcohol 
or tobacco and 
cannabis)
Type C (soft drug 
and hard drug)
Risk factor ORa Significance OR Significance OR Significance
Age (years) 2.17 *** 3.09 *** 2.58 ***
Gender (ref = girls) 0.96 1.80 ** 2.51 **
Urbanisationb 0.62 * 0.69 0.63
School type (reference = lower vocational education)
First-class secondary 
school
0.61 * 0.76 0.44 *
Lower general 0.91 1.29 0.53
Higher general 0.73 0.69 0.50 *
Pre-university 0.47 ** 0.42 * 0.20 *
Ethnicity (reference = Dutch)
Caribbean 0.72 0.79 0.30
Surinamese 0.38 *** 0.81 0.75
Moroccan 0.03 *** 0.11 *** 0.06 **
Turkish 0.14 *** 0.20 * 0.58
Other 0.53 ** 0.84 1.40
Notes
aOR, corrected odds ratio.
bindex = very densely urbanised (versus the rest).
*P < 0.05, **P < 0.01, ***P < 0.001.
specific risk factor for ‘soft’ and ‘hard’ polydrug use. Living in a highly urbanised area 
coincided with a smaller risk of becoming an ‘ordinary’ polydrug user. Students who 
attended lower vocational education had the highest risk of polydrug use, and especially 
of ‘hard’ polydrug use. Students who attended pre-university education had the lowest 
risk of polydrug use. Students in higher general education had a significantly lower risk 
of becoming a type C. Students in the first year of secondary school had a significantly 
lower risk of belonging to types A and B.
Compared with different ethnic groups, autochthonous Dutch had a larger risk of 
belonging to any type of polydrug users. Moroccans, in particular, had a very low 
risk of becoming a polydrug user. This also applied, but to a lesser extent, to students 
of Turkish origin and, as far as the A-type was concerned, to Surinamese students 
and students from other ethnic origins. Students from the Caribbean did not differ 
significantly from the Dutch.
Chapter 4
91
Discussion
Main findings
With this study we wanted to answer three questions concerning polydrug use among 
secondary school students: Which combinations occur most frequently and where 
does cannabis fit in? What are the numbers of students per user type? What are the 
corresponding risk profiles? We are now able to answer these questions as follows.
Looking at all the students (abstainers included), almost a quarter (23.7 %) were 
polydrug users. Thus, among a student population of 1 million students in the age range 
12–16 years, approximately 237 000 would be polydrug users. Among students who 
reported using one or more substances (abstainers excluded), almost one-half (41.8 %) 
were polydrug users. We were able to classify nearly all of these polydrug users using a 
simple typology. ‘Ordinary’ polydrug use (only alcohol and tobacco), which extrapolates 
to 142 000 students per million, was by far the most common type. This was followed at 
some distance by a group of 65 000 students who might be classified as ‘soft’ polydrug 
users (alcohol or tobacco combined with cannabis). ‘Hard’ polydrug use (alcohol, 
tobacco or cannabis combined with a hard drug) is relatively rare, extrapolating to 
20 000 students.
Thus, the position of cannabis use in the context of polydrug use is an ambiguous 
one. On the one hand, cannabis use is more strongly associated with drinking and 
smoking than with the use of hard drugs. On the other hand, cannabis users show 
higher prevalence rates of hard drug use than is the case among drinkers and smokers. 
In other words, cannabis use occupies the ‘middle ground’ between alcohol/tobacco 
and ‘hard drug’ use. The risk of belonging to a ‘soft’ or ‘hard’ type of polydrug user 
increases with age, is largest for ethnically Dutch students, is very low among Moroccans 
and limited among Turkish and Surinamese students, and seemed to be concentrated 
mostly in the lower educational school types. Compared with girls, boys have a specific 
risk of becoming a ‘soft’ or ‘hard’ polydrug user; however, the risk of becoming an 
‘ordinary’ polydrug user is equal for both sexes.
Limitations of this study
Before we discuss the implications of our findings, we want to address the limitations 
of our study. Firstly, our data come from a cross-sectional study. Therefore, we cannot 
make causal inferences. However, the associations found can be helpful in identifying 
groups at risk. Secondly, the data were based on self-reports. Consequently, recall 
errors could have occurred (Engels et al., 1997). However, we expect these errors to 
play only a minor role, because the questionnaire was concerned with recent behaviour, 
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i.e. during the last four weeks. This idea finds empirical support elsewhere (O’Malley 
et al., 1983; Johnston and O’Malley, 1985). Systematic errors (bias) in self-reports are 
another concern. It is conceivable that not all students disclosed the true rates of their 
drug use and some under- or over-reporting cannot be ruled out.
Thirdly, in this study polydrug use was measured as the use of two or more substances 
in the four weeks preceding the study. It is possible that this type of polydrug use is less 
harmful and therefore of less importance than simultaneous polydrug use, when a user 
combines two or more substances on the same occasion (see Earlywine and Newcomb, 
1997; Collins et al., 1998). However, regarding these effects, the distinction between the 
forms of polydrug use is not unequivocal, because metabolites of a substance can still 
be present in the body when another substance is used several days later. Moreover, the 
study of Collins et al. (1998) showed that, among people who used several substances 
during the previous year, 76 % used these substances simultaneously.
Finally, because we have only looked into substance use during the preceding four 
weeks, it is unknown whether it concerned occasional (i.e. experimental) use or a 
longer history of substance use. In addition, this study does not provide information on 
the frequency and the amounts that were used. For example, while we have proposed 
that a ‘hard’ polydrug group of users exists, we cannot determine whether this group 
represents problematic behaviour as we have no additional information on the length 
and frequency of the use and the amounts used.
Implications for future research
Taking into account the findings and limitations of this study, we want to present the 
following considerations. First, Table 3 and Figure 1 suggest an ‘axis of use’, with 
alcohol on one side being the most commonly used substance, followed by tobacco, 
cannabis, ecstasy, cocaine and amphetamines, and ending with heroin. A Norwegian 
study (Pedersen and Skrondal, 1999) found an almost identical sequence, although they 
did not include cocaine. Similar sequences are also found in longitudinal studies (cf. 
Bailey, 1992; Kandel et al., 1992).
Since cannabis is usually smoked, it is suggested that cigarette smoking might act as a 
‘gateway’ to cannabis use (Kandel et al., 1992). However, although there seems to be 
a natural sequence in the use of the various substances, it is not clear whether there is a 
direct causal influence. For example, Lynskey et al. (1998) concluded from their results 
that correlations between tobacco, alcohol and cannabis use during adolescence are 
largely or wholly non-causal and arise because the risk factors and life pathways that 
encourage the use of one substance also encourage the use of other substances.
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Furthermore, there are also indications for a reverse influence. Amos et al. (2004) 
found that, among those who wanted to quit smoking, cannabis use reinforced cigarette 
smoking (see also Coggans, this monograph). While smoking and alcohol use often 
precede cannabis use, most drug users use cannabis first before progressing to other 
drugs. Findings from a 21-year longitudinal study of a New Zealand birth cohort 
seem to support the view that cannabis may act as a gateway, encouraging the use 
of hard drugs. However, the authors state that they cannot rule out the possibility that 
the association is non-causal and reflects uncontrolled confounding factors (Fergusson 
and Horwood, 2000). The mere existence of a sequence does not imply a causal role. 
More important is the question of how many people follow this route, and how far they 
venture on that route. Considering our data, we are inclined to conclude that, as far as 
a ‘route’ exists, it does not imply that everybody takes that route, or follows it to its full 
‘extent’.
Our cross-sectional snapshot study identifies some groups that were more inclined to 
venture a long way on this route. These were mainly ethnically Dutch boys in the lower 
secondary school types. Explaining why this is so, although an intriguing subject, lies 
beyond the scope of this study. Again, it must be emphasised that in this ‘snapshot’ 
study, the observed sequence cannot be read as a deterministic longitudinal pathway of 
individual drug use careers.
Second, the HOMALS analysis reveals an interesting finding: use of cannabis was 
relatively far removed from the use of hard drugs. Likewise, ‘hard’ polydrug use was 
less prevalent than either ‘soft’ or ‘ordinary’ polydrug use. This might be, in part, a 
reflection of the Dutch policy on drug use, in which the markets for soft and hard drugs 
are separated as much as possible, in order to prevent people who buy cannabis getting 
into contact with hard drugs and criminality (Verdurmen and Van Laar, 2005). However, 
how the licit/illicit divide affects the prevalence rates cannot be deduced from our data.
Third, this study shows that drug use should, to a very large extent, be equated with 
polydrug use, especially as far as alcohol, tobacco and cannabis are concerned. Until 
now, information regarding polydrug use was lacking in the Netherlands and it is fairly 
rare elsewhere. This information gap forms an obstacle for adequate policymaking.
Finally, the polydrug use patterns discerned in this study could be leveraged in future 
research:
Can the typology found in this study be replicated?t
What are the prevalence rates per user type, and do these rates differ across t
countries?
Is each user type associated with a distinct risk profile, enabling high-risk groups to t
be recognised and targeted?
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In longitudinal studies, can we determine whether young people progress toward t
the use of harder drugs by moving from one user type to another?
What kind of qualitative research will help us shed light on the main drivers (or t
motives) that influence how a student moves from one user type to another?
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Setting the context
The great societal themes — power, status, wealth, religion, tolerance, class, 
mainstream culture, subcultures, generational divides, crime, respect for the law — all 
have a bearing on drug use and the way it is perceived. In Europe, in a similar way to 
consumption patterns, societal acceptance of cannabis use and perceptions of its users 
varies greatly across the continent.
As if to demonstrate the complexity of cannabis’s role in society, the languages 
of Europe have spawned entire vocabularies to describe cannabis, its users, its 
paraphernalia and its cultural symbolism. Cannabis has many street names in all 
European languages. In English, dictionaries of cannabis slang run to several hundred 
terms. When crossing linguistic borders from Lisbon to Helsinki, a cannabis cigarette will 
be variously named a ‘charro’, ‘porro’, ‘pétard’, ‘joint’ or ‘pind’. It may be associated 
with all kinds of youth tribes and subgroups, from surfers and skaters, through okupas 
and pasotas, casseurs, hoodies, clubbers and kiffers, new bohemians and bobos, to 
rastas, hip-hoppers, and — perhaps the core archetype — hippies. Yet cannabis will 
also be consumed by people who would consider themselves entirely mainstream, and 
not affiliated to any particular sociological groups.
In this chapter, we take an anthropological look at cannabis. Based on structured 
interviews with cannabis users, the author examines social attitudes to cannabis use 
in Finland. Subcategories of cannabis users are defined, and the author looks at 
reasons why people smoke cannabis and the meanings they attach to the substance. In 
including this case study in a European monograph, the EMCDDA does not suggest that 
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observations in the Finnish context will translate wholeheartedly to a wider Europe in 
which diversity, not homogeneity, is the norm.
Nonetheless, readers are likely to recognise many of the experiences, thoughts and 
ideas expressed by the interviewees. Numerous concepts bubble up to the surface: 
escapism, group affiliation and individuality, clandestine activity, fear of exclusion from 
employment, confrontation, rebellion and rejection, taboo-breaking, societal withdrawal 
and engagement. There are also interesting insights common to all societal subgroups: 
visible signals of affiliation to the group and adapting behaviour to fit when in a 
mainstream environment.
Further reading
Amos, A., Wiltshire, S., Bostock, Y., Haw, S., McNeill, A. (2004), ‘ “You can’t go without a fag … 
you need it for your hash” — a qualitative exploration of smoking, cannabis and young people’, 
Addiction 99(1): 77–81.
Becker, H. (1963), Outsiders: studies in the sociology of deviance, The Free Press, New York.
Downes, D., Rock, P. (2003), Understanding Deviance, 4th edition, Oxford University Press, Oxford.
Lalander, P., Salasuo, M. (eds) (2005), NAD Nr 46 drugs and youth cultures — global and local 
expressions, Nordic Centre for Alcohol and Drug Research, Helsinki.
Melrose, M., Turner, P., Pitts, J., Barrett, D. (2007), The impact of heavy cannabis use on young 
people: vulnerability and youth transitions, Joseph Rowntree Foundation, York.
Miles, S. (2000), Youth lifestyles in a changing world, Open University Press, Buckingham.
Parker, H., Measham, F., Aldridge, J. (2001 [1998]), Illegal leisure. The normalisation of adolescent 
recreational drug use, Routledge, New York.
Chapter 5
99
Cannabis users and their relation 
to Finnish society
Taru Kekoni
Abstract
This article examines the relationship of Finnish cannabis users to society. A total of 35 
cannabis users were interviewed for the study. The narrative modes that were identified, 
which interviewees employ to describe their relationship to Finnish society, included 
‘concealed use’, ‘open activism’ and ‘social withdrawal’.
In the narrative of ‘concealed use’ the cannabis user wishes to appear as an upholder 
of traditional values and conventional lifestyles, even though there is a hidden, ‘deviant’ 
behaviour in the background. The most significant denominators of the relationship 
to society are controls and mechanisms related to concealment. In the narrative of 
‘open activism’ the relationship to society is constructed on the basis of an openly 
alternative lifestyle connected to cannabis use and the associated activism. In the ‘social 
withdrawal’ narrative, the user’s relationship to society is characterised by experiences of 
being offended or excluded because of his or her cannabis use. Withdrawal may also be 
a personal choice to stay outside the constraints of social activity.
Background to cannabis use in Finland
Cannabis is the most frequently used illegal narcotic substance in Finland, though 
cannabis prevalence is low compared with the European average. According to 
information for 2004, lifetime prevalence in the age group 15–64 years was 12.9 %, 
last year prevalence 2.9 % and last month prevalence 1.6 %. Judging by these figures, 
the maximum number of ‘regular cannabis users’ in Finland could be estimated at 
about 40 000. The majority of cannabis users are below 29 years of age, and two-thirds 
are male. As regards socio-economic status and marital status, cannabis use is most 
prevalent among students and unmarried or co-habiting persons, reflecting the young 
age of the majority of users. In terms of geography, cannabis use is clearly concentrated 
in the capital region around Helsinki and elsewhere in southern Finland. Overall, 
prevalence of use and experimentation with cannabis increased by about 50 % from the 
mid-1990s to the 2000s, although in recent years the level of experimentation reported 
among school students has declined. Increases in regular use are estimated to have 
levelled off at the beginning of the 2000s (Hakkarainen and Metso, 2003). Cannabis 
use, home growing, possession, buying, importing and distribution are all criminalised 
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under Finnish law. The consequence of being caught using cannabis is most often a 
fine, although incarceration of up to 10 years is a possible penalty for cannabis-related 
crimes.
Seppälä and Mikkola (2004) consider that the cultural meaning of cannabis use in 
Finland is distributed along at least two distinct axes. On the one hand, cannabis does 
not possess a single homogeneous ‘world of meaning’, but different circles associate 
it with widely divergent ‘meanings’. In addition to its symbolic value, cannabis has 
emerged as a kind of ‘universal drug’, with its use defined not only by different 
meanings related to subcultures, but also by loose and flexible mainstream meanings. 
On the other hand, cannabis use itself is associated with an abundance of tangible 
cultural products and paraphernalia, which is manifested, for example, by various 
implements for its use, by cannabis varieties and by historical and cultural stories linked 
to cannabis.
In their study of cannabis use from the viewpoint of research into social identity, 
Hammersley et al. (2001) note that cannabis users are connected to the surrounding 
society and the mainstream population in many ways. Nevertheless, their use of 
cannabis also requires the ability to manage an illegal activity carrying negative 
sanctions, including potential exclusion from arenas of social activity. This is equivalent 
to managing a hidden ‘disability’ (Goffman, 1963) or hidden deviancy (Becker, 1963) 
(cf. Young, 1999). There is a requirement that cannabis use is hidden from one set of 
people but revealed to another, to the right people under the right social circumstances. 
The social identity of the user is, in fact, shaped depending on the situation (Hammersley 
et al., 2001), and is a continuously evolving, dynamic characteristic.
Analysis and description of the data
This chapter examines the relationship of Finnish cannabis users to society, and the 
conditions under which the relationship is constructed. The users’ ‘relationship to society’ 
is defined as the individual’s experience of his or her own social status and the means 
by which this status is constructed and maintained in relationship to the mainstream 
population and social constraints. The questions posed were:
In relation to personal cannabis use, how did the user perceive his or her t
relationship to the structures of surrounding society and the mainstream population?
What meanings, behaviours and coping mechanisms do the cannabis users t
associate with their relationship to society?
The analysis combines the methodological approaches of grounded theory and 
narrative research. It aims to identify the narrative modes which cannabis users employ 
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in interviews to describe their relationship to Finnish society to the researcher. These 
narrative modes have been structured into concepts that have been categorised into 
‘concealed use’, ‘open activism’ and ‘social withdrawal’. In the analysis of the data, it is 
considered possible to move between realistic and constructionist discourse (cf. Glassner 
and Loughlin, 1987: 34–35). The data reveal something of what actually happens but, 
at the same time, information is generated precisely in the research situation and for it 
(cf. Pösö 2004: 35–36).
A total of 35 cannabis users were interviewed for the study. Since the focus of interest 
was the ideological thinking and social activity related to cannabis use in more general 
terms, data collection was initiated by submitting an interview request to the electronic 
mailing list of the Finnish Cannabis Association. Leaflets containing a description of 
the study and the researcher’s contact data were also distributed during the Million 
Marijuana March in Tampere in the spring of 2003. The way in which data were 
collected has a clear effect on the selection of interviewees. The data were considerably 
affected by the recruitment of persons who use cannabis exclusively, or as their main 
drug. Because of this, the extensive group who use cannabis in addition to other drugs 
has been almost completely excluded from the data. On the other hand, it seems 
obvious that the data do not include people who deny using cannabis, people who use 
it only very occasionally and people who express very little (or no) ideological ‘choice’ in 
using cannabis.
The majority of the interviewees were men (23). The average age of the interviewees was 
32 years, ranging from 19 to 56 years. The interviewees mainly lived in or near large 
cities in south and south-west Finland, but a few came from further north and smaller 
localities. All the interviewees contacted the researcher voluntarily.
‘Concealed use’ as the relationship to society
‘Concealed use’ is defined as the type of cannabis use and the associated relationship 
to society in which efforts are made to conceal use of cannabis from organisations and 
persons who might have a negative impact on the user’s social status if they learned 
about its use. Among the interviewees who described their relationship to society within 
a ‘concealed use’ narrative, nine were students in secondary or tertiary education, six 
were gainfully employed and one was unemployed at the time of interview. Among 
the total of 12 women in this study, 10 were placed in this category. The average age 
of the group members was 29.5 years, ranging from 19 to 47 years. The youngest 
interviewees belonged to this group. Two of the interviewees were married, seven were 
co-habiting and six were single, of whom one was divorced and one lived with his 
parents.
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In terms of gender and employment, the figures for this group differ significantly 
from the statistical data available on Finnish cannabis users (see Hakkarainen and 
Metso, 2003). The narrative of ‘concealed use’ appears understandable in the light 
of the socio-economic situation of those who described their relationship to society 
within this narrative. In one way or another, being revealed as a cannabis user could 
endanger the relatively stable social status these interviewees had achieved, or could 
lead to unfortunate consequences for the family situation or other social relationships. 
‘Concealed use’ has clear links with the ‘hidden deviancy’ behaviour described by 
Becker (1963). The person’s behaviour deviates in some aspects from social rules and 
norms, and the behaviour is concealed from the mainstream population (Oinonen, 
2002).
The general motives mentioned for ‘concealed use’ are the fear of losing one’s job or 
study opportunity or, in general, the fear of being stigmatised if cannabis use becomes 
known to the employer or a teacher. The fear in itself is not groundless, for several 
interviewees had actually lost their jobs after being revealed as cannabis users. On 
the other hand, a significant cause for fear is that a projected course of study or work 
career would founder due to cannabis use if a narcotics crime were to be listed on 
the user’s criminal record. In Finland, an extract of criminal records is required of 
persons applying for jobs with minor children, and one of the categories relevant to this 
occupation is crimes related to narcotics.
Another important motive for concealed use is the fear of being caught by the 
authorities. Besides an entry in their criminal records, the interviewees fear a house 
search or surveillance by the police. Interviewees with families also fear the intervention 
of the social services in family life if the parents are found to be using cannabis. The 
fear of being caught is most acutely linked to the buying of cannabis, which often brings 
the users in contact with ‘actual’ drug criminals. In fact, after becoming parents many 
interviewees have purposefully distanced themselves from criminal circles. Users do not 
necessarily want to give up cannabis because of their children, though all interviewed 
mothers did report that they had given it up during pregnancy and breast-feeding, and 
the solution adopted may be to grow cannabis either at home or at a friend’s home.
Means of concealment
Cannabis users describe various ways in which concealment is practised and their 
relationship to society maintained. ‘Not telling’ as a means of concealment means that 
the use is hidden from most of one’s acquaintances and only revealed to one’s most 
intimate circle, who are themselves often users or otherwise approve of cannabis use. 
‘Not telling’ is the easiest solution if one wants to avoid guilt-inducing or condemnatory 
reactions from third parties. Not telling is also relatively easy. Cannabis use is not a 
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general topic of conversation. On the contrary, several interviewees report that a kind of 
‘culture of silence’ prevails both within families and in public.
‘Controlling use’ is another important means of concealment vis-à-vis the mainstream 
population. At the same time, it is a qualitative or quantitative check on the habit. 
Means of control may be related to the place and time of use, as well as to the mode 
and intensity of use. In most cases, use is reported to take place at home or in another 
private space, alone or with certain friends. Users also report that the time of use is 
significant in terms of how ‘deviant’ they consider their behaviour to be. Users mostly 
say that use is generally accepted in the evening, which is when the interviewees mostly 
reported using cannabis. Controlling use in order to be courteous and well mannered 
are also described. For instance, it is not considered appropriate to use cannabis in 
children’s play areas, in non-smoking areas, or in situations where others may feel 
offended or confused because of it. These controls of use are described as ‘gentlemen’s 
agreements’, whose purpose is not to reveal one’s use to others, and also not to weaken 
the reputation of cannabis use in general any further.
‘Not telling’ may be experienced as an awkward solution, if one feels compelled to 
hide a part of one’s life that is important for one’s identity. In addition to relaxation or 
enjoyment, cannabis use may contain other meanings, which may be religious, ritual or 
otherwise strongly linked to one’s world view (see, for example, Booth, 2003). In spite of 
this, it may be necessary to hide one’s use to safeguard one’s social status, and this may 
actually be experienced as the biggest problem related to cannabis use. For this reason, 
affiliation to cannabis culture may be indicated by various symbolic signals. Dreadlocks, 
or an exceptionally relaxed style of dress, may indicate membership to those who are 
able to read these symbolic messages. Cannabis use may also be referred to by using 
terms which outsiders may not understand in the context or by employing gestures which 
only another user can understand.
It has been noted within cultural criminology research (Ferrel, 2003) that deviant and 
criminal subcultures are becoming fragmented in a world of symbolic communication. 
Symbolic communication for cannabis users may partly depend on the desire to 
experience a community and belonging with other cannabis users, but also on practical 
needs and the usefulness of revealing oneself or another person as a user. The 
usefulness may be linked, for instance, to a desire to extend the established circle of 
users, perhaps with the interest of finding new channels of acquiring cannabis.
‘Open activism’
Instead of concealment, the relationship to society of a cannabis user may also be 
based on ‘open activism’. This denotes a relationship with the mainstream population 
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and social domains in which there is no attempt to hide cannabis use. Rather, there is 
a desire to bring the matter out into the open, as a topic of debate in both private and 
public spheres. In the ‘open activism’ narrative, the most important aspect of cannabis 
use in relation to social status is considered to be the desire to break the so-called 
‘culture of silence’ surrounding cannabis use. In this context, the interviews also often 
refer to the taboo aspect of cannabis. The aim of ‘open activists’ is to bring cannabis, 
as a topic, from the marginal to the mainstream arenas. On the other hand, in the open 
activism narrative, openness is also manifested as the personal choice of individuals. 
Since the matter is strongly linked to the user’s way of life, he or she does not want to 
keep it a secret, but rather shows honestly in all situations his or her personal attitude 
towards it.
Among the cannabis users interviewed, 13 were ‘open activists’. They were all male. 
The average age of the group was 32.5 years, ranging from 21 to 56 years. Nine of 
the interviewees were employed at the time of the interview, two were unemployed, one 
was a secondary school student and one in civilian service (in lieu of conscripted military 
service). Eight of the interviewees were unmarried, two married, two co-habiting, and 
one was divorced. Their educational level varied from comprehensive school to university 
degrees, as in other groups. However, in this group the proportion of interviewees with 
university degrees was slightly higher than in the others: four out of the total of eight 
university graduates belonged to this group (three belonged to the ‘concealed use 
group’ and one to the ‘withdrawal from society’ group).
The desire to act as an active proponent of cannabis may be rooted in events in the 
person’s biography, or may be a lifestyle choice. Some activists reported that they were 
motivated by events in their early childhood. For example, someone with alcoholic 
parents may view society’s relatively permissive attitudes about alcohol and sharply 
condemnatory attitudes about cannabis as contradictory. This may lead to active defence 
of cannabis. Similarly, someone who has once been strongly labelled as a cannabis user 
and faced the consequences may be encouraged to become an open activist. Someone 
who has already served a prison sentence may feel that loss of social status is already 
complete, and that it is therefore relatively easy to become an activist.
By contrast, younger activists did not necessarily report alienating experiences related 
to cannabis use. For them, activism may be only one way of working towards a better 
and more liberated society. In this narrative, cannabis activism is viewed not so much 
as a discrete movement but more as a part of a ‘culture of resistance’ or a general 
lifestyle that attempts to call into question current values and to create a new, individual 
value base. It might include criticism of consumer behaviour and the global or national 
economy. Similarly, the unpleasant effects of continued concealment of cannabis use 
and the fact that cannabis has become increasingly important for one’s lifestyle may 
have the result that even a younger user becomes an activist. In this narrative, even 
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being caught by the police may appear as positive, as was noted by an interviewee 
when describing this situation: ‘So I also thanked the police and said, like, “hey, this is 
great, now you know about me so I needn’t try to hide anything!” ’
In the ‘open activism’ narrative, the relationship to society was described from the 
viewpoint of personal ideology and lifestyle more markedly than with the preceding 
group. For activists, personally defending cannabis as a positive substance, a medication 
and the raw material of various industries is so important that they are ready to 
jeopardise their own social status.
Means of open activism
As might be expected, open activists are more likely to be active members of a cannabis 
advocacy organisation than those belonging to the two other groups. For them, activity 
in organisations serves as a means of making their cannabis-related thinking and 
lifestyle more visible and also more acceptable in different social spheres. At the same 
time, it serves their needs for a community and for sharing experiences with like-minded 
people. Although the use of cannabis is not regarded personally as wrong or as a 
criminal activity, the culture constructed around it is constrained by the fact that cannabis 
use is nonetheless illegal.
Activist organisations strive to spread their message chiefly by means of information 
provided on their internet pages and through the discussion groups they maintain. 
Among activists, online media are regarded as very useful channels for disseminating 
information and promoting more favourable attitudes. By contrast, the Million Marijuana 
March introduced in 2001 in Finland is regarded as a slightly more dubious way of 
spreading the message of legalising cannabis. Some of the activists do not take part in 
the march, for they believe that it attracts stigma for both the participants and cannabis 
users in general. Finland’s longest-established association, the Finnish Cannabis 
Association (FCA), active since 1991, has been most assiduous among the cannabis 
organisations in attempting to establish dialogue with members of parliament and 
political decision-makers. The means used by FCA for this include position papers and 
press releases drafted as a result of membership and/or board meetings, which are 
distributed as widely as possible, including to members of parliament and other political 
actors. FCA was also consulted when Finland’s first national drug strategy was drawn up 
in 1997.
Cannabis activists are also prepared to discuss the topic in the arenas of their 
‘opponents’ or the mainstream population, and in a manner approved by these 
opponents. In the open activism narrative, an important enabler of discussion with the 
mainstream population is the way in which the discussion is conducted. This involves 
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such concepts as ‘adjustment to censorship’ and ‘orientation to the media’. These 
imply that it is important to present their message in a form that is not too aggressive 
towards general social attitudes to cannabis and does not directly offend anyone, not 
even those who oppose cannabis most strongly. The activists report that they achieve 
this by ‘disguising’ the message so that, for example, an item in the press may not even 
mention the word cannabis, but the attitudes involved are visible in the text in other 
ways. Another point stressed by interviewees was that the story needs to match the 
format of the particular media outlet to which it is offered.
The most infrequent means of activism in the interview data is the attempt to exert 
influence in mainstream arenas. In the data this primarily means activity in party or 
municipal politics, and defending cannabis together with other personal values in this 
context. One of the interviewees describes involvement in party politics as a means of 
open activism and as a personal cause:
It’s like, they [cannabis use and becoming aware of its social status] have had a fairly strong 
impact on my, let’s say, awakening, on becoming a conscious human being instead of a 
sleepwalker, so to speak. So I read the papers more carefully, looked for ways to make an 
impact, I even joined the party and went to the party convention. Incidentally, I even gave a 
speech at the convention. There are people there, too, who support legalisation, and, well, 
my three minutes were that, it was a reply to another speech, in which I mentioned that in my 
personal opinion people who can’t distinguish say, marijuana from coke, then I think a person 
like that is incapable of taking decisions at all in this matter. Meaning, get informed, you guys, 
get informed.
Withdrawal from society
The third narrative mode is one in which cannabis users describe their relationship to 
society within the narrative of withdrawal from arenas of social activity. ‘Withdrawal’ 
may be explained as a personal choice, which is resorted to in order to avoid conflict 
with the authorities, or more generally, with condemnatory attitudes. On the other hand, 
withdrawal may also include strong elements of exclusion, whether economically from 
working life, socially from the mainstream population or judicially from the spheres 
of ‘decent citizens’. In this case, withdrawal may be understood as social exclusion as 
defined by Young (1999). The withdrawal narrative may also be linked by a strong 
feeling of being mistreated by society, which is linked either to judicial conflicts or more 
generally to a feeling of losing one’s ‘human rights’ and being shunned because of 
one’s lifestyle.
Six cannabis users described their relationship to society within the social withdrawal 
narrative. Two of them were female, and the average age of the group was 36 years, 
Chapter 5
107
with actual ages varying from 26 to 50 years. Thus, those classified as belonging to this 
group were slightly older than those in the other groups. At the time of interview, one of 
the interviewees was employed, four were unemployed and one was on parental leave. 
Four group members had completed comprehensive school, one had a secondary-level 
qualification and one an almost complete university degree. The group included one 
co-habiting couple, one married person with minor children, one divorced and two 
unmarried single persons. An interesting distinguishing factor in the demographic data 
of the social withdrawal group is that they reported having started using cannabis 
considerably earlier than the other groups. The most commonly reported starting age in 
the interview data was around 20 years, but in this group the most general starting age 
was 13–15 years. The average age in Finland for starting the use of cannabis is about 
16–18 years (Hakkarainen and Metso, 2003).
The interviewees within the ‘social withdrawal’ narrative reported problems with 
intoxicant use more frequently than interviewees in the other groups. They reported 
earlier problematic use of other illegal drugs, medications or alcohol, which had then 
been dropped as cannabis became the drug they chiefly used. One of the interviewees 
did not report earlier problematic use of other substances, but did report continuing 
experimental use of other illegal drugs. In this narrative, more clearly than in the other 
groups, interviewees suggested that earlier use of cannabis and also current cannabis 
use was linked, to some degree, to problems or addiction. The problems could be 
associated with social relationships and with the necessity of withdrawing from them, 
conflicts with the judiciary, family problems, health problems or difficulties in finding 
work. Many reported several of these problems. On the other hand, the interviewees 
could also have experienced addiction as a neutral or even a pleasant experience.
Within the ‘social withdrawal’ narrative, use was almost invariably justified from the 
viewpoint of maintaining mental balance and/or of mental health problems, mostly 
depression. The interviewees felt that cannabis use helped to ‘smooth the edges’ of an 
otherwise bumpy life or to ‘heal traumas’ created during one’s life. Several interviewees 
reported having used mood medication earlier for the same problems, but had felt that 
it was of no help or that it had caused severe addiction or other problems.
Two people within the ‘social withdrawal’ narrative reported that a significant factor for 
their habit was its medicinal impact on physical illnesses which had not been alleviated 
by any other medicine. Physical symptoms of varying severity (such as headache, 
flu, asthma, menstrual cramps, migraine, nausea, indigestion) were also reported as 
the cause of use in the other groups, but the social withdrawal narrative includes the 
interviewees who reported using cannabis primarily for medicinal reasons.
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Withdrawal as a relationship to society
For these interviewees, social withdrawal primarily meant being excluded from society 
in one way or another and an experience of being labelled as criminal or otherwise 
unfit for society. Three people within this narrative talked about recent experiences of 
being caught by the police or customs. They had been charged with growing cannabis 
at home, driving under the influence of cannabis and with a crime related to the sale of 
cannabis products. A house search by the police and the subsequent sentence appears 
as one example of experienced social exclusion. A cannabis user recently sentenced for 
the sale of seeds describes the experience as one entailing severe exclusion, which also 
has unfortunate future consequences:
But now I’ve actually lost everything, in that I lost all the money I had and it’s really difficult 
getting a job in Finland now that I’ve a record of drug crimes. And all the liquids that they 
found, fertilisers and spices, they were sent to the drug laboratory, and they took my photos, 
my employment certificates and all possible documents. They took my bank statements, my 
mobile phone and just everything … And apparently they figured that I’m some drug Mafia 
man or something. And they just walked into my flat on the grounds that they wanted to see if 
I had any weapons and so on …
This extract imparts a strong feeling of an experience of stigmatisation, apparent in 
such terms as ‘drug Mafia man’ used by the interviewee to describe himself through 
the eyes of the authorities. Becker (1963) noted that deviancy does not consist of the 
behaviour itself, but of the stigmatisation as deviant of a behaviour, as a result of the 
rules and norms of the mainstream population. Thus, a deviant person is a person 
labelled as such. According to Becker, stigmatisation is a two-directional process. With 
stigmatisation of the deviant, changes occur in the identity of the person and he or she 
also begins to feel excluded from society on the level of his or her identity.
More frequently than the other two, the ‘social withdrawal’ narrative describes the 
user’s intimate circle as consisting mainly of other users. The circle may also include 
users of stronger drugs than cannabis or persons with links to the sale of cannabis and 
other criminal activity. This could naturally be caused simply by the fact that friends 
and acquaintances are generally selected from among people who uphold the same 
values and have the same hobbies. On the other hand, the mainstream population and 
old friends may also shut out a cannabis user if, for example, he or she is labelled as 
criminal or otherwise deviant. Clearly, more often than the other two, the narrative of 
social withdrawal is linked to unemployment.
Chapter 5
109
Conclusions
Finnish cannabis users’ relationship to society has been categorised into the narratives 
of ‘concealed use’, ‘open activism’ and ‘social withdrawal’. The interviewees suggested 
that in Finland users of illegal drugs are often portrayed in black and white terms and 
assumed to exist outside domains of social activity, at the margin of society, where 
distinctive modes and motives of action are constructed for them. Cannabis use is not 
portrayed differently from use of other illegal substances. On the other hand, cannabis 
use in the present day may be seen as involving a diverse group of people — especially 
in the framework of relaxation or recreational use — and it is not necessarily regarded 
as having any impact on the conditions of a person’s relationship to society.
A positive outcome of this study is to reach a set of cannabis users who have been 
invisible in Finnish drug research before. Reaching and researching hidden populations 
is one important role of qualitative drug research (Rhodes, 2000). To my knowledge, 
the relationship of cannabis users and cannabis use to society has previously not 
been researched or called into question in Finland or in any other European country. 
According to Rhodes (2000), both the nature of knowledge itself and the process by 
which it is acquired shape the lived experience and perceived meaning of drug use. Two 
key tenets of qualitative research are to describe the social meanings participants attach 
to drug use experiences and the social processes by which such meanings are created, 
reinforced and reproduced (Moore, 1993; Rhodes, 1995; Agar, 1997). An examination 
of Finnish cannabis users’ relationship to society reveals how cannabis use is lived and 
interpreted through social interactions.
I have shed some light on the motives, means and ideologies attached to cannabis use 
in Finland. The study reveals the mechanisms and controls that are employed to make 
cannabis use possible in a social situation, an activity that carries a risk of relatively 
strict control policy and judicial sanctions. It also brings to light different ways of viewing 
society and the divergent positions in which people live. In addition, it reveals different 
meanings and contents in the internal culture of cannabis use, which may not be easily 
visible to the mainstream population and therefore unidentified by them.
When studying the use of drugs, one should bear in mind the thesis presented by 
Howard S. Becker (1970), concerning research on deviancy, according to which it is not 
the researcher’s task to be involved in the value debate concerning the research topic, 
but simply to study deviancy as behaviour that is condemned by some and approved 
by others. The study of internal meanings of the culture of use and its relationship to 
society is one way of understanding cannabis users’ way of regarding drug use and its 
meanings.
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Setting the context
In 1956, the novelist William Burroughs wrote about cannabis that ‘the effects of this 
drug have been frequently and luridly described’. He mentioned such effects as ‘acute 
sensitivity to impressions’, ‘disturbance of space–time perception’ and an increase in 
appetite. Yet he also warned that cannabis was ‘a sensitizer’ and that its effects are ‘not 
always pleasant’: ‘depression becomes despair, anxiety panic’ (1).
So what, 50 years later, can be said about the health effects of cannabis use and 
cannabis smoking in particular? Cannabis use has been associated with a range 
of adverse health effects, and new studies regularly appear that are extending our 
knowledge of the possible adverse health consequences of cannabis use.
From a review of this growing literature, John Witton argues in this chapter that it still 
remains difficult to make conclusive statements about the health effects of cannabis. 
Despite the wealth of available information, there still remains a shortage of robust 
research from well-designed studies. Moreover, a number of basic hurdles exist that 
make it difficult to disentangle the effects of cannabis from other drug use and other 
confounding factors. These methodological problems are compounded by the difficulties 
of ascertaining dose–response relationships.
Nonetheless, some health problems can be identified. Links between chronic cannabis 
use and respiratory disease, carcinogenesis and adverse child development after 
 (1) Burroughs, W. (1956), ‘Letter from a master addict to dangerous drugs’, British Journal of 
Addiction 53(2).
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maternal cannabis use have been identified. There has also been a recent increase in 
research interest examining the association between cannabis use and psychosis and 
depression. This brief chapter summarises the many hundreds of studies into the health 
effects of cannabis. It is important to note, however, that new research is emerging in 
this area at such a pace that any review is likely to become quickly out of date. 
So while this chapter represents a snapshot of current knowledge — a recent Spanish 
monograph (Ramos Atance et al., 2007) covers the subject of cannabis and mental 
health in further detail — it is likely that the knowledge base on the health effects of 
cannabis will develop further over the coming years, and any conclusion drawn based 
on the current evidence must be regarded as tentative.
Further reading
Advisory Council on the Misuse of Drugs (2008), Cannabis: classification and public health, Home 
Office, London.
Copeland, J. (2006), ‘Cannabis use, depression and public health’, Addiction 101: 1380.
Corrigan, D. (this monograph, Volume 1), ‘The pharmacology of cannabis: issues for understanding 
its use’.
EMCDDA (2007), Drugs profiles: cannabis 
www.emcdda.europa.eu/?nnodeid=25484
Inserm (2001), Cannabis: Quels effets sur le comportement et la santé?, Les éditions Inserm, Paris.
Kalant, H., Corrigal, W., Hall, W., Smart, R. (eds) (1999), The health effects of cannabis. Addiction 
Research Foundation, Toronto.
Ramos Atance, J. (ed.) (2007), Aspectos psiquiátricos del consumo del cannabis, Sociedad Española de 
investigación en cannabinoides (SEIC), Madrid.
See also the grey literature list in the Appendix to Volume 1 of this monograph.
Chapter 6
117
Cannabis use and physical and 
mental health
John Witton
Introduction
The health effects of cannabis have been the subject of a number of scientific reviews 
by national and international bodies since the seminal Indian Hemp Commission of 
1893–4. Yet, over a century later, the health effects of cannabis are still regularly 
debated. Uncertainty about these effects seems to contribute to confused scientific, public 
and political arguments. This is perhaps a surprising situation, given that there is now no 
shortage of recent authoritative reviews to draw upon to help weigh up the evidence (Joy 
et al., 1999; Kalant et al., 1999; Inserm, 2001; Hall and Pacula, 2003; UK Advisory 
Council on the Misuse of Drugs, 2002; Kalant, 2004; Iversen, 2005). So what makes it 
so difficult to arrive at a consensus view about the health effects of cannabis?
In his chapter in this monograph, Wayne Hall outlines the factors that prevent us from 
arriving at the same kind of consensus view of cannabis as we have for alcohol and 
tobacco. In particular, there is a paucity of good quality studies of cannabis and health 
effects or long-term studies that enable a careful assessment of the possible causal role 
of cannabis in the development of a range of health concerns (Macleod et al., 2004).
Analysts seeking to make conclusive statements on the health aspects of cannabis are 
faced with three major hurdles. The first is the absence of a standardised product. 
Cannabis cigarettes — ‘joints’ — can contain varying doses of the main psychoactive 
constituent of cannabis, tetrahydrocannabinol (THC), and many of the studies under 
review can only provide approximate indicators of the amount of THC consumed. As 
cannabis is an illicit product, how can we assume, with confidence, that the joint smoked 
by one consumer is comparable with the next joint, and the next consumer? These issues 
are further confounded by differences in how the substance is consumed, embracing 
such aspects as joint construction, other modes of administration (water pipe, vaporiser), 
intensity of use and frequency of use (2).
 (2) For a discussion of screening for intensive use, see Beck and Legleye, this monograph. More work 
is needed on the nature of THC dosage among regular cannabis users and polyconsumption 
patterns, in particular the simultaneous use of other substances together with cannabis. 
Nonetheless, some studies on intensive use patterns have been published with European 
relevance. In the United Kingdom, Atha and Blanchard (1997, 1998) have estimated THC 
exposure among regular UK users; in Spain, some attempt has been made to divide regular 
users into ‘pure’ users who use cannabis alone and ‘polyconsumers’ who use cannabis and other 
illicit drugs (Calafat et al., 2000); in the Netherlands, a recent study examines intensive use of 
high potency cannabis (Mensinga et al., 2006).
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The second hurdle is that cannabis is often consumed with other substances. It is most 
commonly mixed with tobacco in a joint, and frequently used concurrently with other 
substances, especially alcohol. Thus, the question arises: ‘how can we disentangle the 
effects of each substance on the cannabis smoker?’.
A third hurdle is that cannabis use is more common among adolescents and young 
adults — generally, a physically healthy population — who often give up consuming 
cannabis before their mid-30s. This, combined with the paucity of long-term studies of 
cannabis users into middle and old age, means that the precise role played by cannabis 
in health problems later in life is difficult to determine.
Together, these three hurdles have meant that, although there has been a recent surge 
in cannabis research adding to the large number of extant studies, it is premature to 
pronounce conclusively on a range of long-term health concerns surrounding cannabis 
use.
The research evidence presented in this brief review has been identified according to 
the standard criteria for causal inference. These criteria imply that evidence should 
demonstrate that there is a relationship between cannabis use and a health outcome 
using an accepted type of research design. Thus, studies should have ‘built-in’ 
trustworthiness and show that:
through statistical testing, the relationship is unlikely to be due to chance;t
drug use precedes the adverse effect; andt
that the evidence eliminates as far as possible the likelihood that the relationship t
is due to some other variable that is related to both cannabis use and the adverse 
health effect.
So this brief review presents the best currently available evidence, together with 
comments on any shortcomings of this evidence in the light of the above criteria.
Acute effects of cannabis
The reported effects of acute cannabis use are a sense of euphoria and relaxation, 
perceptual distortions, time distortion and the intensification of sensory experiences such 
as listening to music. Cannabis use in social settings can lead to increased talkativeness 
and infectious laughter followed by states of introspection and dreaminess. The user 
typically has a feeling of greater emotional and physical sensitivity that can include 
greater interpersonal empathy. Short-term memory and attention are also impaired 
(Joy et al., 1999; Hall and Pacula, 2003). Acute subjective effects have been found to 
be significantly increased according to dose of THC in laboratory studies (Hart et al., 
2001).
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Cannabis use can increase the heart rate by 20–100 % above baseline. This increase is 
greatest in the first 10–20 minutes after use then decreases rapidly thereafter. The rate 
of decrease depends on whether smoked or oral cannabis is used, lasting 3 hours in the 
former and 5 hours in the latter (Joy et al., 1999). Blood pressure is increased while the 
person is sitting and decreased while standing. The change from sitting to standing can 
cause faintness and dizziness due to the change in blood pressure. These cardiovascular 
effects are of negligible clinical significance because most cannabis users are young and 
healthy and develop tolerance to these effects (Joy et al., 1999; Sidney, 2002).
However, these changes may present serious problems for older users, particularly 
individuals with pre-existing heart disease (Joy et al., 1999; Sidney, 2002). Cases of 
acute cardiovascular death in which THC was present in post-mortem blood samples, 
indicating recent cannabis use, have been reported (Bachs and Morland, 2001). 
An interview-based study of 3 882 patients (1 258 women) with recent myocardial 
infarctions found that the cannabis smokers in the group were 4.8 times more likely to 
experience a myocardial infarction 1 hour after smoking than during periods of non-
use. The small number of 124 cannabis smokers in the study were also more likely to 
be male, overweight and cigarette smokers, and cannabis was a rare trigger of acute 
myocardial infarctions in this study group (Mittleman et al., 2001). A longitudinal study 
of risk factors for coronary artery disease in a group of young adults aged 18–30 did 
not find an association between cannabis use and cardiovascular risk factors such as 
elevated cholesterol levels and blood pressure or high body mass index (Rodondi et al., 
2006). There have been a small number of case reports of strokes following cannabis 
use, but further research is needed to determine the relationship of cannabis use to 
cerebrovascular disease (Moussouttas, 2004).
Acute mood effects
Adverse mood effects can occur, particularly in inexperienced users, after large doses 
of cannabis. Anxiety and paranoia are the most common of these effects, which also 
include depersonalisation, panic, dysphoria (unpleasant mood), depression, delusions, 
illusions and hallucinations. These effects normally disappear a few hours after cessation 
of use and are responsive to reassurance and a supportive environment (Adams and 
Martin, 1996; Joy et al., 1999).
Acute toxicity
The acute toxicity of cannabis is very low and there is no overdose risk from cannabis. 
While there have been occasional reports of human deaths suspected of being related to 
cannabis use, these have not been confirmed by appropriate analytic techniques (Tewari 
and Sharma, 1980; Hall and Pacula, 2003).
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Chronic effects of cannabis
Immune system
While cannabis smoking has been found to impair the function of lung macrophages, 
which provide a defence against inhaled pathogens, there is no conclusive evidence that 
cannabis impairs immune function to any significant extent (Roth et al., 2004; Kraft and 
Kress, 2004). The few studies that have suggested that cannabis has an adverse effect 
on the immune system have not been replicated. Two prospective studies of HIV-positive 
men have shown that cannabis use is not associated with progression to AIDS (Kaslow et 
al., 1989; Hollister, 1992; Joy et al., 1999).
Respiratory system
Cannabis smoke contains many of the same components as tobacco smoke, while 
having a higher proportion of particulate matter and some carcinogens (Tashkin, 1999). 
As much as four times the amount of tar can be deposited on the lungs of cannabis 
smokers as cigarette smokers if a cigarette of comparable weight is smoked. This 
difference is probably the result of differences in administration. Cannabis smokers 
usually develop a larger puff volume, inhale more deeply and hold their breath several 
times longer than tobacco smokers (Wu et al., 1988; Joy et al., 1999).
Chronic cannabis smoking effects are similar to those of tobacco smoking. Regular 
heavy use of cannabis can produce chronic inflammatory changes in the respiratory 
tract, resulting in increased symptoms of chronic bronchitis such as coughing, shortness 
of breath, production of sputum and wheezing (Tashkin et al., 2002). As many cannabis 
smokers also smoke tobacco, analysis of data from a prospective study of almost 
1000 young adults in the Dunedin, New Zealand, birth cohort study (see below) took 
this possible confounding factor into account in assessing the effects of cannabis and 
tobacco on lung function. After correcting for the contribution of tobacco smoking, 
symptoms of bronchitis were 61–144 % more frequent in in dependent cannabis smokers 
than in non-smokers (Taylor et al., 2000).
The epidemiological literature on the effect of cannabis on chronic obstructive 
pulmonary disease (COPD) is inconclusive. In a prospective study involving 990 
individuals aged under 40, ‘non-tobacco’ smoking had a larger effect on respiratory 
function than tobacco smoking, an effect that was maintained in a follow-up of the 
sample (Bloom et al., 1987; Sherrill et al., 1991). In contrast, a longitudinal study 
following groups of cannabis-only smokers, cannabis and tobacco smokers, tobacco-
only smokers and a control group found no significant change in lung function in the 
smoking groups after initial assessments (Tashkin et al., 1987; Tashkin et al., 1997). 
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Lung function was also examined in the Dunedin birth cohort during the follow-ups at 
ages 18, 21 and 26. While a correlation was found between the amount of cannabis 
smoking in this period and a decrease in expiratory flow rate, an indicator of COPD, 
this correlation became of statistically marginal significance only once the subjects’ 
tobacco use was taken into consideration in the statistical analysis (Taylor et al., 2002). 
A recent exploratory study with a convenience sample of 339 participants, mainly 
recruited via the media, found a dose-related impairment of the large airway function, 
resulting in an obstruction of air flow and causing increased pressure on the lungs, with 
more adverse effects reported at higher doses (Aldington et al., 2007).
Carcinogenicity
Respiratory cancer
There is no conclusive evidence that cannabis causes cancer in humans, including those 
cancers associated with tobacco use. However, cellular, genetic and human studies 
suggest that cannabis smoke may be an important risk factor for the development of 
respiratory cancer. Laboratory studies have found little evidence that THC can cause 
mutations in bodily cells that may lead to cancer (Hall and MacPhee, 2002). While 
reviews of laboratory studies have shown that cannabis smoke can produce mutations 
and cancerous changes, these laboratory studies have typically used doses of the drug 
larger than those used by humans on a regular basis and indicate the possibility rather 
than the probability of such changes occurring in humans who smoke cannabis (Kalant, 
2004). Biopsy samples taken from a group of crack, cannabis and tobacco smokers 
found evidence of biochemical and gene alterations — indicators of precancerous 
change (Barsky et al., 1998). These changes occurred in more of the biopsy samples 
taken from the smokers, whether the drugs were smoked alone or in combination, than 
those from the non-smokers.
There is not yet any evidence from controlled studies showing a higher rate of 
respiratory cancers among chronic cannabis smokers. However, there is evidence of an 
additive effect of cannabis and tobacco smoking on histopathological abnormalities in 
lung tissue, similar abnormalities to those that precede lung cancer in tobacco smokers 
(Joy et al., 1999; Tashkin et al., 2002; Hall and Pacula, 2003). However, several factors 
militate against cannabis smokers developing lung cancer. Patterns of cannabis use 
differ to those of cigarette smoking. Cannabis use tends to be time-limited, with most 
smokers stopping in their early to-mid-20s. Those who do continue their cannabis use 
tend to smoke 1–3 cannabis cigarettes a day, compared with 10–30 tobacco cigarettes 
by tobacco smokers. Finally, there are far fewer cannabis smokers than tobacco smokers 
(Hall and MacPhee, 2002).
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There have been case reports of cancers in the aerodigestive tract of young adults with 
a history of heavy cannabis use. These findings are significant because these kinds of 
cancers are rarely found in the adults under the age of 60, even among those who 
smoke tobacco and drink alcohol. This suggests that cannabis smoking may potentiate 
the effects of other risk factors, such as tobacco smoking, and is a more important risk 
factor than tobacco and alcohol use in the early development of respiratory cancers 
(Sridhar et al., 1994; Joy et al., 1999).
Epidemiological studies have provided conflicting evidence for the likelihood of cannabis 
smokers developing cancers. A cohort of 64 855 members of the Kaiser–Permanente 
Medical Care Program in California were recruited to a prospective study over a 6-year 
period. They were asked about their cannabis use on entry into the study and data 
on cancer incidence among the group were collected from a cancer registry and the 
California mortality data system (Sidney et al., 1997). The study did not find an excess 
of cancers among those who used cannabis at the entry to the study or who were current 
smokers compared with those who did not use cannabis when the study started. While 
there was a small but significant risk of developing cancer of the prostate in men and 
cancer of the cervix in women, there was no evidence of a risk of developing tobacco-
related cancers. However, with only 22 % of the people in the study being current 
cannabis smokers, the numbers were small and most were also followed up to an 
average age of 43, too young to find evidence of excess cancers among the cannabis 
smokers.
A second prospective study at the same centre, this time following 133 811 members 
over a period of up to 21 years, found that those who smoked cannabis at least once 
a month had an increased risk of developing malignant primary adult-onset gliomas, 
tumours most commonly developed in the brain and spinal cord. However, other 
important risk factors, such as ionising radiation, were not considered in this study (Efirt 
et al., 2004).
Another epidemiological study retrospectively followed the medical histories of 173 cases 
of head and neck cancers (upper aerodigestive tract) matched with 176 blood donors 
at the same hospital without a history of cancer who were matched by age, sex, race, 
education and alcohol and tobacco use (Zhang et al., 1999). Cancer risk was 2.6 times 
higher in the cannabis smokers than among the non-smokers, and three times higher 
in those who were 55 or younger. There was an increase in cancer risk according to 
increasing frequency and duration of cannabis use. While this study added more weight 
to the suspicion that cannabis smoke may be linked to cancer, it had a number of 
methodological limitations, including the small numbers involved in the study and the 
possible role of other factors not taken into account in the study.
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Two other studies failed to find an association between cannabis use and oral cancers 
(Llewellyn et al., 2004; Rosenblatt et al., 2004). The first, a case–control study of young 
adults, had only 10 % heavy cannabis smokers in its sample of 116 patients. The study 
by Rosenblatt et al. was a large community-based case–control study with 407 patients 
and 615 controls aged 18–65. The study found no relation between the risk of oral 
cancer and ever in lifetime cannabis use or increasing duration and average frequency 
of use. The authors suggested that the discrepancy between their findings and those 
of Zhang et al. arose from the low frequency of cannabis use in the control subjects in 
Zhang’s study, while the frequency of cannabis use in the control subjects in their study 
matched that predicted from population surveys of adults in the USA. However, the study 
had relatively low participation and may have missed cases who had used cannabis.
A recent study attempting to address the methodological deficiencies of the earlier 
studies used a population-based case–control design, with 1 209 cancer patients aged 
between 18 and 59 identified by the Los Angeles County Cancer Surveillance Program, 
matched to cases on age, gender and neighbourhood. Interview data were collected 
on lifetime histories of alcohol, tobacco and illicit drug use, socio-demographic factors, 
diet, family history of cancer and occupational exposures. Cumulative cannabis use 
was measured in joint-years, where 1 joint-year equalled 365 joints. Preliminary 
analysis of the data did not find a positive association between cannabis use and lung 
and aerodigestive tract cancers, with a positive association absent with the long-term 
heavy smokers as well (Morgenstern et al., 2005). Another recently reported study 
examined cannabis use in 611 people who had developed lung cancer and 601 people 
who had developed cancer of the head or neck, matching them on age, gender and 
neighbourhood with 1 040 people without cancer. Heavy cannabis smokers in this study 
had smoked more than 22 000 joints, while moderately heavy smokers had smoked 
between 11 000 and 22 000 joints. Neither group were at increased risk of developing 
cancer and were not at increased risk compared with those in the study who smoked less 
cannabis or none at all (Tashkin et al., 2006).
Childhood cancers
Three studies exploring the risk of cancer in childhood have found evidence of a link 
with maternal cannabis use during pregnancy. The most notable of these studies 
found an association between maternal cannabis use and acute non-lymphoblastic 
leukaemia (ANLL). This case–control study was designed to assess the impact of 
the parents’ environmental exposure to petrochemicals, pesticides and radiation on 
childhood cancer, with maternal cannabis use recorded as one of the factors included 
in the analysis. The results showed that mothers of children with the cancers were 11 
times more likely to have smoked cannabis than the comparison group. When the 
rate of cannabis use was adjusted among the control group to bring it up to the level 
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of other studies of childhood cancer, the risk of cancer was still three times greater 
(Robinson et al., 1989). In the other two case–control studies, again investigating a 
range of factors that may have had an impact on childhood cancers, an increased risk 
of rhabdomyosarcoma and astrocytomas was found in children born to mothers who 
smoked cannabis during their pregnancy (Kuitjen et al., 1992; Grufferman et al., 1993). 
However, there is no evidence for an increase in incidence of these cancers over the 
period 1979–95, which would be expected if maternal cannabis use was a cause of 
these cancers (Hall and MacPhee, 2002).
Reproductive system
THC has been found to inhibit reproductive function in the few human studies reported, 
although these studies have yielded inconsistent evidence. On the basis of research on 
animals, it has been argued that cannabis would probably decrease fertility for both 
men and women in the short term (Joy et al., 1999). It has been suggested that the 
possible effects of cannabis use on spermatogenesis and testosterone may be most 
significant for those males whose fertility is already impaired, for example those with a 
low sperm count (Hall and Pacula, 2003).
The results of research studies on the effects of prenatal cannabis use and birth outcome 
have been small and inconsistent. Some studies have suggested that cannabis smoking 
in pregnancy may reduce birth weight. Controlled studies, including a recently reported 
study analysing the records of live births in New South Wales hospitals over a 5-year 
period, found that this relation remained after controlling for any confounding variables, 
although this relation has not always been found in other studies (Zuckerman et al., 
1989; Joy et al., 1999; Burns et al., 2006). The effects of cannabis smoking where an 
association has been found are small compared with tobacco (Fried et al., 1998). There 
is some evidence that gestation is shorter, especially for adolescent mothers (Cornelius 
et al., 1995; English et al., 1997; Burns et al., 2006). The relative contributions of 
smoking and THC are not known from the evidence available. Large, well-controlled 
epidemiological studies have found no evidence that cannabis causes birth defects 
(Zuckerman et al., 1989).
Maternal cannabis use and infant development
A review of the consequences of prenatal cannabis exposure found that, while prenatal 
exposure did not have an impact on global IQ, it did appear to have an impact on 
aspects of executive function, and, in particular, attentional behaviour and visual 
analysis/hypothesis testing beyond the infant stage. However, the reviewers draw 
attention to the limited literature, the small sample sizes and the quasi-experimental 
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nature of the studies reviewed and urged caution when interpreting the results of their 
review (Fried and Smith, 2001).
There are two major ongoing longitudinal studies examining prenatal exposure and 
subsequent effects on growth, cognitive development and behaviour. The first is the 
Ottawa Prospective Prenatal Study (OPPS), under way since 1978. The sample in this 
study consists of low-risk, white and predominantly middle-class families. The second 
study, the Maternal Health Practices and Child Development Study (MHPCD), began in 
1982. The study sample is high-risk, with low socioeconomic status and just over half 
are African American (Goldschmidt et al., 2000).
The OPPS found that there was a developmental delay after birth in the infant’s visual 
system with an increased rate of tremors and startle among the children of cannabis 
users. These effects had disappeared after 1 month and there were no detectable effects 
on standardised ability tests at 6 months and 12 months (Fried and Smith, 2001). The 
cohort has now been followed up to age 13–16 years. Effects were found on memory at 
age 4, attention at age 6 and visual integration and attention and visual-related aspects 
of executive function in 9- to 12-year-olds. There was no difference between children 
who were and were not prenatally exposed to cannabis on global IQ scores but there 
were differences in tasks that required visual memory, analysis and integration at age 
13–16 (Fried et al., 2003).
A recent study from the Pittsburgh MHPCD examined the effects of prenatal cannabis 
and alcohol exposure on academic achievement at age 10. In contrast to the OPPS, 
which found no effects of prenatal exposure to cannabis on school performance, use of 
cannabis in the first trimester was associated with poorer performance on reading and 
spelling tests and a lower performance evaluation by the children’s teachers. Analysis 
suggested these effects were mediated by the effect of first-trimester use of cannabis on 
the children’s anxiety and depression symptoms. Cannabis use in the second trimester 
was significantly associated with underachievement in school performance. While a 
range of factors, including socioeconomic, home environment and maternal prenatal 
and current drug use, were taken into account in the study, other important factors such 
as motivation and parental involvement in the child’s education did not feature in the 
statistical analysis (Goldschmidt et al., 2004).
Premature mortality
The two prospective studies on mortality amongst cannabis smokers are inconclusive. 
The Swedish study of conscripts showed an increased risk of premature death among 
those who smoked cannabis 50 or more times before the age of 18. Violence and 
accidental death were the main causes of death. This association disappeared after 
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alcohol and other drug use amongst this group were taken into account in the statistical 
analysis (Andreasson and Allebeck, 1990).
In an American study, regular cannabis use had a small association with premature 
mortality, which was entirely explained by the increased deaths from AIDS in men in 
the study. However, only men up to an average age of 43 were included in this study. 
With cigarette smoking and alcohol only modestly associated with premature mortality, 
it is too early to conclude from this study that cannabis use does not increase premature 
mortality (Sidney et al., 1997).
Cannabis and dependence
The US classification of psychiatric disorders, the Diagnostic and Statistical Manual of 
Mental Disorders (DSM), lists seven criteria for assessing substance dependence. These 
criteria are:
tolerance;t
withdrawal;t
the substance is often taken in larger amounts or over a longer period than was t
intended;
there is a persistent desire or unsuccessful attempts to stop or cut down use;t
a great deal of time is spent trying to obtain or use the substance;t
important social, occupational or recreational activities are given up or reduced t
because of substance use; and
use is continued despite knowledge that the substance is causing or exacerbating t
physical or psychological problems.
A diagnosis of substance dependence is given if at least three of these symptoms are 
experienced in the same 12-month period (American Psychiatric Association, 1994).
Human and animal studies have found that tolerance to many of the physiological and 
behavioural effects of cannabis develops after repeated exposure to the drug (Adams 
and Martin, 1996; Joy et al., 1999). A laboratory study in which oral THC was given to 
human subjects over a 30-day period found a decline in the acute cardiovascular and 
psychological effects of THC (Jones and Benowitz, 1976). In another laboratory study, 
tolerance to the subjective effects of cannabis developed after oral administration of a 
small amount of THC for several days, with greater tolerance developing with increased 
amounts of THC (Jones, 1983).
Laboratory studies, while using a range of experimental approaches, have identified 
a number of adverse symptoms associated with withdrawal from cannabis. The most 
common symptoms include restlessness and nervousness, irritability, loss of appetite and 
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sleep disturbance. However, the extent to which the pattern of cannabis use contributes 
to the severity of withdrawal symptoms is undetermined. Most of the laboratory studies 
have involved heavy daily users as their subjects and the extent to which withdrawal may 
affect light or non-daily users is unclear (Budney and Hughes, 2006).
Using standardised diagnostic criteria for dependence such as DSM, epidemiological 
studies have estimated the extent of cannabis dependence in the general population. For 
example, the US Epidemiologic Catchment Study (ECA) estimated that 4.4 % of the US 
adult population had either abused cannabis or were dependent on it at some point in 
their life (Robins and Regier, 1991). Seventeen per cent of those in the ECA study who 
used cannabis more than five times had met DSM-III criteria for dependence at some 
point in their lives (Anthony and Helzer, 1991). Studies of long-term cannabis users in 
Australia found a substantial proportion of them were dependent. In a study of 200 
young Sydney adults who had used cannabis at least weekly for 11 years, 77 % met the 
DSM-III criteria for dependence in the past year and 40 % were classified as severely 
dependent (Swift et al., 1998).
National drug treatment systems have recorded an increase in the number of people 
seeking treatment for cannabis problems including dependence (see Montanari et al., 
this monograph). However, several studies have found that most regular cannabis users 
discontinue their use of cannabis by their mid-20s. For example, a longitudinal study 
of US school students found that less than 15 % of them were using cannabis daily by 
the age of 28–29 (Kandel and Davies, 1992). While studies of cannabis users who 
are unable to discontinue their use with assistance found that they were experiencing 
impaired functioning and a reduction in the quality of their lives, for the most part those 
with cannabis dependence seem to be able to remit their cannabis use without treatment 
(Budney and Moore, 2002; Hall and Pacula, 2003).
Cannabis and psychosis
There is evidence that large doses of THC can produce an acute psychosis marked 
by confusion, amnesia, delusions, hallucinations, anxiety, agitation and hypomanic 
symptoms. Nonetheless, such high THC doses are rare among cannabis smokers, 
given that they are likely to stop smoking if they experience undesired effects. Cases do 
exist, however, of high doses following ingestion of cannabis (cannabis cookies, space 
cake), where the user has less immediate control over THC titration. Such reactions may 
also occur after heavy cannabis use, or in some instances, after acute cannabis use by 
sensitive/vulnerable individuals. These effects abate rapidly after discontinuing cannabis 
use. There is little evidence that cannabis alone produces a psychosis that persists after 
the period of intoxication in non-vulnerable cannabis users (Joy et al., 1999; Hall and 
Degenhardt, 2000).
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Cannabis has been found to have an adverse effect on the clinical course of 
schizophrenia. In a Dutch prospective study which assessed patients each month over 
a year, the 24 people in the cannabis-using group had significantly earlier psychotic 
relapses than the non-cannabis-using group, an effect that was dose-related (Linszen et 
al., 1994). Similar findings emerged in a 3-year follow-up community study of psychotic 
and non-psychotic patients also in the Netherlands. The cannabis users at the beginning 
of the 3-year study were more likely to have psychotic symptoms and particularly severe 
ones at follow-up. Those who were diagnosed as psychotic at the beginning of the study 
had more adverse effects from cannabis use than those who were not psychotic at the 
start of the study (van Os et al., 2002). In a study that followed up 81 patients in acute 
psychiatric wards weekly for 6 months, a higher frequency of cannabis use led to more 
psychotic relapses in the patients, after controlling for other established factors leading 
to relapse in the statistical analysis (Hides et al., 2006). In contrast, a follow-up study 
of alcohol- and cannabis-using patients in a psychiatric outpatient continuing care 
programme in Canada found that symptoms of schizophrenia-spectrum disorders were 
reduced at 12 months (Margolese et al., 2006).
Findings from national surveys in the USA, Australia and the Netherlands have 
found higher rates of cannabis use in patients with schizophrenia than the general 
population. For example, the US National Epidemiological Catchment Area study 
(Robins and Regier, 1991) indicated that 50 % of those identified with schizophrenia 
also had a diagnosis of substance use disorder (abuse or dependence), compared 
with 17 % of the general population (Regier et al., 1990). People who used cannabis 
on a daily basis were 2.4 times more likely to report psychotic experiences than non-
daily cannabis users, after controlling for a variety of confounding variables such as 
socio-demographic factors, social role and psychiatric conditions (Tien and Anthony, 
1990). A study of cannabis use and psychotic symptoms at age 18 in a cohort of 3 500 
Greek adolescents found positive associations between frequency of cannabis use and 
psychotic experiences after controlling for other drug use and depressive symptoms in 
the statistical analysis, with a stronger association for those who started their cannabis 
use before age 15. However, the rates of cannabis use in the study group was low, with 
6 % reporting lifetime cannabis use and 0.9 % reporting daily or near-daily use (Stefanis 
et al., 2004).
Four main views on the nature of this association have been proposed. Firstly, the 
link may be due to socio-demographic, economic or genetic factors common to both 
substance use and schizophrenia. Secondly, the self-medication hypothesis suggests 
that patients with schizophrenia may be using cannabis and other drugs as a form of 
self-treatment for their condition. Thirdly, some suggest that cannabis causes psychosis. 
Finally, the vulnerability hypothesis proposes that the use of cannabis can increase the 
risk of schizophrenia among people with a predisposition to the illness.
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A number of carefully designed prospective studies have helped to assess the value of 
these hypotheses. These studies have been used to chart the development of a number 
of psychosocial and behavioural topics, and cannabis is just one issue the datasets 
have allowed to be explored. The findings from these studies have been summarised 
in a number of reviews (Arseneault et al., 2004; Smit et al., 2004; Degenhardt and 
Hall, 2006) and two meta-analyses and one systematic review (Henquet et al., 2005a; 
Semple et al., 2005; Moore et al., 2007).
The Swedish conscript study
A 15-year prospective study of cannabis use and schizophrenia in 50 465 Swedish 
military conscripts was the first study to report a potential link between cannabis use 
and later schizophrenia. The study recruited conscripts who were 18–20 years old in 
1969–70. Conscripts who were hospitalised for schizophrenia or psychosis and could 
be linked to their military medical records were identified. Through this linkage, the 
relationship between cannabis use and the onset of schizophrenia might be established.
The relative risk for a diagnosis of schizophrenia was 1.3 times higher for those who 
had used cannabis 1–10 times, three times higher for those who had used cannabis 
1–50 times and six times higher for heavy users of cannabis (defined as use on more 
than 50 occasions) than among those who had not used cannabis. However, over half 
of the heavy users had had a diagnosis of a psychiatric condition other than psychosis 
at conscription and when the analysis took this factor into account the relative risk fell to 
2.3 (Andreasson et al., 1987; Allebeck, 1991).
A follow-up of the conscripts reported in 2002. Again, heavy cannabis users were found 
to be 6.7 times more likely than non-users to be at risk of a diagnosis of schizophrenia 
after 27 years. The risk held when the analysis was carried out on a subsample of 
conscripts who had used cannabis only. While not an exhaustive array, when other 
possible confounding factors such as psychiatric diagnosis at conscription, IQ, growing 
up in a city and cigarette smoking were taken into account the risk, though reduced, still 
remained, with heavy cannabis users having a threefold relative risk of a diagnosis of 
schizophrenia (Zammit et al., 2002).
The Dunedin Multidisciplinary Health and Development Study
The Dunedin Study from New Zealand has followed a birth cohort of 1 037 people from 
the general population born in 1972–3. At age 11 they were examined to identify any 
self-reported psychotic symptoms before cannabis use may have begun. At 15 and 18 
they were examined for self-reported cannabis use, enabling the investigation of the 
age of onset in relation to later outcomes. At age 26 the subjects were interviewed to 
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see if they met the criteria of schizophreniform disorder according to DSM-IV diagnostic 
criteria. A diagnosis of schizophreniform disorder enabled the elimination of psychotic 
symptoms resulting from being under the influence of alcohol or drugs. Ninety-six per 
cent of the birth cohort had remained in the study at this point.
Those who used cannabis at ages 15 and 18 had higher rates of psychotic symptoms 
at age 26 than non-users, a relationship that remained after the analysis controlled 
for psychotic symptoms predating cannabis use. Those who started using cannabis 
by the age of 15 showed a fourfold increase in the likelihood of a diagnosis of 
schizophreniform disorder by the age of 26. The analysis also showed that cannabis use 
by age 15 did not predict depression at age 26, suggesting the outcome was specific 
to the cannabis use. The study reported that 10.3 % of the 15-year-olds using cannabis 
received a diagnosis of schizophreniform disorder by the age of 26, compared with 3 % 
of the controls. The number of 15-year-olds smoking cannabis in the study was small, 
however (Arseneault et al., 2002).
The Christchurch Health and Development Study
Another New Zealand Study followed a birth cohort of 1 265 people born in 
Christchurch urban region, with annual measurements up to the age of 16. Additional 
measurements were taken at age 18, including whether the individuals had a DSM 
diagnosis of cannabis dependence and whether psychotic symptoms were identified. 
This examination was repeated at ages 21 and 25. Researchers were able to draw on 
a sample of 1 055 participants for whom information on cannabis use and psychotic 
symptoms were available at ages 18, 21 and 25, when 1 011 people remained in the 
study. Psychosis symptomatology was measured with psychosis items selected from of the 
symptom checklist as representative of the psychotic symptoms. This study addressed two 
main questions about the relationship between cannabis and psychosis in its analysis. 
It attempted to control for residual confounding in its analysis and examine whether 
reverse causality may be in play, with an increased susceptibility to use cannabis 
resulting from the individual’s psychological state. A wide range of confounding factors 
were controlled for in the analysis, including family socioeconomic status, family 
functioning, child abuse including physical punishment, educational achievement and 
psychotic symptoms at the previous assessment. Analysis also took into account non-
observed fixed sources of confounding (Fergusson et al., 2003, 2005).
The results showed that young people using cannabis daily had rates of psychotic 
symptoms that were between 2.3 and 3.3 times higher than those of non-users. After 
adjusting the analysis to take into account the confounding factors, this relationship 
persisted with daily users 1.6–1.8 times more likely to be experiencing rates of psychosis 
than non-cannabis users. While the study could not control for all possible confounding 
factors and the diagnostic tools used in the study may not have found all the aspects 
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of psychosis, the research shows that increasing use of cannabis was associated 
with increases in the risks of psychotic symptoms, and that the increases in psychotic 
symptoms were not associated with increased rates of cannabis use, casting doubt on 
the self-medication hypothesis (Fergusson et al., 2005).
The Netherlands Mental Health Survey and Incidence Study 
(NEMESIS)
This study followed 7 076 adults aged 18–65 years randomly selected from the Dutch 
general population, who were examined in 1996, 1997 and 1999. A total of 4 848 
people were still in the study at the 1999 follow-up, 4 045 of whom were considered as 
the ‘at-risk’ set. The attrition of participants was covered in the analysis of findings from 
the study. At the 3-year point those who used cannabis at baseline were three times 
more likely to show psychotic symptoms than non-users. This relationship persisted after 
controlling for a range of factors in the analysis, such as ethnic group, marital status, 
educational level and urbanicity. The study also found a dose–response relationship, 
with the highest risk of psychotic symptoms amongst those who used cannabis more 
frequently at the beginning of the study. Lifetime history of cannabis at baseline was 
a stronger predictor of later psychosis than cannabis use at follow-up, suggesting that 
the relationship between cannabis use and psychosis is not simply one resulting from a 
short-term psychotic episode (van Os et al., 2002).
The early developmental stages of psychopathology (EDSP) study
The EDSP study examined the prevalence, incidence, risk factors and 4-year course of 
mental disorders in a random representative sample of adolescents and young adults 
aged 14–24 in Munich. The baseline survey with 3 021 participants was conducted in 
1995, with follow-up data for 2 437 participants in 1999. After adjusting for a range 
of factors in the analysis, cannabis use at baseline moderately increased the risk of 
psychotic symptoms at follow-up. The effect of cannabis was stronger for those with 
any predisposition for psychosis at baseline than those without, with a dose–response 
relation with increasing frequency of use. Predisposition to psychosis did not predict 
cannabis use at follow-up in the analysis, suggesting that the cannabis was not used as 
self-medication in this group (Henquet et al., 2005b).
What is the relationship between cannabis and 
psychosis?
While these various studies used a range of methodologies, measurements of cannabis 
use and psychosis and, in the cases of the Dunedin and NEMESIS studies, were marked 
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by small sample sizes, there was some consistency in the risk of developing psychosis 
after cannabis use across all the populations studied. The Moore et al. meta-analysis 
concluded that those who had ever used cannabis were 40 % more likely to experience 
a psychotic outcome than non-users and regular cannabis use increased the chances of 
developing later schizophrenia or schizophrenia-like psychotic illness by approximately 
two- to threefold (Arseneault et al., 2004; Henquet et al., 2005a; Semple et al. 2005; 
Moore et al., 2007). In the Dunedin study, those who started their cannabis use by age 
15 had a higher risk of developing schizophreniform disorder by age 26 than those 
who started at age 18, suggesting that early cannabis use may provide higher risk 
of psychosis outcomes (Arseneault et al., 2002). The analysis from the Christchurch 
population study has gone the furthest in terms of controlling for a wide range of 
possible confounding demographic, social and individual factors in their analysis, 
suggesting that the association between cannabis use and psychosis in the study 
population is unlikely to be due to confounding factors (Fergusson et al., 2005). The 
analysis also suggested that the direction of causality was from cannabis to psychosis.
With the Christchurch and other studies eliminating the self-medication hypothesis, 
the studies also eliminated the idea that other drugs may be involved and found that 
cannabis makes its own unique contribution to the development of later schizophrenia or 
psychotic symptoms.
The significance of the relationship between cannabis and 
schizophrenia to public health
However, the increased rates of cannabis use in the last 30 years have not been 
accompanied by a corresponding increase in the rates of psychosis in the population 
(Degenhardt et al., 2003a). The studies reviewed here suggest that cannabis is a 
modest statistical risk factor, with studies calculating that 6–8 % of schizophrenia could 
be prevented if cannabis use was removed from the general population of adolescents 
and young adults (Arseneault et al., 2004; Henquet et al., 2005b). The vast majority of 
young cannabis smokers do not develop psychosis, and this supports the hypothesis that 
a small minority of users may be vulnerable to the effects of cannabis and time of onset 
to psychotic illness. The vulnerability hypothesis has received some support from a study 
that explored substance use and psychotic experiences in daily life. The acute effects 
of cannabis were stronger among participants with high vulnerability for psychosis 
(experiencing at least one bizarre psychotic symptom or at least two non-bizarre 
symptoms over the first month). Those vulnerable participants reported increased levels 
of perceived hostility and unusual perceptions, and also decreased levels of pleasure 
associated with the experience of using cannabis (Verdoux et al., 2003). That cannabis 
is a risk factor for earlier onset is further supported by a study examining first-episode 
psychosis in the Netherlands, which found that cannabis users in the group presented 
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to treatment earlier than non-users, with a median age difference of 7.5 years (Veen 
et al., 2004). Adding further weight to the strength of the vulnerability hypothesis is a 
recent study that examined a gene–environment interaction in the Dunedin population, 
finding that a gene called COMT moderated the influence of adolescent cannabis use 
on developing adult psychosis in the Dunedin population, a finding also reported in an 
experimental setting (Caspi et al., 2005; Henquet et al., 2006). However, this interaction 
was reported only in a small subgroup of participants in each study and awaits further 
replication.
Cannabis and depression and anxiety
There have been a number of case reports of panic reactions after cannabis use. In a 
survey of 1 000 young adults in New Zealand, acute anxiety and panic was the most 
common psychiatric problem reported by cannabis smokers in the study (Thomas, 
1996). Lifetime cannabis dependence, measured using DSM criteria, was significantly 
related to an increased risk of panic attacks in a large statewide randomly sampled 
household survey conducted in the USA (Zvolensky et al., 2006). National population 
studies have found evidence for a link between cannabis use and depression. A study 
of a nationally representative sample of 7 000 adults aged 15–45 in the USA found a 
small increased risk of depression among the current users of cannabis (Chen et al., 
2002). Another study of a nationally representative sample of 40- to 50-year-olds in 
the USA found a small increased risk, but one that was associated with earlier onset of 
cannabis use rather than current use (Green and Ritter, 2000). A national population 
study in Australia found that cannabis users were between two and three times more 
likely to meet criteria for a mood disorder than non-users. Prevalence of mood disorders 
increased from 6 % in non-users to 14 % of those who met criteria for cannabis 
dependence (Degenhardt et al., 2001).
A meta-analysis of cohort studies found a modest but significant association between 
early onset heavy use of cannabis and later depression but no evidence that depression 
increased the probability of later use of cannabis (Degenhardt et al., 2003b). For 
example, a follow-up study of participants with no depressive symptoms at the beginning 
of the Epidemiologic Catchment Area study found that those with a diagnosis of 
cannabis abuse at baseline were four times more likely than those without a cannabis 
abuse diagnosis to have depressive synmptoms at follow-up (Bovasso, 2001). In a 
longitudinal study of a representative sample of 1 601 secondary school students in the 
Australian state of Victoria, weekly or more frequent use led to a doubling of the risk 
for later anxiety or depression by the age of 20, while female daily users had a fivefold 
increase in later depression and anxiety (Patton et al., 2002). Depression and anxiety in 
the students did not predict later cannabis use in the analysis, suggesting that cannabis 
was not used for self-medication. However, findings from the smaller New Zealand 
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Dunedin sample indicated that those in the sample using cannabis by age 15 did not 
have a significantly higher risk of later depression by the age of 26 than non-users 
did, although the sample size may have prevented the identification of a relationship 
in the statistical analysis (Arseneault et al., 2002). In a follow-up study of the New 
Zealand Christchurch sample, the analysis controlled for a range of confounding factors 
that might explain the association between cannabis and a range of psychosocial 
outcomes including depression and suicide attempts. The link between cannabis and 
these outcomes and heavy (at least weekly) cannabis use still persisted, suggesting that 
cannabis was contributing directly to these outcomes (Fergusson et al., 2002). A recent 
analysis of data from the ongoing National Longitudinal Survey of Youth of 1979 with a 
large cohort of 12 686 men and women born between 1957 and 1964 did not find that 
past-year cannabis use predicted later development of depression (Harder et al., 2006). 
However, the study group may have been too old and restricted in age range for the 
relatively low level of their cannabis use to result in significant symptoms of depression 
(Copeland, 2006). Overall, a recent meta-analysis has concluded that the majority of 
studies of cannabis and affective mental health problems have not adequately addressed 
the issue of reverse causation, and the evidence for a link is not strong (Moore et al., 
2007).
Impact of increased potency of cannabis
High-THC cannabis is reported to have become increasingly available, although the 
published evidence for this is scant (Hall and Swift, 2000; King et al., 2005). This 
may reflect an increased market for more potent cannabis amongst regular users and 
improved methods of growing high-potency cannabis. The health implications of this 
development are unclear. Those who use these high-potency products may increase their 
risks of developing respiratory disease or experiencing psychotic symptoms (Hall and 
Pacula, 2003). However, regular users may be able to titrate their dose and decrease 
the risks of respiratory disease, and naive users who experience adverse effects may be 
deterred from further cannabis use (Hall and Pacula, 2003). As yet, there is insufficient 
evidence to inform a conclusive view of the risks to health posed by high-potency 
cannabis (King et al., 2005).
Conclusion
Most cannabis users cease smoking cannabis by their late 20s or early 30s and the 
vast majority do not experience any adverse effects from their use. A minority continue 
their use into middle age, and such long-term heavy users have reported a range of 
negative health effects (Reilly et al., 1998; Gruber et al., 2003). However, the causal 
role of cannabis in the development of negative physical and mental health problems 
for some users remains uncertain and in need of further investigation. Recent research 
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has provided more information on the involvement of cannabis in the development 
of psychiatric disorders such as depression and psychosis in vulnerable people, or 
bronchial problems resulting from cannabis smoke. But more research work is needed to 
address the precise role of cannabis in health-related problems and the broad research 
agenda for cannabis remains much the same as 30 years ago.
References
Adams, I., Martin, B. (1996), ‘Cannabis: pharmacology and toxicology in animals and humans’, 
Addiction 91: 1585–1614.
Aldington, S., Williams, M., Nowitz, M., Weatherall, M., Pritchard, A., McNaughton, A., Robinson, 
G., Beasley, R. (2007), ‘Effects of cannabis on pulmonary structure, function and symptoms’, 
Thorax: 1–7.
Allebeck, P. (1991), ‘Cannabis and schizophrenia: is there a causal association?’ in Nahas, G. G., 
Latour, C. (eds), Physiopathology of illicit drugs: cannabis, cocaine, opiates, Pergamon Press, 
Oxford.
APA (1994), Diagnostic and statistical manual of mental disorders, American Psychiatric Association, 
Washington DC.
Andreasson, S., Allebeck, P. (1990), ‘Cannabis and mortality among young men: a longitudinal study 
of Swedish conscripts’, Scandinavian Journal of Social Medicine 18: 9–15.
Andreasson, S., Allebeck, P., Engstrom, A., Rydberg, U. (1987), ‘Cannabis and schizophrenia: a 
longitudinal study of Swedish conscripts’, Lancet 2: 1483–1486.
Anthony, J. C., Helzer, J. E. (1991), ‘Syndromes of drug abuse and dependence’, in Robins, L. N., 
Regier, D. A. (eds), Psychiatric disorders in America: the epidemiologic catchment area study, Free 
Press, New York, 116–154.
Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., Moffitt, T. (2002), ‘Cannabis use in 
adolescence and risk for adult psychosis: longitudinal prospective study’, British Medical Journal 
325: 1212–1213.
Arseneault, L., Cannon, M., Witton, J., Murray, R. (2004), ‘Causal association between cannabis and 
psychosis: examination of the evidence’, British Journal of Psychiatry 184: 110–117.
Atha, M., Blanchard, S. (1997), Regular users: self-reported drug consumption patterns and attitudes 
towards drugs among 1333 regular cannabis users, Independent Drug Monitoring Unit (IDMU), 
Wigan.
Atha, M., Blanchard, S. (1998), ‘Consumption patterns of regular cannabis users’, in Written evidence 
for the House of Lords Science and Technology Select Committee, Sub-committee I: cannabis, 
submission of the Independent Drug Monitoring Unit, Independent Drug Monitoring Unit (IDMU), 
Wigan.
Bachs, L., Morland, H. (2001), ‘Acute cardiovascular fatalities following cannabis use’, Forensic 
Science International 124: 200–203.
Barsky, S., Roth, M., Kleerup, E., Simmons, M., Tashkin, D. (1998), ‘Histopathologic and molecular 
alterations in bronchial epithelium in habitual smokers of marijuana, cocaine and/or tobacco’, 
Journal of the National Cancer Institute 90: 1198–1205.
Bloom, J., Kaltenhorn, W., Paoletti, P., Camilli, A., Lebowitz, M. (1987), ‘Respiratory effects of non-
tobacco cigarettes’, British Medical Journal 295: 1516–1518.
Bovasso, G. (2001), ‘Cannabis abuse as a risk factor for depressive symptoms’, American Journal of 
Psychiatry 158: 2033–2037.
Budney, A., Hughes, J. (2006), ‘The cannabis withdrawal syndrome’, Current Opinion in Psychiatry 
19: 233–238.
Cannabis use and physical and mental health
136
Budney, A., Moore, B. (2002), ‘Development and consequences of cannabis dependence’, Journal of 
Clinical Pharmacology 42: 28S–33S.
Burns, L., Mattick, R., Cooke, M. (2006), ‘The use of record linkage to examine illicit drug use in 
pregnancy’, Addiction 101: 873–882.
Calafat, A., Fernández, C., Becoña, E., Gil, E., Juan, M., Torres, M. (2000), ‘Consumo y consumidores 
de cannabis en la vida recreativa’, in Calafat, A., Bobes, J. (eds), Monografía cannabis, Plan 
Nacional sobre Drogas, Madrid.
Caspi, A., Moffitt, T., Cannon, M., McClay, J., Murray, R., Harrington, H., Taylor, A., Arseneault, 
L., Williams, B., Braithwaite, A., Poulton, R., Craig, I. W. (2005), ‘Moderation of the effect of 
adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catachol-
O-methyltransferase gene: longitudinal evidence of a gene-environment interaction’, Biological 
Psychiatry 57: 1117–1127.
Chen, C.Y., Wagner, F., Anthony, J. (2002), ‘Marijuana use and the risk of major depressive episode. 
Epidemiological evidence from the United States National Comorbidity Survey’, Social Psychiatry 
and Psychiatric Epidemiology 37: 199–206.
Copeland, J. (2006), ‘Cannabis use, depression and public health’, Addiction 101: 1380.
Cornelius, M., Taylor, P., Geva, D., Day, N. (1995), ‘Prenatal tobacco and marijuana use among 
adolescents: effects on offspring, gestational age, growth and morphology’, Pediatrics 95: 
738–743.
Degenhardt, L., Hall. W. (2006), ‘Is cannabis use a contributory cause of psychosis?’, Canadian 
Journal of Psychiatry 51: 566–574.
Degenhardt, L., Hall, W., Lynskey, M. (2001), ‘The relationship between cannabis use, depression 
and anxiety among Australian adults: findings from the National Survey of Mental Health and 
Well-Being’, Social Psychiatry and Psychiatric Epidemiology 36: 219–227.
Degenhardt, L., Hall, W., Lynskey, M. (2003a), ‘Testing hypotheses about the relationship between 
cannabis use and psychosis’, Drug and Alcohol Dependence 71: 37–48.
Degenhardt, L., Hall, W., Lynskey, M. (2003b), ‘Exploring the association between cannabis use and 
depression’, Addiction 98: 1493–1504.
Efirt, J., Friedman, G., Sidney, S., Klatsky, A., Habel, L., Udaltsova, N., Van Den Eden, S., Nelson, L. 
(2004), ‘The risk for malignant primary adult-onset glioma in a large multiethnic mamanger-care 
cohort: cigarette smoking and other lifestyle behaviors’, Journal of Neuro-oncology 68: 57–69.
English, D., Hulse, G., Milne, E., Holman, C., Bower, C. (1997), ‘Maternal cannabis use and birth 
weight: a meta-analysis’, Addiction 92: 1553–1560.
Fergusson, D. M., Horwood, L. J., Swain-Campbell, N. (2002), ‘Cannabis use and psychosocial 
adjustment in adolescence and young adulthood’, Addiction 97: 1123–1135.
Fergusson, D. M., Horwood, L. J., Swain-Campbell, N. R. (2003), ‘Cannabis dependence and 
psychotic symptoms in young people’, Psychological Medicine 33: 15–21.
Fergusson, D. M., Horwood, L. J., Ridder, E. M. (2005), ‘Tests of causal linkages between cannabis 
use and psychotic symptoms’, Addiction 100: 354–366.
Fried, P. A., Smith, A. M. (2001), ‘A literature review of the consequences of prenatal exposure: an 
emerging theme of a deficiency in aspects of executive function’, Neurotoxicology and Teratology 
23: 1–11.
Fried, P.A., Watkinson, B., Gray, R. (1998), Differential effects on cognitive functioning in 9- to 
12-year-olds prenatally exposed to cigarettes and marihuana’. Neurotoxicology and Teratology 
20: 293–306.
Fried, P. A., Watkinson, B., Gray, R. (2003), ‘Differential effects on cognitive functioning in 13- to 
16-year-olds prenatally exposed to cigarettes and marihuana’, Neurotoxicology and Teratology 
25: 427–436.
Goldschmidt, L., Day, N. L., Richardson, G. (2000), ‘Effects of prenatal marijuana exposure on child 
behavior problems at age 10’, Neurobehavior and Toxicology 22: 325–336.
Chapter 6
137
Goldschmidt, L., Richardson, G., Cornelius, M., Day, N. (2004), ‘Prenatal marijuana and alcohol 
exposure and academic achievement at age 10’, Neurotoxicology and Teratology 26: 521–532.
Green, B. E., Ritter, C. (2000), ‘Marijuana use and depression’, Journal of Health and Social Behavior 
41: 40–49.
Gruber, A., Pope, H., Hudson, J., Yurgelin-Todd, D. (2003), ‘Attributes of long-term heavy cannabis 
users: a case–control study’, Psychological Medicine 33: 1415–1422.
Grufferman, S., Schwartz, A., Ruymann, F., Maurer, H. (1993), ‘Parents’ use of cocaine and 
marijuana and increased risk of rhabdomyosarcoma in their children’, Cancer Causes and Control 
4: 217–224.
Hall, W., Degenhardt, L. (2000), ‘Cannabis use and psychosis: a review of clinical and epidemiological 
evidence’, Australian and New Zealand Journal of Psychiatry 34: 26–34.
Hall, W., MacPhee, D. (2002), ‘Cannabis and cancer’, Addiction 97: 243–247.
Hall, W., Pacula, R. (2003), Cannabis use and dependence: public health and public policy, 
Cambridge University Press, Cambridge.
Hall, W., Swift, W. (2000), ‘The THC content of cannabis in Australia: evidence and policy 
implications’, Australian and New Zealand Journal of Public Health 24: 503–508.
Harder, V. S., Morral, A. R., Arkes, J. (2006), ‘Marijuana use and depression among adults: testing 
for causal association’, Addiction 101: 1463–1472.
Hart, C. L., van Gorp, W., Haney, M., Foltin, R. W., Fischman, M. W. (2001), ‘Effects of acute smoked 
marijuana on complex cognitive performance’, Neuropharmacology 25: 757–765.
Henquet, C., Murray, R., Linszen, D., van Os, J. (2005a), ‘The environment and schizophrenia: the 
role of cannabis use’, Schizophrenia Bulletin 31: 608–612.
Henquet, C., Krabbendam, L., Spauwen, J., Kaplan, C., Lieb, R., Wittchen, H-U., van Os, J. (2005b), 
‘Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms 
in young people’, British Medical Journal 330: 11–14.
Henquet, C., Rosa, A., Krabbendam, L., Papiol, S., Fananás, L., Drukker, M., Ramaekers, J., van Os, 
J. (2006), ‘An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-
9-tetrahydrocannabinol-induced effects on psychosis and cognition’, Neuropsychopharmacology 
12: 48–57.
Hides, L., Dawe, S., Kavanagh, D. J., Young, R. M. (2006), ‘Psychotic symptom and cannabis relapse 
in recent-onset psychosis’, British Journal of Psychiatry 189: 137–143.
Hollister, L. (1992), ‘Marijuana and immunity’, Journal of Psychoactive Drugs 24: 159–163.
Inserm (2001), Cannabis: Quels effets sur le comportement et la santé?, Les éditions Inserm, Paris.
Iversen, L. (2005), ‘Long-term effects of exposure to cannabis’, Current Opinion in Pharmacology 5: 
69–72.
Jones, R. T. (1983), ‘Cannabis tolerance and dependence’, in Fehr, K. O., Kalant, H. (eds), Cannabis 
and health hazards, Addiction Research Foundation, Toronto, 617–689.
Jones R. T., Benowitz N. L. (1976), ‘The 30 day trip: clinical studies of cannabis tolerance and 
dependence’, in Braude, C., Szara, S. (eds), Pharmacology of marijuana, Raven Press, New York, 
627–642.
Joy, J., Watson, S., Benson, J. (eds) (1999), Marijuana and medicine: assessing the evidence base, 
National Academy Press, Washington.
Kalant, H. (2004) ‘Adverse effects of cannabis on health: an update of the literature since 1996’, 
Progress in Neuro-Psychopharmacology and Biological Psychiatry 28: 849–863.
Kalant, H., Corrigal, W., Hall, W., Smart, R. (eds) (1999), The health effects of cannabis, Addiction 
Research Foundation, Toronto.
Kandel, D. B., Davies M. (1992), ‘Progression to regular marijuana involvement: phenomenology 
and risk factors for near-daily use’, in Glantz, M. D. (ed.), Vulnerability to drug abuse, American 
Psychological Association, Washington DC, 211–253.
Cannabis use and physical and mental health
138
Kaslow, R. A., Blackwelder, W. C., Ostrow, D. G. (1989), ‘No evidence for a role of alcohol or 
other psychoactive drugs in accelerating immunodeficiency in HIV-1 positive individuals: a report 
from the Multicentre AIDS Cohort Study’, Journal of the American Medical Association 261: 
3424–3429.
King, L., Carpentier, C., Griffiths, P. (2005), ‘Cannabis potency in Europe’, Addiction 100: 
884–886.
Kraft, B., Kress, H. G. (2004), ‘Cannabinoids and the immune system: of men, mice and cells’, 
Schmerz 18: 203–210.
Kuitjen, R. R., Bunin, G. R., Nass, C. C., Meadows, A. T. (1992), ‘Parental occupation and childhood 
astrocytoma’, Cancer Research 52: 782–786.
Linszen, D. H., Dingemans, P. M., Lenior, M. E. (1994), ‘Cannabis abuse and the course of recent 
onset schizophrenic disorders’, Archives of General Psychiatry 51: 273–279.
Llewellyn, C. D., Linklater, K., Bell, J. (2004), ‘An analysis of risk factors for oral cancer in young 
people: a case–control study’, Oral Oncology 40: 304–313.
Macleod, J., Oakes, R., Copello, A., Crome, I., Egger, M., Hickman, M., Oppenkowski, T., Stokes, 
H., Davey Smith, G. (2004), ‘Psychological and social sequelae of cannabis and other illicit drug 
use by young people: a systematic review of longitudinal, general population studies’, Lancet 363: 
1579–1588.
Margolese, H. C., Negrete, J. C., Tempier, R., Gill, K. (2006), ‘A 12-month prospective follow-up 
study of patients with schizophrenia-spectrum disorders and substance abuse: changes in 
psychiatric symptoms and substance use’, Schizophrenia Research 83: 65–75.
Mensinga, T., de Vries, I., Kruidenier, M., Hunault, C., van den Hengel-Koot, C., Fijen, M., Leenders, 
M., Meulenbelt, J. (2006), Dubbel-blind, gerandomiseerd, placebogecontroleerd, 4-weg gekruist 
onderzoek naar de farmacokinetiek en effecten van cannabis, RIVM rapport 267002001/2006, 
Bilthoven.
Mittleman, M. A., Lewis, R. A., MacLure, M., Sherwood, J. B., Muller, J. E. (2001), ‘Triggering 
myocardial infarction by marijuana’, Circulation 103: 2805–2809.
Moore, T. H. M., Zammit, S., Lingford-Hughes, A., Barnes, T. R. E., Jones, P. B., Burke, M., Lewis, 
G. (2007), ‘Cannabis use and risk of psychotic or affective mental health outcomes: a systematic 
review’, Lancet 370: 319–328.
Morgenstern, H., Greenland, S., Zhang, Z-F., Cozen, W., Mack, T. M., Tashkin, D. P. (2005), 
Marijuana use and cancers of the lung and upper aerodigestive tract: results of a case–control 
study’, in International Cannabinoid Research Society. 2005 Symposium on the Cannabinoids, 
ICRS, Burlington, VT, 49.
Moussouttas, M. (2004), ‘Cannabis use. and cerebrovascular disease’, The Neurologist 10: 47–53.
Patton, G. C., Coffey, C., Carlin, J. B., Degenhardt, L., Lynskey, M., Hall, W. (2002), ‘Cannabis use 
and mental health in young people: cohort study’, British Medical Journal 325: 1195–1198.
Regier, D., Farmer, M. E., Rae, D. S. (1990), ‘Comorbidity of mental disorders with alcohol and other 
drug abuse: results from the epidemiologic catchment area (ECA) study’, Journal of the American 
Medical Association 264: 2511–2518.
Reilly, D., Didcott, P., Swift, W., Hall, W. (1998), ‘Long-term cannabis use: characteristics of users in 
an Australian rural area’, Addiction 93: 837–846.
Robins, L. N., Regier, D. A. (1991), Psychiatric disorders in America: the epidemiologic catchment area 
study, Free Press, New York.
Robinson, L., Buckley, J., Daigle, A., Wells, R., Benjamin, D., Arthur, D. C., Hammond, G. D. (1989), 
‘Maternal drug use and the risk of childhood nonlymphoblastic leukemia among offspring; an 
epidemiologic investigation implicating marijuana’, Cancer 63: 1904–1911.
Rodondi, N., Pletcher, M. J., Liu, K., Hulley, S. B., Sidney, S. (2006), ‘Marijuana use, diet, Body Mass 
Index, and cardiovascular risk factors (from the CARDIA study)’, American Journal of Cardiology 
98: 478–484.
Chapter 6
139
Rosenblatt, K., Daling, J. R., Chen, C., Sherman, K. J., Schwartz, S. M. (2004), ‘Marijuana use and 
risk of oral squamous cell carcinoma’, Cancer Research 64: 4049–4054.
Roth, M. D., Whittaker, K., Salehi, K., Tashkin, D. P., Baldwin, G. C. (2004), ‘Mechanisms for 
impaired effector function in alveolar macrophages from marijuana and cocaine smokers’, 
Journal of Neuroimmunology 147: 82–86.
Semple, D. M., McIntosh, A. M., Lawrie, S. M. (2005), ‘Cannabis as a risk factor for psychosis: 
systematic review’, Journal of Psychopharmacology 19: 187–194.
Sherrill, D. I., Krzyzanowski, M., Bloom, J. W., Lebowitz, M. D. (1991), ‘Respiratory effects of 
non-tobacco cigarettes: a longitudinal study in general population’, International Journal of 
Epidemiology 20: 132–137.
Sidney, S. (2002), ‘Cardiovascular consequences of marijuana use’, American Journal of Clinical 
Pharmacology 42: 64–70.
Sidney, S., Beck, J. E., Tekawa, I. S., Quesenberry, C. P., Friedman, G. D. (1997), ‘Marijuana use 
and mortality’, American Journal of Public Health 87: 585–590.
Smit, F., Bolier, L., Cuijpers, P. (2004), ‘Cannabis use and the risk of later schizophrenia’, Addiction 
99: 425–430.
Sridhar, J. S., Raub, W. A., Weatherby, N. L. (1994), ‘Possible role of marijuana smoking as a 
carcinogen in the development of lung cancer at a young age’, Journal of Psychedelic Drugs 26: 
285–288.
Stefanis, N. C., Delespaul, P., Henquet, C., Bakoula, C., Stefanis, C. N., van Os, J. (2004), ‘Early 
adolescent cannabis exposure and positive and negative dimensions of psychosis’, Addiction 99: 
1333–1341.
Swift, W., Copeland, J., Hall, W. (1998), ‘Choosing a diagnostic cut-off for cannabis dependence’, 
Addiction 93: 1681–1692.
Tashkin, D. (1999), ‘Effects of cannabis on the respiratory system’, in Kalant, H., Corrigal, W., Hall, 
W., Smart, R. (eds), The health effects of cannabis, Addiction Research Foundation, Toronto, 
311–345.
Tashkin, D. et al. (2006), ‘Marijuana use and lung cancer: results of a case–control study’, in the 
American Thoracic Society, Proceedings from the 2006 annual meeting, presented May 23, 
2006.
Tashkin, D. P., Coulson, A. H., Clark, V. A., Simmons, M., Borque, L. B., Duann, S., Spivey, G., Gong, 
H. (1987), ‘Respiratory symptoms and lung function in habitual heavy smokers of marijuana 
alone, smokers of marijuana and tobacco, smokers of tobacco alone, and non-smokers’, 
American Review of Respiratory Disease 135: 209–216.
Tashkin, D. P., Simmons, M. S., Sherill, D. I., Coulson, A. H. (1997), ‘Heavy habitual marijuana 
smoking does not cause an accelerated decline in FEV1 with age’, American Journal of Respiratory 
and Critical Care Medicine 155: 141–148.
Tashkin, D. P., Baldwin, G. C., Sarafian, T., Dubinett, S., Roth, M. D. (2002), ‘Respiratory and 
immunologic consequences of marijuana smoking’, Journal of Clinical Pharmacology 42: 
71–81.
Taylor, D. R., Poulton, R., Moffitt, T. E., Ramankutty, P., Sears, M. R. (2000), ‘The respiratory effects 
of cannabis dependence in young adults’, Addiction 95: 1669–1677.
Taylor, D. R., Ferguson, D. M., Milne, B. J., Horwood, L. J., Moffitt, T. E., Sears, M., Poulton, R. 
(2002), ‘A longitudinal study of the effects of tobacco and cannabis exposure in young adults’, 
Addiction 97: 1055–1061.
Tewari, S. N., Sharma, J. D. (1980), ‘Detection of delta-9-tetrahydrocannabinol in the organs of a 
suspected case of cannabis smoking’, Toxicology Letters 5: 279–281.
Thomas, H. (1996), ‘A community survey of the adverse effects of cannabis use’, Drug and Alcohol 
Dependence 42: 201–207.
Cannabis use and physical and mental health
140
Tien, A. Y., Anthony, J. C. (1990), ‘Epidemiological analysis of alcohol and drug use as risk factors 
for psychotic experiences’, Journal of Nervous and Mental Disease 178: 473–480.
UK Advisory Council on the Misuse of Drugs (2002), The classification of cannabis under the Misuse 
of Drugs Act 1971, Home Office, London.
van Os, J., Bak, M., Hanssen, M., Bijl, R. V., de Graaf, R., Verdoux, H. (2002), ‘Cannabis use 
and psychosis: a longitudinal population-based study’, American Journal of Epidemiology 156: 
319–327.
Veen, N. D., Selten, J. P., van der Tweel, I., Feller, W. G., Hoek, H. W., Kahn, R. S. (2004), ‘Cannabis 
use and age of onset of schizophrenia’, American Journal of Psychiatry 161: 501–506.
Verdoux, H., Gindre, C., Sorbara, F., Tournier, M., Swendsen, J. D. (2003), ‘Effects of cannabis and 
psychosis vulnerability in daily life: an experience sampling test study’, Psychological Medicine 
33: 23–32.
Wu, T. C., Tashkin, D. P., Djahed, B., Rose, J. E. (1988), ‘Pulmonary hazards of smoking marijuana 
as compared with tobacco’, New England Journal of Medicine 318: 347–351.
Zammit, S., Allebeck, P., Andreassson, S., Lundberg, I., Lewis, G. (2002), ‘Self reported cannabis use 
as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study’, British 
Medical Journal 325: 1199–1201.
Zhang, Z.-F., Morgenstern, H., Spitz, M. R., Tashkin, D. P., Yu, G.-P., Marshall, J. R., Hsu, T. C., 
Schantz, S. P. (1999), ‘Marijuana use and increased risk of squamous cell carcinoma of the head 
and neck’, Cancer Epidemiol Biomarkers Prev 8: 1071–1078.
Zuckerman, B., Frank, D. A., Hingson, R. Amaro, H., Levenson, S. M., Kayne, H., Parker, S., Vinci, 
R., Aboagye, K., Fried, L. E. Cabral, H., Timperi, R., Bauchner, H. (1989), ‘Effects of maternal 
marijuana use on fetal growth’, New England Journal of Medicine 320: 762–768.
Zvolensky, M. J., Bernstein, A., Sachs-Ericsson, N., Schmidt, N. B., Buckner, J. D., Bonn-Miller, M. O. 
(2006), ‘Lifetime associations between cannabis use, abuse, and dependence and panic attacks 
in a representative sample’, Journal of Psychiatric Research 40: 477–486.


143
Chapter 7
The public health significance 
of cannabis in the spectrum of 
psychoactive substances
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health
Setting the context
There has been a growth in interest in measuring and quantifying the public health 
impact of specific health issues, from influenza outbreaks, through obesity, tobacco 
smoking and heart disease, to behavioural items such as sports and workplace injuries 
and risks associated with mobile phones. The discipline is increasingly termed ‘health 
impact assessment’ (HIA), with an international conference on HIA in its eighth year in 
2007.
Illicit and licit drugs, in particular alcohol and tobacco, are no exception to this euro- 
and dollar-counting trend. Increasingly, public health economists are joining forces with 
epidemiologists and treatment professionals to estimate or quantify the impact of drug 
use — social, economic or, more specifically, in terms of healthcare service and resource 
allocation. Specifically for cannabis, however, methodologies to gauge the global public 
health impact of cannabis use are yet to emerge, although studies have examined areas 
such as the treatment of cannabis use disorders, prevention costs, secondary health risks 
such as driving under the influence of cannabis (see Mann et al., this monograph) and 
indirect costs (truancy, workplace absenteeism or sick leave, etc.).
As this chapter demonstrates, measuring the global impact of cannabis use represents 
serious methodological challenges, even when compared with other areas of drug 
policy. There are confounding issues that arise from consumption of cannabis together 
with alcohol and tobacco. And whereas other illicit drugs with better understood health 
risks offer more clear-cut features to measure — in terms of toxicology and effects 
on physical health — cannabis health effects are more amorphous and offer fewer 
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opportunities for benchmarking harms (see Witton, this monograph). For example, 
studies of the impact of needle exchange, or prison-based harm reduction projects are 
able to record changes in drug-related deaths, HIV or hepatitis transmission. Similarly, 
studies of the impact of smoking bans might measure air quality in bars and clubs, or 
look at improvements across the general population with regards to smoking-related 
problems (respiratory problems, heart disease and lung cancer). While some measures 
can be made of the prevalence of treatment demand, population-level screening for 
problems related to cannabis use is underdeveloped. Furthermore, cannabis treatment 
takes many shapes and forms (an overview is provided by Rödner Sznitman, this 
monograph), making estimations of ‘average cost of treatment’ difficult. 
Any further precision into the public health costs specifically for cannabis in Europe is 
likely to draw strongly on the expertise of the EMCDDA’s Reitox national focal points, 
and on their scrutiny of treatment demand and treatment costs in particular. Yet this 
task is far from easy. Estimates were recently made for the EMCDDA on ‘health and 
social care expenditure’ for all illicit drugs in Europe (Reitox national reports, 2007; 
EMCDDA Annual Report, 2007). The exercise showed high variability in reporting: a 
figure for total drug-related public expenditure in the EU on illicit drugs ranged from 
EUR 13 billion to EUR 36 billion. Tangible expenditure on illicit drugs — treatment, 
prevention, enforcement, epidemiology — is subject to a wide range of labels, and is 
typically distributed across a range of actors: ministerial budgets, NGOs, private and 
public health insurance, police, customs, etc. In Europe, these actors differ not just within 
each country in Europe, but also on a federal or provincial level. There are further issues 
of country size, currency conversion, differing levels of cannabis prevalence, varying 
patterns of co-consumption (alcohol, tobacco, other illicit drugs) and divergence in the 
relative cost of healthcare provision and policing across the EU. So, estimating the full 
impact of cannabis on health with an accountant’s accuracy is a distant prospect, even 
at the level of single Member States.
Nonetheless, the UNODC has begun exploration into the area, and has proposed using 
treatment demand rates as one of the means to ‘weigh’ the dangers of illicit drugs. It 
estimated in 2005 that 78 per 1 000 users of opiates undergo treatment, higher than 
for cocaine (66 per 1 000 users), amphetamines (16) or cannabis (7) (UNODC, 2005). 
Work by the European Brain Council, while looking at wider mental health problems, 
has also improved understanding of the global public health ‘footprint’ of brain 
disorders.
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Robin Room
The public health significance of psychoactive substances: 
the risk of harm
Cannabis is one among a whole spectrum of psychoactive substances used by humans. 
They are used not only for their psychoactive properties, but also in various other 
practical functions, depending on the substance — for example, as a medicine, a food, 
a thirst-quencher, a solvent. Apart from their physical effects, strong values (both positive 
and negative) are attached to psychoactive substances — in different circumstances, they 
may serve as a sacrament, as a taboo object, as a symbol of fellowship, as a symbol of 
stigmatisation (Room, 2005a).
Along with the positive effects and symbolic values of psychoactive substances, to a 
greater or lesser extent the substances also carry the risk of harm, particularly to the 
user but also sometimes to those around the user. The public health significance of 
psychoactive substances lies in these potential and actual harms. Establishing the harms 
is a prerequisite for deciding on effective public health responses.
It is a commonplace in the literature that the harms associated with psychoactive 
substances are multidimensional, and that they are greatly affected by the mode and 
context of use. A recent British publication on Dangerousness of Drugs, for instance, 
rates different psychoactive substances in terms of nine different domains of harm, and 
also in terms of seven domains of factors (such as route of administration or context of 
use) that can increase or reduce the dangers. Best et al. (2003) make ‘no attempt … 
to rank order the target substances, even within each of the domains specified. This is 
because the dangers are not uni-dimensional nor do they generally occur in isolation’. 
They continue: ‘Drugs are not, of themselves, dangerous, with the risk residing in the 
interaction between the substance, the individual, the method of consumption and the 
context of use’ (Best et al., 2003).
The dangers are indeed multidimensional and greatly affected by mode and context 
of use. But still, in a public health policy context it is worthwhile to consider the risk 
of different psychoactive substances in an overall frame. The present international 
drug control regime, and national drug control regimes operating in accordance 
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with it, generally classify drugs into a set of classes according to ‘the harm they may 
cause’ (Advisory Council on the Misuse of Drugs, 2002). Any effort to arrive at an 
improved classification or ranking must start from the rankings implied by the existing 
classifications.
However, there is presently no clear agreement on how to arrive at an improved and 
scientifically defensible ranking of dangerousness or of the degree of social and public 
health problems from different substances (in various use-forms).
Comparing present levels of social and health harm
One relevant policy consideration, obviously, is the present level of harm in a given 
society, or on a global basis. Comparisons are most available here between tobacco 
(considering primarily cigarettes), alcohol and all illicit drugs taken together. For 
instance, according to the World Health Organisation’s estimates for the Global Burden 
of Disease in 2000, tobacco accounts for 4.1 % of the total burden in disability-adjusted 
life-years globally, alcohol for 4.0 %, and illicit drugs for 0.8 %. For developed societies 
such as the United Kingdom, the corresponding figures are 12.2 %, 9.2 % and 1.8 % 
(Ezzati et al., 2002). Another mode of comparative estimation of harm is in terms of 
the economic costs to a society from use of different psychoactive substances. While 
the assumption behind such estimations are subject to substantial criticism (e.g. NIAAA, 
1994: 253–259), they do have the advantage of including some of the social as well as 
the health costs. A representative set of estimates in this mode is for Canada for 1992: 
CAD 9.6 billion for tobacco, CAD 7.5 billion for alcohol, and CAD 1.4 billion for illicit 
drugs (Single et al., 1998). In general, the costs for illicit drugs are dominated by the 
criminal justice costs, primarily of policing the illicit market and punishment for illicit 
dealing or use.
In a new cost-of-illness analysis for Canada, cannabis, despite being by far the most 
commonly used illegal drug, accounted for a relatively small part of the estimated 
health burden from illicit drugs: 6.4 % of the overall healthcare costs due to illegal drugs 
and 2.3 % of the years of life lost due to mortality from illegal drugs (calculated from 
analyses prepared for Rehm et al., forthcoming).
Comparing the potential for harm
The most obvious objection to basing policy decisions on such estimates is that the 
present levels of social and health harm are not necessarily the same as what the levels 
of harm would be if policies changed. The question this leaves, however, is: what is, 
then, the appropriate basis for judging between psychoactive substances in terms of 
their adverse effects? Presumably, the answer to this question should be in terms of 
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realistic scenarios of the substance’s potential for harm — its dangerousness — in cases 
of heavy use. In a research team of which I was a member (Hall et al., 1999), we took 
the approach to this of comparing the importance (probability and severity) of effects 
resulting from heavy use of the different substances in their most harmful commonly 
used form – in the case of cannabis, use by smoking. A more nuanced approach, from 
a public health perspective, would pay attention to likely rates of such heavy use in a 
whole population with ready and cheap availability. Rates of dependence or heavy use 
among users in current circumstances may give some indication in this direction, but for 
illicit substances they obviously fall short of the full test with ready and cheap availability. 
At this stage in Europe, cannabis is an in-between case; it could be argued that in the 
Netherlands cannabis use might not rise much from present levels with full legalisation 
(cf. MacCoun and Reuter, 2001).
Comparison on dimensions of danger: overdose
One important dimension of dangerousness or harm is the likelihood of an overdose 
from the substance. This dimension is obviously of special significance not only for 
overdoses among recreational and heavy users, but also in more general terms of 
poison control — for example, labelling and child-proofing containers of the substance. 
The first column of figures in Table 1 shows partial results of a recent review of the 
literature by Gable (2004). The ‘safety ratio’ shown is the ratio between ‘the usual 
effective dose for nonmedical purposes’ and the usual lethal dose, for the mode 
of administration specified. Gable comments, concerning the wider range of drugs 
considered in his review, that ‘the range of safety ratios is so wide that the data appear 
to have the attributes of an ordinal scale’. In such a scale, cannabis would be in the 
lowest-risk group, those substances with a ratio of 100 or above.
Comparison on dimensions of danger: degree of intoxication
Another dimension of dangerousness is the level of intoxication produced by the 
substance, which ‘increases the personal and social damage a substance may do’ (Hilts, 
1994). Obviously, the level of intoxication produced by taking a substance is highly 
influenced by the dose taken, and the set and setting of the consumption. A glass of 
alcohol with dinner will not result in intoxication, while on the other hand, traditional 
ways of using tobacco among some indigenous South Americans routinely resulted 
in intoxication to the point that the smoker passed out (Robicsek, 1978). But despite 
these caveats, there are inherent differences in the propensity of different psychoactive 
substances to intoxicate. The second column of Table 1 shows rankings made by Jack 
Henningfield and Neal Benowitz on this (Hilts, 1994). Cannabis was ranked as more 
intoxicating than tobacco, but less so than alcohol, cocaine and heroin.
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Comparison on dimensions of danger: dependence
The dependence potential or addictiveness of a substance plays rather little part in 
the formal criteria for scheduling of substances under the international conventions 
(Room, 2005b). Nevertheless, there is no doubt that the popular imagery of addiction 
and addictiveness plays a part in setting the policy stage; in countries like the USA, 
arguments about the addictiveness of nicotine, for instance, have been secondary only 
to arguments about second-hand smoking in moving the political process of tobacco 
control forward. Accordingly, ratings are also available of the dependence potential or 
addictiveness of different substances. For instance, Henningfield and Benowitz (Hilts, 
1994) give comparative ratings of the different substances on withdrawal, tolerance, 
reinforcement and dependence (‘how difficult it is for the user to quit, the relapse 
rate’, etc.). The recent report of the UK Prime Minister’s Strategy Unit (2005) offers a 
rating on ‘potential addictiveness’, and a French committee chaired by Bernard Roques 
(1999) offers a rating on ‘psychic dependence’ (see last three columns of Table 1). The 
UNODC proposed a ‘harm/risk factor’ for drugs for use in creating an Illicit Drugs Index 
(UNODC, 2005), using treatment demand data as a measure of harmfulness. Though 
there is some disagreement in the rankings for other drugs, each of these rankings 
places cannabis at the lowest level for the substances in the table (the Strategy Unit 
shows a lower ranking for LSD).
Comparisons on dimensions of danger: more global ratings
The Roques committee also took a more global approach to the issues of 
dangerousness. Table 2 shows the Roques committee’s rankings on ‘Toxicité générale’ 
(general toxicity) and ‘Dangerosité sociale’ (social dangerousness). In the usage of 
the Roques report, ‘toxicity’ includes long-term health effects such as cancer and liver 
disease, and infections and other consequences of mode of use, as well as the acute 
effects represented by the safety ratio. The concept of ‘social dangerousness’ focuses on 
Table 2: Ratings on global dimensions of ‘dangerousness’ (Roques, 1999)
General toxicity Social dangerousness
Cannabis Very weak Weak
Benzodiazepines (valium) Very weak Weak (except when driving)
MDMA/ecstasy Possibly very strong Weak (?)
Stimulants Strong Weak (possible exceptions)
Tobacco Very strong None
Alcohol Strong Strong
Cocaine Strong Very strong
Heroin Strong (except therapeutic use of opiates) Very strong
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Table 3: A summary of adverse effects on health for heavy users of the most 
harmful common form of each of four drugs (according to Hall et al., 1999)
Cannabis Tobacco Heroin Alcohol
Traffic and other accidents * * **
Violence and suicide **
Overdose death ** *
HIV and liver infections ** *
Liver cirrhosis **
Heart disease ** *
Respiratory diseases * **
Cancers * ** *
Mental illness * **
Dependence/addiction ** ** ** **
Lasting effects on the fetus * * * **
**Important effect, *less common or less well-established effect.
‘states of comportment which can generate very aggressive and uncontrolled conduct 
… induced by the product or varied disorders (fights, robberies, crimes …) in order to 
obtain it and risks for the user or others, for example in the case of driving a vehicle’ 
(Roques, 1999: 296; original in French). It will be seen that the Roques ratings on 
‘general toxicity’ are compatible with the safety ratios reported by Gable (2004), and 
that the ‘social dangerousness’ ratings are compatible with the ratings by Henningfield 
and Benowitz on intoxicating effect (Hilts, 1994). Cannabis is ranked ‘weak’ on ‘general 
toxicity’, and ‘very weak’ on ‘social dangerousness’.
Hall et al. (1999) took another approach to a global rating of adverse effects of 
psychoactive substances, comparing four classes of substances in terms of whether there 
was ‘important effect’ or a ‘less common or less well-established effect’ on each of 
11 dimensions (Table 3). According to these rankings, alcohol clearly has the greatest 
potential for harm; among the four substances, cannabis has the lowest number of 
asterisks.
Nutt et al. (2007) used another global method, identifying three main factors that 
together determine the harm associated with different drugs: (i) the physical harm 
to the individual user caused by the drug; (ii) the tendency of the drug to induce 
dependence; and (iii) the effect of drug use on families, communities and society. 
Within these categories, they recognised three components to create a nine-category 
‘matrix of harm’. Physical harms were split into ‘acute’, ‘chronic’ and ‘intravenous’ 
harm. Dependence was split into ‘intensity of pleasure’, ‘psychological dependence’ 
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and ‘physical dependence’. Social harms were split into ‘intoxication’, ‘other social 
harms’ and ‘healthcare costs’. Expert panels gave scores, from 0 to 3, for each category 
of harm for 20 different drugs. Cannabis was rated at 11th most harmful out of 20 
substances: heroin and cocaine were rated the most harmful, while both alcohol and 
tobacco were rated more harmful than cannabis, with khat, alkyl nitrates and ecstasy 
rated as least harmful.
Accounts have appeared in Swedish newspapers of a recent ranking of drugs 
according to their dangerousness, circulated by the Swedish authority for prosecutions 
(Åklagarmyndigheten) to all Swedish prosecutors. Heroin was listed as the most 
dangerous drug, with others in descending order: ecstasy, amphetamines, cannabis, 
khat (TT, 2005).
In summary, on every comparison of dangerousness we have considered, cannabis is at 
or near the bottom in comparison with other psychoactive substances.
The implications of the comparative findings
The ratings above, and the literature considered elsewhere in this volume, do not 
by any means exonerate cannabis as a public health concern. In recent years, as 
noted elsewhere in this volume, there has been some strengthening of the evidence 
that cannabis may play a part in precipitating or worsening psychosis. The evidence 
on the adverse effects of driving under the influence of cannabis has also somewhat 
strengthened (see Mann et al. in this volume). In my view, the asterisks in Table 3 
already accommodate these findings, in terms of relative ratings and public health 
significance. But, whichever way one looks at it, the findings emphasise that, as with 
most psychoactive substances, use of cannabis can be harmful for some users and in 
some circumstances.
Comparing degrees of dangerousness is a fraught topic. General comparisons of 
this type have often faced substantial opposition in the course of publication. The 
material from the Prime Minister’s Strategy Unit was only released on 1 July 2005, 2 
years after compilation, in partial compliance with a Freedom of Information request 
(Travis, 2005). The report by Hall et al. (1999) was eventually published after a media 
storm (Anonymous, 1998) over its omission from the report for which it was originally 
commissioned (WHO, 1997). The Roques report also caused considerable controversy 
when it appeared. As a French review noted, there were complaints not only about 
including alcohol among ‘drugs’, but also that the group of experts ‘banalized the 
danger of cannabis by putting in evidence the weak physical and psychic dependence 
from this product, compared with those of tobacco and alcohol’ (Jauffret-Roustide, 
2004: 17–18; original in French).
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The news reports of the Swedish prosecutors’ ranking noted that ‘few Swedish politicians 
admit that certain kinds of drugs are less dangerous than others’. One quoted expert 
noted the ranking was just ‘from a legal perspective’, and another that ‘one must 
differentiate between public debate and jurisprudence’. In this perspective, distinctions 
on dangerousness should remain hidden knowledge: ‘if one talks about drugs to youth 
one has to keep to what is important for them’ (TT, 2005). To the question of which 
are the most dangerous drugs, the Swedish police website answers: ‘According to the 
National Police Board’s decision, there is no reason to discuss the dangerousness of 
different drugs. Preparations classed as narcotics are forbidden or require prescription; 
hence they are dangerous or harmful to misuse’ (Rikspolisstyrelsen, 2005).
There is an enormous commitment by many involved in the international control system 
and equivalent national systems to keeping the status quo, with the outer defensive line 
often set around cannabis. But, in a broad public health perspective on psychoactive 
substances and their potential for harm, it is clear that, on the one hand, tobacco and 
alcohol are greatly underregulated in current international drug control and regulatory 
systems, while on the other hand, the restrictions on cannabis are too harsh.
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Chapter 8
Assessing the population health 
impact of cannabis use
Keywords: cannabis – drug policy – economics – health – mental health – 
public health
Setting the context
There is a tendency in discussions of responses to cannabis use to rely on faulty logic. 
From the perspective of drugs professionals, these might manifest themselves in terms 
of a mild prejudice: ‘study finds that mass media prevention campaign had boomerang 
effect’ becomes ‘mass media preventions do not work’. Or perhaps ‘higher prevalence 
of schizophrenia among cannabis users’ becomes ‘there is a causal link between 
schizophrenia and cannabis use’.
In a stronger form, the media may encourage the inference of unrelated behaviours 
in relation to cannabis. Issues of cannabis potency, mental health and crime often 
share headlines. We may cite examples noted in the EMCDDA’s press corpus during 
production of this monograph: ‘Deranged cannabis smoker obsessed with Satanism 
stabbed country vicar to death’ (1); ‘Son twisted by “skunk” knifed father 23 times’ (2). 
Public and political debate on cannabis users can sometimes be drowned out by the 
noise generated by such salacious headlines.
This chapter — written by Wayne Hall, one of the world’s most published experts 
on cannabis use — advocates a sceptical eye with regard to claims made for the 
public health impact of cannabis. Developing the theme of public health impact 
studies discussed by Robin Room in the previous chapter, this chapter looks at the 
difficulties involved in assessing the global effect of cannabis use on the health of entire 
populations.
 (1) London Evening Standard, 17 October 2007.
 (2) Daily Mail, 23 July 2007.
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On a practical level, the chapter provides a checklist to help researchers to question any 
assumptions or to avoid causal inferences (3). From an epidemiological point of view, 
the data on the precise impacts of chronic cannabis use are weak, especially compared 
with what we know about alcohol and tobacco. Furthermore, assessing the impact of 
cannabis problems is difficult and beset with ethical problems, not least because of the 
illicit status of the drug and a tendency for it to be discussed in conjunction with, or 
compared with, other illicit drugs that carry higher toxicological risks.
The chapter also mentions an ‘inflationary–deflationary dialectic’, in which cannabis 
problems have been both demonised by moralists and belittled by pro-cannabis 
organisations. Decoupling cannabis from political discussions is necessary in order 
to quantify the harms of cannabis, and to place them against a neutral background 
where they are compared with other health issues. The chapter also suggests that 
the temptation to focus on adverse health effects needs to be balanced with potential 
positive effects of cannabis use. This argument is often applied to defend moderate 
alcohol use vis-à-vis the harms of binge drinking or alcoholism. While efforts to quantify 
the public health harms of illicit drug use are currently only in an embryonic stage, 
research into any ‘balancing’ public health benefits is extremely rare.
Further reading
Hall, W., Pacula, R. (2003), Cannabis use and dependence: public health and public policy, 
Cambridge University Press, Cambridge.
MacCoun, R., Reuter, P. (2001), Drug war heresies: learning from other vices, times and places, 
Cambridge University Press, Cambridge.
Mackay, C. (1852), Memoirs of extraordinary popular delusions and the madness of crowds, Office 
of the National Illustrated Library, London.
See also the grey literature list in the Appendix to Volume 1 of this monograph.
 (3) See also the comments on meta-reviews by Bergmark, this monograph.
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Assessing the population health 
impact of cannabis use
Wayne Hall
There are major technical challenges in assessing the impact that cannabis use has on 
the health of users and public health (Hall, 1999). These include difficulties in deciding 
whether cannabis use is a contributory cause of the adverse health and psychological 
effects attributed to its use and in quantifying the magnitude of these adverse health 
effects. These technical challenges are amplified by the difficulties in separating the 
political debate about the legal status of cannabis use from appraisals of its health 
effects.
Making causal inferences
Before a claim can be accepted that cannabis causes an adverse health outcome there 
must be evidence that there is an association between cannabis use and the health 
outcome; the association is not due to chance; cannabis use preceded this outcome; and 
we can make a case for the implausibility of alternative, non-causal explanations of the 
association (Tukey and Brillinger, 1984; Hall, 1987; Strom, 2000).
Evidence of association: reasonable evidence of an association between cannabis t
use and a health outcome (e.g. schizophrenia) is provided by finding a relationship 
between cannabis use and the outcome in case–control, cross-sectional, cohort or 
experimental studies.
Excluding chance: evidence that chance is an unlikely explanation of the relationship t
is provided by constructing a confidence interval around the sample value of a 
measure of association. We infer that an association exists if the confidence interval 
does not include the null value (i.e. the value consistent with no relationship). The 
width of the confidence interval provides an indication of the degree of uncertainty 
surrounding the inference, while its upper limit indicates how large an association 
may have gone undetected (Altman and Gardner, 2000).
Ascertaining temporal order: if cannabis use is the cause of an effect, then there t
should be good evidence that cannabis use precedes it. The strongest evidence that 
cannabis use precedes certain health effects is provided by either a cohort study or 
an experiment. In the former the researcher observes that cannabis use precedes 
the health effect while in the latter the experimenter ensures by design that it does 
so.
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Deciding between alternative explanations: the hardest criterion to satisfy is that of t
excluding the possibility that the relationship between cannabis use and the health 
outcome is due to an unmeasured variable that causes both cannabis use and the 
adverse health outcome. In surveys of high-school-aged adolescents, for example, 
cannabis users typically perform more poorly at school than non-cannabis users 
(Hawkins et al., 1992). This may be because cannabis use is a cause of poor school 
performance but an equally plausible hypothesis is that learning difficulties cause 
both poor school performance and cannabis use (Lynskey and Hall, 2000).
Experimental evidence provides the ‘gold standard’ for ruling out these common causal 
explanations (Fisher, 1947; Cook and Campbell, 1979; Shadish et al., 2002). Randomly 
assigning adolescents to use cannabis or not, for example, would ensure that cannabis 
users and non-users were equivalent before using cannabis. Hence, any subsequent 
differences in educational performance could be attributed to cannabis use rather 
than to pre-existing differences in ability. When studying anything except acute and 
innocuous health effects, random assignment of individuals to use cannabis or not is 
impossible for ethical and practical reasons. It would be unethical, for example, to force 
some adolescents to use cannabis, and impracticable, even if ethical, to prevent those 
assigned not to use the drug from doing so.
Experimentation using laboratory animals is one way of getting around the impossibility 
of human experimentation. But suitable experimental animal models are not available 
for many of the putative adverse psychosocial effects of cannabis use such as psychosis, 
school performance and personal adjustment. In addition, there are problems in 
extrapolating results across species, different routes of administration (e.g. oral and 
parenteral in animals versus smoked in humans), and the very high doses that are 
typically used in animal studies.
When a suitable animal model does not exist, and randomisation of human subjects 
is impractical or unethical, statistical methods must be used to adjust for the effects of 
pre-existing differences in risk between cannabis users and non-users. If the relationship 
persists after statistical adjustment, the confidence is increased that the relationship 
is not attributable to the variables for which statistical adjustment has been made 
(MacLeod et al., 2004). This type of control has been used, for example, in longitudinal 
studies of adolescent cannabis use and psychosis (e.g. Caspi et al., 2005; Fergusson et 
al., 2005; Henquet et al., 2005).
Acute health effects
The acute health effects of any drug are easier to appraise than the chronic effects: the 
temporal order is clear; drug use and the effects occur closely together in time; and 
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if the effects are not dangerous, they can be reliably reproduced by giving the drug 
under controlled conditions. All this is true of the most common psychoactive effects 
of cannabis (e.g. euphoria, relaxation, sociability) and some of the more commonly 
reported adverse acute effects such as anxiety, panic and depression (Hall and Pacula, 
2003).
It is more difficult to decide upon the causal contribution that cannabis use makes to 
relatively rare, acute adverse experiences such as flashbacks and psychotic symptoms. 
It is difficult to decide whether these are rare events that are coincidental with cannabis 
use, the effects of other drugs which are often taken together with cannabis, rare 
consequences of cannabis use that only occur at doses that are much higher than those 
used recreationally, cannabis effects that require unusual forms of personal vulnerability 
or the results of interactions between cannabis and other drugs.
Chronic health effects
Causal inferences about the long-term effects of chronic cannabis use become more 
difficult the longer the interval between use and the adverse effects. It takes time 
for adverse effects to develop and usually it takes even longer for a connection to 
be suspected between the two. This is largely because the longer the time interval 
between cannabis use and the health consequence, the more numerous the alternative 
explanations of the association that need to be excluded.
We often have to trade off rigour and relevance in evidence on the effects of chronic 
cannabis use. The most rigorous evidence is provided by laboratory investigations using 
experimental animals, but its relevance to human use is often uncertain. Epidemiological 
studies are manifestly more relevant in assessing human health effects, but they are 
usually less rigorous in assessing exposure to cannabis and in excluding alternative 
explanations of the associations. The consequence is increased uncertainty about 
the interpretation of epidemiological studies that affects interpretations of the causal 
significance of associations (‘positive’ studies) as well as studies that fail to find such 
relationships (‘negative’ studies).
A common interpretative problem with positive findings is that cannabis use is correlated 
with alcohol, tobacco and other illicit drug use that also adversely affect health. 
Generally, the heavier the cannabis use, the more likely that the person also uses these 
other psychoactive drugs (Newcomb and Bentler, 1989; Kandel and Yamaguchi, 1993). 
This can produce spurious associations between cannabis use and health outcomes, 
which makes it difficult to confidently attribute any adverse health effects to cannabis. 
This has been the case, for example, in interpreting the evidence on the role of cannabis 
use in motor vehicle accidents (Hall and Pacula, 2003; Mann et al., this monograph).
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When studies fail to find adverse health effects of chronic cannabis use, for example 
immunological effects, it may be unclear whether this means that THC has few, if any, 
immunological effects in humans, or that our research has not had the sensitivity to 
detect its effects. The answer to this question depends upon the likely magnitude of any 
adverse effects, their relationship to dose, frequency and duration of use, and the ability 
of studies with small sample sizes to detect them (Hall and Einfeld, 1990).
An overall appraisal of causal hypotheses
Causal inferences are often made in the light of a research literature by judging the 
extent to which standard criteria such as those outlined by Hill (1977) are met. These 
criteria are not sufficient for establishing that an association is a token of a causal 
relationship since it is possible for the criteria to be met and yet to be mistaken in 
making a causal inference. In general, however, the more of the criteria that are met, 
the more likely it is that the association is a token of a causal relationship.
Strength of association: relationships that are stronger indicate that if cannabis is used 
there is a high likelihood that the health effect will also occur. Stronger relationships are 
generally more deserving of trust than weaker ones because the latter are more easily 
explained by measurement or sampling biases.
Consistency of relationship: relationships which are consistently observed by different 
investigators, studying different populations, using varied measures and research 
designs, are generally more credible than relationships which are not. This is because 
a relationship that persists despite differences in sampling and research methods is less 
likely to be explained by sampling, measurement or other biases.
Specificity is a desirable but not a necessary condition. It exists when cannabis use is 
strongly associated with the outcome, and the health outcome is rare in the absence 
of cannabis use. Specificity is desirable in that if it exists we can be more confident 
that there is a relatively simple and direct causal relationship but its absence does not 
exclude the possibility of a more complex causal relationship (e.g. in which the effect is 
conditional on the presence of other factors).
Biological gradient refers to the existence of a dose–response relationship between 
cannabis use and the health outcome: the more heavily cannabis has been used, 
the greater the likelihood of the health outcome. Satisfaction of this criterion is also 
desirable but not necessary since there may be other patterns of relationship between 
exposure and disease, for example a threshold effect, an ‘all or none’ effect or a 
curvilinear relationship.
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Biological plausibility refers to the consistency of the relationship with other biological 
knowledge. If we can think of no conceivable mechanism whereby cannabis can 
produce such an effect, then we may have grounds for scepticism. But in the face of 
compelling evidence of association from well-controlled studies, implausibility may be 
a signal that existing theories are wrong or that we need to develop new theories that 
explain previously unknown phenomena.
Coherence means that the relationship coheres with, or makes sense of, other 
information about the natural history and biology of the disease. This, too, is desirable 
but not necessary: it is desirable that we have independent information that we can trust 
but its absence is not fatal, since the other information with which it is inconsistent may 
be in error.
Assessing the magnitude of risk
The standard epidemiological measures of risk magnitude are relative risk and 
population attributable risk. The relative risk is the increase in the odds of experiencing 
an adverse health outcome among those who use cannabis compared with those who 
do not. It may be quantified as a relationship between the frequency and duration of 
cannabis use and the risk of experiencing an adverse health outcome. The population 
attributable risk represents that proportion of cases with an adverse outcome that can be 
attributed to cannabis use, if it is causal.
The two measures of risk have different uses and implications. Relative risk is most 
relevant to individuals attempting to estimate the increase in their risk of experiencing 
an adverse outcome if they use a drug. Attributable risk is of most relevance to a 
societal appraisal of the harms of drug use. The importance of the two measures of risk 
magnitude depends upon the prevalence of drug use and the base rate of the adverse 
outcome. An exposure with a low relative risk may have a low personal significance but 
a large public health impact if a large proportion of the population is exposed (e.g. 
cigarette smoking and heart disease). Conversely, an exposure with a high relative risk 
may have little public health importance because very few people are exposed to it, but 
it may have major significance for those individuals who are exposed.
Another way of assessing the health risk posed by cannabis use is to compare its health 
risks with those of other widely used recreational drugs such as alcohol, tobacco, 
cocaine and heroin (Hall et al., 1999). Such comparisons minimise double standards 
in the appraisal of the health effects of cannabis use by using a common standard for 
comparison. The comparison, however, is more difficult than it seems at first, even in the 
case of the more widely used and best-studied drugs, alcohol and tobacco. Comparison 
is even more difficult in the case of less commonly used illicit drugs like cocaine, heroin, 
ecstasy and amphetamine.
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First, we know much more about the risks of acute and chronic tobacco and alcohol use 
than we do about the risks of cannabis use. The legal drugs have been consumed by 
substantial proportions of the population over centuries and there have been more than 
50 years of scientific studies of the health consequences of their use (see English et al., 
1995). Cannabis, by contrast, has been much less widely used in Western society, for 
a shorter period, and primarily by healthy young adults who have usually discontinued 
their use in their mid- to late 20s (Hall and Pacula, 2003).
Second, the prevalence of regular use of cannabis is much lower than that of alcohol 
and tobacco. In principle, this problem could be addressed by estimating what the 
health effects of cannabis use would be if its prevalence approached that of alcohol and 
tobacco. Although conceptually simple, in the absence of good data on the quantitative 
risks of cannabis use a large number of contestable assumptions have to be made in 
order to make such estimates.
We cannot simply estimate what the health risks of cannabis use would be if it were 
as commonly used as alcohol and tobacco by multiplying its estimated risks on current 
patterns of use by the number of potential users in the population. This calculation 
assumes that the risks are the same regardless of who uses cannabis, or the legal 
regime under which it is used. These may be unreasonable assumptions because (i) 
the variability among the characteristics of cannabis users or the diversity of ‘types’ 
of people who use cannabis when its prevalence of use is low might increase under a 
regime of legal use and (ii) if cannabis use were legal it would be possible to reduce 
some of the respiratory risks of cannabis smoking by encouraging cannabis users to 
ingest or vaporise rather than to smoke the drug. It would also be easier if cannabis use 
was legal to give users advice on how to reduce other risks, for example by not driving a 
car for several hours after using the drug, and restricting the frequency of use to weekly 
or less often.
Are there any benefits of cannabis use?
The benefits of cannabis use are rarely discussed in cannabis policy debates. The 
exception is its possible use to treat symptoms of chronic illnesses that are unresponsive 
to current medical treatment (Hall and Pacula, 2003). The key role played by health 
effects in the policy debate has meant that there has been very little research on the 
benefits of recreational cannabis use. If, as economists argue, adults are the best judges 
of their own interests, then the fact that a substantial proportion of adults in developed 
societies use cannabis for recreational purposes is prima facie evidence that some 
cannabis users benefit from its use (Hall and Pacula, 2003). There is an absence of 
evidence for more specific benefits of cannabis use, although a number of such effects 
have been suggested.
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One possible benefit is that moderate cannabis use may improve mental health, as 
recent evidence suggests may be true for moderate use of alcohol (Rodgers et al., 
2000). In the case of cannabis, epidemiological studies to date have typically found 
that the heavier the cannabis use is, the poorer the user’s mental health (see Hall and 
Pacula, 2003, Chapter 13) but more and much better controlled research is needed 
(MacLeod et al., 2004).
The evidence is also limited and mixed on a second possible benefit of cannabis 
use, namely, that of substituting for the use of arguably more harmful drugs like 
alcohol, cocaine and heroin. The epidemiology of alcohol and cannabis use suggest 
a complementary relationship in that heavy consumers of alcohol are more likely to 
be heavy cannabis users and vice versa, particularly among young people (see Hall 
and Pacula, 2003, Chapter 13). The evidence among adults is more mixed, with race, 
ethnicity and country of origin influencing the findings. The evidence on the relationship 
between cannabis and other illicit drugs is controversial (Hall and Pacula, 2003). Both 
questions deserve to be better investigated.
There is better evidence for the therapeutic uses of cannabis. There is reasonable 
evidence for the therapeutic use of THC as an antiemetic agent in the treatment of 
nausea and vomiting caused by cancer chemotherapy. More effective antiemetic agents 
are now available, so it remains to be seen how widely the cannabinoids will be used for 
this purpose. There is also reasonable evidence for the efficacy of THC in the treatment 
of AIDS-related wasting. There is evidence that cannabinoids may have analgesic and 
antispasmodic properties that warrant further research into their effectiveness (Hall and 
Degenhardt, 2003).
The social and political context of appraisal
Appraisals of the hazards of most drug use are affected by the societal approval or 
disapproval of the drug (Room, 1984). Those who approve of using the drug tend to 
engage in ‘problem deflation’ by minimising the adverse health and social effects of 
its use. Those who disapprove tend to engage in ‘problem inflation’ by uncritically 
accepting any evidence of harm.
An inflationary–deflationary dialectic has affected appraisals of the health effects of 
cannabis use. Politically conservative opponents of cannabis use, for example, justify 
its continued prohibition by citing personal and social harms of its use (e.g. Nahas and 
Latour, 1992). When the evidence is uncertain, they resolve the uncertainty by assuming 
that cannabis use is unsafe until proven safe. Complementary behaviour is shown by 
those proponents of decriminalisation who discount evidence of harm and resolve 
uncertainties about the ill-effects of cannabis use by demanding evidence that is difficult 
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to provide, arguing that until uncertainty is resolved individuals should be allowed to 
choose whether or not they use the drug.
Problem deflationists typically discount the adverse effects of their preferred drugs by 
denying that there is a causal connection between drug use and particular adverse 
health effects. A popular way of discounting evidence of adverse health effects of drug 
use is to set such a high standard of proof that we can never ‘know’ whether it causes 
the effect. The standard of proof reflects the degree of confidence we require in a 
causal connection between drug use and harm. In courts of law, the standard of proof 
demanded depends upon the seriousness of the offence and the consequences of a 
conviction. The standard is ‘beyond reasonable doubt’ in criminal cases that may lead 
to imprisonment if convicted while the ‘balance of probabilities’ is acceptable in civil 
cases where the penalties are fines. Sceptics often demand something close to ‘beyond 
reasonable doubt’.
The standard legal method for resolving a dispute in the face of uncertainty is to create 
a default outcome by placing a burden of proof upon one or the other side in the case. 
The arguer who bears the burden of proof loses the case if they fail to discharge their 
burden. The accused in a murder trial, for example, is presumed to be innocent until 
proven guilty because it is the prosecution’s burden to make a case for guilt beyond 
reasonable doubt; failure to do so means that the defendant has to be acquitted.
In the debate about the legal status of cannabis, the question of who bears the burden 
of proof is controversial (see Rescher, 1977, Chapter 12). If the burden of proof falls on 
those who claim that the drug is safe, uncertainty will be resolved by assuming that it 
is unsafe until proven otherwise; conversely, if the burden falls on those who claim that 
the drug is unsafe, then it will be assumed to be safe until proven otherwise. Proponents 
of continued prohibition of cannabis use appeal to established practice (Whately, 1963 
[1846]), arguing that since the drug is illegal the burden of proof falls on those who 
want to legalise it to demonstrate its safety. Proponents of legalisation often argue 
that there was no evidence that cannabis was harmful when its use was criminalised. 
Some argue that, in any case, the burden of proof falls upon those who wish to use the 
criminal law to prevent adults from choosing to use a drug (e.g. Husak, 1992).
Improving assessments of the health effects of cannabis
The following proposals aim to improve assessments of the health risks of cannabis by 
ensuring that ignorance is disclosed, making it easier to identify what we need to know 
in order to reduce it, and making it less likely that empirical issues will be confused with 
moral ones and vice versa.
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Avoid treating cannabis as a special case
According to some, cannabis is a ‘mind-expanding’, ‘consciousness-raising’ drug, which 
is especially benign in its effects on health. To its opponents, cannabis is a ‘deceptively 
dangerous’ drug in which the absence of acute toxic effects disguises its insidious 
adverse effects on users and society (Nahas and Latour, 1992). We should instead 
adopt the same approach to evaluating the health effects of cannabis use that are used 
in appraising the health effects of alcohol, tobacco and other illicit drugs.
Burden of proof should be responsive to evidence
Any inquiry into the health effects of cannabis should begin with the assumption derived 
from pharmacology and toxicology that it may harm the health of some users when used 
at some dose, frequency or duration of use, or some methods of administration (Fehr 
and Kalant, 1983). Given that cannabis is an intoxicant like alcohol, and a drug that is 
usually smoked like tobacco, there are additional reasons to expect that cannabis will 
share at least some of the acute and chronic health effects of these two drugs.
This expectation does not mean that we assume that cannabis use is unsafe until proven 
safe. Rather, it means that the burden of proof will be responsive to the state of the 
evidence and it may vary for different health effects. If there is a prima facie case for 
cannabis causing a specific harm, then evidence of safety should be required. A prima 
facie case could comprise either direct evidence that cannabis has ill effects in humans 
(e.g. from a case–control study), or a compelling argument for such an effect, for 
example the fact that the constituents of cannabis and tobacco smoke are similar, and 
that tobacco smoking causes respiratory cancers, makes it likely that heavy cannabis 
smoking is also a contributory cause of these cancers (Hall and MacPhee, 2002).
Use a reasonable standard of proof
If we require proof beyond reasonable doubt that there are adverse health effects of 
cannabis, then very few conclusions will be drawn about its health effects, and very little 
advice can be given on how to reduce these risks. Reasonable inferences and sensible, 
if fallible, health advice can be given if evidential criteria are used to draw conclusions 
about the probable adverse health effects of cannabis in the same way as we do about 
any other drug. This standard may be taken to be satisfied by the consensus of informed 
scientific opinion that sufficient evidence has been provided to infer a causal connection 
between cannabis use and a health outcome. A consensus is indicated by the views 
expressed in authoritative reviews in peer reviewed journals and consensus conferences 
of experts (e.g. Institute of Medicine, 1982; Fehr and Kalant, 1983; WHO Programme 
on Substance Abuse, 1997).
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Apply standards consistently
There will continue to be disagreements about standards of proof, burden of proof and 
what kinds of evidence count, but whatever evidential standards are used should be 
applied even-handedly. The best protection against the use of double standards in their 
application is for those conducting appraisals of the health effects of cannabis to be as 
explicit as possible about the evidential standards that they have used, and as even-
handed as possible in their application.
Separate the legal and health issues
We would improve our appraisal of the health effects of cannabis if we clearly separated 
it from the legal issue. The two issues are connected since the adverse health effects of 
cannabis use are one of the justifications offered for treating cannabis use as a criminal 
offence. Consequently, if there were no adverse health effects of cannabis use, a 
different justification would need to be found for its continued prohibition.
Even if there are adverse health effects of cannabis, the connection between the adverse 
health effects of cannabis and its legal status is not as simple as has been assumed. 
If adverse health effects were a sufficient warrant for the legal prohibition of cannabis 
use then logic would demand that alcohol and tobacco use should also be prohibited. 
Our failure to prohibit alcohol and tobacco use indicates that socially important values 
other than personal or public health are at stake. These include individual autonomy 
and personal liberty, and the economic and social costs of trying to prevent a substantial 
proportion of the adult population from doing something that they want to do. These 
values must be weighed against public health, and a balance produced as the outcome 
of a political process that is informed by a fair appraisal of the health risks of cannabis 
use (Hall and Pacula, 2003).
The failure to separate the health and legal issues means that the appraisers’ views 
about the legal status of cannabis often prejudice their appraisals of its health effects. 
A clear distinction between the two issues is the best way of ensuring a fair and useful 
discussion of both.
Conclusions
Causal inferences about the adverse health effects of cannabis are complicated by a 
dearth of good studies of relationships between cannabis use and health outcomes; 
uncertainty in some cases about which came first, the cannabis use or the health 
effect; difficulties in excluding plausible alternative explanations of associations that 
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findings, uncertainty as to whether they provide reasonable evidence of the absence 
of effects, or only an absence of evidence. An estimation of the magnitude of the 
health risks of cannabis is handicapped by the absence of epidemiological studies that 
provide quantitative estimates of the risks in representative samples of users. Attempts 
to compare the public health significance of cannabis use with that of more widely used 
drugs like alcohol and tobacco are complicated by the greater comparative ignorance of 
the adverse health effects of cannabis use, and by the marked difference in their current 
prevalence of use. More attention needs to be given to evaluating evidence for and 
against benefits claimed for cannabis use.
A fair appraisal of the health effects of cannabis has been hampered by a deflationary–
inflationary dialectic between opponents and proponents of cannabis use. Problem 
deflation has been assisted by demands for unreasonably high standards of proof, and 
the disagreement about who bears the burden of proof has prevented a resolution of 
uncertainty about these health effects.
Our appraisals of the health effects of cannabis would be improved if we: stopped 
treating cannabis use as a special case; distinguished clearly between health and legal 
issues; varied the burden of proof depending upon the state of the evidence about 
adverse health effects; used a reasonable standard of proof; and above all else, applied 
evidential standards consistently and even-handedly.
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Chapter 9
Cannabis use and driving: 
implications for public health and 
transport policy
Keywords: cannabis – driving – DUIC – road safety – roadside testing
Setting the context
While cannabis has been a topic of research interest for many years, it has only 
been recently that the issue of cannabis and road safety has been the subject of a 
substantial amount of public and government interest. In Europe, the subject has 
received considerable attention in recent years. An EMCDDA literature review on the 
effects of drug use on driving, originally published in 1999, was updated in 2007, 
while a selected issue on drugs and driving formed part of the 2007 Annual report. At 
the European Member State level, numerous initiatives have been carried out on drugs 
and driving, including specific interventions to reduce driving under the influence of 
cannabis. For example, in France a major research and prevention campaign (1) was 
launched in 2006, while a supporting study estimated that cannabis accounted for an 
additional 230 annual road deaths in France, with a significant proportion of these 
deaths affecting young people under 25 (French national report, 2005). A survey into 
drug use in recreational settings in the Czech Republic (n = 1 010) found that 56 % of 
respondents reported driving under the influence, a higher rate than for alcohol (41°%) 
(Czech Republic national report, 2005).
From a law enforcement perspective, a number of European countries have tightened 
drug driving laws in the past decade, for example to stipulate mandatory toxicological 
tests in the case of fatal accidents or to enable roadside drug testing. Furthermore, 
increased traffic controls for drug driving have been tested, although approaches vary 
— controls typically take the form of behavioural ‘sobriety’ tests and/or device-based 
‘quick’ screening (typically, saliva testing), which are later validated with urine and/or 
blood analyses (EMCDDA, 2007). Yet, the ‘operationalisation’ of penalties in a similar 
 (1) See www.cannabisetconduite.fr for information on the campaign, together with supporting 
studies.
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way to the blood alcohol concentration (BAC) limits commonly used for drink driving is 
not as commonplace in Europe for cannabis as in the USA (Grotenhermen et al., 2005). 
Exceptions exist, however: Belgium and Luxembourg, for example, use a threshold of 
2 ng THC/mL blood (Belgian national report, 2006; Luxembourg Ministry of Transport, 
2007). Some states in the USA also provide blood THC concentrations to guide judicial 
practice.
Thus, driving under the influence of cannabis (DUIC) has become an increasingly 
important issue from a public policy and road safety perspective. Available evidence 
suggests that while the prevalence of DUIC in the general population is relatively 
low (Walsh and Mann, 1999), it is substantially higher in important subgroups of the 
population, in particular young, male drivers (Lenne et al., 2004). Among users of 
cannabis, and in particular those who seek treatment for cannabis problems, 50 % 
or more may report DUIC at least once in the previous year (Albery et al., 1999; 
Macdonald et al., 2004a). As well, among young drivers in North America at least, the 
prevalence of DUIC is similar to or higher than the prevalence of driving after drinking 
(Adlaf et al., 2003; Asbridge et al., 2005).
While no data on trends in DUIC over time are available, if cannabis use increases in 
the population DUIC, it is likely that DUIC will increase as well. Thus, there is a clear 
need to assess the evidence on the impact of cannabis use on collision risk, in order 
to provide an evidence-based perspective to discussions of the magnitude of the DUIC 
problem and the need for legislative or programme action. The principal objective of 
this chapter is to examine critically the findings connecting cannabis and traffic crashes, 
and a second objective is to consider the problems in developing methods to assess 
cannabis impairment for legal purposes.
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Cannabis use and driving: 
implications for public health and 
transport policy
Robert E. Mann, Gina Stoduto, Scott Macdonald and 
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Impairment: effects of cannabis on performance
A substantial amount of information has accumulated on the effects of cannabis on 
human performance. Of particular interest here are those studies most relevant to the 
possible effects of the drug on driving behaviour. According to Maes et al. (1999), 
research measures can be grouped in the following categories: attention tests (simple 
and divided attention); vigilance tests (ability to sustain attention); auditory and visual 
tests (visual acuity, accommodation to darkness/light); reaction time (simple and choice 
reaction time); cognitive tests (e.g. digit/symbol substitution test, Stroop word/colour test, 
letter cancellation test); memory tests; mental arithmetic; flicker fusion test; visual–motor 
coordination tests; body sway; physiological measurements (EEG, eye movements, 
pulse, blood pressure); and self-awareness measures. Additionally, studies may involve 
simulated or actual driving tasks.
Several comprehensive reviews of this literature have emerged, and the results appear 
to be very consistent. A consistent conclusion is that the acute effect of moderate or 
higher doses (2) of cannabis impairs the skills related to safe driving and injury risk. 
Moskowitz (1985) concluded that marijuana use impairs driver performance under a 
variety of experimental conditions. Berghaus and Guo (1995) conducted a meta-analysis 
of 60 studies and concluded that marijuana causes impairment of every performance 
area connected with safe driving of a vehicle, such as tracking, psychomotor skills, 
reaction time, visual functions, and attention. Of these performance criteria, the 
most deterioration from marijuana use was found for measures of attention (e.g. the 
continuous performance task), tracking (e.g. the pursuit rotor task) and psychomotor 
skills (e.g. simple reaction time) (Coambs and McAndrews, 1994; Berghaus and Guo, 
1995). Similar conclusions have been reached by other reviews (Hollister, 1981; Maes 
et al., 1999; Smiley, 1999; Ashton, 2001; O’Kane et al., 2002; Ramaekers et al., 
2004; Lenne et al., 2004). Some authors have postulated that the various cognitive 
impairments mentioned previously are related to duration of drug use (Hall and Solowij, 
1998). Johns (2001) notes that cannabis use can occasionally result in short-term 
 (2) See Corrigan, this monograph, for a discussion of dosage and the pharmacology and 
pharmacodynamics of cannabis.
Cannabis use and driving: implications for public health and transport policy
176
psychiatric distress and even psychotic states, and that cannabis may provoke relapse 
and aggravate existing symptoms in people with major mental illnesses such as 
schizophrenia. In addition, potential withdrawal effects of heavy, long-term cannabis 
use, such as restlessness, insomnia, and anxiety, could also influence injury risk (Ashton, 
2001).
Smiley (1999) concluded that marijuana impairs skills and ability. She speculated that 
drivers are aware of this impairment, which may prompt them to slow down and drive 
more cautiously, suggesting that experienced cannabis users can compensate for the 
deleterious effects of cannabis on driving skills. This compensation for the effects of 
the drug is a form of tolerance to its effects. Tolerance is defined as a reduction in 
response to a particular dose of a drug with repeated administration, or the requirement 
that larger amounts are needed to obtain the same drug effect (Kalant et al., 1971). 
Tolerance to cannabis over repeated administrations is observed in animal studies with 
cannabis (Ashton, 2001), but little systematic research on cannabis tolerance in humans 
is available. When considering the extent to which tolerance to cannabis might influence 
drivers, it is useful to consider possible parallels between tolerance to cannabis and 
tolerance to alcohol. Tolerance is observed for both drugs, and substantial research 
has addressed the issue of alcohol tolerance in humans (e.g. Vogel-Sprott, 1992). The 
impairing effect of alcohol on psychomotor tasks is readily observed. However, under 
conditions where reinforcement is provided for non-impaired performance, tolerance will 
develop over a series of drinking sessions (Mann and Vogel-Sprott, 1981; Beirness and 
Vogel-Sprott, 1984), and the extent of tolerance development is related to awareness of 
impairment and efforts to compensate (Mann et al., 1983). Nevertheless, impairment 
returns when reinforcement contingencies are withdrawn (Mann and Vogel-Sprott, 1981; 
Zack and Vogel-Sprott, 1993). This return of impairment indicates that even tolerant or 
experienced users will display impairment of psychomotor performance. Thus, the same 
process that Smiley (1999) suggested may alleviate performance deficits in experienced 
cannabis users has been extensively studied with human subjects in laboratory research 
with alcohol. These studies indicate that even in those who learn to compensate for a 
drug’s impairing effects, substantial impairment in performance can still be observed 
under conditions of general task performance (i.e. when no contingencies are present to 
maintain compensated performance).
Other researchers have investigated the effects of cannabis combined with alcohol on 
laboratory performance measures. These studies have been stimulated in part by the 
apparent frequency with which both drugs are used together (Cimbura et al., 1990; 
Jonah, 1990; Stoduto et al., 1993; Walsh and Mann, 1999). In general, these studies 
typically, but not always, reveal that the effects of cannabis plus alcohol are greater 
than the effects of cannabis alone (Liguori et al., 2002; Chait and Perry, 1994). The 
research suggests that the effects of combining cannabis with alcohol on skills necessary 
for safe driving such as visual search and road tracking are either additive, in which 
the effects of both drugs together are roughly equivalent to adding the effects of the 
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two together, or multiplicative, in which the effects of the two drugs together are greater 
than the effects of the two individually (e.g. Robbe, 1998; Laemers and Ramaekers, 
2001). In reviewing this literature, O’Kane et al. (2002) observed that alcohol’s effects 
are strongest on integrative tasks while the effects of cannabis are strongest on tasks 
requiring attention and psychomotor skills.
Epidemiological studies on collision risk associated with 
cannabis use
Epidemiological studies are necessary to assess the impact of cannabis use on collision 
risk. In the past two decades, several studies have been published on the involvement 
of cannabis in collisions. In this review of the literature, conclusions from three types 
of studies will be drawn: (i) descriptive and analytical epidemiological studies on the 
prevalence of cannabis use through drug testing in injured drivers; (ii) studies of collision 
risk of clinical samples of cannabis users; and (iii) studies of collision risk among 
general populations of drivers. The purpose of this section is to review the available 
empirical research in order to assess the risks that cannabis may pose for traffic 
collisions. This assessment of risk is central to our understanding of the role of cannabis 
in traffic safety.
Studies using drug tests of injured drivers to detect cannabis 
metabolites
Studies that obtained drug tests of urine, blood or saliva from injured drivers are 
included in this section. Also included are studies of special populations where drug tests 
were taken of drivers suspected of driving under the influence or of reckless driving. A 
large number of descriptive studies have been conducted where the blood or urine of 
injured drivers has been analysed for the presence of cannabis metabolites. Thirty-two 
studies were found. The research methodologies and results in terms of the proportion 
testing positive for cannabis metabolites are described in Table 1.
There have been many epidemiological studies that have reported drug tests of fatally 
and non-fatally injured drivers. The percentage of fatally injured drivers testing positive 
for cannabis ranged from 1.4 to 27.5 % (mean = 10.7 %); while for non-fatally injured 
drivers the percentage ranged from 5 to 15.7 % (mean = 11.5 %) (Macdonald et al., 
2003). The prevalence rates for cannabis are highest for the special driver populations, 
that is, those suspected of drug or alcohol impairment or reckless driving. The 
percentage of impaired or reckless drivers testing positive for cannabis ranged from 7.4 
to 65.9 % (mean = 34.6 %).
Although many studies have been conducted on the prevalence of positive drug tests 
among injured drivers, few studies incorporated control groups so that assessments 
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Table 1: Summary of study results on the percentage of injured drivers  
testing positive for cannabis (continued)
  
 
Reference Jurisdiction Consent 
required
% positive 
cannabis
Comparison group Study group Comments
Brookoff et al. 
(1994)
Memphis, Tennessee, 
USA
No 33 % No 150 drivers stopped for reckless driving 12 % positive for both cocaine and cannabis. 18.7 % 
positive for alcohol (0.03–0.21 mg/dL)
Budd et al. 
(1989)
Los Angeles, California, 
USA
No 19.6 % 
(preliminary), 
18.5 % (follow-up)
No Preliminary study: 102 fatally injured drivers. 
Follow-up study: 492 fatally injured drivers
18.6 % positive for alcohol + cocaine/cannabis/
both (preliminary). 16.2 % positive for alcohol + 
cocaine/cannabis/both (follow-up)
Christopherson 
et al. (1990)
Norway No 31.5 % No 3 159 drivers suspected of driving under the 
influence of alcohol and drugs
One or more drugs present in 67 %
Cimbura et al. 
(1990)
Ontario, Canada No 10.9 % — 
drivers; 7.6 % — 
pedestrians
No 1 169 fatally injured drivers, 225 fatally injured 
pedestrians (aged 14 or over)
9.2 % positive for cannabis + alcohol (drivers). 
5.8 % positive for cannabis + alcohol (pedestrians)
Crouch et al. 
(1993)
Salt Lake City, Utah, USA No 13 % No 168 fatally injured truck drivers Impairment due to cannabis use in all cases where 
THC level exceeded 1.0 ng/mL 2.3 % positive 
cannabis + alcohol. 20 % of accidents positive for 
drugs had driver fatigue
Drummer 
(1995)
Melbourne, Australia No 11 % Yes; drivers not 
responsible
1 045 fatally injured drivers, 1990–93 Responsibility analysis conducted. No statistical 
significance for cannabis
Drummer et al. 
(2003)
Australian states: 
Victoria, New South 
Wales and Western 
Australia
No 13.5 % fatally 
injured drivers
No 3 398 fatally injured drivers, 1990–99 11.8 % positive for car drivers; 22.2 % positive for 
motorcycle drivers; 6.5 % positive for truck drivers; 
15.9 % positive for single vehicle crash; 11.1 % 
positive for multiple vehicle crash; 10.9 % positive 
for 1990–93; 13.5 % positive for 1994–6; 15.6 % 
positive for 1997–9
Dussault et al. 
(2002)
Quebec, Canada No for fatal 
drivers; yes 
for controls
19.5 % for fatal 
drivers; 6.7 % for 
controls
Yes 354 fatally injured drivers; 11 952 roadside 
controls
Fatalities were significantly associated with positive 
tests for cannabis in the case–control study. 
No significant relationship was found for the 
responsibility analysis. Selection bias due to the 
49.6 % response rate of providing a urine sample 
for the control group could have inflated the odds 
ratios
Everest and 
Tunbridge 
(1990)
England and Wales No 2.6 % No 1 273 fatalities (drivers, passengers, motorcycle 
drivers, pedestrians)
8.3 % of those positive for drugs were also positive 
for alcohol (> 0.08 mg/100 mL)
Fortenberry et 
al. (1986)
Alabama, USA No 11 % — 
drivers; 5 % — 
passengers; 1 % 
— pedestrians
No 510 fatally injured drivers, passengers, and 
pedestrians with urine samples
8.8 % positive for both cannabis + alcohol
Holmgren et al. 
(2005)
Sweden No 33 cases positive 
for THC
No 855 fatally injured drivers
Kintz et al. 
(2000)
Strasbourg, France No 9.6 % No 198 injured drivers (car, motorcycle, truck, 
bicycle) aged 13–57
Laumon et al. 
(2005)
France No At-fault drivers 
— 8.8 %; control 
drivers — 2.8 %
Yes; 3 006 not-at-fault 
fatally injured drivers
6 766 at-fault fatally injured drivers Cannabis increased fatal collision risk in a dose-
related manner after controlling for alcohol, age, 
type of vehicle and time of crash
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Table 1: Summary of study results on the percentage of injured drivers  
testing positive for cannabis (continued)
  
 
Reference Jurisdiction Consent 
required
% positive 
cannabis
Comparison group Study group Comments
Brookoff et al. 
(1994)
Memphis, Tennessee, 
USA
No 33 % No 150 drivers stopped for reckless driving 12 % positive for both cocaine and cannabis. 18.7 % 
positive for alcohol (0.03–0.21 mg/dL)
Budd et al. 
(1989)
Los Angeles, California, 
USA
No 19.6 % 
(preliminary), 
18.5 % (follow-up)
No Preliminary study: 102 fatally injured drivers. 
Follow-up study: 492 fatally injured drivers
18.6 % positive for alcohol + cocaine/cannabis/
both (preliminary). 16.2 % positive for alcohol + 
cocaine/cannabis/both (follow-up)
Christopherson 
et al. (1990)
Norway No 31.5 % No 3 159 drivers suspected of driving under the 
influence of alcohol and drugs
One or more drugs present in 67 %
Cimbura et al. 
(1990)
Ontario, Canada No 10.9 % — 
drivers; 7.6 % — 
pedestrians
No 1 169 fatally injured drivers, 225 fatally injured 
pedestrians (aged 14 or over)
9.2 % positive for cannabis + alcohol (drivers). 
5.8 % positive for cannabis + alcohol (pedestrians)
Crouch et al. 
(1993)
Salt Lake City, Utah, USA No 13 % No 168 fatally injured truck drivers Impairment due to cannabis use in all cases where 
THC level exceeded 1.0 ng/mL 2.3 % positive 
cannabis + alcohol. 20 % of accidents positive for 
drugs had driver fatigue
Drummer 
(1995)
Melbourne, Australia No 11 % Yes; drivers not 
responsible
1 045 fatally injured drivers, 1990–93 Responsibility analysis conducted. No statistical 
significance for cannabis
Drummer et al. 
(2003)
Australian states: 
Victoria, New South 
Wales and Western 
Australia
No 13.5 % fatally 
injured drivers
No 3 398 fatally injured drivers, 1990–99 11.8 % positive for car drivers; 22.2 % positive for 
motorcycle drivers; 6.5 % positive for truck drivers; 
15.9 % positive for single vehicle crash; 11.1 % 
positive for multiple vehicle crash; 10.9 % positive 
for 1990–93; 13.5 % positive for 1994–6; 15.6 % 
positive for 1997–9
Dussault et al. 
(2002)
Quebec, Canada No for fatal 
drivers; yes 
for controls
19.5 % for fatal 
drivers; 6.7 % for 
controls
Yes 354 fatally injured drivers; 11 952 roadside 
controls
Fatalities were significantly associated with positive 
tests for cannabis in the case–control study. 
No significant relationship was found for the 
responsibility analysis. Selection bias due to the 
49.6 % response rate of providing a urine sample 
for the control group could have inflated the odds 
ratios
Everest and 
Tunbridge 
(1990)
England and Wales No 2.6 % No 1 273 fatalities (drivers, passengers, motorcycle 
drivers, pedestrians)
8.3 % of those positive for drugs were also positive 
for alcohol (> 0.08 mg/100 mL)
Fortenberry et 
al. (1986)
Alabama, USA No 11 % — 
drivers; 5 % — 
passengers; 1 % 
— pedestrians
No 510 fatally injured drivers, passengers, and 
pedestrians with urine samples
8.8 % positive for both cannabis + alcohol
Holmgren et al. 
(2005)
Sweden No 33 cases positive 
for THC
No 855 fatally injured drivers
Kintz et al. 
(2000)
Strasbourg, France No 9.6 % No 198 injured drivers (car, motorcycle, truck, 
bicycle) aged 13–57
Laumon et al. 
(2005)
France No At-fault drivers 
— 8.8 %; control 
drivers — 2.8 %
Yes; 3 006 not-at-fault 
fatally injured drivers
6 766 at-fault fatally injured drivers Cannabis increased fatal collision risk in a dose-
related manner after controlling for alcohol, age, 
type of vehicle and time of crash
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Table 1: Summary of study results on the percentage of injured drivers  
testing positive for cannabis (continued)
  
 
Reference Jurisdiction Consent 
required
% positive 
cannabis
Comparison group Study group Comments
Logan and 
Schwilke (1996)
Washington State, USA No 11 % No 347 fatally injured drivers 10 % positive for alcohol + drugs; 15 % positive for 
drugs alone; 63 % of cannabis users positive for 
alcohol
Longo et al. 
(2000a,b)
Australia No 10.8 % Yes; non-culpable 
drivers
2 500 injured drivers admitted to an ER 7.1 % tested positive for cannabis-only. Blood tests 
taken — most drivers who tested positive for THC 
acid, the inactive metabolite
McBay (1986) Los Angeles, California, 
USA
No 13.4 % No 2 610 fatally injured drivers 2.8 % of drivers were positive for cannabis without 
any other drug; 28 % positive for drugs + alcohol
McLean et al. 
(1987)
Tasmania, Australia No 6 % of total 
sample
Yes; 387 blood 
donors
194 road users (42 fatally injured, 37 accident 
survivors, 115 breath-tested drivers/riders)
8 % of those positive for alcohol (> 0.5 g/L) had also 
used cannabis. Non-significant differences in drug 
use between groups
Marquet et al. 
(1998)
France No drivers — 13.9 %; 
patients — 7.6 %
Yes; 278 non-injured 
patients, aged 18–35
296 injured drivers, aged 18–35 Prevalence of cannabis among female drivers 
was significantly higher than for female patients 
(P < 0.05)
Mason and 
McBay (1984)
North Carolina, USA No 7.8 % No 600 fatally injured drivers 11 % positive for alcohol + drugs; 2.8 % positive for 
drugs alone
Mercer and 
Jeffery (1995)
British Columbia, 
Canada
No 13 % No 227 fatally injured drivers 11 % positive for alcohol + drugs
Movig et al. 
(2004)
The Netherlands Yes 12 % hospitalised 
drivers; 6 % 
controls
Yes; 816 roadside 
survey controls
110 injured drivers admitted to hospital Urine/blood test determined drug positivity. 39 % of 
injured drivers had urine test versus 85 % of controls 
had urine test. Effect of cannabis on risk of injury 
accident not significant
Mura et al. 
(2003)
France 10 % of drivers, 
5 % of controls
Yes; 900 controls 
admitted to 
emergency room of six 
hospitals
900 injured (non-fatal) drivers 10 % injured drivers positive for THC, 5 % of controls 
positive for THC. Among under-27-year-olds, 
cannabis increased collision risk significantly
Orsay et al. 
(1994)
Chicago, Illinois, USA No 7.4 % of total 
sample
Yes; 300 non-
impaired, injured 
drivers
285 alcohol or drug-impaired, injured 
motorists and motorcyclists
Impaired drivers had higher injury severity scores 
than control drivers (P < 0.001). Impaired drivers 
more frequently involved in collisions, cited for 
moving violations; found to be at fault
Peel and Jeffrey 
(1990)
Canada No 20 % of impaired 
drivers
No 492 cases: 94 injured; 172 impaired and 226 
fatally injured drivers
Of 53 impaired drivers, 4 % positive for cannabis
Poklis et al. 
(1987)
St Louis, Missouri, USA No 47 % No 137 drug positive DUI drivers, Jan. 1983 to 
May 1986
32 different drugs detected
del Rio and 
Alvarez (2000)
Northern Spain No 1.4 % No 285 fatally injured drivers Of all positive for drugs, 19.6 % were also positive 
for alcohol
Risser et al. 
(1998)
Vienna, Austria Yes 47 % of 19 
samples in 1993; 
72 % of 99 
samples in 1996
No 205 reckless drivers from 1993 to 1996, aged 
17–24 years. 199 car drivers; six motorcycle 
drivers
Increase in cannabis use increased significantly over 
time (P < 0.05)
Seymour and 
Oliver (1999)
Strathclyde, Scotland No 39 % of impaired 
drivers
Yes; 151 fatally 
injured drivers
752 drivers suspected of being impaired Drugs were present in 19 % of fatally injured drivers; 
polydrug use was prevalent; alcohol detected in 
33 %
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Table 1: Summary of study results on the percentage of injured drivers  
testing positive for cannabis (continued)
  
 
Reference Jurisdiction Consent 
required
% positive 
cannabis
Comparison group Study group Comments
Logan and 
Schwilke (1996)
Washington State, USA No 11 % No 347 fatally injured drivers 10 % positive for alcohol + drugs; 15 % positive for 
drugs alone; 63 % of cannabis users positive for 
alcohol
Longo et al. 
(2000a,b)
Australia No 10.8 % Yes; non-culpable 
drivers
2 500 injured drivers admitted to an ER 7.1 % tested positive for cannabis-only. Blood tests 
taken — most drivers who tested positive for THC 
acid, the inactive metabolite
McBay (1986) Los Angeles, California, 
USA
No 13.4 % No 2 610 fatally injured drivers 2.8 % of drivers were positive for cannabis without 
any other drug; 28 % positive for drugs + alcohol
McLean et al. 
(1987)
Tasmania, Australia No 6 % of total 
sample
Yes; 387 blood 
donors
194 road users (42 fatally injured, 37 accident 
survivors, 115 breath-tested drivers/riders)
8 % of those positive for alcohol (> 0.5 g/L) had also 
used cannabis. Non-significant differences in drug 
use between groups
Marquet et al. 
(1998)
France No drivers — 13.9 %; 
patients — 7.6 %
Yes; 278 non-injured 
patients, aged 18–35
296 injured drivers, aged 18–35 Prevalence of cannabis among female drivers 
was significantly higher than for female patients 
(P < 0.05)
Mason and 
McBay (1984)
North Carolina, USA No 7.8 % No 600 fatally injured drivers 11 % positive for alcohol + drugs; 2.8 % positive for 
drugs alone
Mercer and 
Jeffery (1995)
British Columbia, 
Canada
No 13 % No 227 fatally injured drivers 11 % positive for alcohol + drugs
Movig et al. 
(2004)
The Netherlands Yes 12 % hospitalised 
drivers; 6 % 
controls
Yes; 816 roadside 
survey controls
110 injured drivers admitted to hospital Urine/blood test determined drug positivity. 39 % of 
injured drivers had urine test versus 85 % of controls 
had urine test. Effect of cannabis on risk of injury 
accident not significant
Mura et al. 
(2003)
France 10 % of drivers, 
5 % of controls
Yes; 900 controls 
admitted to 
emergency room of six 
hospitals
900 injured (non-fatal) drivers 10 % injured drivers positive for THC, 5 % of controls 
positive for THC. Among under-27-year-olds, 
cannabis increased collision risk significantly
Orsay et al. 
(1994)
Chicago, Illinois, USA No 7.4 % of total 
sample
Yes; 300 non-
impaired, injured 
drivers
285 alcohol or drug-impaired, injured 
motorists and motorcyclists
Impaired drivers had higher injury severity scores 
than control drivers (P < 0.001). Impaired drivers 
more frequently involved in collisions, cited for 
moving violations; found to be at fault
Peel and Jeffrey 
(1990)
Canada No 20 % of impaired 
drivers
No 492 cases: 94 injured; 172 impaired and 226 
fatally injured drivers
Of 53 impaired drivers, 4 % positive for cannabis
Poklis et al. 
(1987)
St Louis, Missouri, USA No 47 % No 137 drug positive DUI drivers, Jan. 1983 to 
May 1986
32 different drugs detected
del Rio and 
Alvarez (2000)
Northern Spain No 1.4 % No 285 fatally injured drivers Of all positive for drugs, 19.6 % were also positive 
for alcohol
Risser et al. 
(1998)
Vienna, Austria Yes 47 % of 19 
samples in 1993; 
72 % of 99 
samples in 1996
No 205 reckless drivers from 1993 to 1996, aged 
17–24 years. 199 car drivers; six motorcycle 
drivers
Increase in cannabis use increased significantly over 
time (P < 0.05)
Seymour and 
Oliver (1999)
Strathclyde, Scotland No 39 % of impaired 
drivers
Yes; 151 fatally 
injured drivers
752 drivers suspected of being impaired Drugs were present in 19 % of fatally injured drivers; 
polydrug use was prevalent; alcohol detected in 
33 %
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Table 1: Summary of study results on the percentage of injured drivers  
testing positive for cannabis (continued)
  
 
Reference Jurisdiction Consent 
required
% positive 
cannabis
Comparison group Study group Comments
Soderstrom et 
al. (1995)
Baltimore, Maryland, 
USA
No 12 % No 1 338 injured (1 077 car drivers; 261 
motorcyclists)
Stoduto et al. 
(1993)
Toronto, Ontario, 
Canada
No 13.9 % No 339 injured drivers admitted to trauma unit 
(291 car drivers; 48 motorcyclists)
16.5 % positive for alcohol + drugs
Sugrue et al. 
(1995)
Sydney, Australia No 15.2 % drivers 
(> 100 ng/
dL); 8 % cyclists 
(> 200 ng/dL); 
13 % passengers 
(> 200 ng/dL); 
14% pedestrians 
(> 200 ng/dL)
No Total 262 (164 injured drivers, 12 pedal 
cyclists, 31 pedestrians, 55 passengers)
16 % positive alcohol + drugs
Terhune and 
Fell (1982)
Washington DC, USA No 10 % No 500 injured drivers 25 % positive for alcohol
Williams et al. 
(1985)
California, USA No 37 % No 440 fatally injured male drivers aged 15–34 Percentage of crash responsibility increased 
significantly from zero drugs to two or more 
detected drugs (P > 0.001); 81 % of cannabis users 
positive alcohol
of relative risks could be estimated. The best methodological studies are analytic 
epidemiological studies that utilise the case–control method (Meulemans et al., 1996; 
Marquet et al., 1998; Dussault et al., 2002; Mura et al., 2003). However, these studies 
are very difficult to conduct, and other investigators have used methods based on 
analysis of crash responsibility (e.g. Drummer, 1995; Longo et al., 2000a,b; Dussault 
et al., 2002; Drummer et al., 2004) (see Table 1). The logic of these studies is that if 
a drug increases collision risk, drivers under the influence of the drug are more likely 
to be considered responsible for the collision based on police reports (Terhune and 
Fell, 1982).
In a case–control study conducted in France, 296 injured drivers at emergency room 
departments and 278 non-injured control patients matched by age were urine tested for 
the presence of cannabis (Marquet et al., 1998). Methodologically, this study is unique 
among case–control studies in the field because consent was not required for urine tests 
of either cases or controls and, therefore, the results are free of selection biases. Results 
indicated that drivers testing positive for cannabis were not significantly more likely 
than controls to be involved in collisions. However, when the analyses were restricted to 
women only, the relationship became significant (Marquet et al., 1998).
Findings of another case–control study have recently been reported for 354 fatally 
injured drivers and 5 931 roadside controls in Quebec (Dussault et al., 2002). The odds 
ratio was statistically significant and indicated that fatally injured drivers were 2.2 times 
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Table 1: Summary of study results on the percentage of injured drivers  
testing positive for cannabis (continued)
  
 
Reference Jurisdiction Consent 
required
% positive 
cannabis
Comparison group Study group Comments
Soderstrom et 
al. (1995)
Baltimore, Maryland, 
USA
No 12 % No 1 338 injured (1 077 car drivers; 261 
motorcyclists)
Stoduto et al. 
(1993)
Toronto, Ontario, 
Canada
No 13.9 % No 339 injured drivers admitted to trauma unit 
(291 car drivers; 48 motorcyclists)
16.5 % positive for alcohol + drugs
Sugrue et al. 
(1995)
Sydney, Australia No 15.2 % drivers 
(> 100 ng/
dL); 8 % cyclists 
(> 200 ng/dL); 
13 % passengers 
(> 200 ng/dL); 
14% pedestrians 
(> 200 ng/dL)
No Total 262 (164 injured drivers, 12 pedal 
cyclists, 31 pedestrians, 55 passengers)
16 % positive alcohol + drugs
Terhune and 
Fell (1982)
Washington DC, USA No 10 % No 500 injured drivers 25 % positive for alcohol
Williams et al. 
(1985)
California, USA No 37 % No 440 fatally injured male drivers aged 15–34 Percentage of crash responsibility increased 
significantly from zero drugs to two or more 
detected drugs (P > 0.001); 81 % of cannabis users 
positive alcohol
more likely to test positive for cannabis than controls. However, this result should be 
treated cautiously owing to the possibility of systematic bias in the study. Little bias is 
likely for the proportion testing positive among the fatal drivers (19.5 %); however, for 
the control group, consent was required by participants to provide a urine test. Only 
49.6 % of controls agreed to provide a urine sample. The authors used saliva samples 
to assess the degree of possible bias, with the rationale that the reason drivers refused 
both urine samples and saliva sample would be the same (fear of detection). The 
participation rate for saliva tests was 84.6 %, which suggests that a large proportion of 
people found urine tests more invasive. The high rate of refusal to provide a saliva test 
indicates that the results should be interpreted with caution.
Meulemans et al. (1996) conducted a study where urine tests were taken from injured 
drivers at emergency rooms in Belgium. The authors examined injury severity of those 
in crashes. Being positive for cannabis metabolites was not significantly related to injury 
severity.
Mura et al. (2003) conducted toxicological tests on blood samples from 900 drivers 
involved in a non-fatal collision and 900 controls attending emergency rooms for non-
traumatic reasons in France. Younger drivers (under 27) with cannabis alone in their 
blood were significantly more likely to be involved in collisions (OR = 2.5). This was 
somewhat less than the OR associated with alcohol alone (3.8), and when alcohol and 
cannabis were combined the OR for collision involvement increased to 4.6.
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Several Australian studies have used responsibility analysis techniques and also had 
access to blood samples. Blood samples permit analyses of both the active and inactive 
ingredients of tetrahydrocannabinol (THC) and are the best approach for determining 
likely cannabis impairment. Longo et al. (2000a,b) obtained drug tests from 2 500 
injured drivers. Their analysis found no significant differences in the degree of culpability 
associated with cannabis-positive compared with cannabis-negative drivers. Drummer 
(1995) examined the blood samples of driver fatalities linked with traffic reports in an 
Australian study. Similarly, he found no significant elevation of collision risk associated 
with cannabis use. More recently, Drummer et al. (2003, 2004) reported a responsibility 
analysis of 3 398 drivers killed in collisions in the Australian states of Victoria, New 
South Wales and Western Australia. Cannabis alone increased the likelihood of 
involvement in a fatal collision in a dose-related manner. The odds ratio (OR) for fatal 
collision involvement for those positive for cannabis only was 2.7; however, when 
analyses were restricted to those with concentrations greater than 5 ng/mL, the OR rose 
to 6.6.
A recent study from France employed responsibility analysis methods with a large 
sample of fatally injured drivers for whom blood samples were available. Laumon et 
al. (2005) reported on 10 748 drivers killed in France between October 2001 and 
September 2003. Blood levels of $9-tetrahydrocannabinol were compared in 6 766 
drivers considered to be at fault for their collisions and 3 006 drivers, selected from the 
3 982 other drivers, not considered to be at fault. These authors found that cannabis 
increased risk of involvement in a fatal collision in a dose-related manner, after 
controlling for presence of alcohol, age, type of vehicle and time of crash. The adjusted 
odds ratio for fatal collision involvement associated with blood levels of 5 ng/mL or over 
was 2.12. As well, these authors estimated that 2.5 % of fatal crashes in France could be 
attributable to cannabis.
Studies using clinical samples of cannabis abusers in treatment
The characteristics of studies using clinical samples of cannabis users in treatment are 
summarised in Table 2. We know from existing studies that clinical substance abuse 
populations are likely to drive after using cannabis. In one study, of a sample of 210 
users in treatment for heroin dependency, 58 reported driving after drug use, and 62 % 
of these reported driving at least once after using cannabis (Albery et al., 1999). In 
a study of those in treatment for alcohol, cannabis or cocaine abuse, 63 % reported 
driving after use of cannabis (Macdonald et al., 2004a).
Few studies exist that examine collision risks experienced by clinical samples of 
individuals receiving treatment for cannabis. In the first of these studies, Smart et al. 
(1969) observed elevated collision rates in abusers of one or more drugs other than 
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alcohol, but the sample was very small (n = 30). In another study of 144 male substance 
abusers aged 21–40, Mann et al. (1993) examined collision rates in the year before 
entry into treatment and compared these rates to collision rates in the general male 
population of the same age. The subjects estimated that about 50 % of their collisions 
in the preceding year occurred while they were under the influence of alcohol and/or 
drugs. As well, results suggested that the frequency of any substance use, as opposed 
to the use of specific substances, predicted collision involvement and significant 
post-treatment reductions were found in moving violations, DWI convictions, and total 
collisions (Mann et al., 1995).
A recent study examined the driving records of a large sample of cannabis abuse clients 
in treatment (Macdonald et al., 2004b). This study utilised blind linkage procedures a 
note to explain this method to avoid non-respondent bias, and compared the clinical 
sample to a randomly selected, frequency-matched (age, gender, location) control 
group of drivers. Significant elevations in collisions were found for abusers of cannabis 
compared with population controls, both prior and after treatment (Macdonald et al., 
2004b). While this study demonstrates an association between cannabis abuse and 
elevated collision risk, alternative explanations for this relationship cannot yet be ruled 
out.
Studies using general populations of drivers
Recently, Asbridge et al. examined the impact of self-reported DUIC on collision risk 
among high-school students in the four Atlantic provinces of Canada. These authors 
observed a significant elevation of collision risk (OR = 1.84) among students who 
reported DUIC, after controlling for demographic factors, driver experience, and self-
reported driving after drinking. Similarly, Mann et al. (2005) examined the association 
of collision risk with DUIC among a representative sample of adults surveyed in Ontario. 
Reporting DUIC in the past year increased significantly the odds of reporting a collision, 
after controlling for age, gender and other demographic variables (OR = 2.61).
General discussion of cannabis and collision risk
Early reviews of the literature on the association of cannabis use with collision risk 
concluded that conclusive demonstrations of cannabis use as risk factor for collisions 
did not exist (Robbe and O’Hanlon, 1993; Ferrara et al., 1994; Chesher, 1995; 
Christopherson and Morland, 1997; Hunter et al., 1998; Bates and Blakely, 1999; de 
Gier, 2000; Morland, 2000; Vingilis and Macdonald, 2002; Macdonald et al., 2003). 
However, more recent studies clearly suggest that cannabis use increases collision 
risk (e.g. Dussault et al., 2002; Mura et al., 2003; Drummer et al., 2004; Laumon et 
al., 2005;). Recent reviews of this literature are reflecting this growing body of studies 
finding a collision-enhancing effect of recent cannabis use (e.g. Kalant, 2004).
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Numerous epidemiological studies have been found where drug tests were conducted of 
injured drivers. Early analytical epidemiological studies that used responsibility analysis 
or case–control methods did not provide clear proof that cannabis use is related to 
increased injury risk from collisions (Bates and Blakely, 1999). These studies often 
have poor statistical power because the presence of drug metabolites is relatively rare 
and large sample sizes are required to detect significant effects. To demonstrate that 
a relationship exists, much larger sample sizes are likely required with methodological 
approaches free of biases that could inflate odds ratios.
Several methodological issues complicate the use of some types of drug tests. For 
example, urine test results cannot be used to measure drug impairment, only whether 
drug use occurred sometime in the past, up to a few weeks for cannabis (Kapur, 1994). 
Since urine tests are detecting those that are not under the influence of cannabis, the 
measure lacks specificity and, therefore, extremely large sample sizes may be needed 
to find a statistically significant increase in collision rates for those testing positive. 
Blood tests offer a more promising approach for the assessment of whether drivers are 
more likely to be under the influence; however, because of their more intrusive nature, 
they may only be feasible for studies using responsibility analysis of fatally injured 
drivers. Few studies that use drug tests have control groups, thereby making it difficult 
to determine whether drug presence is a risk factor. The likely reason few studies 
include controls is that consent from this group is usually required. Consent is likely to 
discourage the participation of drug users more than non-users, which would translate 
into inflated relative risks or odds ratios. Some studies have used comparison groups 
of pedestrians; however, this approach is likely too conservative because the pedestrian 
could also be at fault.
Some studies have noted that different drugs are used in combination with each other, 
possibly resulting in increased risk for injury. Drug metabolites, for example, are often 
found in combination with alcohol. Therefore, it is important to separate out the relative 
role of other drugs from alcohol. Although many studies reported the proportion of 
collisions that involve alcohol, research has largely failed to separate out the role of 
alcohol from cannabis in collisions.
Under these circumstances other means to assess the contribution of cannabis to 
collision risk are useful. One approach is to examine collision risks of known heavy 
users of cannabis, such as people in treatment for a cannabis abuse problem. A recent 
study found cannabis clients have significantly elevated rates of collisions compared with 
population controls (Macdonald et al., 2004b). Another approach is to examine collision 
risks associated with self-reported DUIC in survey data. Recent studies have found 
that collision risks are significantly elevated in samples on adolescents and adults who 
report DUIC (e.g. Asbridge et al., 2005). However, studies of clinical groups or survey 
samples are limited in their ability to draw causal inferences, or to control for potential 
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confounders. Other factors may be causally related to both drug use and collisions. 
Recent studies and reviews on set variables, such as aggression (Beirness, 1993; 
Deffenbacher et al., 2000; Wiesenthal et al., 2000; Gidron et al., 2001), risk-taking/
impulsiveness (Beirness, 1993; Jonah, 1997; Vavrik, 1997), stress (Veneziano and 
Veneziano, 1992; Simon and Corbett, 1996; Norris et al., 2000), fatigue (Horstmann et 
al., 2000; Masa et al., 2000; Connor et al., 2001) and criminality (Wells-Parker et al., 
1986; Denison et al., 1997) confirm the importance of these characteristics in predicting 
collisions. Studies have found that many of the characteristics described above are over-
represented in substance abuse populations, which might also explain higher collision 
rates. Withdrawal effects from cannabis, such as exhaustion, anxiety, agitation, mood 
swings and depression, and long-term effects of abuse, such as chronic sleep disruption, 
distractibility and depression (Cohen and Sas, 1993; Coambs and McAndrews, 1994; 
Herscovitch, 1996) could also increase risks.
One of the strengths of studies of clinical and survey samples is the accessibility and 
validity of information gathered. Although these studies suffer from the same limitations 
as survey studies of non-clinical samples, the biases related to self-reports are likely 
much less pronounced in the clinical samples. Since those who seek treatment have 
already acknowledged that they have a problem, they are more likely to provide 
accurate accounts regarding that problem. Good validity of self-reports has been 
established among substance users both during and after treatment (Hindin et al., 1994; 
Nelson et al., 1998).
Detecting cannabis in drivers
The availability of accurate and simple-to-use breath tests for alcohol have been 
central to current efforts to reduce drink driving (Mann et al., 2001). There has been a 
continued interest in the development of a breath test for cannabis over the years, but to 
date no scientifically validated tests have been reported (Verstraete, 2000). Blood tests 
are the ‘gold standard’ for assessing levels of cannabis and metabolites in the body. 
Results of blood tests can be influenced by such factors as the temperature at which the 
sample is stored and binding to the inner surface of plastic vials (O’Kane et al., 2002). 
The logistic and legal issues involved in obtaining and testing blood samples from 
drivers suspected of DUIC are complex.
As noted earlier, the mere presence of cannabis in plasma may not indicate impairment. 
A current focus of research is to identify a relationship between THC in blood (and other 
body fluids) and behavioural change, drug influence and impairment (Martin and Cone, 
1999). This has led to the suggestion that per se levels of cannabinoids in plasma may 
be identified for legal purposes, similar to the identification of per se levels for alcohol 
(Martin and Cone, 1999). Ramaekers et al. (2004), in considering this question, note 
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that meta-analyses of laboratory studies indicate that maximal performance impairment 
is seen at THC concentrations greater than 14 ng/mL in plasma or 7 ng/mL in whole 
blood. However, they note that the link between these levels and elevated collision risk 
has not been absolutely established.
Urine tests are used in situations where any relatively recent use of cannabis and other 
drugs is of interest (e.g. in sports, in addictions treatment), regardless of whether that 
use occurred in the previous few hours, days or even weeks. However, urine tests do not 
permit an accurate assessment of when drug use occurred (Kapur, 1994). A driver who 
has a positive urine test for cannabis may have used the drug in the preceding hours or 
days (or even weeks), and, thus, his or her driving skills may not be influenced by the 
drug at the time the sample is taken.
The detection of cannabinoids in saliva and sweat has been an active area of research. 
Current kits to measure saliva involve taking a swab from the mouth and include a 
rapid detection kit (O’Kane et al., 2002). Available data suggest that saliva THC levels 
arise from a drug that has remained in the mouth during smoking or ingestion, and 
initial data suggest that these levels are associated with degree of impairment observed 
(Menkes et al., 1991). The EU has run two projects, Rosita-1 and Rosita-2, to examine 
technology for enabling roadside drug screening. The first Rosita project in 1999–2000 
established criteria for acceptable tests (sensitivity and specificity > 90 %, accuracy 
> 95 %) for amphetamines, benzodiazepines and cannabis. As rapid screening in a 
roadside situation should aim to be as non-invasive as possible, the Rosita-2 project 
aimed to evaluate the useability and analytical reliability of nine on-site oral fluid (saliva) 
drug testing devices between 2003 and 2005. Six European countries and four states 
in the USA took part. At the end of the period, none of those devices met the criteria 
proposed during the Rosita-1 project. Six devices registered a failure rate of greater than 
25 %. The procedure of obtaining the saliva samples varied greatly in terms of handling, 
quantities and acceptance by officials testing and persons tested, sometimes easy to 
perform, sometimes difficult to follow.
Assessing behavioural effects of cannabis
There has been substantial recent interest in programmes involving the training of police 
officers and others to detect the physiological and behavioural effects of cannabis in 
individuals suspected of DUIC, and research on this topic is beginning to appear. Drug 
recognition expert (DRE) programmes have been developed to enable police officers 
to identify an individual who may be under the influence of a drug. These indicators 
can range from pupil size and body sway to the presence of drug paraphernalia in the 
vehicle. Walsh and Cangianelli (2002) reported that, in drivers suspected of driving 
under the influence of drugs (DUID) by DRE-trained police officers, subsequent blood 
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testing revealed that 32.5 % were positive for at least one drug other than alcohol. This 
low level of sensitivity improved to 79.3 % when officers were subsequently given an 
improved training programme. Tzambazis and Stough (2002) presented evidence that 
cannabis-induced impairment of performance on behavioural tests (standardized field 
sobriety tests, SFSTs) was significantly correlated with impairment of driving. Similarly, 
Papafotiou et al. (2004) showed that impairment of SFST performance increased with 
increasing dose of cannabis.
Driving under the influence of cannabis legislation in 
Europe
Currently, European Union countries have legal provisions on driving under the 
influence of drugs but impairment must be proven in court in most countries (Moeller et 
al., 1999; EMCDDA, 2007). Germany (in 1998), Belgium (in 1999), Sweden (in 1999; 
Jones, 2004) and Finland (in 2003; Lillsunde et al., 2004) passed laws that allow for 
sanctions based on detection of drugs alone and other countries have proposed similar 
laws. This type of legislation depends on the police force’s authority to collect human 
specimens at the roadside for testing or for confirmatory analysis, and this authority 
is regulated by other legislation that differs by jurisdiction. Some countries allow the 
police to control and test the public randomly and suspicion is not necessary for testing. 
However, the majority of countries treat roadside testing as an infringement of civil 
rights and suspicion is necessary for testing. Some countries have improved the process 
for initial suspicion by training the police to identify intoxicated drivers on the basis of 
physical and psychomotor signs.
Germany and Belgium currently use roadside testing devices routinely (sweat and urine 
are collected) and some countries have used urine or saliva or sweat test devices on 
an experimental basis with the driver’s consent. Very few European countries have 
regulations prohibiting the use of roadside drug testing devices. However, many do 
not use these devices because of concerns regarding their validity or because of their 
unavailability. The preferred test is a single use, multi-parameter test, which is able to 
provide a clear, unambiguous test result within 5 minutes. According to Moeller et al. 
(1999), saliva is the preferred test specimen for cannabis due to its easy availability, low 
invasiveness and good correlation with impairment. Sweat was the second in preference 
because it allows testing without collaboration of the driver, and its low invasiveness and 
good availability at the roadside. Roadside drug screening is being trialled in a number 
of European Member States at the time of writing (EMCDDA, 2007). There have been 
some teething issues. For example, tests carried out in France in the summer of 2007 
used three different devices and required the presence of a doctor for validating a urine 
sample. Introduction of Drugwipe saliva tests in Luxembourg in 2007 required explicitly 
by the Transport Ministry that the tests would not serve to incriminate drivers taking 
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legal medicines (3). Portuguese police reported problems with a faulty batch of Oratec-3 
testing kits. Nonetheless, there is commitment at ministerial level to introducing saliva-
based drug testing across many Member States.
Conclusions
The impact of cannabis on traffic safety is an issue of substantial public and political 
interest at present and will likely continue to be of interest for some time. As has become 
clear in this review, there is a substantial amount of information available that can shed 
light on this issue, but in many areas the available evidence is sparse or unclear.
First, it appears clear that, in laboratory settings, cannabis impairs the skills thought 
to be necessary for safe driving. This impairment is not restricted to high levels of the 
drug (see earlier note that this dosage level may need some explanation) and occurs 
at the dosage levels that result from typical use of the drug. Tolerance may occur with 
continued use, but even individuals who have acquired tolerance to some of the effects 
of cannabis may demonstrate impairment on task performance. Combining alcohol with 
cannabis will result in an increase in the effects of cannabis, and the interaction could 
be multiplicative.
After alcohol, cannabis is the drug most often found in fatally and non-fatally injured 
drivers. In recent, studies cannabis has been found in up to 27.5 % of dead drivers 
(Macdonald et al., 2003). However, epidemiological studies employing control groups 
are necessary to identify more precisely the contribution of the drug to collision 
causation. While earlier reviews of the literature were unable to conclude that cannabis 
increased collision risk, more recent studies employing larger samples and more 
rigorous methods are demonstrating with more consistency that recent cannabis use 
will increase collision risk (e.g. Mura et al., 2003; Drummer et al., 2004; Laumon et 
al., 2005). Studies employing clinical samples or using survey data provide additional 
indications of an increase in collision risk associated with cannabis use, however, in 
these studies the possibility that the increased risk may be due to factors other than the 
effects of cannabis cannot yet be ruled out.
Central to the problems of assessing the impact of cannabis on collision risk and to 
the problem of detecting cannabis-impaired drivers is the problem of measuring the 
presence of cannabis in the body. Difficulties in measuring cannabis in the body have 
hampered research on the effects of cannabis and the potential development of legal 
initiatives to address cannabis-impaired driving. Research is now assessing issues of 
dose–response effects on skills and behaviour. As well, measures that may assist in the 
 (3) See www.gouvernement.lu/salle_presse/communiques/2007/10/03lux/
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detection of DUIC (saliva tests, DRE programmes, standardized field sobriety tests) show 
promising results in field trials.
While much information is now available, there is a clear need for more research to 
determine the degree and nature of the association between cannabis use and collision 
risk. The impact of several variables on the cannabis–collision risk relationship needs 
to be examined, including personality characteristics such as risk-taking, aggression, 
criminality and stressful life events. Additional research to discover and validate easily 
administrable measures of cannabis use and impairment is also needed. Nevertheless, 
recent research has provided a much clearer picture of the contribution of cannabis to 
collision risk than was available only a few years ago.
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Setting the context
One of the fears that has accompanied increasing cannabis prevalence in Europe is 
that more people, or rather more vulnerable people, are being exposed to problematic 
use. In particular, there are concerns about cannabis’s role as a potential trigger or 
precipitator of mental health problems such as psychosis, depression, schizophrenia and 
anxiety (see this monograph’s chapters by Witton, Hall and Montanari et al.). Anxiety 
has focused particularly on adolescents and young adults, the core cannabis-using 
demographic.
Few argue that more and more people — and in particular adolescents and young 
adults — are seeking professional help for cannabis problems. Cannabis treatment 
indicators were the topic of a selected issue in EMCDDA’s 2004 Annual Report. Key 
findings were that 12 % of all treatment clients and 30 % of new clients to drug treatment 
recorded using cannabis as their main problem drug, and that a steady rise has been 
seen since the mid-1990s. The most recent data indicates that the share of those seeking 
help for cannabis among treatment clients has increased further to 20 %, although the 
share of new clients has remained stable, at 29 % (EMCDDA, 2007). Concerns about 
youth exposure to problems seem justified: nearly all cannabis clients new to treatment 
are under 30 years old, and the majority are male. Teenagers in specialised drug 
treatment are more likely to report cannabis as the primary drug.
Not surprisingly, health professionals – both specialists and general practitioners – are 
increasingly seeking advice on best practices for treating cannabis problems. While 
Chapter 14 by Rödner Sznitman is descriptive, answering the question ‘What cannabis 
treatment is available in Europe today?’, ideally, this chapter would now be prescriptive, 
detailing ‘What cannabis treatment should be available in Europe today?’
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Yet, this chapter cannot be prescriptive. As with other types of drug treatment, no ‘gold 
standard’ for cannabis exists. Nonetheless, there is some cause for optimism. The 
author finds that as cannabis treatment becomes more commonplace, the evidence 
base for ‘what works’ is likely to improve. What is more, the need to measure efficacy is 
increasingly being ‘built into’ emerging programmes from the start, as opposed to being 
tagged on as an afterthought.
Specialised cannabis treatment centres are being opened in a number of European 
countries — for example, in 2005, France opened 250 cannabis consultation centres, 
while promising psychosocial therapy development projects are underway, such as 
CANDIS in Germany and the five-country INCANT project (Belgium, Germany, France, 
Netherlands, Switzerland), and the Maria Youth Centre Project in Sweden (EMCDDA, 
2007). The EMCDDA organised a Reitox academy in Berlin in March 2007 on cannabis 
prevention and treatment (see link below). Nonetheless, policymakers should perhaps 
bookmark this chapter with a large Post-it note reading ‘research funding needed here’.
Further reading
EMCDDA, Annual reports, published each year in November.
EMCDDA (2007), Presentations at the Reitox Training Academy, on cannabis prevention and 
treatment (29–30 March, Berlin) 
http://academy.emcdda.europa.eu/index.cfm?fuseaction=public.Content&nnodeid=23154
EMCDDA (2004), Annual report 2004 — Selected issue on ‘Cannabis problems in context — 
understanding the increase in European treatment demands on Cannabis treatment, European 
Monitoring Centre for Drugs and Drug Addiction, Lisbon 
http://ar2004.emcdda.europa.eu/en/page155-en.html
Lundqvist, T., Petrell, B., Blomqvist, J. (2007), Improvement in cognitive and social competence in 
adolescent chronic cannabis users — Results from a manual based treatment programme at Maria 
Youth Centre, Stockholm, Sweden, Drug Addiction Treatment Centre, Lund University Hospital, 
Lund.
Projekt CANDIS website (2005–2007), http://candis-projekt.de/cannabis.html
Projekt INCANT website (2006–2007), www.incant.de/
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Treating cannabis use disorders: 
perspectives and best practices
Anders Bergmark
As in most other cases within the field of treatment of substance misuse there is no solid 
consensus concerning the specific effects of different treatment interventions for cannabis 
use disorders. Current cannabis treatment options are limited compared with those for 
alcohol and opiates and have only developed in recent years as the need for treatment 
has become more apparent. To a large extent the available knowledge-base is hard 
to interpret, due to a lack of standardisation of core components in clinical trials (such 
as client characteristics and comparison interventions). This challenge is compounded 
by the small amount of treatment studies to draw upon, and the reliance upon meta-
analysis and reviews of clinical studies, which in itself is subject to flaws.
A digression on the limitations of scientific reviews
When mapping the fast-developing field of cannabis treatment, it is crucial to take 
into account both the immaturity of the existing evidence base and the challenges of 
making clear-cut secondary reviews. So before reviewing current work on cannabis 
treatment, a didactic digression is included here to encourage peers to apply a critical 
eye when dealing with cannabis treatment. It reviews the doubts that have been cast on 
the existing evidence base for alcohol treatment, thus serving as a warning to cannabis 
treatment researchers to avoid similar pitfalls.
Recent years have seen a shift within scientific studies away from original studies and 
towards more ‘exhaustive’ reviews. It is no longer sufficient to underpin a clinical 
position by a single primary study or by synthesising a handful of primary studies, 
but to review all relevant studies. In some cases several hundred studies must be 
analysed. However, the resulting secondary studies need to be read critically, and there 
is considerable discussion on the limitations of reviews in clinical and psychological 
literature (Widiger et al., 1990; Deeks, 1998; Rosenthal and DiMatteo, 2001).
For substance treatment, there are three broad types of scientific review: the ‘narrative 
review’, the ‘box-score review’, and the ‘meta-analysis’.
Narrative reviews are conducted without an explicit systematic approach concerning t
the synthesis of the results of the primary studies that are included.
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Box-score reviews set out to differentiate between evidence by comparing any given t
treatment modality’s proportion of positive findings vis-à-vis the total number of 
studies for that modality.
Meta-analyses are built upon ‘effect sizes’ (ES), an index of treatment efficacy that t
enables the study to determine how a standard deviation in the results for one 
treatment group compares to control groups.
Although guidelines exist for how a review should be conducted, the majority of reviews 
— across many clinical fields — fail to follow them (Widiger et al., 1990; Breslow et 
al., 1998; Wilson, 2000; Altman et al., 2001; Bergmark, 2001). Over time ‘narrative 
reviews’ have become less important. While they are rarely without value — essentially 
relying upon the insight of the authors — they are not fit for analysing a large number 
of original studies and because they lack statistical analysis.
Meanwhile, the difficulties involved in producing valid box-score reviews have been 
underestimated, and this situation is not helped by the existence of competing reviews, 
that is reviews that reach contradictory conclusions from the same primary material 
(Petticrew and Kennedy, 1997). Finney (2000), a leading substance misuse treatment 
researcher, has provided strong arguments to favour pessimistic interpretation of existing 
research in the alcohol treatment field, and points to four major problems connected 
with box-score reviews:
 1 lack of statistical power to identify differences between the intervention and control 
group;
 2 multiple statistical tests for treatment effects;
 3 variable comparison (control) groups across studies;
 4 lack of consistent and adequate data on client characteristics across studies.
The number of clients in alcohol treatment studies is generally limited to a size that 
only gives a 50 % chance to detect a medium-size effect at the P < 0.05 level (Morley 
et al., 1996). This means that there is a substantial risk that conclusions concerning 
treatment effects are dependent on variation in statistical power among studies that are 
included in a review. It has been shown that studies on treatment settings that did detect 
positive differences in effects have an average probability of 77 % to do so, whereas 
studies with negative findings only had a 55 % chance to do the same (Finney et al., 
1996). There is also a trend to compensate for weakness in statistical power; that is, 
the use of small groups of clients in studies by using a large number of tests without 
any regard for the type I error rate (Finney, 2000); that is, for false positive findings 
owing to the fact that a large number of tests will increase the probability for positive 
findings because of chance. In a study of settings effects it was found that studies that 
did identify positive effects had an average of 18.6 tests for the identified treatment 
effects, while those studies that did not identify any treatment effects had an average of 
4.9 tests (Finney et al., 1996). A lack of standard procedure when it comes to the use 
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of comparison groups, that is the fact that there often is a great variation concerning 
what type of control condition is used within different studies, undermines the possibility 
of using original studies in reviews. It has been shown (Floyd et al., 1996) that only 
30 % of treatment studies used comparison groups that were exposed to no or minimal 
treatment, and as a consequence the identification of treatment effects will be dependent 
on which type of intervention the comparison group was subjected to. In a similar 
manner, the lack of information on relevant client characteristics constitutes a serious 
threat against the possibility of making comparisons between different studies. In a 
recent review of methodological issues (Floyd et al., 1996) more than two-thirds of the 
studies lacked information on how many years the clients have had substance misuse 
problems, and only 16 % had any information concerning to what extent clients had 
received previous substance misuse treatment.
Meta-analysis is generally considered to be a better alternative than a box-score 
review. This is mainly because meta-analysis can avoid the serious bias connected to 
limited statistical power in the original studies by establishing so-called combined effect 
sizes. However, all the problems do not go away. As with box-score reviews there are 
substantial problems related to the lack of standardised comparison groups and an 
absence of information on relevant client characteristics. Combined, these problems 
bring Finney to conclude that currently, in the field of alcohol treatment, it is not possible 
to establish any synthesis that could direct an evidence-based practice about alcohol 
treatment.
It is telling that some of the most well-known researchers who have been extensively 
involved in such reviews have radically different views on whether existing reviews are 
inconsistent or not. For example, while Miller and Willbourne (2002) are encouraged by 
what they identify as considerable convergence between different reviews, Finney (2000) 
takes the opposite position.
The scientific knowledge base for treatment of cannabis 
use disorders
Meta-analyses
To date there have been two reviews that are specifically directed towards treatment of 
cannabis use disorders: SBU (2001; The Swedish Council on Technology Assessment in 
Health Care) and Fridell (2003). However, these two reviews, which both make use of 
meta-analytical techniques, arrive at two different qualitative answers to the question 
of whether any effective treatment for cannabis use disorders exist. They are in fact 
strongly related to each other: Fridell’s study is an update of the SBU study (Fridell 
was the author of the chapter in the SBU study that dealt with psychosocial treatment 
for drug dependence). Most treatment approaches to cannabis use disorders involve 
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psychosocial approaches, which may include elements of psychological interventions 
such as cognitive–behavioural therapy or motivational interviewing or aspects of the 
client’s environment, notably in interventions involving the client’s family. But while the 
SBU study concluded ‘there is no documentation of reliable effects for any psychosocial 
treatment for cannabis abuse’ (p. 48, vol. II, author’s translation), Fridell summarises his 
findings as follows: in 4 out of 13 published studies, behaviour therapy (pp. 5, 7) and 
family therapy (pp. 70, 88, 97) had a significant effect compared with control conditions 
for marijuana-smoking teenagers with a still-existing family network (p. 354).
The difference in the conclusion drawn in these reviews does not stem from the inclusion 
of new studies; although Fridell’s study includes 13 studies and SBU 11, the two 
studies that were added to the former analysis were published in 1989 and 1982 (and 
should, according to the inclusion criteria stated in the latter analysis, also have been 
included in the SBU study). While the SBU study directly refers to the effect size (ES) of 
the meta-analysis that was undertaken for all psychosocial interventions, Fridell makes 
no explicit reference to the ES derived from his meta-analysis. Instead, he points to the 
fact that some treatment interventions have support for effects. But this approach begs 
the question why the overall meta-analysis was performed at all. To the extent that 
Fridell intended to evaluate the effects of specific treatment modalities, he should also 
have included the studies with no or weak effects that are included in the meta-analysis, 
otherwise the claim that behaviour and family therapy have support in some studies 
cannot be considered as meaningful (as the treatment modalities that are identified also 
are present in studies with no support for an effect).
While the meta-analysis in the SBU study produced an ES of 0.05 and, thus, points in 
the direction of no effects for psychosocial interventions for cannabis use disorders, 
Fridell’s meta-analysis yields an ES of 0.24, that is, just above the 0.20 level which 
commonly is identified as the lower limit for a low ES (0.20–0.50; Cohen, 1978). The 
difference in ES from the two meta-analyses does not seem to be primarily connected 
to the inclusion of two new studies but to a difference in the estimated ES for three 
studies that are present in both studies. A study by Lewis is assigned an ES of 0.25 in 
SBU, while the corresponding value in Fridell’s analysis is 0.49; a study of Joanning 
et al. (1992) has an ES of 0.63 in SBU and an ES of 1.01 in Fridell’s analysis, and 
finally, a study by Henggeler et al. (1998) has an ES 0.54 in SBU and an ES of 0.93 
in Fridell’s analysis. Taken together, such inconsistencies undermine the possibility of 
interpreting the relationship between these two reviews and drawing conclusions that 
could guide practice. Thus, both the SBU’s and Fridell’s meta-analyses suffer from 
several of the problems dealt with in the preceding section. Neither of them considers 
the effects of the fact that there are important differences between the client groups 
in the studies included. Most importantly, neither distinguish between studies that only 
include adolescents and those directed towards adults. In the same fashion, there are 
no attempts to analyse the effects of the fact that there is a substantial variation in 
comparison groups between the studies that are included.
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Recent treatment studies
Adolescent treatment
There are some new, substantial studies that are not included in SBU’s or Fridell’s 
analyses that underline the difficulties of identifying best practice. The most important is 
the CYT (cannabis youth treatment) study (Dennis et al., 2004). This multisite study sets 
out to analyse the effects of five different treatment interventions for adolescent cannabis 
use disorders. The design of the study aims at an identification of effects of treatment 
intensity as well as of treatment modalities. A combination of motivational enhancement 
treatment (MET) and cognitive–behavioural therapy (CBT) in five sessions was compared 
with the MET/CBT in 12 sessions and family support network (FSN, which was based 
on MET/CBT in 12 sessions and an addition of six parent education group meetings, 
four home visits, and case management). In a second trial of the study the five-session 
version of the MET/CBT intervention was compared with the adolescent community 
reinforcement approach (ACRA) and multidimensional family therapy (MDFT). While all 
the interventions led to improvements measured by days of abstinence and proportion of 
adolescents in recovery, the authors conclude, ‘Overall, the clinical outcomes were very 
similar across sites and conditions’ at 12-month follow-up. The study did not produce 
any support for the idea that an increase of the dosage of treatment had a differential 
effect on cannabis use, and neither did it provide any support for family-based treatment 
to being superior to the other interventions (which has been suggested for drug misuse 
in general, e.g. by Stanton and Shadish, 1997).
Brief interventions for adolescent cannabis users have been tested in a multisite study 
with non-treatment seeking adolescents in 10 educational colleges in London in the 
United Kingdom. At 3-month follow-up, the treatment group receiving a 1-hour face-to-
face motivational interviewing session had reduced their weekly frequency of cannabis 
use by 66 %, while a no-treatment control group had increased the weekly frequency 
of their cannabis use by 27 % (McCambridge and Strang, 2004). These effects had 
diminished at 12-month follow-up, although cannabis use levels were significantly 
reduced from those at baseline (McCambridge and Strang, 2005).
Adult treatment
Concerning treatment for adults with cannabis use disorders, six relevant studies that 
are not included in the analyses from SBU and Fridell have been published: MTP 
Research Group (2004), Copeland et al. (2001), Budney et al. (2000, 2006), Stephens 
et al. (2000), Carroll et al. (2006). The first three of these studies set out to study the 
differential effect of treatment dosage and to compare treatment interventions with 
a delayed treatment control (DTC). All studies establish a significant effect for all 
interventions compared with DTC, but in two of the studies (Copeland and Stephens) 
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there is no significant difference in effect between the minimal intervention and the more 
extensive intervention.
However, methodological aspects of these studies may have detracted from the 
potential benefits of longer treatments. Small numbers of cannabis users were studied 
and recruitment may have resulted in a sample of patients more likely to succeed in 
treatment. Less experienced therapists conducted the interventions in group settings 
rather than tailoring them to individual need, and they had abstinence from cannabis 
use as their goal. The multisite study, involving 450 mostly cannabis-dependent 
treatment seekers from three US states from the MTP Research Group (2004), attempted 
to avoid these shortcomings. In this study, outcomes from two interventions and a 
delayed treatment group were compared. Both interventions involved manual-based 
programmes flexible enough to be directed at individual requirements and included 
a moderation goal as well as abstinence. There was a more positive effect for the 
more intensive treatment intervention involving motivational and cognitive–behavioural 
elements, as well as practical issues such as transport, childcare and housing than 
an intervention involving two motivational enhancement sessions provided a month 
apart. While the study confirmed that brief interventions can lead to improvements, at 
each of the follow-up points at 3, 9 and 15 months those who had received the longer 
therapy showed greater improvements: using cannabis less often; greater reductions 
in symptoms of dependence and attaining abstinence in greater numbers. The results 
suggest that many cannabis-dependent patients might benefit from a one- or two-
session intervention involving motivational interviewing combined with an introduction 
to ways of moderating use, while longer courses of motivational interviewing and 
cognitive–behavioural therapy should be available for those who need it (Ashton, 2005).
In the study by Budney et al. (2000), a contingency management approach was used. 
Contingency management usually involves providing patients with vouchers redeemable 
for goods and services in exchange for the patients provided drug-free urine tests, 
treatment attendance or medication compliance. The value of the vouchers can vary 
in order to reinforce desired outcomes. For example, in the recent Carroll et al. study 
with young cannabis-dependent adults, participants received a voucher worth USD 25 
for the first session attended, with increases of USD 5 increments for each subsequent 
session attended. Participants also received USD 25 for each cannabis-free urine sample 
they provided after testing, which also increased in USD 5 increments to a maximum of 
USD 540 if all urine specimens provided during the course of the study were negative. 
Recent meta-analyses found effective outcomes from interventions using voucher-
based and contingency management approaches compared with a range of control 
conditions (Lussier et al., 2006; Prendergast et al., 2006). The Budney et al. study 
randomised 60 cannabis-dependent adults to four individual sessions of motivational 
enhancement therapy (MET), 14 sessions of a MET and cognitive–behavioural 
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therapy (CBT) combination or a MET/CBT intervention together with contingency 
management. Although this study indicated that monetary incentives in the form of 
vouchers exchangeable for retail items increased abstinence in comparison to MET- and 
CBT-based interventions, the fact that no long-term follow-up was performed made it 
uncertain if this extrinsically motivated abstinence was sustained for a longer period of 
time. A subsequent study of these interventions by the same research group assessed 
outcomes for 12 months after treatment. Monetary incentives led to continuous periods 
of abstinence during treatment. CBT did not add to this during treatment effect but 
results showed that CBT did help with post-treatment maintenance of the initial positive 
effects of the vouchers. However, only half of the people in the study were able to 
achieve abstinence during the treatment and the majority continued to use cannabis 
after treatment and experience cannabis-related problems (Budney et al., 2006).
Another US study tested contingency management with young adults referred to 
treatment by the criminal justice service. Here 136, mainly male, cannabis-dependent 
probationers between the ages of 18 and 25 were randomised to one of four treatment 
conditions: a motivational enhancement/cognitive–behavioural intervention (MET/
CBT) based on the manualised approach of the MTP study, either with or without a 
contingency management element; or individual counselling with or without contingency 
management. Contingency management was provided by incentives in the form of 
vouchers redeemable for goods or services dependent on treatment session attendance 
or submission of cannabis-free urines. The interventions with contingency management 
interventions had a significant positive effect on treatment retention and the number 
of cannabis-free urine specimens, with the motivational enhancement/cognitive–
behavioural intervention with contingency management proving the most effective of 
the interventions. While there were few positive effects of MET/CBT compared with drug 
counselling during the treatment period, the patients receiving the MET/CBT intervention 
showed more signs of continuing improvement after treatment and continued to reduce 
their cannabis use when followed up at 3 and 6 months (Carroll et al., 2006).
In addition to the examination and evaluation of reviews and specific original studies 
with a bearing on treatment effects for cannabis use disorders, it might also be 
worthwhile to consider some results from more general reviews of drug misuse treatment 
interventions (Stanton and Shadish, 1997; Ozechowski and Liddle, 2000; Williams 
and Chang, 2000; Prendergast et al., 2002). The review by Prendergast et al. (2002) 
does not find any differences between treatment modalities, but Stanton and Shadish 
(1997), Ozechowski and Liddle (2000) and Williams and Chang (2000) all find support 
for family therapy (in different forms) as a more effective intervention than non-family 
modalities. But such findings are contradicted by the studies of Dennis et al. (2004) and 
Waldron et al. (2001). Multisystemic therapy (MST) (which must be considered as family 
based) has been cited by NIDA (the US National Institute on Drug Abuse) as an effective, 
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evidence-based treatment intervention, but a recent, Cochrane-based review by Littell 
et al. (2005) on MST comes up with the conclusion that MST has few if any significant 
outcomes compared with usual services or alternative treatments.
There is an ongoing study, Projekt CANDIS (1), Targeted Treatment for Cannabis 
Disorders, at the Dresden University of Technology, due for completion in January 2008. 
CANDIS seeks to develop a modular treatment programme for cannabis use disorders 
based on treatment packages and components that have been shown to be effective 
in previous US and Australian trials (Copeland, 2001), and to adapt these materials 
to the needs of its target population (German-speaking problematic cannabis users 
over 16 years of age). The treatment package includes motivational enhancement, 
cognitive–behavioural and psychosocial problem-solving components. While results are 
not yet available at the time of publication, initial feedback is encouraging, with first 
results expected in November 2007 (2).
Pharmacological treatments
There have been a small number of studies assessing potential medications for the 
amelioration of cannabis withdrawal symptoms, all by the same research group and 
involving adult participants (Hart, 2005). Bupropion, a medication that has been found 
to be successful in treating nicotine dependence, was found to exacerbate some of the 
symptoms of cannabis withdrawal in a laboratory study involving non-treatment seeking 
regular cannabis users (Haney et al., 2001). Another laboratory study using nefazadone, 
an antidepressant with sedative abilities, found that the medication alleviated only some 
of the withdrawal symptoms (Haney et al., 2003). Divalproex, used in the treatment 
of epilepsy, mood disorders and migraine headaches, was found to worsen cannabis-
associated withdrawal mood (Haney et al., 2004). Finally, administering doses of oral 
THC, at doses which did not produce subjective effects, was found to reduce withdrawal 
symptoms and reverse other effects associated with withdrawal, such as weight loss 
(Haney et al., 2004).
Naltrexone, an antagonist medication used in the treatment of opiate dependence, has 
been examined in relation to cannabis dependence. Antagonists block the effects of 
drugs by binding to receptors in the brain, with different antagonists working on different 
receptors and consequently blocking the effects of different drugs. Laboratory studies 
have demonstrated that opiates and cannabis share common receptors and animal 
studies have found that naltrexone can inhibit the development of cannabis dependence. 
However, human studies have found that naltrexone does not alter the subjective effects 
of low-dose oral THC and may also enhance the positive subjective effects of higher 
doses of oral THC (Haney et al., 2003).
 (1) www.candis-projekt.de
 (2) E-mail communication with Dr Eva Hoch, CANDIS project leader, October 2006.
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Conclusion
By and large, it seems as if there is still no conclusive evidence for any specific treatment 
intervention concerning cannabis use disorders. On the other hand, there are indications 
that anything works. That is, that the treatment modality in itself is of less importance 
than the treatment context and the individual’s choice to enter treatment. Support for this 
perspective is provided both by the CYT project (Dennis et al., 2004) and Project MATCH 
(Babor and Del Boca, 2003). In both of these projects, different treatment interventions 
produce the same (desired) outcome, although these outcomes did not seem to be 
facilitated by the stipulated theoretical mechanisms intended to produce these outcomes.
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Cannabis prevention in the EU
Keywords: cannabis – EMCDDA – indicated prevention – judicial referrals – 
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Setting the context
Cannabis is the most widely consumed illicit drug. It is targeted in one way or another 
by most prevention interventions. However, few interventions have targeted cannabis 
specifically. So cannabis prevention in Europe takes place in a vast and varied 
landscape. What may seem an abstract term — prevention — in practice diffuses 
across all manner of concrete programmes. These range from diplomacy and treaty 
negotiation, through health promotion by ministries and community schemes, to physical 
products such as pamphlets, videos and leaflets.
This chapter attempts to map the diversity of interventions in Europe within the three-tier 
‘Gordon’ classification framework of universal, selective and indicated prevention. The 
chapter is illustrative rather than exhaustive. A general overview of prevention is made 
difficult because of the sheer diversity of prevention projects that have been developed. 
Moreover, the actors and implementers involved are far from uniform across Europe (1).
What is certain is that the evidence base for cannabis prevention in the EU needs 
considerable work. Budgets for prevention campaigns in Europe run into tens of millions 
of euros, yet while considerable effort is spent on describing their scale (number of 
leaflets printed, number of advertisements aired, etc.) more research is needed into their 
effectiveness. Much knowledge originates from alcohol and tobacco prevention and 
from non-European studies (the USA in particular). While the evaluation of programmes 
 (1) An EMCDDA project monitors national drugs strategies across Europe, see www.emcdda.europa.
eu/?nnodeid=1360
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has matured in Europe, the evidence base is too small to develop definitive conclusions 
for good practice. Political efforts should focus on evaluation and rigorous outcome 
evaluations.
Further reading
DrugInfo Clearinghouse (2005), Prevention reading and resource list: Cannabis, Melbourne.
EMCDDA (2002), Drugs in focus no. 5: Drug prevention in EU schools — includes a short reading 
list.
EMCDDA (ongoing), Prevention and evaluation resources kit (PERK) 
www.emcdda.europa.eu/themes/prevention/perk
Informa Healthcare (journal: six issues per year), Drugs: Education, Prevention & Policy.
Matthys, N., Van Hal, G., Beutels, P. (2006), Evidence based cannabispreventie in Vlaanderen, 
Onderzoek uitgevoerd in opdracht van Inge Vervotte, Vlaams minister van Welzijn, Volksgezondheid 
en Gezin, Brussels.
UNODC (2006), Monitoring and evaluating youth substance abuse prevention programmes, Vienna.
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Cannabis prevention in the EU
Gregor Burkhart and Amador Calafat
This chapter focuses on a number of cannabis-specific prevention programmes 
in Europe. It also provides a brief overview of the rationale behind them. It must, 
nonetheless, be stressed that cannabis prevention rarely takes place in isolation. 
Furthermore, the weighting given to illicit drugs (cannabis included) in universal 
prevention has recently been eroded. Europe has shifted away from interventions that 
divide licit and illicit substances, and has moved towards an approach based on relative 
harms and complementary drugs, with particular focus on alcohol and tobacco in 
combination with illicit drugs prevention (2).
Cannabis in the context of polydrug prevention and 
health education
Cannabis prevention is typically delivered in the context of wider informational activities, 
and shares a platform with prevention for other substances — other illicit drug use, 
alcohol, tobacco and prescription drug misuse. Beyond substance use prevention, 
cannabis interventions are also frequently combined with public health prevention 
programmes that go beyond substance misuse, for example to cover personal health 
(mental health, addiction, healthy lifestyles, eating disorders, safe sex, etc.) and social 
education (citizenship, crime, ethics), particularly in the school environment.
A difficulty when analysing cannabis prevention activities is to identify, in this all-inclusive 
prevention environment, approaches that can offer insights specifically for cannabis. 
Reviews focusing specifically on cannabis prevention (e.g. Matthys et al., 2006) are rare. 
Yet, some formal approaches to analysing prevention have emerged, and prevention 
experts have in the past two decades begun to formalise their approach to analysing 
programmes, and a typology of interventions has emerged (universal, selective, 
indicated — see Box 1). This has enabled a more focused approach to evaluation of 
prevention initiatives.
For example, prevention can be categorised along criteria such as coverage (populations 
targeted), scope, duration, efficacy (what works in research conditions), effectiveness 
(what works in real life), resource-efficiency and cost-efficiency (what offers the best 
return on investment). A number of general evidence-based prevention manuals have 
been produced with European relevance (3). However, cannabis-specific handbooks 
 (2) See EMCDDA (2006c).
 (3) International examples include EU-Dap (2005); van der Stel (1998); UNODC (2002).
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Box 1: Prevention classification systems
Gordon (1987), Mrazek and Haggerty (1994) and Kumpfer and Baxley (1997) 
have proposed a three-tiered preventive intervention classification system: 
universal, selective and indicated prevention. Amongst others, this typology has 
gained favour and has been adopted by the US Institute of Medicine, National 
Institute of Drug Abuse (NIDA) and the EMCDDA.
Universal prevention strategies address the entire population (national, local 
community, school, district) and aim to prevent or delay the onset of alcohol, 
tobacco and other drug use. All individuals, without screening, are provided with 
information and skills necessary to prevent the problem.
Selective prevention focuses on groups who are either known to be drug users or 
at heightened risk of developing problems of substance abuse or dependence. 
The subgroups may be distinguished by characteristics such as age, gender, family 
history or economic status.
Indicated prevention involves a screening process, and aims to identify individuals 
who exhibit early signs of substance abuse and other problem behaviours. 
Identifiers include falling grades among students, known problem consumption or 
conduct disorders, alienation from parents, school and positive peer groups, and 
so on.
Outside the scope of this three-tier model are environmental prevention strategies. 
Environmental approaches are typically managed at the regulatory/legislative 
or community level, and focus on interventions to deter drug consumption. 
While prohibition can be viewed as the ultimate environmental restriction, in 
practice environmental strategies for cannabis include increased policing in 
sensitive settings (near schools, at music festivals), legislative guidelines aimed 
at precipitating punishments (warnings, penalties, fines) and actions to limit the 
prevalence of complementary licit drugs (for example, alcohol advertising bans 
and public place smoking bans).
Another classification scheme is primary, secondary and tertiary prevention. 
Primary prevention aims at preventing drug use and is usually the aim of universal 
programmes. Secondary prevention aims to prevent drug use from becoming 
problematic or leading to addiction. Tertiary prevention aims at preventing the 
harm caused by those who are using drugs.
On the borders of prevention and treatment is the strategy of early intervention. 
Based on detection of harmful alcohol or drug use, early intervention typically 
targets treatment of cases before they are aware that their substance use might 
cause problems or major psychosocial complications.
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and guidelines on specific measures for cannabis are less common, yet do exist (4). And 
despite considerable research effort, the prevention literature is largely weighted towards 
alcohol, smoking and general drug prevention (e.g. Aveyard et al., 2001; Loxley et al., 
2004).
A panel of prevention experts recently commented that ‘(…) what we know about 
effectiveness (of illicit drug prevention) is almost entirely grounded in work with 
alcohol and tobacco’ (Stockwell et al., 2005). This is mostly due to the nature of 
the phenomenon. In order to reach statistical power for prevention effects on a low 
prevalence problem such as cannabis use in pre-teens, a much higher number of cases 
to be treated is needed compared with alcohol and tobacco.
From informal to formalised programmes
As with misuse of other illicit drugs and alcohol, cannabis use is strongly associated 
with psychosocial risk factors that go beyond the drug’s pharmacological properties and 
patterns of use (5). Those who use cannabis occasionally and those who use it frequently 
may have different risk factors, different problems, and may therefore benefit from 
different prevention and supportive approaches. Cannabis components of prevention 
in Europe are increasingly being formulated to reflect such specific needs. With regard 
to schools programmes, more countries than before have introduced, expanded or 
are planning more structured prevention programmes, and quality programmes have 
been prioritised in many Member States (EMCDDA, 2006a). In many respects, the 
information on drugs provided as part of these programmes has evolved in parallel with 
the evidence generated through relevant epidemiology and screening instruments (6). As 
the most recent example in France, a 2005 MILDT/DGESCO addiction prevention guide, 
firmly based on epidemiology (7), was tested at 80 schools and proposes sequencing 
 (4) Exceptions include: in Germany, Schule und Cannabis (BZgA, 2004) and materials for the Bekifft in 
der Schule project (SuchtPräventionsZentrum Hamburg, 2004); in Switzerland, Ecoles et cannabis 
(OFSP, 2004); in France, Repérage précoce de l’usage nocif de Cannabis (INPES, 2006); in the 
UK, School drug policy: a review process (Blueprint, UK Home Office, 2004) and Advice for 
teachers on delivering drug education (Drug Education Forum, 2004); in Belgium, Maat in de 
Shit (CAT Infopunt and VAD, 2006). A number of cannabis-specific prevention manuals have 
emerged in recent years from Australia (DrugInfo Clearinghouse, 2005), New Zealand and the 
USA (NIDA, 2003; see also Sloboda, this monograph).
 (5) For a synthetic review of risk and protective factors, see Coggans, this monograph; Frisher et al. 
(2007); Dillon et al. (2006); Hawkins et al. (1991, 1992); Vázquez and Becoña (2000) and the 
website www.drugsprevention.net.
 (6) See Hibell and Coggans, this monograph, for a discussion of epidemiology in schools and 
psychosocial correlates of cannabis use. See Beck and Legleye, this monograph, for discussion 
of screening instruments. The EMCDDA’s next monograph seeks to address harm reduction in 
general.
 (7) The guide ‘Prévention des conduites addictives: Guide d’intervention en milieu scolaire’ is 
available at: http://eduscol.education.fr/D0190/guide.htm
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prevention according to age group and substance focus: 11–12 years, tobacco; 13–14 
years, alcohol; 15–16 years, cannabis; 17–18 years, polydrug consumption (French 
national report, 2006).
Common ground on prevention
A standard EU approach to prevention is notably absent (see Reitox national reports). 
Nonetheless, the EMCDDA’s annual report and EDDRA database have attempted 
to encourage pan-European awareness of what different Member States are doing. 
Encouragingly, cross-border collaboration is now more commonplace.
Consistency yet gradation
There is a continuum between drug-free society prevention approaches and moderation 
approaches. For example, prevention policies might target younger groups with a just 
say no message (minimising onset and experimentation), experimenting youths with 
a quit message (minimising continuation, e.g. Germany’s Quit the Shit programme), 
regular users with a moderation message (e.g. the UK Talk to Frank Cannabis: Too 
much too often guide, Belgium’s Maat in de Shit peer-based approach), and heavy or 
problematic users with a harm reduction or seek treatment message. Prevention projects 
in Europe now show some gradation in objectives: to postpone (the next) consumption, 
to suspend use for some (extendable) time, to refuse offers, to reduce consumption, to 
distance oneself from consuming peers, etc. (Canning et al., 2004). However, the core 
scientific base remains consistent: all programmes emphasise the substance’s illegality, 
risks and harms.
Heterogeneous actors and settings
Delivery of cannabis prevention in Europe, as elsewhere in the world, may involve a 
range of actors: ministries (health and interior affairs), parliamentarians, teachers, 
police, the judiciary, health professionals, drugs workers, community groups, theatre 
groups, youth services, parents (including parents of former drug users), Scouts, 
churches and religious communities, charities and NGOs, the media and commercial 
publishers. In such a populous environment where materials are freely available, 
‘official’ programmes may compete with programmes which are not officially 
endorsed (8). This is particularly the case for selective programmes. Jones (2004) 
 (8) For a discussion of various non-governmental prevention materials producers and Internet 
materials, see Tammi and Peltoniemi (1999), 39–40. Some controversy has arisen in the 
activities of Narconon, affiliated to the Church of Scientology (Czech Republic national report, 
2005; The Sunday Times, 7 January 2007).
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highlights that moves towards selective prevention constitutes a general shift in which 
European drug prevention programmes have become increasingly expansive in nature 
as they attempt to influence complex social environments of risk. Attention should 
be paid to possible problems which ensue from this. While irresponsibility is rare, 
such competing publications are subject to little public health endorsement, and their 
neutrality depends largely on who publishes them (9). For instance, different agencies 
may have different conceptions of vulnerability and risk behaviours, complicating 
interagency cooperation (Powell et al., 2003). Additionally, complications may arise 
from unsuccessful negotiation of boundaries between prevention, treatment and criminal 
justice agendas (Kimberlee et al., 2003). Indeed, research has shown that programmes 
tend to lose effectiveness as they are rolled out over time and across settings (Buston et 
al., 2002; Dusenbury et al., 2003).
Environmental prevention strategies
Environmental prevention strategies (e.g. legislative and regulatory controls, taxes, bans, 
community and school rules) have gained popularity and are currently being introduced 
for alcohol, tobacco and cannabis in several EU Member States. While blanket 
prohibition could be seen as the strictest form of environmental strategy, there are 
many possible variations. These include: full and partial smoking bans in public places; 
EU-wide tobacco advertising bans; developments at EU level on a European Alcohol 
Forum to develop a code of conduct for reducing alcohol-related harm (10); integration 
of roadside drug screening alongside drink driving tests; EU-wide indexation of existing 
minimum excise duties on alcohol; and alternative measures to criminal prosecution 
for personal cannabis possession. The level of enforcement of anti-smoking policies in 
EU Member States consistently correlates with the level of adolescent smoking (Aspect 
Consortium, 2004; Eurostat, 2002) and, without implying causality, there is appreciable 
correspondence between tolerant tobacco policies, prevalence of tobacco smoking 
among youth and prevalence of cannabis use (EMCDDA, 2006a). The vast majority of 
cannabis consumers are tobacco smokers. Inversely, there seems to be a strong intrinsic 
relationship between cannabis and cigarette smoking, in the sense that cannabis use 
perpetuates cigarette smoking (Amos et al., 2003).
Potential environmental prevention strategies for cannabis are limited by the illegal 
status of the drug (11). Nonetheless, advertising controls on tobacco products or alcohol, 
 (9) Producers of non-official prevention-like materials include pro-drugs lobbyists, church groups 
(Christian, Islamic, Scientologists), parents-against-drugs and similar charities, and groups with 
strong commercial interests (for example, cannabis magazine publishers and seed sellers).
 (10) http://europa.eu/rapid/pressReleasesAction.do?reference=IP/07/774&format=HTML&aged=0&
language=EN&guiLanguage=en
 (11) For discussion of hypothetical environmental measures, see Room, this monograph.
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together with anti-binge measures (such as happy hour restrictions) are proven to 
reduce consumption of these substances, and may have a knock-on effect on comorbid 
cannabis consumption, although little research exists on this topic.
Cannabis advertising is generally indirect in Europe, yet is, nonetheless, present. 
Advertisers include seed suppliers, growshops and head shops, cannabis smoking clubs 
and vendors of paraphernalia such as bongs and hydroponic equipment. Publicity 
channels include a burgeoning cannabis culture media — The High Times, Softsecrets, 
Pot-TV.net and the High Life trade fair — as well as general media (inflight magazines, 
music magazines, etc.). Mirroring the brand-stretching vogue that has accompanied 
tobacco marketing controls (Camel Active, Marlboro Classics) a number of products 
are marketed using cannabis or cannabis-leaf logos in Europe. As well as ‘directly 
associated’ products, such as bongs and cigarette rolling papers, products include 
Cannabis cough drops and Swiss Hemp Ice Tea drinks (Slovakian national report, 
2005), and clothing and accessories, often manufactured with hemp (in France, brands 
include Made in Chanvre and Terre de Chanvre). Yet, controlling such marketing and 
cannabis products is very much a grey area. The Australian Federal Government has 
promoted legislation to ban the sale of bongs and drug equipment, with a ‘bong ban’ 
recently put in place in the state of Queensland, although the effects of such legislation 
need to be measured.
At the ‘micro’ level, structural prevention measures targeting the availability of cannabis 
and the social norms around legal drugs are less developed than the evidence base 
would advise. An advertising ban forms part of the AHOJ-G prosecution guidelines for 
Dutch coffee shops (see Korf, this monograph). Some Dutch municipalities are beginning 
to ensure coffee shops are not established in the vicinity of schools, while overall retail 
outlet density has decreased. Policing of smart shops and growshops has tended to 
maintain vigilance for any shops that cross legal boundaries and actually sell cannabis: 
a recent parliamentary proposal in Spain called for regulating cañamerias (growshops). 
Meanwhile, some structural strategies have targeted the ‘periphery’ of substance use 
(e.g. municipal bans on drinking or drug-taking in public). Nonetheless, the apparent 
contradiction persists in Europe where advertisements for a legal product (e.g. tobacco) 
are banned yet not those for products relating to cannabis, an illegal drug.
Universal prevention: school-based approaches and mass media 
campaigns
Universal, multi-substance prevention programmes are the norm across Europe, with the 
predominant focus on school-based and mass media approaches (EMCDDA, 2006a).
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Rationale
An important prevention rationale for universal school-based approaches is the gateway 
hypothesis, whereby delaying onset of adolescent alcohol, tobacco and cannabis use 
is hypothesised to reduce rates of subsequent illicit drug consumption and problematic 
use and other comorbid harms (e.g. truancy, delinquency). Other rationales include 
general health promotion and preventing comorbid behaviour such as harmful alcohol 
use, school drop-out rates, risky sexual behaviour, early sexual activity or pregnancies, 
violence and social exclusion. There is some evidence that preventing or delaying 
tobacco or alcohol use can reduce subsequent use of cannabis (Botvin, 2000; Caulkins 
et al. 2002, 2004; Ellickson et al., 2003), yet strong proof for reductions for ‘harder’ 
illicit drug use has proved both elusive and heavily contended in the USA (Gerstein and 
Green, 1993; Manski et al., 2001).
The political rationale for general universal prevention is robust (12). Economies of scale 
are gained as the targeted population is large, while the health objectives — smoking, 
alcohol, drugs and obesity — are wide (Roe and Becker, 2005). By targeting youths 
and young adults, school-based and young adult-oriented programmes target a 
demographic where prevalence is highest, potential lifetime benefits the strongest, and, 
in many Member States at least, cannabis use is growing (EMCDDA, 2006a; Hibell 
et al. (ESPAD), 2003). Nonetheless, large-scale universal programmes also lead to 
high absolute cost, while covering large populations (low per-capita costs). Economic 
research into prevention cost-effectiveness remains both rare and perhaps politically 
sensitive in Europe.
Content considerations
A typology of different kinds of universal prevention interventions has been produced for 
the EMCDDA’s PERK project and reflects the developments of the last two decades (13). 
It divides content into (Burkhart and Crusellas, 2002; McGrath et al., 2006; EMCDDA, 
2007):
knowledge of drugs (prevention by providing health information to influence t
decision-making);
personal skills (clarification of values and encouragement of responsible decision-t
making);
social skills (in particular, peer resistance);t
 (12) Political commitment to school-based prevention is intuitive, as seen in a recent letter to Addiction: 
‘If we do not have up-to-date evidence then we must fall back upon rationality and human and 
societal values, and I tend to agree (…) that alcohol education, in the absence of evidence, 
should continue to be valued.’ (Foxcroft, D., Addiction 101: 1057–1059).
 (13) www.emcdda.europa.eu/index.cfm?fuseaction=public.Content&nNodeID=9753
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normative beliefs (myth correction, correcting overestimation of the ‘acceptability of t
use’);
alternatives to drug use (activities that are deemed incompatible with drug use);t
structural or regulatory measures (reducing acceptance and availability of t
complementary substances such as tobacco and alcohol); and
multi-component (a combination of these).t
Debate is strong about the effectiveness of each approach, and there has been a shift 
away from ‘traditional’ or ‘intuitive’ prevention (knowledge and affective) to social skills, 
competence enhancement, and structural/regulatory and multi-component approaches 
based on scientific theory (Burkhart and Crusellas, 2002). Typical prevention approaches 
include theatre-based approaches (Canning et al., 2004) and, increasingly, IT- and 
Internet-based approaches (Tammi and Peltoniemi, 1999; Drugscope, 2006).
In terms of evaluating effectiveness of cannabis prevention programmes, Europe is, to 
a large degree, forced to look at US reviews which are furthermore focused on general 
substance prevention and not cannabis-specific prevention (Skara and Sussman, 2003; 
Faggiano et al., 2005; Thomas and Pereira, 2006). School-based approaches have 
generally been found to have scarce effects but — considering the methodological 
difficulties of implementation and research — they should not be underestimated 
(Milford et al., 2000; Gorman, 2002; Tucker et al., 2002; Coggans et al., 2003; 
Ellickson et al., 2003; Bühler and Kröger, 2006, Thomas and Pereira, 2006; Faggiano 
et al., 2005). Studies from Europe represent a small minority among those aimed at 
preventing drug use. For example, only one small study (Hurry and McGurk, 1997) was 
included in the Faggiano review. Among those aimed at preventing tobacco use, some 
failed to detect any effect (Eveyard et al., 2001) while others show inconsistent results 
across centres (de Vries et al., 2003) or no long-term yet limited short-term effects 
(Thomas and Pereira, 2006).
Beyond objections of societal comparability and applicability of general substance 
findings to cannabis, the US evidence is far from conclusive on programme content. 
The Cochrane (Faggiano) review suggests that skills-based approaches can reduce 
subsequent drug use compared with normal curricula. Another review in the USA (Skara 
and Sussman, 2003) found that 8 out of 25 studies examined programme effects on 
cannabis and all showed positive interim effects (3–24 months). However, only one 
study reported data that allowed the calculation of the percentage reduction compared 
with control groups and other studies did not have enough data to determine relative 
differences with control groups. Four studies provided long-term outcomes (24 months), 
of which two showed positive outcomes and two showed no significant differences. The 
programmes that showed positive outcomes for cannabis use were all based on the 
social influence model and the majority had more than one type of intervention. About 
half of these programmes used peer educators, as well as adults. Most had booster 
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sessions or a long-term component and the length of follow-up varied between 27 and 
72 months.
Best practices
Prevention research tends to be descriptive and available proof of effectiveness is 
limited. While the literature is almost universally cautious on making recommendations, 
there are several examples of organisations that have distilled research into actionable 
materials. Practice is informed by a number of international manuals (van der Stel, 
1998; WHO, 2000; UNODC, 2002, 2006), synthetic monographs in the field (e.g. 
EMCDDA, 1997; Bukowski and Sloboda, 2003) and exemplary projects (Ferrer-Wreder 
et al., 2004; the EMCDDA EDDRA database and PERK). The EMCDDA’s PERK project, 
the Prevention and Evaluation Resources Kit, aims to provide an online resource in the 
area.
NIDA’s Red Book recommendations (NIDA, 2003) recur in many European publications. 
These are:
target all forms of drug misuse, including alcohol and tobacco;t
be family-focused, including a component for parents;t
be long term across a school career;t
be age specific and culturally sensitive;t
address local problems and seek to strengthen community norms against drug use.t
A study of prevention reviews (Cuijpers, 2002; Gottfredson and Wilson, 2003; Kumpfer 
et al., 2003; Skara and Sussman, 2003; Shepard and Carlson, 2003) lists the following 
guidelines, although with some caveats on the strength of recommendations (McGrath et 
al., 2006):
Interactive approaches are preferable to didactic (ex cathedra) approaches.t
Peer-led approaches offer a mild increase in effectiveness.t
Social skills approaches are generally more effective, although resistance skills t
training offers little evidence of effectiveness.
Booster sessions may help effectiveness, particularly for cannabis.t
Higher programme intensity (e.g. 10 lessons or more) offers little added benefit.t
Weak evidence suggests that programmes are best delivered to students 11–14 t
years old (14).
 (14) Frisher et al. (2007) suggest that the evidence for an ‘optimal age group’ for prevention is unclear, 
although results of late-teen interventions (> 17 years) are generally weaker. They also suggest 
that as problematic patterns of use typically appear in later adolescence (15–16 years), ‘attempts 
to modify behaviour at this age may be more productive’. A case for gradation in prevention 
campaigns (early ages: abstentionism, older groups: less use and quitting) would require more 
research.
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The evidence base for favouring family-based programmes over other approaches t
is weak, although where used with behavioural parent training, family-skills training 
and family therapy offer some benefits.
Recent trends in universal prevention in Europe
Standardised programmes
In terms of recent European trends at the universal prevention level, a general trend is 
the increased reliance on standardised programmes (EMCDDA, 2006a) and inclusion 
or prioritisation of alcohol and tobacco within general substance prevention (EMCDDA, 
2006c). For example, the EU-Dap trial to develop and evaluate a European school 
prevention programme has reported encouraging results for cannabis, finding that its 
programme reduced occasional cannabis use by 23 % and 24 % respectively (EU-Dap, 
2006). The programme, implemented in a considerable number of countries (Belgium, 
Germany, Greece, Spain, Italy, Austria and Sweden, now joined by Poland and the 
Czech Republic), involves 143 schools, 345 classes and 7 079 students. The early 
findings after one year need long-term validation during phase II of the project (begun 
in October 2006). Still, it is worthy of mention that the EU-Dap project has strong initial 
results while also straddling different prevention and drug consumption cultures.
Gender focus
Gender aspects are increasingly being taken into account in prevention, although 
there is a trend in many countries in Europe for gender consumption patterns for 
cannabis to be eroded, notably in Ireland (EMCDDA, 2006a; Frisher et al., 2007). 
Male gender predicts more intense use (Butters, 2005), while a study suggests that 
girls are more responsive to parental disapproval and are more cautious in selection 
of their peers (Butters, 2004). For girls, the programmes that are most effective in 
sustaining positive effects on substance use prevention after their completion focus 
on behaviourally orientated life skills. In contrast, methods of delivery that involve 
interaction with peers or adults are particularly effective in boys (Springer et al., 2004). 
Competence enhancement approaches, for example, can target gender differences. 
For boys, a number of European projects (e.g. Beer-Group in Germany, Risflecting 
in Austria, Bagmaendene in Denmark) focus on the lack of flirting skills among boys 
which may be related to intensive use of alcohol or cannabis in order to feel able to 
approach girls. Nonetheless, across Member States, gender-specific programmes remain 
underdeveloped (EMCDDA, 2006b).
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Recreational settings
A number of prevention programmes have targeted cannabis in the context of other 
recreational settings. These include campaigns at music festivals, Dutch coffee shops 
and nightlife settings. As with general community prevention programmes, reports 
emphasise the importance of engaging various actors in the process (police, licensees, 
staff, organisers) (EMCDDA, 2006d; Reitox national reports).
Risk perception and normative beliefs
Risk perception is a complex but important factor in prevention. Risk perception is not 
easy to modify with knowledge approaches alone. Own experiences, observation of 
others and common myths associated with cannabis modulate perception more than 
knowledge itself (Springer et al., 1996). Normative beliefs are particularly important 
as cannabis-using youth tend to extrapolate the level of use of their immediate peers 
to ‘normality’ and overestimate the prevalence of drug use (Page and Roland, 2004). 
This might also happen through drug-using peer selection. Recently, considerable 
symbolism or ‘brand value’ surrounding cannabis has emerged, which encourages 
acceptance. Cannabis is often associated with ideas such as ecology, alternative culture, 
non-conformism and left-wing attitudes. While some prevention programmes focus 
on deconstructing or neutralising such ‘marketing’ of cannabis, research is needed on 
their effectiveness. Some Member States have reported attempts to reverse the social 
perception of cannabis use as normative behaviour, that is to correct the misconception 
that the majority of adults and adolescents use drugs (EMCDDA, 2004; McGrath et 
al., 2006). The recent introduction in Europe of ‘strong’ public place smoking bans is 
also being monitored for any knock-on effects on cannabis, particularly with regards to 
adolescent smoking.
At the schools level, structural and regulatory policies — school rules — have an even 
higher impact than universal prevention programmes on preventing or delaying legal 
and illegal substance use (Hawks et al., 2002). Tobacco smoking is a good predictor for 
cannabis use and its escalation (Duncan et al., 1998, Vázquez and Becoña, 2000) and 
prior experiences with legal substances may be a significant risk factor for later illegal 
drug use (von Sydow et al., 2002). Consequently, some Member States encourage 
that schools have drug policies in place which define procedures and rules about use 
and availability of cannabis as well as dealing with legal and illegal substances in 
and around school premises. A number of countries have focused on guiding school 
drugs policy, and in particular approaches to ‘problem students’ and dealing with 
those found using drugs. These include the UK’s Drugs: guidance for schools (DfES, 
2004) and School drug policy: a review process (Blueprint, 2004), Ireland’s Guidelines 
for developing a school substance use policy (Department of Education and Science, 
2003), and France’s Prévention des conduites addictives: guide d’intervention en milieu 
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scolaire (CNDP-MILDT, 2006). Some Member States have introduced drug testing in 
schools, although this practice is contested on ethical grounds (McKeganey, 2005) 
and because either no preventive effect has been demonstrated in the extant research 
literature (Council of Europe, 2005; Drug Education Forum, 2006) or the evidence base 
is insufficient (UK Home Office, 2007). Further research on the subject is part of the 
Pompidou Group’s current work programme.
Family approaches
The family has an influence on drug use, and pro-social family processes have a 
significant impact on children’s peer association, decreasing involvement with antisocial 
peers, and a significant negative effect on substance use initiation (Oxford et al., 2000; 
Ferrer-Wreder et al., 2004). A recent review of risk factors found that parental discipline, 
family cohesion and parental monitoring are among the strongest (Frisher et al., 2007). 
Compared with alcohol, parents have more difficulties to talk and address cannabis use 
of their children openly and to negotiate disciplinary boundaries (Highet, 2005). There 
are not many examples of structured and evaluated family-based prevention approaches 
in Europe, although parenting programmes with positive evaluation based on US studies 
(Kumpfer et al., 2003) have been introduced in Spain, Norway and the United Kingdom. 
Prevention programmes (websites, books, workshops, helplines) aimed specifically at 
assisting parents with children’s drug problems have long been part of the European 
prevention landscape. Publications dealing exclusively with adolescent cannabis use are 
rarer, although examples exist (15).
Mass media campaigns
Mass media campaigns have been a popular option in prevention and especially in 
cannabis prevention. Recent major cannabis campaigns include the UK’s 2006 Brain 
Warehouse campaign, Spain’s Drogas: hay trenes que es mejor no coger and France’s 
Cannabis et Conduite campaign (16), with a trend to use mass media within multi-
component programmes (McGrath et al., 2002, updated 2006, citing Flay, 2000). 
Research — again, broadly drawn from non-European sources — suggests, however, 
that their effectiveness, and especially efficiency, is limited and largely depend on the 
objectives. They can have effects on attitudes and knowledge (Carroll et al., 2000), but 
rarely on behaviour (Derzon and Lipsey, 2002). The overall evidence for the impact of 
 (15) Examples include: in the USA, Marijuana: facts parents need to know (NIDA, 2004); in Switzerland, 
Cannabis: mit Jugendlichten darüber sprechen (SFA/ISPA, 2005); in France, Cannabis: les risques 
expliqués aux parents (MILDT, 2005) (www.inpes.sante.fr/CFESBases/catalogue/pdf/806.pdf).
 (16) The Brain Warehouse cannabis campaign (www.brainwarehouse.tv) included a TV advertisement, 
scratchcards, leaflets and a dedicated website. The EUR 2.2 million Drogas: hay trenes… 
campaign included a TV and radio spot and posters. The Cannabis et conduite (www.
cannabisetconduite.fr) campaign included a website and radio campaign.
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mass media campaigns on consumption patterns is not strong and has mainly focused 
on how many people were reached by campaign messages (Paglia and Room, 1999; 
Hall and Pacula, 2003). Isolated studies provide evidence that recall of anti-drug 
advertising was associated with a lower probability of cannabis and cocaine/crack use 
(Block et al., 2002) or have shown that mass media campaigns aimed at high sensation 
seekers may be effective (Stephenson, 2003). However, the large-scale evaluation of 
the US billion-dollar National Youth Anti-Drug Media Campaign showed no or even 
negative behavioural outcomes, suggesting a ‘boomerang effect’ whereby those exposed 
to the campaign were more likely to consume (EMCDDA, 2007).
Selective prevention
Selective prevention is led by risk factor-specific research allowing for the identification 
of risk groups (see Coggans, this monograph) mostly by social and demographic 
variables. An understanding of risk factors associated with cannabis use and its adverse 
consequences has immediate benefits for the design, targeting and implementation of 
drug prevention (Kandel et al., 1978; Susser, 1987; Daugherty and Leukfeld, 1998).
Contrary to the traditional approach of secondary prevention, which targets those 
who already use drugs because they consume, more recent strategies acknowledge 
that cannabis consumption alone is not a useful predictor for the problems to be 
prevented (see Coggans, this monograph). The strength of selective prevention is that 
it is not guided by the idea that risk equals substance use, but by social and personal 
vulnerability factors for problematic drug use. If drug use alone is to be used as a 
criterion of the need for prevention, the danger is high that youths with transitory drug 
experimentation are wrongly classified and stigmatised as a high-risk group (Schmidt, 
2001).
Selective prevention in the school setting
The most convenient setting for selective prevention interventions targeting experimenting 
or vulnerable youth is while they are still attending school. There are, however, 
challenges in selectively addressing vulnerable adolescents when the mainstream 
prevention messages are health promotion and non-use and when teachers are (if at all) 
only trained in universal prevention methods but are not prepared to deal with ‘difficult’ 
or experimenting youngsters (Parker and Eggington, 2002).
The main subgroups at which selective prevention in schools is aimed are students 
with social behavioural problems such as anti-social behaviour (Tarter et al., 2002), 
academic underachievement (Lynskey and Hall, 2000), low bonding, infrequent school 
attendance, and impaired learning because of drug use (Hawkins et al., 1991, 1992; 
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Lloyd, 1998). Targets may also include pupils with high truancy or who have been 
excluded from school (Goulden and Sondhi, 2001; Powis and Griffiths, 2001), students 
with family problems (e.g. running away from home), immigrant students and those 
belonging to ethnic minorities (17). Academic performance and school attendance are 
good predictors for drug problems, and monitoring these enables early and accurate 
intervention (EMCDDA, 2006a). Other strong patterns include early adolescent smoking 
and heavy drinking (Gil et al., 2002; de Vries et al., 2003; Orlando et al., 2005; 
Paddock, 2005), with tobacco having strong associations with later cannabis use 
(Duncan et al., 1998; Vázquez and Becoña Iglesias, 2000).
Social vulnerability factors
Formerly, it was believed that elements from social influence and life skills programmes 
would not work well in selective prevention approaches (e.g. Tobler et al., 2000). 
However, several elements of such programmes are suggested as moderately effective 
for vulnerable youth (Sussman et al., 2004; Roe and Becker, 2005; McGrath et al., 
2006). The associated contents — normative restructuring (e.g. learning that most 
peers and the opposite sex disapprove of use), assertiveness training, motivation and 
goal-setting, as well as myth correction — are still not included in the typical contents of 
European selective prevention intervention for cannabis. The focus is instead generally 
placed on knowledge approaches.
Selective prevention within the criminal justice system
The association between cannabis use and crime or delinquency is well documented 
(Fergusson et al, 2002; Hall and Pacula, 2003). A study in Spain by the Centro de 
Estudios sobre Promoción de la Salud (CEPS, 2004) of a sample of youths at protection 
and reform centres found approximately one-third reported weekly cannabis use. A 
UK study of youth arrest referrals reported the following use of substances: cannabis 
(30 %), tobacco (30 %) and alcohol (23 %), with other drugs much lower (cocaine, 4 %, 
crack, 1 %, heroin, 1 %) (UK Home Office, 2007). Two Dutch studies (Vreugdenhil et 
al., 2003; Korf et al., 2005) also reported a high prevalence of cannabis use among 
youths in detention centres (see Netherlands national report, 2006). However, caution 
must be applied in that (i) there is consensus that there are associations, not causal 
links, between cannabis and offending; (ii) many studies embrace all types of drug use 
(illicit drugs, alcohol) not cannabis in isolation, with persistent offending associated 
with harder drugs (Flood-Page et al., 2000); (iii) ‘crime’ runs the gamut, from serious 
offences to delinquency and misbehaviour; and (iv) consumption is an offence per se. 
 (17) For an overview of screening instruments for assessing cannabis use, see Beck and Legleye, this 
monograph.
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A recent study suggests that the gateway effect of ‘soft’ drug use for later progression 
into delinquency may be overplayed (Pudney, 2003). Moreover, studies have illustrated 
the importance of situational, social and peer influences in contrast to individual 
psychological problems in initiating drug use among young people (Rhodes et al., 2003; 
Butters, 2004).
While the ethics of coercion into compulsory treatment have been debated, the criminal 
justice system represents an important setting for selective prevention in the form of 
referrals. In most Member States, corresponding legal provisions exist for referral 
of prisoners and offenders. Young offenders (especially those first notified for drugs 
offences) are treated with particular consideration. Drug testing for adult and (less 
commonly) young arrestees has been introduced in some countries. However, specific 
guidelines are often missing and the cooperation and coordination between social 
(prevention) services and judicial services, although of key importance, are considered 
difficult (Newburn, 1999; UK Home Office, 2007). Selective prevention programmes in 
the criminal justice system (see Box 2 for examples) rely on the fact that cannabis use 
and possession are illegal, opening up a referral opportunity for targeted intervention 
for young people at risk. The evaluation of the Austrian project Way Out showed that 
it could be introduced successfully in schools and by public health officers as well as 
school doctors, although the main channel for referrals was the police. The evaluation 
found fewer personality deficits among youngsters first notified for cannabis offences 
than expected.
Selective prevention in informal settings
A recurrent question is how to get in touch with those youngsters at risk of developing 
problematic consumption patterns but who are not reached at school or in other formal 
settings. There are many situations where it is only possible to approach adolescents in 
informal or recreational settings. Haas et al. (2001) point out that in Austria youngsters 
who experiment with drugs are frequently excluded from youth services, thereby 
increasing their social exclusion. As a result, occasions for selective and indicated 
prevention are missed. Attractive drop-in and counselling facilities with a judgement-free 
attitude is one strategy option. In some Member States, pro-active approaches — called 
‘interventionist tracking’ — for vulnerable youth are applied, mostly through cooperation 
of different services (Green et al., 2001) and social actors (Arbex Sanchez et al., 2002).
Many strategies and projects focus on identifying, approaching and attracting vulnerable 
young people in order to intervene at an early stage of problem development and to 
provide counselling or referral to specialised services. Outreach work (18) traditionally 
reaches out to obviously problematic drug users and is less associated with approaching 
 (18) The EMCDDA’s web page on outreach work is at www.emcdda.europa.eu/?nnodeid=1576
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Box 2: Selective prevention for cannabis/illicit drug use – examples from Exchange on 
Drug Demand Reduction Action (EDDRA)
The EMCDDA’s EDDRA database offers information on a broad range of 
evaluated drug demand reduction actions in the EU Member States. Selection 
criteria for this small sample were outcome-evaluated interventions with a 
predominant focus on cannabis. None has a control group design and outcome 
variables are not necessarily drug use related.
Step by Step (Austria and Germany) is a computer program for early diagnosis of 
drug-related problems and for possible interventions at schools. It helps teachers 
who are confronted with problem pupils to find out whether or not these pupils 
use drugs.
www.emcdda.europa.eu/html.cfm/index52035EN.html?project_id=5957&tab=overview
FreD (Austria and Germany) is a programme that targets first-time offenders up 
to the age of 25 who have been arrested due to the consumption of illegal drugs. 
They are referred to a course which motivates them to change their drug use.
www.emcdda.europa.eu/html.cfm/index52035EN.html?project_id=2091&tab=overview
Way out (Austria) is an early intervention for young drug-using first offenders. 
Support is offered over a period of approximately 6 months with the aim of 
encouraging abstinence for illegal drugs, moderation for legal substances and 
avoidance of drug-related problems.
www.emcdda.europa.eu/html.cfm/index52035EN.html?project_id=5038&tab=overview
MSF — Solidarite Jeunes (Luxembourg) provides therapy to youths consuming 
drugs and to their families referred from judicial or educational systems.
www.emcdda.europa.eu/html.cfm/index52035EN.html?project_id=3656&tab=overview
Ámbits-Esport (Catalonia, Spain) provides a sport-based programme for 
immigrant youths from North Africa, sub-Saharan Africa and Latin America 
aimed at reducing smoking and illicit drug consumption (in particular, cannabis), 
together with integration with Catalan peers.
www.emcdda.europa.eu/html.cfm/index52035EN.html?project_id=2918&tab=overview
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vulnerable youth and cannabis users who are not addicted. From some Member States, 
centres for mobile youth or street work are reported, which closely cooperate with 
relevant help organisations so that assistance may be provided at the earliest stage 
possible. Such measures and their relevance for vulnerable and experimenting youth are 
intensively discussed, for example in Austria, and are foreseen to attain an increasing 
geographical coverage (Haas et al., 2001, 2002).
Indicated prevention
There are some conditions that have been identified as potentially increasing the risk 
for intense cannabis use, such as attention deficit disorder (ADD) (Giedd, 2003), and 
affect dysregulation (Simons and Carey, 2002) in the sense of emotional instability 
and impulsivity. Children and adolescents with ADD might seek to relieve their state of 
anxiety, tension and dysphoric mood and the sensation of ‘noise’ in the brain (due to the 
low synaptic dopamine availability in the essential brain areas) through ‘self-treatment’ 
with cannabis. However, systematic early detection, treatment and follow-up involving 
general health services and paediatricians are reported only from Germany, Italy and 
Sweden in their national reports. An increase in cannabis-related psychoses is reported 
from psychiatric services (see Witton, this monograph, volume 2), and according 
to recent reviews there is evidence that cannabis is a risk factor for schizophrenia 
(Arseneault et al., 2004; Smit et al., 2004). There seems to be a strong case to pay 
increased attention to reducing the intensity of consumption in order to respond to 
cannabis-related public health problems. Motivational interviewing, for instance, has 
shown to reduce the intensity of consumption without formal treatment (McCambridge 
and Strang, 2004), although there is evidence to suggest that short-term gains are not 
maintained at 1-year follow-up (McCambridge and Strang, 2004).
Between prevention and treatment
While provision of drug treatment is often the most immediate reaction of policymakers 
to drug use, a strategy of expanding counselling or early intervention offers for cannabis 
users in cone structures may have difficulties in reaching the target population. These 
problems might be increased if the services for cannabis clients are offered in the 
same setting as for heroin users. There is a reluctance of cannabis users to consider 
themselves as drug users or as having a drug problem and to seek help and advice for 
themselves.
Member States are increasingly acknowledging this need to reach out to a wider 
vulnerable population. Approaches which are less treatment-focused stress the 
importance of literacy, academic capacities, employment, gender, social integration, 
body (self) perception, rationality, social networks, and the functionality of use (Boys 
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and Marsden, 2003). Some municipalities in Denmark have been successful in offering 
help to groups of young people with an emerging cannabis problem via day centres, 
where they gather in small groups (up to 10) and are supported by a therapist or 
social worker. They are offered space and time to talk about their life, problems 
and drug use. Supportive methods are favoured: offering help, for example, to plan 
for the future, to pursue their education or to get a job. Evaluation shows that the 
participants profit greatly from contact with adults who offer support, respect and who 
accept them on their own conditions. Results also suggest that the increasing but not 
yet full-blown drug problem ‘solves itself’ if help with other problems (school, family, 
friends) is offered (Danish national report, 2005). The specific support for integration 
into the educational system or the workplace has shown to be of great importance in 
preventing further social exclusion. Several Member States have similar projects. The 
German web-based counselling programme Quit the Shit (19) is another example of an 
innovative approach for cannabis users who want to reduce or stop using cannabis. It 
comprises a 50-day programme, based on cognitive–behavioural principles, including 
information and featuring a diary that is submitted to an intervention team for regular 
feedback. Those who made use of the online support to quit using cannabis had their 
average consumption quantity reduced by a third 3 months after the completion of the 
programme. The number of days on which cannabis was consumed went down by 50 % 
(Die Drogenbeauftragte der Bundesregierung, 2005).
Conclusions and challenges
Cannabis use prevalence is generally increasing among youth in the EU and the 
perception of its risks has generally decreased in recent years (20). The large majority of 
European cannabis smokers have already smoked tobacco, and there is an association 
between a tolerant tobacco policy, smoking prevalence and cannabis consumption. This 
suggests that there is considerable scope of action for structural prevention, directed at 
attitudes and normative frameworks in respect to legal substances as well as cannabis. 
The effects of current public place smoking bans in Europe should be monitored to look 
specifically at knock-on effects on cannabis.
Cannabis use is mostly experimental, but compared with other illegal drugs, the number 
of regular and daily users is higher (EMCDDA, 2006a). About 9 out of 10 persons 
who have ever used cannabis began at around 14 and stopped before the age of 
24. This implies that there is a ‘vulnerability window’ where prevention interventions 
should focus on preventing experimenters beginning to develop cannabis-related 
problems and where entering regular consumption patterns. Even if the majority will 
 (19) www.drugcom.de/
 (20) See Hibell, this monograph.
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never develop problematic use, the opportunity for selective and indicated prevention 
or early intervention to identify those at risk and to be able to assist them with targeted 
interventions is considerable. Appropriate offers of early intervention and support at the 
border between prevention and treatment might be more attractive to this group than 
traditional drug help facilities.
Even regular cannabis users rarely seek support, help or treatment on their own 
initiative. Counselling or early intervention services are not likely to be appropriate when 
there is no problem awareness among the users themselves. However, the illegal status 
of cannabis may sometimes be strategically helpful in the sense that cannabis users 
are being brought into contact with cannabis counselling or other interventions through 
contact with the criminal justice system for possession offences. Reports that very young 
people sometimes appear in treatment centres with advanced cannabis use patterns 
after only a short period of use indicates that some powerful personal and social risk 
factors can lead to rapid progression of cannabis-related problems. Supporting such 
children at an early stage is a challenge for indicated prevention.
The majority of available projects in the EU publicised through EDDRA do not have 
sufficient evaluation, which makes European intervention planning still largely dependent 
on US research and evaluation findings (Matthys et al., 2006). Consumption reduction 
is rarely assessed as an outcome, and the cost-effectiveness of programmes is difficult to 
calculate (Matthys et al., 2006). Moreover, while there has been a search for evidence-
based universal intervention in the USA, the notion of what works is fraught with 
questions about the philosophy, objectives and measures of effectiveness (Cohen, 2001; 
Gorman, 2002; Ashton, 2003).
There is some cause for optimism: a recent Scottish literature review of school-based 
drug prevention programmes concluded that prevention, ‘in general can be effective 
[and] that some types and features of drug education are more effective than others. 
In particular, drug education using highly interactive methods and social influences 
approaches, specifically including resistance skills and normative education elements, is 
consistently shown to be more effective’ (Stead and Angus, 2007). Moreover, there is an 
increased understanding of common risk and protective factors and trajectories of drug 
use (e.g. Advisory Council on the Misuse of Drugs, 2006), and some of this has been 
translated into practical instruments and materials. A particularly prescriptive report is 
Australia’s National Cannabis Strategy 2006–2009, albeit in a non-European context. 
Yet, there are also challenges to face. A Belgian study concludes that ‘Researchers 
continue to come up against substantial methodological, practical and ethical problems 
if they want to put in place effectiveness evaluations relating to drug prevention’ (Matthys 
et al., 2006).
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Setting the context
As mentioned in the previous chapter, a significant amount of what we know about 
drugs prevention is based on research from the USA. This chapter — written by the 
former Director of the Division of Epidemiology and Prevention Research of the National 
Institute on Drug Abuse (NIDA) — provides a useful overview of recent experiences in 
school-based prevention in the USA, together with a presentation of a number of more 
prescriptive studies of ‘what works’ in the US context.
One of the questions that may arise from this chapter is the transferability of the US 
experiences within the European — or universal — context. We have seen in the first 
chapter of this volume (Vicente et al.) that the USA not only has relatively high cannabis 
prevalence in comparison with European countries. On a generational level, use of the 
drug became more widespread around 10 to 20 years earlier than in the majority of 
Western European countries.
To a considerable extent, we have also seen throughout this monograph that there 
remains the issue of diversity within Europe as regards cannabis and other drugs. A 
Europe approaching 500 million citizens is far from a monolithic society from most 
perspectives — economic, political, linguistic, sociocultural. European drug use patterns 
remain similarly heterogeneous. While there may be some approximation of US levels 
of cannabis prevalence among young adults in high-prevalence countries in Europe 
— such as the United Kingdom, Spain and Italy — many European countries report 
extremely low levels of cannabis use. Differences persist even among neighbours in 
Europe: one need only compare reported last month prevalence among 15- to 24-year-
olds in the Czech Republic (15.4 %) and Slovakia (3.9 %), Spain (18.6 %) and Portugal 
(5.5 %), Denmark (8.2 %) and Sweden (1.6 %). If prevention is to be tailored to the needs 
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of a schools population, and given priority over other items within a school curriculum, 
it should reflect the likelihood of students to both experiment and progress to more 
intensive use of drugs.
Universalism should not, however, be dismissed. The promising early experiences 
of some transnational prevention projects across very different drug-using countries 
and cultures — such as EU-Dap — suggest that good practice can cross borders 
successfully. There are several early intervention initiatives — such as the HIT and 
Jellinek knowcannabis self-help site — that have resulted from international cooperation. 
Moreover, as we have seen, European knowledge of prevention practice is subjected 
to increasing study, data collection and cooperation. While, historically, prevention 
knowledge has benefited from much borrowing from the US literature, increasingly there 
is scope for transatlantic dialogue, with European studies contributing new experiences 
and ideas to the debate.
Further reading
EMCDDA, Annual reports, published each year in November.
Journals
Drugs: Education, Prevention and Policy
Journal of Alcohol and Drug Education
Websites
NIDA website on preventing drug abuse among children and adolescents 
www.nida.nih.gov/Prevention/Prevopen.html
EELDA website on School-based drug prevention 
http://en.eelda.org/index.aspx?o=1076
See also the grey literature list in the Appendix to Volume 1 of this monograph.
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Zili Sloboda
Introduction
Prior to the 1970s there was little knowledge on which to base the development of 
prevention programming in the USA (Sloboda, 2003). As is the case today in much 
of Europe, efforts in schools to prevent or delay initiation of smoking, alcohol or drug 
use lacked any research basis. However, the creation of the National Institute on Drug 
Abuse (NIDA) in 1974 began a period of important research that served to move 
prevention from an art to a science (Bukoski, 2003). Longitudinal cohort studies that 
followed children and adolescents over time and national surveys that were administered 
at regular intervals were funded. These research efforts not only gave more accurate 
assessments of trends in substance use in the country but also specification of those 
biological, individual, family, school, peer and community factors that increased the 
susceptibility of some children and adolescents to the use of alcohol, tobacco, marijuana 
and other drugs (Kandel, 1975; Hawkins et al., 1992). In addition, the longitudinal 
cohort studies (e.g. Kandel, 1975; Newcomb and Bentler, 1986) showed a progression 
from ‘legal’ substances (tobacco and alcohol) to illicit drugs (marijuana and cocaine) 
(Kandel, 1988; Kandel and Yamaguchi, 1999). These epidemiological findings greatly 
influenced prevention programme developers and researchers. The vast predominance 
of substance abuse prevention programmes that were evaluated and found effective 
grew from the research on the initiation of use. As such, these programmes target all 
children and adolescents no matter their level of susceptibility and specifically address 
the use of tobacco and alcohol, as well as marijuana and other illicit drugs (to include 
inhalants).
Furthermore, as the research also indicated that the initiation of most substance 
use among adolescents takes place through peer influence, prevention researchers 
based their programmes on social learning incorporating the concept of self-efficacy 
(Bandura, 1977). These programmes are centred around social resistance skills training 
(Botvin and Griffin, 2003) as they increase students’ resistance to those influences 
that encourage substance use and they focus on providing students with the skills 
they need to resist offers to use alcohol, tobacco or illicit drugs and to practise these 
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resistance skills in ‘virtual’ situations that are realistic to them. Most of these universal (1) 
programmes are delivered in schools as curricula. Other prevention programmes 
address the needs of more vulnerable children and adolescents and their families 
through counselling or more in-depth therapies.
Evidence-based school-based prevention programming
Meta-analyses and reviews of evaluation studies of prevention programmes had been 
conducted in the late 1980s and throughout the 1990s to identify the determinants of 
effectiveness. These analyses and reviews, however, were very much restricted by what 
reports were available at the time. For instance, Schaps and his colleagues (1981), 
Bangert-Drowns (1988) and Brunvold and Rundell (1988) found in their analyses that 
prevention programmes of the late 1970s and early 1980s were effective in providing 
knowledge to participants but impacting attitudes and drug-using behaviours were more 
difficult to address and that the use of peer facilitators, use of interactive instructional 
style and high ‘doses’ of exposure to prevention programming led to better outcomes.
Tobler’s work, summarised in her 2000 article, ‘Lessons learned’, used meta-analytic 
approaches using data from studies of 207 school-based drug prevention programs with 
drug use measures that were reported in the literature (1992, 1997 and 2000). Each 
review had subsequently better data, reflecting improvements in measurements and in 
the quality of data collection efforts. Her analyses looked at content, delivery method, 
and programme size. Her findings indicate what works and what doesn’t work. As can 
be seen in Table 1, programmes with content that covers both short- and long-term 
consequences of substance use, address misconceptions regarding the normative nature 
of adolescent substance use, and provide opportunities to learn and practice decision 
making/problem solving, assertiveness and resistance skills had larger effect sizes. In 
addition, delivery or instructional style was found to be important. Adolescents learn best 
when they are actively involved through small group discussions, role play, and given 
sufficient time to practise their new skills. These elements were also found by Tobler and 
her colleagues to be important specifically for the prevention of marijuana use (Tobler 
et al., 1999). Other reviewers of prevention programmes have had similar findings 
even when using other analytical techniques (e.g. Brunvold, 1993; Harachi et al., 1999; 
Cuijpers, 2002; Nation et al., 2003). Elements added through these reviews included 
having a theoretical framework and addressing commitment or intentions not to use.
 (1) In 1994, the mental health and substance abuse fields adopted a classification system for 
prevention programming depending on the level of risk of the targeted group. Universal 
programmes address general populations while selective programmes target those segments 
of the population that present greater than normal risk to develop a disorder and indicated 
programmes focus on those subgroups that exhibit signs or symptoms of developing a 
disorder.
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Table 1: Tobler (2000) findings of what works and what doesn’t work
Works Doesn’t work
Content Content
Short-term effects
Long-term health consequences
Feedback on peer use from school surveys
Addressing media and social influences that 
promote pro-drug attitudes and behaviours
Adjustment of perceptions regarding peer 
substance use
Provide/practise drug refusal skills, 
assertiveness skills, communication skills, safety 
skills, coping skills, goal-setting, decision-
making/problem-solving skills
Not including short-term consequences
Not addressing perceptions of peer substance use
Not addressing media and social influences
Allowing values or moral and ethical decision-
making
Not developing interpersonal skills or drug refusal 
skills
Focusing primarily on intrapersonal aspects
Focusing only on self-esteem building
Delivery Delivery
Active involvement of everyone in class
Active participation between peers
Role plays around scenarios generated by 
students
Developmentally appropriate activities to 
promote bonding
Eliciting positive/supportive comments from 
peers
Rehearsal of resistance/refusal skills with 
modelling of appropriate behaviours
Lots of practice time
Allowing passive participation on the parts of the 
students
Teacher-centred discussions and lecturing solely
Dialogues without structure
Use of effective classroom management 
techniques without a drug programme
In another review of school-based prevention programmes conducted under the 
Cochrane Collaboration, only evaluations using randomised controlled trials (RCTs) or 
controlled prospective studies (CPSs) were reviewed. Of the 32 selected for review, 28 
were from the USA. Most of the studies used post-test or intervention assessments and 
focused on students in the sixth and seventh grades, i.e. around 12–14 years of age. 
Separate reviews were made for RCT (n = 29) and CPS (n = 3) evaluations. No significant 
results were found among the CPS while the RCT programmes that offered skills training 
had the best outcomes (Faggiano et al., 2005).
The movement from examining the elements or principles of prevention to a focus on 
programmes and practices began when NIDA sponsored the first conference on drug 
abuse prevention in 1996 (Putting Research to Work for the Community). The goal of 
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the conference was to introduce the findings from prevention research in a user-friendly 
style to practitioners. The outcome of the conference was a booklet, Preventing drug use 
among children and adolescents: a research-based guide (Sloboda and David, 1997) 
written in a question–answer format that presented how research findings could be used 
to plan and develop prevention programming and practices for the community. The 
approach taken was to present ‘principles’ of prevention related to content, structure 
and delivery. The result was a list of 13 underlying principles drawn from commonalities 
found in both epidemiological and prevention research (an updated version of these 
principles is presented in Table 2).
In addition, however, the booklet summarised the findings from evaluations of 
prevention interventions funded through NIDA that had significant outcomes at least 1 
year after the intervention. At the time, 10 programmes were described (six considered 
universal, two selected, one indicated and one addressing all three levels of risk). The 
publication of this booklet stimulated other groups to develop their own criteria for 
effectiveness and their own lists.
Most dominant of these groups are the federal funding agencies for school- and 
community-based prevention efforts, the Education Department’s Safe and Drug-Free 
Schools and Communities programme (SDFSC) and the Center for Substance Abuse 
Prevention (CSAP). There are a number of interesting similarities and differences in how 
each of these agencies addresses the issue and as a result, the lists that have been 
compiled have very little overlap (Table 3 and Figure 1). Another important difference 
between these two listings is that while procedures are in place to update and add newly 
evaluated prevention strategies to the CSAP list, there are no such procedures in place 
for the SDFSC list. The fact that funding is tied to selecting only from these listings has 
both positive and negative effects. The positive impact of implementing strategies with 
demonstrated successful outcomes has made communities more accountable and, thus, 
more concerned about delivering prevention strategies that have demonstrated success. 
On the other hand, the lack of consistent criteria and listings both confuses and upsets 
community groups, particularly those that may have prevention programming already 
in place. Furthermore, not only is there a heavy emphasis on selecting ‘evidence-
based’ strategies but funding is also dependent on demonstrating need or defining the 
community drug abuse problem. Often communities will identify their needs but find that 
there are no evidence-based strategies available on the lists to meet them.
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Table 2: National Institute on Drug Abuse — principles of prevention
Prevention programmes should enhance protective 
factors and reverse or reduce risk factors
Prevention programmes should address all forms 
of drug abuse, alone or in combination, including 
the underage use of legal drugs (e.g. tobacco or 
alcohol); the use of illegal drugs (e.g. marijuana 
or heroin); and the inappropriate use of legally 
obtained substances (e.g. inhalants), prescription 
medicines or over-the-counter drugs
Family-based prevention programmes should 
enhance family bonding and relationships and 
include parenting skills; practice in developing, 
discussing and enforcing family policies on 
substance abuse; and training in drug education 
and information
Prevention programmes can be designed to 
intervene as early as pre-school to address 
risk factors for drug abuse, such as aggressive 
behaviour, poor social skills and academic 
difficulties
Prevention programmes for elementary school 
children should target improving academic 
and social–emotional learning to address risk 
factors for drug abuse, such as early aggression, 
academic failure and school drop-out
Prevention programmes for middle or junior 
high and high school students should increase 
academic and social competence
Prevention programmes aimed at general 
populations at key transition points, such as the 
transition to middle school, can produce beneficial 
effects even among high-risk families and 
children. Such interventions do not single out risk 
populations and, therefore, reduce labelling and 
promote bonding to school and community
Community prevention programmes that 
combine two or more effective programmes, 
such as family-based and school-based 
programmes, can be more effective than a 
single programme alone
Community prevention programmes 
reaching populations in multiple settings 
— for example, schools, clubs, faith-based 
organisations and the media — are most 
effective when they present consistent, 
community-wide messages in each setting
When communities adapt programmes to 
match their needs, community norms or 
different cultural requirements, they should 
retain core elements of the original research-
based intervention
Prevention programmes should be long-
term with repeated interventions (i.e. booster 
programmes) to reinforce the original 
prevention goals. Research shows that the 
benefits from middle-school prevention 
programmes diminish without follow-up 
programmes in high school
Prevention programmes should include 
teacher training on good classroom 
management practices, such as rewarding 
appropriate student behaviour. Such 
techniques help to foster students’ positive 
behaviour, achievement, academic motivation 
and school bonding
Prevention programmes are most effective 
when they employ interactive techniques, such 
as peer discussion groups and parent role-
playing, that allow for active involvement in 
learning about drug abuse and reinforcing 
skills
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EVIDENCE-BASED PROGRAMMES
Conceptually sound and internally consistent
programme activities related to conceptualisation
reasonably well implemented and evaluated
PROMISING
? Some positive outcomes
EFFECTIVE
? Consistently positive outcomes
? Strongly implemented and evaluated
MODEL
? Available for dissemination
? Technical assistance available from
research/developer
'JHVSF Substance Abuse and Mental Health Services Administration (SAMHSA) national 
registry of evidence-based programmes
Table 3: United States Department of Education — safe, disciplined and drug-
free schools: exemplary and promising programmes
Criterion
Evidence of efficacy The programme reports relevant evidence of efficacy/effectiveness based 
on a methodologically sound evaluation
Quality of programme The programme’s goal with respect to changing behaviour and/or 
risk and protective factors are clear and appropriate for the intended 
population and setting
The rationale underlying the programme is clearly stated, and the 
programme’s content and processes are aligned with its goals
The programme’s content takes into consideration the characteristics 
of the intended population and setting and the needs implied by these 
characteristics
The programme implementation process effectively engages the intended 
population
Educational significance The application describes how the programme is integrated into schools’ 
educational missions
Usefulness to others The programme provides necessary information and guidance for 
replication in other appropriate settings
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What types of prevention approaches are deemed 
effective?
The school-based programmes target children generally in middle school when they 
are around 8–10 years old and have booster sessions that are delivered over a number 
of years. Several include a homework component that allows students to involve their 
parents.
The school is an appropriate setting for prevention strategies for a number of reasons. 
The most obvious is that it is in the schools where children in the USA spend a great 
proportion of their time. In addition, the school remains a major socialisation institution 
to reinforce societal values, norms and acceptable behaviours. The school is a protective 
environment for children (Schaps and Solomon, 2003). Translating these aspects 
of the school for prevention suggests several approaches that can be taken. As a 
socialisation agent, the school provides children with knowledge and skills to become 
competent citizens and it reinforces pro-social attitudes and behaviours. As a protective 
environment, most schools are substance- or drug-free, provide supervised after-school 
programmes, and have activities to connect parents and families to school personnel. 
Of these aspects of the school environment that lend themselves specifically to substance 
use prevention, it is the cognitive approach to prevention that is the most common and, 
therefore, the most often evaluated. However, altering the school culture to create an 
environment that supports anti-drug use norms, beliefs and expectancies and school 
bonding, that is, connecting the individual to the school experience and community, and 
implementing appropriate school policy have not been as extensively assessed.
Prevention programmes that target the school culture intend to make the school 
environment more attractive to students and to help students succeed within the school 
setting to engage in more pro-social behaviours and in this indirect way reduce the 
likelihood that students will use alcohol, tobacco or other drugs. The common elements 
of strategies that attempt to take advantage of and/or impact school culture to provide 
a positive normative environment for children include: creating anti-/non-substance-
using settings (including tobacco, alcohol and other drugs); dispelling misconceptions 
regarding expectancies (positive experiences) associated with the use of tobacco, alcohol 
and other drugs; and establishing comprehensive programmes that involve students, 
school administration and, when appropriate, parents/caregivers (e.g. the Caring School 
Community; Battistich et al., 2000).
In addition, programmes that address school-bonding share common elements or 
principles that include: focusing on early years, that is, pre-school to middle school; 
enhancing competency in reading and mathematics; providing interpersonal skills 
to relate positively with peers and adults; involving parents in communication and 
parenting skills and in school activities. Among school-bonding programmes that are 
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viewed as promising are the Skills, Opportunities and Recognition (SOAR) programme 
(Hawkins et al., 1999), Incredible Years (Webster-Stratton et al., 2001) and Early Risers 
Skills for Success (August et al., 2003).
An interesting new area for prevention examines policies related to substance use 
within the school building. There is a special appeal to developing policies that reach 
greater numbers of the target population and minimise costs. Common elements 
or principles of effective school policy approaches include: reducing or eliminating 
access to and availability of tobacco, alcohol or other drugs; addressing infractions of 
policies by providing counselling or treatment and special services to the students rather 
than punishing them through suspension or expulsion; selecting policies that do not 
disrupt normal school functioning and those that address the full range of drug-using 
behaviours, from initiation to progression to abuse and dependence and relapse; 
specification of the substances that are targeted; and reflect other community prevention 
efforts.
The challenge of disseminating effective prevention 
programming
A recent conference sponsored by NIDA and CSAP, ‘What do schools really think about 
prevention research? Blending research and reality’ (Kaftarian et al., 2004) brought 
both researchers and practitioners together to discuss the challenges of diffusing and 
disseminating effective prevention strategies. Among the greatest mentioned were 
implementation fidelity (or faithfulness of delivery) and adaptation (Botvin, 2004; 
Greenberg, 2004; Pentz, 2004).
These concerns arise from studies (Hallfors and Godette, 2002; Ennett et al., 2003) that 
found that evidence- or research-based programmes taken ‘to scale’ at the community 
level often are not implemented as they were designed and evaluated. Although 
fidelity of implementation is recognised as important, few studies have examined the 
relationship between level of fidelity and programme outcomes. Tobler and Stratton 
(1997) suggest that decreases in the effect sizes they found in their meta-analyses of 
school-based substance abuse prevention programmes taken to scale may be due 
to implementation issues. Pentz and Trebow (1991) found that children exposed to a 
programme delivered by instructors who maintained high implementation fidelity had 
better outcomes than those exposed to the programme delivered by instructors who 
implemented the programme with low fidelity. Furthermore, children exposed to the 
programme delivered by low implementers had better outcomes than children in the 
control condition.
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As the field of prevention continues to develop theory- and research-based interventions, 
the combined issues of fidelity and reinvention will become increasingly important. 
However, as Dusenbury et al. (2003: 240) emphasise, although the field has fair 
agreement on the definition of fidelity (‘… the degree to which teachers and other 
program providers implement programs as intended by the program developers’), there 
does not appear to be a consensus regarding the specific dimensions of fidelity nor 
on their measurements. Similarly, the degree of adaptation that may take place in the 
community has not been well studied.
Conclusions
So where does this leave us? Professionals in the field of substance abuse prevention in 
the USA have experienced a period of exciting new developments. After a long period of 
limited success, the 1990s brought the field to a new level of prominence that engaged 
researcher, practitioner and policymaker to strategically address substance use among 
our children and adolescents. After rapid dissemination and diffusion of evidence-based 
prevention strategies, the field has now entered a new period of deliberations and 
discussions around improving both the extent of prevention programming within the 
community and the specificity of this programming to meet each community’s needs 
in terms of problem identification, available resources (i.e. social capital and funding), 
and priorities. Governmental demands for fiscal accountability pose both opportunities 
and challenges. On one hand, communities are required to deliver ‘evidence-based’ 
prevention programming, while on the other hand researchers and practitioners are 
not in agreement as to what that means. To further complicate the issue, the proposed 
federal budget for fiscal year 2006 shows reduced funding for demand reduction 
activities, particularly prevention, placing a greater load on states and local governments 
and the private sector for support. Funding for the much-needed research, now solely 
the responsibility of NIDA, will remain flat or will increase negligibly. Given the costs for 
conducting rigorous evaluation research studies, these potential obstacles portend that 
few, if any, much needed new prevention strategies will be forthcoming.
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Chapter 13
Cannabis users in drug treatment 
in Europe: an analysis from 
treatment demand data
Keywords: cannabis – EMCDDA – epidemiology – treatment – treatment 
demand
Setting the context
This chapter analyses the 2005 data on people entering drug treatment for primary 
cannabis use in the Member States. For several years, the EMCDDA has reported an 
increasing number of people reported as seeking treatment for cannabis use. Although 
definitive reasons for this are difficult to specify, it is clear that the explanation is multi-
faceted and requires careful study before drawing firm conclusions (Simon, 2004).
Cannabis treatment, like cannabis use, is usually a young person’s phenomenon. As 
with the use of other types of drugs, treatment for cannabis attracts more males than 
females. While most cannabis treatment clients begin use early in their lives, the spread 
of ages amongst those now entering treatment is much broader, and their drug use 
reaches beyond cannabis to include other illicit drugs also, such as cocaine, other 
stimulants and, occasionally, opiates (EMCDDA, 2003a).
Recent years have shown an increase in demand for cannabis treatment in most 
Member States, even though there are important differences between the countries. In 
particular, there has been an increase in the number of adolescents reporting social 
and psychological problems related to cannabis use, for which they themselves, their 
families or their school request specialised help (EMCDDA, 2003a). A number of factors 
may explain the reported increase, for example a simple improvement of data coverage 
in the EMCDDA reporting system, expansion of treatment availability, or an increased 
number of referrals to treatment by the criminal justice system and by the client’s social 
networks. The reported pattern of use of cannabis in the period immediately prior to 
treatment has been changing, and this does not just mean an increase in the number of 
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People seeking treatment specifically for cannabis use now represent a significant 
proportion of overall drug treatment requests across Europe, though differences between 
countries are substantial. Some countries, such as France, Germany, Hungary and 
Denmark, currently have very high percentages of cannabis clients among people in 
treatment. Other countries, such as Lithuania, Luxembourg, Romania and Portugal, 
report low percentages.
This chapter argues that further investigation of cannabis consumption patterns and 
related problems could identify areas where specialised drug services might provide 
interventions, targeted not only at regular cannabis users but also at any other 
adolescent cannabis users with social, behavioural or psychological problems.
Further reading
Copeland, J. (2004), ‘Developments in the treatment of cannabis use disorder’, Current Opinion in 
Psychiatry 17(3): 161–167.
EMCDDA, Annual report, published each year in November.
UNODC and EMCDDA (2006), Guidance for the measurement of drug treatment demand, United 
Nations Office on Drugs and Crime and European Monitoring Centre for Drugs and Drug 
Addiction, Vienna and Lisbon.
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Cannabis users in drug treatment 
in Europe: an analysis from 
treatment demand data
Linda Montanari, Colin Taylor and Paul Griffiths
Introduction
Cannabis is the most widely used illicit drug in Europe and its use is one of the most 
frequent reasons cited for entering drug treatment. In 2005, 20 % of all drug clients and 
29 % of new drug clients (EMCDDA, 2007a, b) (1) entered treatment for problems related 
to their primary cannabis use. In recent years, drug services in the European Union 
have reported a more or less steady increase in the number of people seeking treatment 
because of problems related to their cannabis use, making cannabis-related treatment 
an increasingly larger proportion of drug treatment demands. In terms of overall 
treatment demand, cannabis now lies behind only the main problem drug type, opiates, 
and is ahead of demands for cocaine-related treatment.
In this chapter, the increase in treatment demand and its implications are analysed 
through data collected under the treatment demand indicator (TDI), a pan-European 
instrument used to monitor data on people entering treatment for drug use (EMCDDA 
and Pompidou Group, 2000) (2).
This chapter highlights a number of key questions arising from the increase in the 
reported demand for cannabis treatment. To build a clear picture of the changing 
situation, it is fundamental to understand how each of these questions is driving the 
current changes in treatment demand.
Does this increase in reported demand represent an increase in the number of t
people in need of help for cannabis use?
If so, to what extent does it result from an increase in use of cannabis in the t
general population — in particular, regular and intensive use?
 (1) See figure TDI-G02 in the Statistical bulletin 2007.
 (2) The TDI is called the treatment demand indicator protocol, but in fact it counts the number of 
people starting a drug treatment for their drug use, as written in the TDI definition. The people 
asking for, but not receiving treatment, are not recorded. People sent to treatment centres not 
on their own initiative are also included in the reported data.
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If so, to what extent is it related to other changing factors among drug users, t
such as their changing patterns of drug use? To what extent is it related to 
physical, social or psychological problems among cannabis users themselves?
Can this increase be explained by factors independent of an increased need for t
help? Explanations might include:
improvements in the coverage of the treatment reporting system;t
expansion of the types of treatment facilities available, and, in particular, t
specific treatment services targeting adolescents and young people, that reach 
out to and attract the cannabis user population more effectively than before;
an increase in referrals to treatment, affecting cannabis users who would not t
otherwise have sought help spontaneously; and
linked to the above, an increase resulting from changes in the way cannabis or t
other drug use is dealt with by the criminal justice system, within schools, or by 
agencies working with young people.
The analysis presented here is a broad one, describing trends across several countries 
in the EU. The chapter questions the extent to which the overall European picture 
is reflected in each of the individual countries, and whether some countries have a 
different pattern of change in treatment demand.
Method and sources for data collection
The data presented in this chapter are primarily obtained through a standard protocol 
used by all EU countries, the TDI, a joint EMCDDA–Pompidou Group Protocol (EMCDDA 
and Pompidou Group, 2000). The protocol establishes harmonised definitions across 20 
questionnaire items. These items relate to drug-related information, socio-demographic 
data and use of services, and aim to obtain consistent information on the number, 
characteristics and patterns of use of people entering treatment for drug use. From 
2000 onwards, European Member States have collected data using the TDI to provide 
information on trends in the treatment of problem drug use. The indicator serves several 
purposes: prevalence estimation; identification of patterns of drug use and use of 
services; service planning; and service evaluation.
TDI data can be regarded as providing a reasonably robust and useful representation of 
the characteristics of clients referred to specialised drug services within the EU. However, 
there are limitations that must be borne in mind, as achieving comparability in data 
from all EU Member States is not easy. While departures from EU comparability persist, 
they are believed not to distort the broader picture of drug treatment patterns.
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One limitation of the EMCDDA’s data is the extent of ‘double-counting’ of clients. The 
number of people entering treatment each year is defined so as to count only one 
episode — that is, a single treatment demand — each year. The task of excluding 
‘repeat’ treatment episodes should therefore ideally be controlled centrally in each 
country, yet in practice some countries’ collection procedures cannot use controls at a 
national level, resulting in a slightly higher count of people. A further potential lack of 
comparability is that treatment for cannabis as the primary drug of abuse is defined 
in the protocol as cannabis being ‘the drug that causes the client the most problems’. 
Different treatment systems may interpret this differently. Reporting can be based on 
problems as defined by clients themselves, or on short diagnoses based on the ICD-10. 
When the primary drug is unclear, usually what is reported is the drug most frequently 
used, or the drug considered most important for the potential consequences on the 
health and social situation of the client.
A stronger caveat must be voiced on how far we can generalise from the consolidated 
European data set. The single factor that impacts most heavily on interpreting the 
findings is the potential for under-reporting, which arises from the varying extent to 
which the reporting system succeeds in covering, each year, all the relevant treatment 
facilities in each Member State. It must be remembered that treatment facilities are not 
fixed: new agencies might enter the reporting system and old ones leave it. Monitoring 
the effect of these changes is a continuing part of data collection, and is the subject of 
current work (see, for example, Simon, this monograph, on the German situation).
The EMCDDA’s TDI data nonetheless remains the major pan-European body of data 
on treatment. The discussion based on this information source will focus on four main 
areas:
profiling cannabis treatment clients — their socio-demographic characteristics (age, t
gender, living and social conditions);
describing patterns of drug use amongst treatment clients (age at first use, t
frequency of use and combination with other drugs);
incidence of client treatment in Europe, and a comparison with general population t
data on cannabis use; and
referral routes into treatment for cannabis.t
The TDI provides good short-term trend information in these four areas, although 
longer-term longitudinal data — 1999 to 2005 — on treatment demand in 20 European 
countries are available (3). For some socio-demographic characteristics (education, 
labour and living status) — and for information on source of referral — only two years 
 (3) See figure TDI-01 in the Statistical bulletin 2007, which provides methodological details on trends 
calculations.
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of data (2001/2002) are available, for seven countries. In these seven countries, a 
specific exercise, not available for other years, was conducted.
Discussion of patterns of drug use, profile of clients and sources of referrals to treatment 
is restricted to outpatient clinics, since these data have the most consistent coverage of 
clinics and individuals.
Cannabis treatment clients
Overall, cannabis is the most used illicit drug in Europe and, over recent years, it has 
risen to become the second most frequently cited drug reported as the primary reason 
for entering specialised drug treatment, after opiates. According to the TDI data in 
2005, around 20 % of all treatment clients and 29 % of first-time treatment clients were 
recorded as having a primary cannabis problem (4) (EMCDDA, 2007a, b).
Polydrug use is often reported among cannabis users. Among drug clients, cannabis can 
be registered as a primary drug, or a secondary drug used along with other substances. 
Among all drug clients entering treatment for primary cannabis use, alcohol (37 %) or 
amphetamines or ecstasy (28 %) were reported as the most frequent secondary drugs 
(5). However, a proportion of clients reported cocaine use (15 %) and/or other opioid 
use (7 %) as secondary drugs, with cannabis reported as the primary drug for treatment. 
Although few in number, these clients are an interesting group who could be more 
carefully examined to better understand patterns of drug use and related problems.
Among all outpatient treatment clients reported by a clinic’s staff, cannabis may also 
be cited as a secondary problematic drug. After alcohol (38 %), cannabis is reported 
as the second most frequently cited secondary substance (17 %) by those receiving drug 
treatment (6). When treatment clients cite cannabis as a secondary drug, analysis shows 
that overall cannabis use is frequently reported as a secondary reason for entering 
treatment among primary cocaine users (28 %), primary users of other stimulants (26 %) 
and primary opiate users (17 %). Similar drug combinations are also found in the 
American treatment data. Analysis of American treatment data shows that marijuana 
appears to be the secondary reason for seeking treatment among clients using alcohol 
(56 %), cocaine (21 %), stimulants (11 %) and opiates (10 %) (DASIS, 2003).
Thus it seems that a group of primary cannabis clients exists which also uses other drugs 
in combination with cannabis. Cannabis can be combined with alcohol, amphetamines 
or ecstasy, but also with other, ‘harder’, drugs such as cocaine or heroin. Among 
 (4) See figure TDI-02 in the Statistical bulletin 2007.
 (5) See table TDI-23 in the Statistical bulletin 2007.
 (6) See table TDI-22 in the Statistical bulletin 2007.
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polydrug users including cannabis, and especially in those clients reporting use of the 
‘hard’ drugs, it is not clear what the role of cannabis is in the request for treatment. 
Polydrug use has became more common in recent years and cannabis might be just one 
among other substances that gives rise to users entering treatment. Limitations in data 
recording, and the small number of absolute cases reported in some countries should be 
considered also.
For simplicity, to analyse changes and trends we have considered here only the group of 
clients reporting cannabis as the primary drug for the first time in their life. Nevertheless, 
this information must be seen in the context of a changing and expanding reporting 
system, the implications of which are discussed below.
When looking at socio-demographic characteristics of cannabis clients, the following 
picture emerges. Cannabis clients new to treatment are predominantly young males. 
The highest male to female ratio among all drugs clients is found among these new 
outpatient clients (6 males:1 female) (7). Higher male to female ratios are found in Italy, 
Portugal, Hungary, Germany, with lower ratios in the Czech Republic, Sweden, Finland 
and the United Kingdom. These differences in the male to female ratios among countries 
is quite similar across the other primary drugs of use. Almost all new clients entering 
treatment for primary cannabis use are younger than 30, and almost 40 % are younger 
than 20. The mean age of cannabis clients is 24 years, whereas in the case of other 
drugs, this age is generally higher. Country differences are found in the age distribution 
of cannabis clients (8). Among the group of people under 20 years old receiving drug 
treatment, the vast majority reports using cannabis as the primary drug (80 % among 
people under 15, 67 % among those aged 15–19) (9).
The age of first cannabis use — onset — is important, since it has been reported 
that the younger the age at which users first consume cannabis, the higher the risk 
of developing drug problems in the future (Kraus et al., 2003). Compared with other 
drug types, which show considerable variation across countries, age of first cannabis 
use among clients requesting treatment for cannabis is quite similar across countries 
in Europe. In the TDI data for cannabis clients starting treatment for the first time, the 
mean age of starting cannabis use is 17 years. Virtually all new cannabis clients start 
their drug use before they are 20 and 33 % before they are 15. The corresponding 
figures for opiates are 45 % before 20 years old, and 5 % before 15 years old, and for 
cocaine, 48 % and 6 %, respectively (10). A comparison of age of onset with age first 
treated shows that there is a time lag of around 7 years between first cannabis use 
 (7) See table TDI-22 in the Statistical bulletin 2007.
 (8) See tables TDI-10 and TDI-102 in the Statistical bulletin 2007.
 (9) See table TDI-10 in the Statistical bulletin 2007.
 (10) See table TDI-11 in the Statistical bulletin 2007.
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and first drug treatment, regardless of where treatment is sought (that is, in different 
countries and in different types of treatment centre).
Finally, looking at available data on other social characteristics in 2002 (11), the 
relatively young age of cannabis clients means that a large proportion, 45 %, are still 
in education, compared with only 8 % amongst clients being treated for problems with 
other drugs. A further 24 % of those being treated for cannabis problems are in regular 
employment, equal to the percentage who are unemployed. This is in stark contrast to 
clients using drugs such as heroin, among whom very few are employed. In addition, 
cannabis clients more often report living in stable accommodation than those being 
treated for problems with other drugs, reflecting the fact that many are young people, 
students, or living with their parents (Agosti and Levin, 2004). However, a few countries, 
such as Greece, also report a number of primary cannabis clients who are older, 
in more precarious social conditions and using other drugs together with cannabis 
(EMCDDA, 2004).
To conclude, the most common characteristics of cannabis clients are that they are 
young male, a student/school pupil and living with parents. However, there are also 
indications of cannabis clients who are older or less socially well-integrated. The same 
patterns were found in the recent review of cannabis specialised treatment reported by 
Rødner Sznitman (this monograph).
Incidence of demands for cannabis treatment
Based on data that were available in 19 EU countries, there are on average 41 persons 
per 100 000 young adults (aged 15–34) each year who enter treatment for cannabis 
use for the first time. Only a tiny proportion — 1 in 200 — last-month cannabis users 
in the young adult population (aged 15–34) report entering specialised drug treatment 
for cannabis use (Table 1). A 2004 detailed review of cannabis treatment demand, 
conducted by the Dutch National Alcohol and Drugs Information System (LADIS), 
confirms that only a small proportion of regular cannabis users in the Netherlands 
receives drug treatment.
Major differences are found between countries in the TDI data set in the proportion of 
clients seeking treatment for cannabis. This varies considerably, from 3 % in Bulgaria 
to 48 % in France and 36 % in Hungary. In terms of new clients, there are also large 
differences between countries, with cannabis clients reaching an almost 70 % share 
of new clients entering drug treatment in France (12). In general, a high prevalence of 
 (11) An ad hoc data collection on social characteristics of cannabis clients was done in 2002, yet is not 
available for other years.
 (12) See tables TDI-04 and TDI-05 in the Statistical bulletin 2007.
Chapter 13
269
Ta
bl
e 
1:
 T
re
at
m
en
t d
em
an
d 
fo
r 
ca
nn
ab
is
 a
s 
pr
im
ar
y 
dr
ug
 a
m
on
g 
ne
w
 d
ru
g 
cl
ie
nt
s 
an
d 
la
st
-m
on
th
 p
re
va
le
nc
e 
of
 
ca
nn
ab
is
 u
se
 a
m
on
g 
yo
un
g 
ad
ul
ts
 in
 2
00
5 
or
 m
os
t r
ec
en
t y
ea
r 
av
ai
la
bl
e:
 in
ci
de
nc
e 
pe
r 
10
0 
00
0 
yo
un
g 
po
pu
la
tio
n 
at
 1
 
Ja
nu
ar
y 
20
06
C
ou
nt
ry
%
 c
an
na
bi
s 
cl
ie
nt
s 
of
 
la
st
-m
on
th
 
pr
ev
al
en
ce
, 
yo
un
g 
ad
ul
ts
N
ew
 
ca
nn
ab
is
 
cl
ie
nt
s 
in
 
20
05
 o
f t
he
 
to
ta
l c
lie
nt
s 
(%
)
N
ew
 c
an
na
bi
s 
cl
ie
nt
s 
20
05
 
(a
bs
ol
ut
e 
nu
m
be
rs
)
C
an
na
bi
s 
cl
ie
nt
s 
pe
r 
10
0 
00
0 
yo
un
g 
ad
ul
t 
po
pu
la
tio
n
La
st
-m
on
th
 
ca
nn
ab
is
 
pr
ev
al
en
ce
, y
ou
ng
 
ad
ul
ts
 2
00
5 
or
 
m
os
t r
ec
en
t y
ea
r 
av
ai
la
bl
e 
(%
)
La
st
-m
on
th
 
pr
ev
al
en
ce
, y
ou
ng
 
ad
ul
ts
 2
00
5 
or
 
m
os
t r
ec
en
t y
ea
r 
av
ai
la
bl
e 
(a
bs
ol
ut
e 
nu
m
be
rs
)
G
en
er
al
 
po
pu
la
tio
n,
 
yo
un
g 
ad
ul
ts
 
(1
5–
34
) i
n 
20
06
 (1
 
Ja
nu
ar
y)
Bu
lg
ar
ia
0.
1
9.
3
36
2
1.
7
37
 2
13
2 
18
8 
99
2
C
ze
ch
 R
ep
ub
lic
0.
3
20
.5
89
6
29
9.
8
30
1 
96
0
3 
08
1 
22
4
D
en
m
ar
k 
1.
1
52
.6
83
0
63
5.
9
78
 1
24
1 
32
4 
13
9
G
er
m
an
y
0.
5
58
.0
8 
13
9
42
7.
6
1 
48
5 
40
9
19
 5
44
 8
50
Ire
la
nd
1.
4
40
.2
80
7
60
4.
3
58
 0
55
1 
35
0 
11
0
G
re
ec
e
0.
5
10
.1
22
5
7
1.
5
45
 5
73
3 
03
8 
20
9
Sp
ai
n
0.
3
20
.3
5 
31
2
42
15
.5
1 
97
1 
23
8
12
 7
17
 6
63
Fr
an
ce
0.
2
67
.3
2 
80
4
17
9.
8
1 
60
8 
24
1
16
 4
10
 6
18
Ita
ly
0.
7
24
.1
8 
47
7
58
8.
8
1 
29
0 
73
3
14
 6
67
 4
16
C
yp
ru
s
1.
7
40
.2
84
35
2.
1
5 
02
5
23
9 
30
5
La
tv
ia
0.
3
17
.0
68
10
3.
7
25
 2
00
68
1 
07
7
Li
th
ua
ni
a
0.
0
0.
3
1
0
1.
5
14
 8
67
99
1 
13
0
H
un
ga
ry
4.
0
52
.0
3 
28
6
11
3
2.
8
81
 4
40
2 
90
8 
57
8
N
et
he
rla
nd
s
0.
8
41
.8
1 
79
7
44
5.
6
22
8 
06
6
4 
07
2 
60
7
Po
rtu
ga
l
0.
4
11
.4
55
2
19
4.
4
12
9 
32
4
2 
93
9 
17
3
Sl
ov
ak
ia
0.
5
28
.8
27
7
16
3.
3
57
 9
68
1 
75
6 
61
5
Fi
nl
an
d
0.
4
34
.0
21
5
17
4.
0
51
 8
02
1 
29
5 
04
2
Sw
ed
en
1.
2
31
.6
42
2
19
1.
5
34
 2
00
2 
27
9 
98
5
U
ni
te
d 
Ki
ng
do
m
0.
5
21
.9
9 
40
0
59
11
.6
1 
84
4 
19
1
15
 8
98
 2
00
To
ta
l
0.
5
29
.0
43
 6
28
41
8.
7
9 
34
8 
62
7
10
7 
38
4 
93
3
N
ot
es
: 
on
ly
 c
ou
nt
rie
s 
th
at
 s
en
t i
nf
or
m
at
io
n 
ab
ou
t f
irs
t t
re
at
m
en
ts
 a
re
 in
cl
ud
ed
.
So
ur
ce
: 
20
06
 R
ei
to
x 
N
at
io
na
l r
ep
or
ts
, S
ta
nd
ar
d 
Ta
bl
e 
3.
 F
or
 to
ta
l n
um
be
r 
of
 c
lie
nt
s 
se
e 
ta
bl
e 
TD
I-2
. F
or
 p
op
ul
at
io
n 
se
e 
Eu
ro
st
at
, d
em
og
ra
ph
ic
 d
at
a 
20
06
 (h
ttp
:/
/e
pp
.e
ur
os
ta
t.
ce
c.
eu
.in
t).
Cannabis users in drug treatment in Europe: an analysis from treatment demand data
270
cannabis use reported in the general population is associated with a high percentage of 
primary cannabis users among treatment clients. In particular, the available data show 
that countries with high or low last-month prevalence in the young adult population 
(15–34 years) have correspondingly high or low incidence of cannabis as a share of 
treatment demand. However, there are a few exceptions: in some countries, high levels 
of last-month cannabis prevalence in the young adult population contrast with low levels 
of treatment demand for cannabis and vice versa (Cyprus, Hungary, France, Portugal — 
see Table 1).
The reasons for discrepancies between use and treatment across countries are 
presumably historically rooted, in both the development of treatment centres and in 
attitudes to treatment, as well as prevalence and patterns of cannabis use. In cases 
where high levels of recent cannabis prevalence contrast with low proportions of 
treatment demand, this could imply that treatment availability for cannabis is insufficient 
or not appropriate. On the other hand, it could simply be because there is no perceived 
need for drug treatment. As shown elsewhere (Corrigan, Beck and Legleye, this 
monograph), it is uncertain to what extent cannabis use triggers a need for treatment. 
In other cases, where high demand for cannabis treatment contrasts with low recent 
cannabis prevalence, this might arise from more restrictive national legislation, or a 
widespread medical approach to dealing with cannabis problems.
Even if cannabis is the most used drug in Europe, only a minor part of the population 
uses it on a regular basis, and an even smaller proportion demands drug treatment 
(Agosti and Levin, 2004; Toxibase and Crips, 2004). One of the various observations 
that may be made from this is that demand for cannabis treatment does not always 
mirror, in a logical and straightforward way, the cannabis prevalence rates in the 
general population. Instead, it is clear that the extent of demand for cannabis treatment 
is a complex issue that is probably related to several factors which lie beyond variations 
in reporting coverage. Contenders for explaining this phenomenon include prevalence of 
intensive cannabis users in the general population, availability of treatment, patterns of 
referral to treatment and national legislation.
Trends in treatment incidence
Between 1999 and 2005, according to the TDI information from 20 countries, the 
number of new clients entering treatment for cannabis as a primary drug increased by 
28 000, from around 15 000 to almost 44 000 reported cases. In 1999 the proportion 
of new cannabis clients represented around 12 % of the total of the new clients, while 
in 2005 it reached almost 28 % (Figure 1). In 11 countries there was an increase in 
the proportion of cannabis clients, and in 11 countries a stable or slightly decreasing 
trend was noted. The highest growth was reported in Hungary (+ 40 %) and France 
(+ 37 %), followed by Slovakia, Germany, Malta, Denmark and The Netherlands (around 
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+ 20 %) while the smallest growth was found in Poland, Portugal, the Czech Republic 
and Romania (13). An analysis carried out in England on cannabis treatment demand 
confirmed this upward trend (DMRD, 2004).
Compared with other substances, primary cannabis treatment demands increased 
faster than demands for treatment of other drugs. In the same time period, new heroin 
clients decreased by 32 %, cocaine clients increased by 11 % and other stimulant users 
increased by 4 %. This reported increase in cannabis treatment demand is not restricted 
to Europe. In the USA, where a different drug treatment registration system is used (14), 
 (13) See table TDI-03 in the Statistical bulletin 2007.
 (14) In the USA, admissions to treatment rather than individuals are registered. In addition, in contrast 
to Europe, alcohol is included among the substances of abuse. See the SAMHSA website 
(www.samhsa.gov); note that in the USA, Canada and Australia the term ‘marijuana’ is used 
because the term ‘hashish’ (cannabis resin) is not common.
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treatment admissions for marijuana increased from around 20 000 in 1992 to nearly 
90 000 in 2000 (SAMHSA, 2003; EMCDDA, 2003b).
Looking at the factors that might have influenced the reported trends, changes are seen 
in the following areas:
reporting system and data coverage;t
drug services organisation;t
sources of referrals to treatment;t
socio-demographic characteristics; andt
patterns of drug use and, in particular, frequency of cannabis use.t
The coverage of the European reporting system has expanded in recent years, with an 
increase in number of units and clients recorded by the system. It is unclear to what 
extent this represents a genuine expansion in treatment offering, as opposed to simply 
the coverage of the treatment reporting system. It is also unclear how treatment offering 
and reporting coverage may have affected the increase in cannabis treatment demands. 
Nevertheless, this growth is not sufficient to explain the increase in cannabis treatment 
demands (EMCDDA, 2003b) (15).
The organisation of drug treatment services has changed in recent years. Because of 
the decrease in proportion of heroin clients, centres have adapted treatment offerings 
to embrace a differentiated client population that includes cocaine and cannabis users. 
This shift in targeted clients might have influenced demand for treatment. In particular, 
countries such as France — where a high proportion of cannabis users is found 
among all treated clients — have created treatment centres for target groups, such 
as adolescents, and these have reported a substantial proportion of cannabis clients 
(EMCDDA, 2003b). Overall, such centres might have added ‘weight’ to the share of 
cannabis users among all treatment clients.
Referral routes into treatment
It is important to identify the channels through which people enter treatment. A number 
of standard options are available in the TDI schedule for recording the source of referral 
for drug users entering treatment. These distinguish (i) drug users who have referred 
themselves and (ii) those who have been referred through other agencies such as health, 
social or criminal justice agencies. Most cannabis clients are referred by family and 
friends, social services or the criminal justice system. In comparison with users of other 
drugs, a smaller proportion of cannabis clients are self-referrals (EMCDDA, 2004). 
A similar picture is also seen in the USA and Canada, where treatment demand for 
 (15) See table TDI-02 in the Statistical bulletin 2007.
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marijuana as a primary substance is largely found not to be self-initiated (EMCDDA, 
2003b). In countries with significant percentages of primary cannabis clients, legal 
authorities and schools play an important role in referring cannabis clients (EMCDDA, 
2003a). In an American analysis of marijuana admissions to treatment based on source 
of referral (DASIS, 2005), marijuana admissions referred by criminal justice were 
also reported to have a different profile from non-criminal justice referrals: they were 
younger, with a higher presence of males, and often occasional users of cannabis with 
no other additional drugs.
Some understanding of the reasons for increases in treatment uptake may be found in 
analysing the changes in the sources of referral to treatment. Between 2001 and 2002, 
in those countries reporting data (16), the total number of cannabis clients referred 
to treatment services by hospital/medical sources and by legal authorities increased 
by 79 % and 58 % respectively, while the known base of clients increased by 37 %. 
By comparison, from 1992 to 2002 the USA also reported increases in marijuana 
admissions referred by the criminal justice system (EMCDDA, 2004).
One of the more problematic measures in the EMCDDA’s TDI is the frequency of use 
of the primary drug in the period immediately before entering treatment. Intended to 
give insight into, amongst other things, the severity of problem to be treated, in practice 
this measure can be strongly tied to the route of referral and how treatment entry 
comes about. Often this ‘frequency of use’ item records, strangely, no or little use of 
the primary drug in the period in question — a phenomenon that might be related to 
referrals from criminal justice, or from a health agency positioned earlier in a referral 
chain. As such, it is difficult to separate its interpretation from referral patterns. For 
example, among clients in treatment for a primary cannabis problem in 2005, 30 % 
of new cannabis clients use the drug occasionally or have not used in the month prior 
to treatment, while 40 % use it daily (17). There are again large differences between 
countries: the highest proportion of daily cannabis users is found in the Netherlands, 
Denmark and Spain, and the highest proportion of occasional users — including clients 
who may not have used in the past month — are found in Hungary, Germany and Italy. 
Compared with the other drugs, in the case of cannabis there is a higher polarisation of 
patterns of use between occasional users — including non-users — and daily users. The 
same patterns are also found in American analysis (NSDUH, 2004).
Among new cannabis users presenting to treatment between 2003 and 2005, the 
proportion of daily users increased by more than 10 % (18). A number of factors may 
be behind this increase, for example artefacts of reporting measures, polydrug use, 
 (16) The countries reporting in these years were Finland, Germany, Greece, Norway, Sweden and the 
United Kingdom.
 (17) See table TDI-18 in the Statistical bulletin 2007.
 (18) See table TDI-18 in the Statistical bulletin 2007.
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and mental health problems among cannabis clients. A number of countries report 
polydrug use where cannabis is reported as the primary substance, yet accompanied 
by the use of alcohol and other drugs. In these cases, it is not totally clear which 
drug precipitates treatment-seeking, even though cannabis might be declared as the 
primary problem. Some countries have examined a purported relationship between 
mental health problems and cannabis use, and specific research has been carried out 
to investigate this relation. The scientific literature indicates that it is not always clear 
whether problematic cannabis use comes before a mental health problem, contributing 
to its appearance or discovery, or whether cannabis is used as a kind of medication for 
pre-existing mental health problems (see Witton, this monograph). However, there is a 
group of people that regularly uses cannabis and seeks help for problems that may be 
related to their cannabis use. This should be seriously taken into consideration by the 
treatment system, and be better investigated by researchers.
Conclusions
The objective of this review has been to describe the observed increase in reported 
cannabis treatment demand, and to analyse the changing reporting environment to 
better understand the trend. In doing so, it has become apparent that many important 
questions that are fundamental to an informed policy debate on this controversial topic 
remain unanswered. What is also apparent is that the available evidence justifies neither 
an alarmist position nor complacency on cannabis treatment demand.
People with cannabis-related problems constitute a non-trivial proportion of treatment 
demands in specialised facilities in some countries, and form an important subgroup 
within the larger treatment population. Most are young males, typically around 20 years 
old, and most started using cannabis at around 17 years of age.
Cannabis clients have different patterns of drug use from those consuming other 
substances. Moreover, there are important differences between cannabis clients, and 
the profiles of different subgroups of cannabis users in treatment are likely to be directly 
relevant to understanding their needs and the provision of appropriate responses. 
Important dimensions for service provision include frequency of use, current and past 
use of other drugs, and referral source. In broad terms, summarising the available 
information at EU level, two client profiles can be postulated (EMCDDA, 2004):
at one extreme, younger users, often students, referred to treatment services by t
family or school, and consuming only cannabis or sometimes together with alcohol 
or stimulants; and
at the other extreme, polydrug users who are typically older and less socially well-t
integrated, and who are referred to treatment more often by legal authorities or 
health and social services, and who overlap with the chronic drug-using population.
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In reflecting on changes in the characteristics of primary cannabis treatment demand 
over time, the available information suggests that there were increases in:
numbers of clients referred from the criminal justice system;t
referrals from family and other social support networks (family, friends, social t
services, school);
the proportion of people using cannabis intensively (daily cannabis use), although t
daily users remain in the minority; and
levels of social and educational problems in some countries (although data in this t
area are still weak).
In considering the increase in treatment demand, it appears that changes in referral 
practice have an impact, and a substantial proportion of those referred appear not to 
be intensive drug users. Nonetheless, in some countries at least, a significant number 
of treatment demands come from individuals whose use of cannabis is intensive. The 
problems experienced by this group remain poorly understood, and research in this area 
is urgently needed. The observation that a majority of treatment demands made by the 
very young are for cannabis suggests that special consideration of the needs, referral 
pathways and responses of this group is required.
It is also important to recognise that treatment demand is not a direct indicator of the 
scale and nature of cannabis problems. General population survey data suggest that, 
compared with occasional use, intensive cannabis use is relatively uncommon. However, 
the widespread general use of cannabis means that considerable numbers of people 
may be using the drug intensively — at least for some part of their life (EMCDDA, 
2004).
Although the effects of cannabis dependence or abuse are less severe than those of 
other drugs, this may, nevertheless, have a considerable public health impact. This is 
because of the scale of cannabis use, and the fact that many of those most affected are 
young and may be using the drug intensively during important developmental stages, 
or when they are particularly vulnerable. Among socially disadvantaged families or 
communities, cannabis dependence or abuse may compound individuals’ problems by 
harming education or employment opportunities.
In summary, there remains a critical need for research to provide an understanding 
of the relationship between different patterns of cannabis use and the development of 
problems. The extent to which cannabis users experience problems and the nature of the 
problems that may be found still remain poorly understood. Methodological tools are 
required to assess problems at the population level. Such information is a prerequisite 
to the development, targeting and implementation of effective public health responses to 
cannabis use in Europe.
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Setting the context
Scientific literature on the treatment of cannabis-related disorders is scarce, particularly 
when compared with opioid treatment. While there have been some synthetic overviews 
(Hall et al., 2001; Steinberg et al., 2002; Loxley et al., 2004), analysis has generally 
been peripheral to wider works on cannabis or restricted to adolescents (e.g. SAMHSA’s 
Cannabis Youth Treatment series in the USA; Elliott et al., 2002; Liddle et al., 2002). 
Scarcity also seems to characterise research on the treatment of cannabis-related 
problems in the European Union. This could be explained by a common belief that 
cannabis problems are not a primary problem for people in drug treatment. Yet Europe, 
like the USA, is recording a trend in which cannabis is mentioned at an increasing rate 
in the context of treatment demand indicators (EMCDDA, 2004, 2006; UNODC, 2006). 
Another explanation is that cannabis does not produce the pharmacological dependence 
syndrome associated with alcohol, nicotine and opioid use. However, as the chapters by 
Witton and Hall in Volume 2 of this monograph indicate, somatic and mental problems 
related to cannabis use affect thousands of people.
Indications do, however, exist, which point towards new directions in regards to cannabis 
treatment. At the level of healthcare policy, domestic and international research, 
cannabis treatment has for some years been gaining a higher level of visibility and 
public funding. In July 2004, the European Council adopted a resolution on cannabis 
proposed by the Horizontal Working Party on Drugs, which called for the EMCDDA to 
continue to monitor ‘conditions for effective prevention and treatment, and examples of 
best practice’ and encourages Member States to ‘promote networking’. 
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In many ways, EU-wide monitoring into cannabis treatment has already benefited from 
scientific collaboration, both in terms of defining a ‘PCU’ (problematic cannabis user) 
and establishing standard treatment indicators. In June 2003, EMCDDA hosted expert 
meetings on the ‘Quality and coverage of TDI and analysis of cannabis client profiles’ 
(1) and ‘The profile of cannabis clients in different regions of the world’(2). In parallel, 
the EMCDDA commissioned a report on ‘Regular and intensive use of cannabis and 
related problems: conceptual framework and data analysis in the EU member states’ 
(Simon, 2004). The Centre also published a selected issue, titled ‘Cannabis problems in 
context: understanding the increase in European treatment demands’ in its 2004 Annual 
Report (EMCDDA, 2004).
Supranational networking is taking place on a number of levels, and is increasingly 
crossing the linguistic barriers which have at times acted as an obstacle to collaboration. 
Cannabis is increasingly mentioned in EMCDDA’s EDDRA  (3) database, including 
specialised cannabis treatment in Lund, Sweden (4), and Berlin, Germany (5). A 
supranational project focused on adolescent therapy, INCANT (International Cannabis 
Need of Treatment Study) has completed pilot phases at centres in Belgium, Germany, 
France, the Netherlands and Switzerland, with the main phase being run from 2006 to 
2009. Cannabis mental health issues and treatment options were covered in a 2006 
Beckley Foundation report (6). Meanwhile, recent forums for international research have 
included the annual HIT Perspectives on cannabis conference in the United Kingdom, 
Therapieladen’s Cannabis — Quo vadis (7) conference in 2005 in Germany, not to 
mention cannabis presentations within general drug treatment conferences, such as 
ICTAB (the International Conference on Treatment of Addictive Behaviors). In terms of 
best practice, Germany’s CaRED (8) project, managed from 2002 to 2004, represents a 
thorough analysis of cannabis treatment, albeit with a domestic focus, and in turn has 
helped stimulate innovative cannabis treatment provision studies, such as CANDIS (9).
 (1) www.emcdda.europa.eu/?nnodeid=1861
 (2) www.emcdda.europa.eu/?nnodeid=1881
 (3) www.emcdda.europa.eu/themes/best-practice
 (4) EDDRA link: 
www.emcdda.europa.eu/html.cfm/index52035EN.html?project_id=1293&tab=overview 
Home page: www.droginfo.com/
 (5) EDDRA link: 
www.emcdda.europa.eu/html.cfm/index52035EN.html?project_id=2915&tab=overview 
Home page: www.drogen-und-du.de
 (6) www.internationaldrugpolicy.net/reports/BeckleyFoundation_Report_08.pdf
 (7) www.therapieladen.de/
 (8) Simon, R., Sonntag, D. (2004), Cannabisbezogene störungen: umfang, behandlungsbedarf 
und behandlungsangebot [Cannabis-related disorders (CareD): prevalence, service needs 
and treatment provision], Bundesministerium für Gesundheit und soziale Sicherung, Munich 
www.bmg.bund.de/nn_604826/SharedDocs/Download/DE/Themenschwerpunkte/Drogen-
und-Sucht/Cannabis/cannabisbezogene-stoerungen,templateId=raw,property=publicationFile.
pdf/cannabisbezogene-stoerungen.pdf
 (9) www.candis-projekt.de/
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This chapter is based on a survey that answered the basic question: What type of 
treatment is available for cannabis use disorders in Europe today? While the results are 
not exhaustive, they help to inform the road ahead.
Further reading
Copeland, J. (2004), ‘Developments in the treatment of cannabis use disorder’, Current Opinion in 
Psychiatry 17(3): 161–167.
EMCDDA, Annual reports, published each year in November.
UNODC and EMCDDA (2006), Guidance for the measurement of drug treatment demand, UNODC and 
EMCDDA, Vienna and Lisbon.
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Cannabis treatment in Europe:  
a survey of services
Sharon Rödner Sznitman
Introduction
In response to an identified lack of data about cannabis treatment provision in Europe, 
the Centre for Social Research on Alcohol and Drugs (SoRAD), in cooperation with 
EMCDDA, conducted a survey on cannabis treatment provision in Europe in 2005. 
The study was designed to provide a base for a preliminary description of cannabis 
treatment in Europe, to examine the availability and nature of different specialist 
treatments for cannabis users, and to profile their clients’ characteristics.
Research method and sample design
The study was conducted in two phases. In phase I, key informants were contacted 
through the EMCDDA’s coordinating network of national focal points. This provided 
access to informants from the 25 Member States and Norway; Switzerland also 
participated. A questionnaire was emailed to these informants in which they were asked 
to provide contact information for key position holders in treatment centres which are 
likely to see cannabis cases. Informants for phase II were thus identified and these were 
contacted by email.
The criterion for including a key expert in the study was ‘any person who is a holder 
of a key position at any centre offering treatment for patients with cannabis use as the 
primary problem’. Respondents were asked to indicate whether their service treated 
cannabis as the primary drug problem but also included other drugs, or solely treated 
cannabis-related problems. The questionnaire asked for information regarding the 
particular treatment offered to the cannabis clients and for summary data on agency’s 
clients.
Problematic issues
Methodological limitations should be considered: since the survey was voluntary only 
some countries responded and they are not proportionately represented in the survey 
(e.g. Sweden returned eight questionnaires, Norway six, while some countries returned 
only one and others did not reply).
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Over 100 questionnaires were sent out in Phase II of the survey, yet only 45 were 
returned. The results of the survey should, thus, be read with caution. They cannot claim 
to be representative of cannabis treatment in Europe overall. In the questionnaires, 
cannabis cases were defined as people who receive treatment mainly due to their 
cannabis use. This definition does not include polydrug users who use cannabis as a 
secondary drug together with other substances (e.g. heroin). The total number of people 
using cannabis is, therefore, underestimated.
Important definitions
For the purposes of the survey a treatment programme for cannabis cases is defined 
as any treatment at the agency for persons who are receiving treatment primarily for 
problems related to their cannabis consumption. Cannabis cases are defined as persons 
who are enrolled at the agencies mainly for their cannabis consumption and do not 
include patients with, for instance, heroin problems who also use cannabis.
Results
Responses were received from 45 individuals representing 45 different treatment 
agencies, from 19 EU Member States, Norway and Switzerland. Member States which 
did not respond and are hence not included in the study are: Estonia, Spain, Ireland, 
Slovenia, Luxembourg and the Netherlands. The respondents hold a wide range 
of positions in their treatment centres, including therapists, coordinators, heads of 
treatment centres, social workers, psychologists and nurses.
Description of the treatment centres
The majority of the responding treatment centres deal with a range of drug-related 
problems, and most of the treatment centres were fairly large. Six centres saw under 
100 clients per year. Twenty-one centres saw between 100 and 500 patients per year, 
with the remainder treating over 500 patients per year. The majority, 72 % (31), of the 
centres treated all or many patients in outpatient ambulatory counselling settings. A 
total of 36 % of the centres treated all or some of their patients in long-term inpatient 
treatment. Short-term, inpatient treatment, treatment in a day clinic or in the community 
was less common.
Table 1 reports respondents’ rating of the importance of modalities provided by their 
service. Short-term psychosocial interventions, long-term psychosocial interventions and 
long-term rehabilitative drug therapy were seen as the most important. In addition, 
on-the-spot psychosocial crisis intervention was rated as a very important or important 
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Table 1: Key informant rating of the importance of the different tasks at the 
agencies
n 1: very 
important 
task, % (n)
2: important 
task, % (n)
3: relatively 
unimportant 
task, % (n)
4: no task 
at all/not on 
offer, % (n)
a On-the-spot psychosocial 
crisis intervention
(42) 24 (10) 38 (16) 31 (13) 7 (3)
b Short-term psychosocial 
interventions: short-term 
counselling
(43) 41 (18) 52 (23) 7 (3) 0
c Long-term psychosocial 
interventions: long-term 
counselling
(45) 49 (22) 45 (20) 5 (2) 2 (1)
d Long-term rehabilitative 
drug therapy: long-term 
psychotherapy 
(43) 40 (17) 42 (18) 7 (3) 12 (5)
e Medical intervention for 
somatic problems
(42) 12 (5) 26 (11) 29 (12) 33 (14)
f Detoxification (42) 24 (10) 26 (11) 21 (9) 29 (12)
g Harm reduction (e.g. 
syringe exchange, 
educating safer-use 
strategies, etc.)
(42) 31 (13) 17 (7) 24 (10) 29 (12)
h Methadone or 
buprenorphine 
substitution
(43) 30 (13) 19 (8) 9 (4) 42 (18)
i Heroin prescription (42) 2 (1) 0 0 98 (41)
j Naltrexone prescription (41) 5 (2) 11 (5) 17 (7) 66 (27)
task by many informants. Fewer identified detoxification, harm reduction, medical 
intervention for somatic problems, methadone or buprenorphine substitution, heroin and 
naltrexone prescription as very important or important tasks of their agencies.
Description of cannabis treatment
Although the recruitment strategy of the study attempted to ensure that questionnaires 
were sent to treatment agencies that include cannabis cases, four of the centres included 
in the study did not currently have any cannabis cases. Thus, the following results are 
based on only 41 treatment centres.
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It is evident from the survey results that cannabis cases for the most part represented 
a minority of the overall clientele in the agencies. In 63 % (25) of the centres cannabis 
cases represented 0–25 % of the entire patient case load. Some centres did, however, 
seem to exclusively treat cannabis cases. In six centres (15 %) — from Belgium, 
Denmark, Sweden, Cyprus and Germany — cannabis cases represented 75–100 % of 
the patient case load.
Out of all the treatment centres, nine (23 %) treated at least some of the cannabis cases 
in a programme within a unit not exclusively for cannabis cases. Fourteen centres (35 %) 
treated the cannabis cases as individual cases among drug users of all sorts. Thus, it 
is evident that a substantial proportion of the agencies do not have a specific cannabis 
treatment programme. It is, however, also evident that treatment programmes exist 
which have an exclusive focus on cannabis cases. Six of the centres (15 %) treated the 
cannabis cases in a unit exclusively for cannabis cases. Three of these were located in 
Sweden, and there was one such unit in each of Belgium, Germany and Italy.
Evidently, units exclusively for cannabis clients exist in Europe, but these must be 
regarded as a scarce phenomenon. This claim is further evidenced by the fact that only 
10 of the respondents knew of only one treatment unit exclusively for cannabis in their 
city while three respondents reported that there were two such units in their city. One 
respondent reported that there were none and 14 respondents did not know how many 
there were.
Treatment
Most of the treatment provided to cannabis cases lasts no longer than 20 sessions. 
Fifteen of the treatment centres treated cannabis cases on average in 1 to 10 treatment 
sessions. Fifteen centres treated the clients in 11 to 20 treatment sessions. Treatment 
over 20 sessions was rare. As such, current treatment seems to correspond well with the 
literature on evidence-based cannabis treatment. Although the literature is scarce, the 
few existing studies mainly indicate that the most useful treatment for cannabis users is 
brief intervention (Stephens et al., 2000; Babor et al., 2004).
The aims of cannabis treatment reported as very important by most of the agencies 
were abstinence (20 agencies, 50 %) and reduction of cannabis use (19 agencies, 48 %). 
Seven agencies (18 %) reported harm reduction (e.g. solving practical life problems 
and no attempt to change cannabis consumption) as a very important aim. Quite a few 
agencies (15), however, reported that harm reduction was an important, but not a very 
important, aim of the cannabis treatment.
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In terms of what type of treatment is offered to cannabis cases, there seems to be a 
wide range of interventions available. As Table 2 shows, the main treatments reported 
by most of the agencies were: individual counselling, talk therapy/counselling about 
cannabis, relapse and treatment, and talk therapy/counselling about conditions of life. 
Also a regular part of treatment in many agencies were detox (10) from cannabis, family 
therapy, therapeutic community (11) and mutual help groups.
 (10) Detox refers to the process of abstinence to clear cannabis from the body, accompanied by social 
and environmental support during the associated physiological and psychological changes.
 (11) Therapeutic community is a term applied to a participative, group-based approach to drug 
treatment that includes group psychotherapy and practical activities, and which may or may not 
be residential.
Table 2: Content breakdown of cannabis interventions, based on number of 
respondents reporting specific treatment types
n 1: main part of 
treatment, % (n)
2: regular part of 
treatment, % (n)
3: not a part of 
treatment, % (n)
a Detox from cannabis (41) 24 (10) 42 (17) 34 (14)
b Peer group counselling (40) 13 (5) 24 (11) 77 (24)
c Individual counselling (41) 78 (32) 22 (9) 0
d Family therapy/
counselling
(41) 22 (9) 71 (29) 7 (3)
e Milieu therapy/
therapeutic community
(37) 0 24 (9) 76 (28)
f Talk therapy/counselling 
about cannabis, relapse 
and treatment
(41) 73 (30) 24 (10) 2 (1)
g Talk therapy/counselling 
about conditions of life 
(relationship problems, 
aggression training, etc.)
(41) 63 (26) 37 (15) 0
h Practical help with 
daily life (to get social 
allowances, clothes, 
housing, education, job)
(40) 13 (5) 48 (19) 40 (16)
i In-patient treatment (39) 8 (3) 21 (8) 72 (28)
j Mutual help group (e.g. 
Narcotics Anonymous)
(41) 0 15 (6) 85 (35)
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Characteristics of cannabis cases
Gender
As in drug treatment in general, cannabis cases are predominantly male. Only one 
treatment agency reported having less than 50 % males. Four agencies reported only 
a slight male dominance (51–59 % of all cannabis cases). Nine agencies reported 
that 60–69 % were male, 13 agencies reported that 70–79 % were male, 10 agencies 
reported that 80–89 % were male and six agencies reported that 90–99 % were male.
Age
The majority of cannabis cases are fairly young. Sixteen agencies (39 %) reported that all 
or the majority of their cannabis cases were 20 years old or younger. Thirteen agencies 
(32 %) reported that all or the majority of their cannabis cases were between 21 and 30 
years old. Only four (8 %) of the agencies reported that the majority of their cannabis 
cases were over 30 years old.
Referral channels
Worries have been expressed concerning increasing demand for cannabis treatment 
evident in many parts of the EU. It has, however, been pointed out that the rise might 
not be due to an increase in cannabis problems or dependence in the population. 
Instead, the rise might, among other things, be due to policy changes, which in turn 
lead to more referrals to treatment by police and school systems. While this study is 
unable to measure any trends over time, it provides indications of which are the most 
common referral channels to treatment for cannabis cases (Table 3).
The most common source of referrals reported was the client’s family and friends. Many 
agencies also reported that self-referrals were most common. However, more agencies 
than not reported that cannabis clients do not enter treatment on their own initiative. 
Other referral sources were also reported; among them the most common were the 
criminal justice system, schools, psychiatrists, psychologists, social workers and general 
practitioners. It must, however, be noted that the separation between self-referrals and 
external referral channels is far from clear-cut. Research from Sweden, for instance, has 
shown that there is a large overlap between reporting self-motivation to treatment and 
reporting pressure from unofficial or official sources to enter treatment (Storbjörk, 2004).
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Table 3: Reported common referral channels for cannabis cases
n 1: most 
common, % (n)
2: common, % 
(n)
3: not at all 
common, % (n)
a Self-referrals (39) 31 (12) 33 (13) 36 (14)
b Client’s/patient’s family/
friends
(39) 38 (15) 53 (21) 8 (3)
c School (40) 8 (3) 40 (16) 52 (21)
d Work (38) 3 (1) 18 (7) 80 (31)
e General practitioner 
(family doctors)
(41) 12 (5) 32 (13) 56 (23)
f Psychiatrist/psychologist/
social worker (out-
patient or private 
practice)
(39) 8 (3) 67 (26) 26 (10)
g Courts, probation, 
parole, police
(39) 18 (7) 41 (16) 41 (16)
h Drug counselling agency 
or drug treatment units
(40) 5 (2) 24 (11) 68 (27)
Twenty-eight respondents reported that 50 % or more of the cannabis clients received 
treatment for their substance abuse for the first time in their life when they came into 
contact with the agency. In fact, as many as 12 respondents reported that 90 % or more 
of their cannabis cases received help for their substance abuse for the first time.
Lifestyles
Most cannabis cases in treatment had a socially well-integrated life before entering 
treatment. A large majority of the agencies reported that it was not at all common 
that the cannabis cases had been homeless or lived in a sheltered environment before 
entering treatment. The most common living conditions among the cannabis cases were 
living with parents or living alone.
A majority of the agencies reported that it was common that the cannabis cases had 
attended school or university or had been employed before entering treatment. There 
were, however, slightly more agencies that reported that it was common that cannabis 
cases were school drop-outs or unemployed prior to treatment.
In terms of mental well-being, less than a majority (30 %) (Table 4) of the respondents 
reported that it was common that cannabis cases had psychiatric problems (based on 
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Table 4: Reported situations for cannabis treatment before entry to treatment
n 1: most common, 
% (n)
2: common, % (n) 3: not at all 
common, % (n)
a Were homeless (41) 0 7 (3) 93 (38)
b Lived in a sheltered 
environment (e.g. 
home for psychiatric 
cases)
(41) 0 7 (3) 93 (38)
c Lived with their 
parent(s) or 
guardian(s)
(41) 46 (19) 46 (19) 7 (3)
d Lived alone (40) 30 (12) 48 (19) 23 (9)
e Lived with friends (40) 3 (1) 28 (11) 70 (28)
f Lived with their own 
family
(41) 10 (4) 49 (20) 42 (17)
g Went to school/
university
(41) 15 (6) 63 (26) 22 (9)
h Dropped out of 
school
(41) 7 (3) 73 (30) 20 (8)
i Worked (41) 7 (3) 61 (25) 32 (13)
j Were unemployed (41) 15 (6) 66 (27) 20 (8)
k Had psychiatric 
problems
(40) 23 (9) 30 (20) 28 (11)
l Had health problems (41) 5 (2) 29 (12) 66 (27)
m Had problems with 
the criminal justice 
system
(40) 23 (9) 65 (26) 13 (5)
n Had family problems (41) 42 (17) 59 (24) 0
o Had financial 
problems
(40) 15 (6) 58 (23) 28 (11)
an affirmative response ‘had psychiatric problems’ to the question ‘According to your 
experience, how common are the following situations for cannabis cases before they 
enter treatment at your agency?’). Many agencies, but less than the majority, also 
reported that it was common for cannabis cases to have problems with the criminal 
justice system prior to treatment entry. Family problems were rated as common for 
cannabis clients by slightly more than half of the respondents. Lastly, most agencies 
(66 %, see Table 4) reported that it was not at all common that the cannabis clients had 
health problems (12).
 (12) The questionnaire is annexed to this chapter.
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Cannabis use and polydrug use
The study shows that cannabis cases for the most part have been using cannabis for 
more than 5 years before entering treatment. Fifteen respondents (37 %) reported that 
all or the majority of the cannabis cases had been using for 5 years or more before 
entering treatment. Nevertheless, cannabis use for less than 5 years was also reported. 
Two respondents reported that the majority of their cannabis cases had used cannabis 
for less than a year and seven respondents (22 %) reported that half of their cannabis 
cases had used cannabis for this period.
In this study the respondents were asked to report on cannabis cases, meaning people 
in their agencies who received treatment mainly for their cannabis consumption. This 
does, however, not exclude the possibility that the cannabis cases also use other drugs. 
Indeed, as shown in the epidemiological section of this issue, polydrug use is far from 
the exception in regards to cannabis consumption (Table 5).
In terms of substance use other than cannabis, the majority of the respondents reported 
that heavy use of cigarettes (more than 20 per day) occurred very often among their 
cannabis cases. Heavy use of alcohol was reported very often by slightly fewer agencies. 
Only one respondent reported that heavy use of cigarettes never occurred, and no 
agency reported that heavy use of alcohol never occurred among their clients.
All other substances were reported as less often used. Cocaine, for instance, was 
reported as very often used by only two of the agencies. This substance was, however, 
reported as sometimes used by the majority of the agencies. Nine agencies also 
reported that cocaine was never used by the cannabis clients.
Table 5: Reported level of other substance use than cannabis among the 
cannabis cases
n 1: very often 
used, % (n)
2: sometimes 
used, % (n)
3: never used, 
% (n)
a Heavy use of alcohol (38) 45 (18) 55 (20) 0
b Heavy use of cigarettes 
(more than 20 cigarettes 
per day)
(40) 63 (25) 35 (14) 3 (1)
c Cocaine (40) 5 (2) 73 (29) 23 (9)
d Amphetamines (40) 20 (8) 68 (27) 13 (5)
e Ecstasy/hallucinogens (40) 15 (6) 80 (32) 5 (2)
f Heroin (40) 8 (3) 50 (20) 43 (17)
g More than three different 
substances
(39) 8 (3) 64 (25) 28 (11)
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Use of amphetamines, hallucinogens and ecstasy were also more often reported as 
sometimes used than very often used. A majority reported that amphetamines were 
sometimes used by the cannabis clients and almost all the agencies reported that 
hallucinogens and ecstasy were sometimes used by the cannabis clients. Also important 
to note is that five agencies reported that amphetamines were never used, and two 
agencies reported that hallucinogens and ecstasy were never used by the cannabis 
cases.
Heroin use seems to be less prevalent among the cannabis cases, but still a substantial 
part of cannabis users seems to use heroin sometimes. Half of the respondents reported 
that the substance was sometimes used by cannabis clients. Nevertheless, also a 
substantial amount reported that heroin was never used by the cannabis clients.
Evidently, cannabis users in treatment tend to be polydrug users, although 11 informants 
indicated that three or more different substances were never used at the same time.
General trends in cannabis cases
According to the informants’ evaluation, there has not been a decrease in cannabis 
cases in the agencies. Twenty-nine respondents (67 %) reported that there had been an 
increase the last 5 years, and 14 respondents (33 %) reported that there had been a 
stable number of cannabis cases in their agencies.
Thirty respondents (67 %) reported that there had been policy changes in their country 
towards cannabis use during the previous 5 years. These changes were overall reported 
as an increasing treatment emphasis and less emphasis on punitive approaches to 
cannabis users. Eighteen respondents reported that there had been more emphasis 
on treatment for cannabis users. Sixteen respondents reported there had been more 
attention to cannabis in treatment agencies, while 14 respondents reported that there 
had been emphasis on less punitive approaches. The policy changes do not, however, 
seem to follow a clear-cut unidirectional trend across Europe. Nine of the respondents 
described the policy changes in terms of more emphasis on punitive approaches 
(including respondents from Belgium, the Czech Republic, Denmark, France, Latvia, 
Austria, Poland and Switzerland).
Summary and conclusion
In this report, various themes in connection with cannabis treatment and cases in Europe 
have been discussed. Based on a small sample of treatment centres, this study is only 
meant to provide a few indicators concerning the current state of cannabis treatment 
in Europe, and the material is not suited for generalisations or comprehensive in-depth 
analysis.
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Overall, it seems that specialised cannabis treatment is a rare phenomenon in Europe 
today. Of the 41 centres which had cannabis cases, 23 had no programme exclusively 
for them. Thus, it can be concluded that many cannabis cases across Europe are treated 
within the same setting as persons with other drug problems. This may be regarded as 
problematic, especially in view of the above findings which indicate that cannabis cases 
are relatively young. Research shows that much drug treatment is built for the adult 
population and does not thereby fit younger ages, and supporting material is often 
based on adult patterns of substance use (regular alcohol use, heroin, cocaine) rather 
than adolescent patterns (primary use of cannabis and alcohol bingeing). It is also 
based on adult experiences (parenting, health problems and adult dialogue examples) 
rather than adolescent experiences (peer pressure and adolescent dialogue examples) 
(Dennis et al., 2002a,b). Another problem which may arise when cannabis cases are 
placed in the same setting as other drug users is stigmatisation and exclusion (Sloboda, 
1999).
While most people who use cannabis do not end up in treatment, there are those who 
do. Furthermore, it is evident that the demand for cannabis treatment is increasing. This 
may be due to any number of reasons: increased availability of treatment; an increased 
pressure to seek treatment; increased cannabis-related problems in the general 
population. Indeed, for the people who do end up in treatment it is not totally evident 
whether or not they actually have a cannabis problem. People might enter treatment due 
to pressures from friends, family or the criminal justice system. These complex issues 
are addressed in more detail by Simon (this monograph) but are also shortly touched 
upon in this study as the above findings indicate that there are many different referral 
channels of cannabis cases. Although there may be many cannabis cases that require 
treatment after awareness of personal cannabis problems, self-referral is not necessarily 
easily interpreted as such, as a person might seek treatment by himself after receiving 
demands from family, friends or the criminal justice system to do so.
Furthermore, it cannot be disregarded that increased cannabis treatment demand is 
an artefact of reporting measures. From this study, it is evident that polydrug use is 
common among cannabis cases, which is important in terms of how cannabis cases are 
registered. Indeed, since cannabis users also use other drugs, it cannot be discounted 
that the cannabis cases may have a complex substance use problem not derived solely 
from one substance. Many might be registered as cannabis cases, based on the criteria 
that cannabis is the drug used most frequently and most heavily. This criterion does, 
however, not exclude the possibility that they also receive or should receive treatment for 
other drug use.
According to the above results, cannabis treatment in Europe focuses on counselling 
about conditions in life in addition to counselling about cannabis use and relapse. 
Furthermore, a substantial proportion of the agencies reported that family therapy was 
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an important part of the treatment offered. In view of the heterogeneous make-up of 
cannabis cases, a variety of treatment offers is probably a useful approach, particularly 
as cannabis cases may have problems which are not directly related to cannabis use. 
Nevertheless, the effect of type of treatment offered should not be overemphasised. 
Indeed, as Bergmark (this monograph) highlights, there is no conclusive evidence for 
any specific treatment intervention for cannabis cases.
There are indications, on the other hand, that anything works, that the context of 
treatment and the individual’s choice to enter treatment is important to treatment 
outcome. A summary of cannabis treatment studies by the Beckley Foundation notes 
that the effectiveness of cannabis treatment is not yet clear, but that there is growing 
evidence that it may fulfil a useful role (Hunt et al., 2006). The report further remarks 
that there is evidence which notes that there may be reason to move towards individual 
and targeted treatment through focusing on ‘high risk’ groups and even genetic 
screening. Indeed, it is a seductive idea that screening and targeting individuals may 
create cannabis treatment effectiveness. In light of the above result, and in light of the 
scarce available information, it does, however, seem that individualised solutions is 
a simplistic way forward that overlooks the complicated horizon related to cannabis 
treatment indicators, embedded in societal disapproval, in criminalisation of cannabis 
use, polydrug use and the highly heterogeneous make-up of the relevant clientele. In 
sum, this report, together with other evidence, suggests that our current understanding 
of and available cannabis treatment is scarce and a much more in-depth understanding 
of the relevant issues is needed.
Acknowledgement
Special thanks to the national focal points who facilitated contact information, and the 
respondents.
Bibliography
Action plan on cannabis research 2003–2006 — Résumé issued 9 December 2003.
Babor, T. F. and the Marijuana Treatment Project Research Group (2004), ‘Brief treatments for 
cannabis dependence: findings from a randomized multisite trial’, Journal of Consulting and 
Clinical Psychology 72(3): 455–466.
Cannabis 2002 Report, Ministry of Public Health of Belgium, Brussels.
Copeland, J. (2004), ‘Developments in the treatment of cannabis use disorder’, Current Opinion in 
Psychiatry 17(3): 161–168 
www.medscape.com/viewarticle473553
Council Resolution on Cannabis. Issued in Brussels, Belgium, 7 July 2004. Cordrogue 59. Reference 
number 11267/04.
Denis, C., Lavie, E., Fatsias, M., Auriacombe, M. (2005), ‘Psychosocial interventions for cannabis 
abuse or dependence in outpatients settings’, in Cochrane Cannabis Protocol.
Cannabis treatment in Europe: a survey of services
294
Dennis, M. L., Babor, T. F., Roebuck, C. M., Donaldson, J. (2002a), ‘Changing the focus: the case for 
recognising and treating cannabis use disorders’, Addiction 97(Suppl. 1): 4–15.
Dennis, M. L., Titus, J. C., Diamond, G., Donaldson, J., Godley, S. H., Tims, F. M., Webb, C., 
Kaminer, Y., Babor, T., Roebuck, M. C., Godley, M. D., Hamilton, N., Liddle, H., Scott, C., ‘The 
CYT Steering Committee (2002b), The Cannabis Youth Treatment (CYT) experience: rationale, 
study design and analysis plans’, Addiction 97(Suppl. 1): 16–34.
EDDRA projects available at http://eddra.emcdda.eu.int/
Elliott, L., Orr, L., Watson, L., Jackson, A. (2002), Drug treatment services for young people: a 
systematic review of effectiveness and the legal framework, Effective Interventions Unit, Substance 
Misuse Division, Scottish Executive, Edinburgh.
EMCDDA, Annual report 1999, 2002, 2004 and 2006.
EMCDDA (2004), Annual report: selected issues, European Monitoring Centre for Drugs and Drug 
Addiction, Lisbon.
EU Drugs Action Plan (2000–2004).
EU Drugs Action Plan (2005–2008).
Fran, M. T., Dennis, M. L., Hamilton, N., Buchan, B. J., Diamond, G., Funk, R., Brantely, L. B. (1997), 
‘Characteristics and problems of 600 adolescents cannabis abusers in outpatient treatment’, 
Addiction 97(Suppl. 1): 46–57.
Hall, W., Degenhardt, L., Lynskey, M. (2001), The health and psychological effects of cannabis — 2nd 
edition, Monograph No. 44, Australian National Drug Strategy, Canberra.
Hunt, N., Lenton, S., Witton, J. (2006), Cannabis and mental health: responses to the emerging 
evidence, Drug Policy Programme, Report 8, The Beckley Foundation, Oxford.
Liddle, H., Rowe, C., Quille, T., Dakof, G., Sakran, E., Biaggi, H. (2002), ‘Transporting a research-
developed adolescent drug abuse treatment into practice’, Journal of Substance Abuse Treatment, 
Special Edition on Transferring Research to Practice (ed. Simpson, D.), 22: 231–243.
Loxley W., Toumbouro, J., Stockwell, T., Haines, B., Scott, K., Godfrey, C., Waters, E., Patton, G., 
Fordham, R., Gray, D., Marshall, J., Saggers, S., Williams, J. (2004), The prevention of substance 
use, risk and harm in Australia: a review of the evidence. Australian Government Department of 
Health and Ageing, Canberra.
McRae, A. L., Budney, A. J., Brady, K. T. (2003), ‘Treatment of marijuana dependence: a review of 
the literature’, Journal of Substance Abuse Treatment 24(4): 369–376.
Newcomb, M. D. (1995), ‘Identifying high-risk youth: prevalence and patterns of adolescent drug 
abuse’ in Rahdert, E. R., Czechowicz, D. (eds), Adolescents drug abuse: clinical assessment and 
therapeutic interventions, NIH Publication 95-3908, NIDA Research Monograph 156, National 
Institute on Drug Abuse, Bethesda, Maryland, 7–38.
Simon, R., Sonntag, Bühringer, D., Kraus, L. (2004a), Cannabisbezogenene StÖrungen: Umfang, 
Behandlungsbedarf und Behandlungsangebot in Deutschland [Cannabis related disorders 
(CaRED): prevalence, treatment needs and provisions services in Germany], Die Drogenbeauftragte 
der Bundesregierung, Munchen.
Simon, R. (2004), ‘Regular and intensive use of cannabis and related problems: conceptual 
framework and data analysis in the EU Member States’, European Monitoring Centre for Drugs 
and Drug Addiction 
www.emcdda.europa.eu/index.cfm?fuseaction=public.AttachmentDownload&nNodeID=6443&s
languageISO=EN
Sloboda, Z. (1999), ‘Problems for the future? Drug use among vulnerable groups of young people’, 
Drugs: Education, Prevention and Policy 6(2): 195–201.
Steinberg, K., Roffman, R., Carroll, K., Kabela, E., Kadden, R., Miller, M., Duresky, D. (2002), The 
Marijuana Treatment Project Research Group, ‘Tailoring cannabis dependence treatment for a 
diverse population’, Addiction 97(1): 135.
Chapter 14
295
Stephens, R., Roffman, R., Curtin, L. (2000), ‘Comparison of extended versus brief treatment for 
cannabis use’, Journal of Consulting and Clinical Psychology 68(5): 598–908.
Storbjörk, J. (2004), Why do alcohol and drug abusers enter treatment? The interplay between 
pressures from others and self-choice. Presented at the annual meeting of the Kettil Bruun Society, 
Helsinki, June.
UNODC (2006), World drugs report, United Nations Office on Drugs and Crime, Vienna.
Cannabis treatment in Europe: a survey of services
296
Questionnaire
Section A: Information on the agency and key-informant
In this section we would like to ask you some questions about your agency, and yourself 
and your position in the agency.
 A1 Please give your agency’s name and address.
 A2 Please give your position in the agency.
 A3 What is your profession?
a Nurse
b Social worker/youth worker
c Clinical psychologist
d Psychiatrist
e Other medical doctor
f Other (please specify):                           
Section B: Information on the treatment programmes
In this section we would like to get information on the structure and the type of treatment 
agency you are working in.
 B1 How many patients/clients does your agency treat? You can answer this in whichever 
way you have the data:
a Number of ‘active’ patients/clients (currently in a treatment episode)
b Number of patients/clients seen in a week
c Number of patients/clients seen in a 12-month period
 B2 How many of the patients/clients at your agency do you treat in one of the following 
settings? Please tick off for each setting.
1: All 2: Many 
but not 
all
3: 
Approximately 
half 
4: A few 5: None
a In the field (e.g. street work, 
prison work)
b Ambulatory (e.g. outpatient, 
ambulatory counselling)
c Day clinic (at least 3 hours per 
visit)
d Short-term inpatient (b 1 month)
e Long-term inpatient (> 1 month)
f Other (please specify)
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B3 Please specify the importance of the different tasks at your agency. Please tick off for 
each task.
1: Very 
important 
task
2: Important 
task
3: Relatively 
unimportant 
task
4: No task 
at all/not on 
offer
a On-the-spot psychosocial 
crisis intervention
b Short-term psychosocial 
interventions: short-term 
counselling
c Long-term psychosocial 
interventions: long-term 
counselling
d Long-term rehabilitative 
drug therapy: long-term 
psychotherapy 
e Medical intervention for 
somatic problems
f Detoxification
g Harm reduction (e.g. syringe 
exchange, educating safer-use 
strategies, etc.)
h Methadone or buprenorphine 
substitution
i Heroin prescription
j Naltrexone prescription
k Other (please specify)           
Section C: Information on cannabis treatment
In this section we would like to get information on treatment programmes for cannabis 
cases at your treatment centre. A treatment programme for cannabis cases is defined 
as any treatment at your agency directed towards persons who are receiving treatment 
first of all for their cannabis consumption. By cannabis cases we mean persons who are 
enrolled at your agency mainly for their cannabis consumption. Hence, we do not want 
you to include patients with, for instance, heroin abuse problems who also use cannabis.
 C1a At your treatment centre, are there currently any cannabis cases?
Yes
No
C1b If no, please jump to section E of the questionnaire. If yes, please proceed to the next 
question.
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C2 Approximately what proportion of the patient case load at your agency are cannabis 
cases?
a 0–10 %
b 11–25 %
c 26–50 %
d 51–75 %
e 76–100 %
C3 In which setting(s) are cannabis cases at your agency treated? More than one option 
is possible.
a In a unit/service exclusively for cannabis cases
b In a programme within a unit not exclusively for cannabis cases
c As individual cases among drug users of all sorts
d Other (please specify) ______________
C4 What is the average number of treatment sessions that cannabis cases at your 
treatment centre attend in the course of a treatment episode?
________sessions per client/patient
C5 What are the aims for treatment of cannabis cases at your agency? Please tick off one 
box for each aim.
1: very 
important aim
2: important 
aim
3: relatively 
unimportant aim
4: no 
aim at all
a Abstinence
b Reduction of cannabis 
use
c Harm reduction or 
solving practical life 
problems (no attempt 
to change cannabis 
consumption)
d Other (please specify)  
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C6 To what extent does the treatment centre emphasise the following interventions for 
cannabis cases? Please tick off for each intervention.
1: Main part of 
treatment
2: Regular part of 
treatment
3: Not a part of 
treatment
a Detox from cannabis
b Peer group counselling
c Individual counselling
d Family therapy/counselling
e Milieu therapy/therapeutic 
community
f Talk therapy/counselling about 
cannabis, relapse and treatment
g Talk therapy/counselling about 
conditions of life (relationship 
problems, aggression training, 
etc.)
h Practical help with daily life (to 
get social allowances, clothes, 
housing, education, job)
i In-patient treatment
j Mutual help group (e.g. Narcotics 
Anonymous)
k Other (please specify)  
        
Section D: Information on the ‘typical’ cannabis case
In this section we wish to obtain information about how your typical cannabis cases can 
be characterised.
D1 What is typically the percentage of males among cannabis cases at your agency?
Male: ______ %
D2 According to your experience, how many cannabis cases are receiving help for their 
substance use for the first time in their life when they come in contact with your 
agency?
_________ % of cannabis cases treated in our agency.
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D3 How many of the cannabis cases at your agency…
1: All 2: Majority 3: Half 4: Minority 5: None
a Are 20 years old or 
younger?
b Are between 21 and 30 
years old?
c Are 31 years old or 
older?
d Have been using 
cannabis for less than a 
year?
e Have been using 
cannabis for 5 years or 
longer?
D4 Typically, how common is it that the cannabis cases are referred from the following 
sources? Please tick off for each source.
1: Most common 2: Common 3: Not at all 
common
a Self-referral
b Client’s/patient’s family/friend
c School
d Work
e General practitioner (family doctor)
f Psychiatrist/psychologist/social 
worker (out-patient or private 
practice)
g Courts, probation, parole, police
h Drug counselling agency or drug 
treatment unit
i Other (please specify)  
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D5 According to your experience, how common are the following situations for cannabis 
cases before they enter treatment at your agency? Please tick off for each situation.
1: Most 
common
2: Common 3: Not at all 
common
a Were homeless
b Lived in a sheltered environment (e.g. 
home for psychiatric cases)
c Lived with their parent(s) or guardian(s)
d Lived alone
e Lived with friends
f Lived with their own family
g Went to school/university
h Dropped out of school
i Worked
j Were unemployed
k Had psychiatric problems
l Had health problems
m Had problems with the criminal justice 
system
n Had family problems
o Had financial problems
D6 Apart from cannabis, what are the most often used substances by cannabis cases? 
Please tick off for each substance.
1: Very often 
used
2: Sometimes 
used
3: Never used
a Heavy use of alcohol
b Heavy use of cigarettes  
(more than 20 cigarettes per day)
c Cocaine
d Amphetamines
e Ecstasy/hallucinogens
f Heroin
g More than three different substances
h Other substances
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Section E: Information on general cannabis-related trends
In this section we would like to obtain more general information related to cannabis 
than the above sections.
E1a According to your knowledge, how many units exclusively for cannabis cases are 
there in your city?
  (enter number)
E1b Please guess how many cannabis cases they treat altogether at one time.
   per week
I cannot even guess
E2 Please provide contact information for one or two other centres in your country that 
treat cannabis cases.
E3 Please evaluate the trend over the last 5 years. In regard to your agency, has there 
been:
a An increase in numbers of cannabis cases
b Stable numbers of cannabis cases
c A decrease in numbers of cannabis cases
E4a Please evaluate the trend over the last 5 years. In your country, has there been any 
policy change towards cannabis use?
Yes
No
E4b If yes, which of the following options best describe the change? More than one option 
is possible.
a More emphasis on treatment for cannabis users
b Less emphasis on treatment for cannabis users
c More emphasis on punitive approaches towards cannabis users
d Less emphasis on punitive approaches towards cannabis users
e More attention to cannabis in treatment agencies
f Less attention to cannabis in treatment agencies
E5 In your opinion, which alterations or developments would be desirable for a better 
treatment of your cannabis cases?
E6 We would be grateful for any further comments or observations. If you have any 
please indicate them below.
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Setting the context
In Europe around 65 000 treatment demands were reported in 2005 where cannabis 
was cited as the primary reason for entering treatment (1). Cannabis use is the primary 
reason for entering drug treatment in about 20 % of all cases and 29 % of new treatment 
demands, making it the next most commonly reported drug in European treatment 
centres, after heroin. There are interesting variations between countries, with cannabis 
being cited by less than 5 % of all clients reported as entering treatment in Bulgaria, 
Lithuania, Poland and Romania and by more than 30 % in Hungary and France. For 
the remaining countries, in 12 European countries, the proportion of cannabis clients is 
between 5 and 20 % and in seven it is between 21 and 29 % (EMCDDA, 2007).
What has fuelled anxiety among policymakers is not that treatment demands are 
unmanageable. A figure of 65 000 treatment demands is a relatively small proportion 
of current cannabis users (13.4 million last month cannabis users in Europe), amounting 
to less than one in every 200 last month cannabis users. Moreover, the risk of entering 
treatment would seem to increase as cannabis use becomes more intensive. Cannabis 
clients in treatment in Europe can be divided into three groups: those who use it 
occasionally (34 %), those using it once to several times a week (27 %) and those using 
it daily (39 %). On a more general level, the 65 000 cannabis treatment demands may 
be compared with the 130 000 treatment demands for opioid use, from an estimated 
population of 1.3–1.7 million problem drug users in Europe: a demand rate of 
approximately 1 in 10. Additionally, given the resource-intensive treatment required by 
opioid clients, as opposed to the outpatient/short intervention norm for cannabis (see 
Rödner Sznitman, this monograph), it is clear that drug treatment should reflect the 
proportional risks of different licit and illicit substances.
 (1) Source: EMCDDA Statistical Bulletin 2007. Data available from 21 countries.
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That said, a worrying trend is that, between 1999 and 2005, the total numbers of 
both new and all reported cannabis treatment demands in Europe have approximately 
trebled. And while the most recent data suggest that this trend may be stabilising in 
some countries, the fact remains that an increasing number of cannabis clients are 
entering drug treatment services. While cannabis-specific treatment options are available 
in Europe today, many drug treatment services have been developed to target ‘problem 
drug users’; that is, those injecting opioids or reporting long-term dependence with 
amphetamines, crack and cocaine. The surge in demand for cannabis treatment thus 
implies a need to develop or adapt existing services towards cannabis client profiles (see 
Montanari, Griffiths and Taylor, this monograph).
The rise in treatment demands is not easy to explain on a European level. Nonetheless, 
some countries have sought to examine, and re-examine, the nature of cannabis 
treatment demand in more detail. One of these countries is Germany. This chapter 
suggests that the reported 500 % increase in cannabis treatment demand between 1992 
and 2003 in Germany reflects a genuine increase in clinically diagnosable cases of 
cannabis use disorders. Alternative hypotheses to explain a rise in treatment demand 
— which might have included changing drug policy priorities, misdiagnosis, ‘coercion’ 
into treatment via referrals, new reporting mechanisms and data collection — were not 
considered significant. The chapter also reveals the type of problems experienced by 
those in treatment for cannabis problems in Germany.
Such a far-reaching ‘revisit’ of treatment demand data is useful for building a clearer 
picture of treatment populations, for validating results, for challenging assumptions and 
for checking the quality of data. One cause for optimism is that such ‘deep’, secondary 
analyses of treatment demand are increasingly common across Europe, enabling higher 
responsiveness to changing drug consumption patterns, both for cannabis and other 
drugs.
Further reading
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http://en.eelda.org/index.aspx?o=1028
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systematic review of effectiveness and the legal framework, Effective Interventions Unit, Scottish 
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cannabis-related disorders 
increased in Germany?
Roland Simon and Ludwig Kraus
Summary
First indications in Germany suggested an increase in treatment demand for primary 
cannabis-related problems. These led the German National Addiction Aid Statistics 
(DSHS) and a research study (CARED) to analyse treatment demands. The results showed 
an increase of roughly 500 % in treatment admissions in outpatient treatment for this 
group in Germany between 1992 and 2003. Three-quarters of these cases fulfilled the 
clinical criteria of a cannabis-related disorder as defined by ICD-10 (F12.1, F12.2x). The 
remaining cases did not reach this level of clinical significance, but might indicate minor 
cannabis-related problems. Where multiple diagnoses exist, no indication was found 
that cannabis was assigned as primary drug incorrectly. As the increase in treatment 
admissions was similar for most types of referrals, changes in treatment admissions 
were very likely not caused by changing treatment availability or external pressure but 
by a genuine increase in treatment need. While last year prevalence of cannabis use 
increased considerably in the population between 1992 and 2003, treatment admissions 
in outpatient centres grew even faster, and it will be necessary to adapt the treatment 
system in Germany to this increasing group of clients.
Introduction
While for decades cannabis use has not been perceived as a problem by many 
addiction therapists and researchers, recent results from basic research as well as from 
clinical and social epidemiology support a more cautious position, which assumes a 
higher risk potential of cannabis, at least for some subgroups of users (Hall and Solowij, 
1997; INSERM 2001; Witton, this monograph, vol. 2). Hall, Degenhardt and Teesson 
(2004), for example, reported that while there is no support for the hypothesis that 
cannabis causes psychotic disorders, there is evidence that cannabis use can precipitate 
schizophrenia and that cannabis use exacerbates psychoses. Patton et al. (2002) found 
a fourfold increase in the risk of depression and anxiety disorders among girls using 
cannabis on a daily basis.
First indications that outpatient treatment demands for primary cannabis-related 
problems might increase were reported by the German National Addiction Aid Statistics 
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(DSHS) in 2000 (Welsch, 2001). An increase in treatment demand could reflect the 
parallel rise in treatment need resulting from an increase in cannabis use as reported 
by population surveys (Kraus, Augustin and Orth, 2005). It is well known that drug 
treatment in Germany primarily focuses on injecting heroin users. Changes in treatment 
needs for cannabis-related problems would, therefore, require modifications in the type 
and organisation of treatment services provided. Increases in treatment demands within 
this group would also have implications for cannabis policy.
A number of possible factors that may have influenced treatment statistics were analysed 
to validate the assumption of a genuine and not artificial increase in treatment demand 
for cannabis-related disorders in outpatient care. The data analysed were derived from 
the DSHS, results from a recent epidemiological survey (Kraus and Augustin, 2005) and 
from a study on cannabis-related disorders (CARED), conducted between 2001 and 
2004 (Simon et al., 2004). Artificial effects might have arisen from invalid diagnoses 
assigned by therapists in their daily work. As most of the staff have social work or 
psychology as a professional background, but no medical training, incorrect diagnoses 
might be assigned to clients. Other external factors might have explained the increase 
in treatment demand, such as increases in availability or accessibility of treatment, or 
increased judicial referrals into treatment. The main questions to be addressed were:
Had there been an increase in treatment demand for primary cannabis-related t
problems?
Were diagnoses for cannabis-related problems valid?t
Were there other external or confounding factors that could have caused the t
observed increase?
How was the increase in treatment demand related to drug use trends in the t
population?
Methodology
German Addiction Aid Statistics (DSHS)
In Germany, national monitoring of drug treatment is based on the German core item 
set (Kerndatensatz, referred to below as ‘KDS’). Within the ‘client and treatment’ module, 
the complete set of items from the EMCDDA’s treatment demand indicator (TDI) protocol 
are used (EMCDDA, 2000). Drug use is assessed on the basis of ICD-10 criteria (WHO, 
1994). Under the KDS, diagnoses can be made for each psychoactive substance 
(ICD-10, F10–F18), provided the criteria of harmful use or dependence syndrome are 
fulfilled. In case of multiple diagnoses the diagnosis related to the drug that causes the 
most severe problems (‘primary drug’) is selected as the ‘main diagnosis’. The choice 
of diagnosis must be based on the intensity and frequency of use of the drug as well as 
on its negative consequences. Full operationalisation of such classifications, however, is 
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not part of the KDS standards. In addition, for the classification of clients the code F19.x 
(multiple drug use) was generally avoided in the German monitoring system when the 
study took place.
Aggregate data from the treatment centres are collected on an annual basis and were 
reported by the German Addiction Aid Statistics (DSHS) for the years 2001 to 2003 
(Welsch, 2002; Welsch and Sonntag, 2003, 2004), while EBIS statistics were reported for 
the years before 1999 (e.g. Türk and Welsch, 2000). Analysis started in 1992 because 
changes in classification of disorders and substances were introduced in that year. In 
addition, data from the new Länder (2) of the former German Democratic Republic were 
included in the common statistics from 1992 onwards, making comparisons with data 
from earlier years impossible.
The CARED study
The study on cannabis-related disorders (CARED) was conducted in a random sample of 
52 outpatient treatment centres participating in the DSHS. All of them used a common 
technical system for data collection (EBIS). All clients (n = 223), who had been treated 
in these centres during the year 2001 and who fulfilled the criteria of a ‘cannabis 
client’ (referred to below as ‘CC’), were included in a paper-based retrospective survey. 
Inclusion criteria were:
 1 A diagnosis of ‘harmful use’ or ‘dependence syndrome’ related to cannabis (ICD-10, 
F12.1 or F12.2) provided by the DSHS
 2 Cannabis being the only or the primary drug (‘main diagnosis’).
A second group (n = 51) of ‘cannabis clients’ (CCs), who had been in treatment between 
December 2002 and October 2003 in the same units, was assessed during treatment 
using a computer-based clinical interview. Diagnoses were based on ICD-10 and 
DSM-IV as assessed by DIA-X (Wittchen and Pfister, 1997). The participation rate in the 
first group was 40 %. For the second group a rate could not be calculated as the total 
number of cannabis clients in treatment during this time period had not been reported 
by the treatment facilities. As part of the CARED study, therapists (n = 183) from the 
participating centres were also asked in a questionnaire about details of the process of 
assigning diagnoses and their experience with cannabis clients.
 (2) Germany is divided into 16 federal states, or Bundesländer. The six Länder of the former East 
Germany that joined in 1990 are Berlin, Brandenburg, Mecklenburg-Vorpommern, Sachsen, 
Sachsen-Anhalt and Thüringen.
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Results
Increase in treatment admissions
The absolute number of clients starting outpatient treatment with a primary cannabis-
related problem (CCs) was examined for the years 1992–2003, as well as the 
proportion of this group among the total group of clients. In 2003, 699 treatment 
centres reported main diagnoses for 106 816 clients to the national treatment 
monitoring system (DSHS), of whom 10 169 or 9.5 % were diagnosed as CCs. This 
group comes third behind alcohol (59.6 %) and opiates (19.8 %). The absolute number 
of CCs increased over this 12-year period and the proportion within the treated clients 
reached 9.5 %, starting at only 2.1 % in 1992 (Table 1).
Participation in the DSHS being voluntary, the number of reporting facilities varied over 
time, ranging from 170 in 1992 to 699 in 2003. In order to make absolute numbers 
of cases comparable between reporting years, the number of clients reported was 
extrapolated to the total number of 1 049 outpatient treatment centres in Germany as 
reported for 2001 (Bundesministerium für Gesundheit, 2002) (3).
The estimated total numbers of admissions for all outpatient treatment centres in 
Germany show an increase in CCs of nearly 600 % between 1992 (n = 2 561) and 2003 
(n = 15 261). A breakdown by gender, which was possible for the years 1999–2003, 
indicates similar developments for male and female clients. The proportion of women 
among CCs increased slightly from 16.8 % in 1999 to 18 % in 2003 (Figure 1). Thus, 
between 1992 and 2003 a clear increase in total treatment admissions was found in 
Germany for clients with a primary cannabis-related problem.
 (3) Two limitations need to be mentioned with regard to the calculations. The total number of 
facilities only includes units which are financially supported by the Länder, which results in an 
underestimation of total demand for Germany as a whole. The majority of units in Germany, 
however, are funded by the Länder (Welsch and Sonntag, 2004) and, thus, the resulting total 
should not be significantly below the real number of CCs. In the same way, using the number of 
units for 2001 as an estimated total, as opposed to the annual figures, might cause errors. Exact 
data were available only for the years 1996–2003. Inspection of this period shows no major 
trend in number of reporting units and, apart from the year 2002, the totals range between 951 
and 1 049 units. No general legal or financial changes took place during this period that might 
have changed the number of treatment units. Given all these facts, the number of facilities in 
2001 may serve as a proxy for this calculation.
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Validity of diagnoses
Diagnosis according to ICD-10
The validity of the observed trend in treatment admissions strongly depends on the 
quality of diagnoses based on the DSHS. This system requires an ICD-10-based 
classification of substance-related disorders. As part of the CARED study the diagnoses 
assigned by the treatment centres’ staff were validated by comparing them to diagnoses 
reassessed by standard instruments (CIDI, DIA-X). For this purpose, questionnaires 
(n = 223) and clinical computerised interviews (n = 51) were conducted and diagnoses 
assigned in compliance with the ICD-10 criteria.
In validation studies the results of a diagnostic instrument (test) are generally compared 
with an observed outcome (e.g. disease). Presented in a two-by-two table, results can 
be assessed for (i) correct classifications, that is, cases that were correctly identified to 
have or not to have the disease, and (ii) incorrect classifications, that is, cases that were 
incorrectly classified by the test instrument as having the disease (false positives) and 
those cases that were incorrectly classified as not having the disease (false negatives). 
In this validation, the test instrument was defined as the ‘gold standard’ (i.e. for 
ascertaining the presence or absence of cannabis-related disorders) and the diagnoses 
selected by the treatment centres as the instrument to be validated. Since the monitoring 
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'JHVSF Admissions of clients with primary cannabis-related problems in German 
outpatient treatment centres, 1992 to 2003
Source: EBIS reports 1994–2001 (Türk and Welsch, 2000); German Addiction Aid Statistics (Welsch, 
2001, 2002; Welsch and Sonntag, 2003, 2004).
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Table 2: Diagnoses in standard monitoring of treatment centres compared to 
diagnoses based on questionnaires or clinical interviews (ICD-10)
No diagnoses  
(%)
Harmful use ICD-10 
(%)
Dependence ICD-10 
(%)
Validation diagnoses based on
 Questionnaire 
(n = 136)
14.1 17.0 69.6
 Interview (n = 39) 25.6 15.4 59.0
Source: Simon et al. (2004).
system only reports positive cases of CCs, the resulting validation is incomplete: only 
those cases can be observed that were correctly or incorrectly (false positives) classified 
by therapists as having the disease (cannabis-related disorder). Self-evidently, the cases 
that were correctly or incorrectly (false negatives) classified by the therapists as not 
having a cannabis-related disorder were not observable.
Table 2 shows the results of the validation analysis. Overall, 25.6 % of the clients were 
classified as not having a diagnosis of either harmful use or dependence if assessed by 
interview. Looking at the results from the opposite direction, 74.4 % of the cases were 
found to fulfil criteria of a clinical diagnosis.
Compared with the original diagnoses of dependence, where 62.5 % of the diagnoses 
were consistent, assessments were less in accordance with ICD-10 criteria if the client 
had received the diagnosis ‘harmful use’ (14.3 %). Clients with an original diagnosis of 
‘harmful use’ received more frequently a diagnosis of ‘dependence’ than a diagnosis of 
‘harmful use’ (42.9 %). Overall, distinguishing between ‘dependence’ and ‘harmful use’ 
in standard diagnostics is much less reliable than the general decision, whether CCs 
meet clinical criteria or not. On the whole, this might partly be a result of problems with 
the two-dimensional concept of ‘abuse’ or ‘harmful use’ and ‘dependence’ (Fulkerson et 
al., 1999).
For more than 74 % of the CCs, validation showed that clinical criteria with respect to 
cannabis were fulfilled, and either ‘harmful use’ (F12.1) or ‘dependence syndrome’ 
(F12.2x) was the resulting diagnosis. Up to one-quarter of the CCs reported by 
outpatient treatment centres might have cannabis-related problems that are below 
clinical relevance. Discriminating between ‘harmful use’ and ‘dependence’, however, 
does not work well in practice, a problem that can be attributed, at least to some 
degree, to the intrinsic weakness of the concepts themselves.
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Table 3: Multiple diagnoses amongst cannabis clients (tobacco-related 
diagnoses excluded)
Questionnaire based  
(n = 184)
Interview based  
(n = 33)
Substance-related diagnoses % %
Cannabis only 33.7 63.6
+ alcohol 15.2 21.2
+ amphetamines/ecstasy 12.0 6.1
+ cocaine 3.8 0.0
+ alcohol + amphetamines/ecstasy 7.6 6.1
+ alcohol + cocaine 2.2 3.0
+ alcohol + amphetamines/ecstasy + cocaine 8.2 0.0
Other combinations 17.4 0.0
Source: Simon et al. (2004).
Main diagnosis and other psychoactive substances
CCs classified with a cannabis-related diagnosis need not only fulfil ICD-10 criteria. 
Cannabis should also be the main substance in cases where other substance-related 
diagnoses are present, and the possibility that cannabis is used as a ‘label’ for clients 
with other problems should be ruled out. In order to examine this question, the 
validation analysed the prevalence of other substance-related diagnoses in the group of 
CCs, and the criteria used to determine the main diagnosis.
This analysis of multiple diagnoses of primary cannabis clients revealed that no other 
substance-related disorders were found in almost two-thirds of the clients. A combination 
of cannabis- and alcohol-related disorders was found in 21.2 % of clients. While in most 
cases alcohol was involved, disorders related to stimulants without alcohol problems 
accounted for roughly 16 % of multiple diagnoses (Table 3).
Therapists reported that the decision about the main diagnosis was based on the 
consequences (65.7 %), patterns (59.3 %) and frequency of cannabis use (41.3 %). This is 
in line with the criteria that are also defined in the KDS for this classification. As no exact 
algorithm has been defined by the standards, validation cannot go beyond this basic 
check.
A considerable number of CCs (nearly two out of three) showed an exclusive cannabis-
related diagnosis. The substance which plays the most important role after cannabis 
in the group of CCs is alcohol. It is not very likely that a cannabis-related diagnosis 
is used to hide alcohol problems. In the diagnostic process, therapists apply criteria 
as defined by ICD-10 and the national KDS. Thus, the classification of cannabis as a 
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main substance seems to be based on empirical evidence and appropriate procedures. 
While single cases of misclassifications may be possible, CCs may not be judged as 
mislabelled in relation to other psychoactive substances.
Main diagnosis and other mental disorders
The same type of misclassification as discussed for substance-related diagnoses could 
also take place in relation to non substance-related mental disorders. In such cases, the 
main problem of the clients in treatment might for example be psychosis, while cannabis 
problems might be only marginal. In order to analyse this question, prevalence of such 
diagnoses amongst CCs, as well as the correlation between disorders and the severity of 
cannabis-related disorders was analysed. Data are sourced from the clinical interviews 
of the CARED study which assessed a number of mental disorders (last 12 months) 
which are well known to be correlated with cannabis consumption (Hall and Solowij, 
1997).
For CCs a number of such disorders was found. Close to 40 % showed mood disorders, 
most often dysthymia (17.3 %). More than one-third of the clients showed phobic 
disorders, and one out of eight showed anxiety disorders. There was a high rate of 
social phobia (17.3 %) and nearly 11 % of the clients suffered from psychotic disorders. 
Diagnoses F06.X were exclusively based on organic factors, including acute effects of 
drugs (Wittchen and Pfister, 1997). The majority of psychotic disorders and about one-
third of the anxiety disorders and affective disorders were, therefore, more closely linked 
to drug use and may have been only of a short-term nature (Table 4).
Besides psychotic disorders, all diagnoses showed a high correlation with the severity of 
the cannabis diagnosis. Only a few cases of ‘phobia’ and ‘mood disorder’ were found 
where a cannabis-related diagnosis could not be validated. For these cases the basic 
problem might not be a cannabis-related disorder but another psychiatric problem 
(Table 5).
There is considerable prevalence of other psychiatric disorders amongst clients, which 
reflects a close relationship between cannabis use and psychiatric comorbidity found 
elsewhere (Hall and Solowij, 1997). As the majority of cases are linked to a validated 
classification of ‘cannabis dependence’, no misclassification arises from this, but rather 
these cases show additional problems which need to be taken into account and treated 
for this group of clients.
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Table 4: Other mental disorders according to DSM-IV (clinical interview, n = 51)
Group of disorders DSM-IV 
code
Diagnoses %
Psychotic disorders 10.9
F06.0 Psychotic disorder with hallucination 4.3
F06.2 Psychotic disorders with delusion 7.8
F23 Short psychotic disorders 2.2
Mood disorders/depression 39.1
F06.32 Affective disorders with characteristics of 
depression
10.9
F32.x MDD, single episode 4.4
F33.x MDD, multiple episodes 13.0
F34.1 Dysthymia 17.3
Anxiety disorders 15.2
F06.4 Anxiety disorder 4.3
F06.42 Panic attacks 10.9
F41.0 Panic attacks without agoraphobia 2.2
F41.1 Generalised anxiety disorder 0.0
Phobia 37.0
F40.0 Agoraphobia without panic attacks 10.9
F40.01 Panic disorders with agoraphobia 13.0
F40.1 Social phobia 17.3
F40.21 Animal phobia 6.5
F40.22 Environmental phobia 6.5
F40.23 Blood phobia 6.5
F40.24 Specific phobia 4.3
Source: Simon et al., 2004.
Table 5: Groups of other mental disorders (DSM-IV) and cannabis diagnosis 
(ICD-10) (clinical interview, n = 46)
Cannabis-related diagnoses
Disorders (DSM-IV) Total (%) None (%) Harmful use (%) Dependence (%)
Psychotic disorders 10.9 16.7 14.8
Mood disorders 39.1 7.7 33.3 55.6
Anxiety disorders 15.2 25.9
Phobia 37.0 23.1 51.9
Source: Simon et al. (2004).
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Other factors
Two external factors were discussed, which might have influenced the increase in CCs: 
one relates to a general increase in treatment admissions, the other to changes in 
referral procedures.
Overall increases in treatment admissions
Possible explanations for the increase in cannabis-related treatment admissions could 
be an overall improvement in (i) treatment availability; (ii) accessibility; or (iii) quality 
of services provided. For the years under inspection no general changes in drug policy, 
treatment standards or funding conditions could be observed in Germany, which may 
have increased the availability of or accessibility to treatment for drug users. So, the 
increase in cannabis-related treatment admissions cannot be attributed to these external 
factors.
This position is supported by data on treatment admissions for other substance-
related disorders involving other drugs. A general positive shift in treatment quality 
or availability would most likely have increased the number of clients for all different 
substances alike. However, as shown in Figure 2, relative to the year 1992, the number 
of cannabis clients in 2003 increased sixfold, the number of clients with stimulants-
related problems more than fourfold, while the number of clients with alcohol- and 
opioid-related problems — the main focus of treatment services up to that time — only 
showed a slight increase.
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This clear increase found for CCs clearly exceeds the general trend for total treatment 
admissions and exceeds all other substances besides ecstasy. Apart from the fact that 
the absolute numbers of ecstasy-related disorders are still small, ecstasy was frequently 
miscoded by the treatment centres under ‘other substances’, which might have inflated 
the rates artificially. This means that there is no indication of a general increase in 
treatment availability. Staff measured in full-time staff member equivalents between 
1996 and 2003 only increased by 1.2 %, which also makes it clear that treatment 
availability did not change dramatically during the reporting period.
Changes in referral procedures
An increase in treatment admissions might also be the consequence of changes 
in referral procedures. If, for example, the Narcotic Drugs Act was enforced more 
rigorously than before, treatment admissions would rise without any changes taking 
place in the underlying medical or psychological treatment needs in the population. In 
order to examine this type of effect, data on treatment referrals from the years 1998 to 
2003 were examined.
In 2003 more than 70 % of all clients entered treatment through three main pathways: 
20 % were ‘internally motivated’ (self-motivated) and came directly to the treatment 
facilities; 25 % were motivated by family or friends and 27 % were referred through 
judicial or police authorities. While compared with 1998 the total number of cannabis 
clients in 2003 increased by 118 %, the number of clients who came directly into 
treatment increased by 96 %, referrals through justice or police by 109 %. The biggest 
increase was due to referrals through other counselling services (Table 6).
Table 6: Access to outpatient treatment for cannabis clients
Compared with 1998 (= 100 %)
Referrals into treatment 2000 2001 2002 2003 Referrals in 
2003 (%)
No referrals/direct access 129 141 161 196 21.5
Relatives/friends 141 153 178 195 24.5
Job/school 118 151 175 214 6.4
GP/psychotherapist 127 158 195 195 3.4
Hospital 158 182 240 236 1.7
Inpatient addiction facility 141 86 166 244 1.9
Drug counselling 149 137 239 338 1.5
Other counselling services 296 412 514 514 8.8
Justice/social administration 105 114 196 209 26.3
Others 161 207 275 286 4.1
Sources: EBIS reports 1994–2001 (Türk and Welsch, 2000); German Addiction Aid Statistics (Welsch, 2001, 2002; 
Welsch and Sonntag, 2003, 2004).
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The hypothesis that the increase in treatment admissions of CCs was caused to a large 
extent by increasing pressure from law enforcement and social administration is not 
supported by these data. Instead, treatment admissions have increased more or less at 
the same extent for a number of types of referring institutions. The biggest increase was 
found for referrals by other counselling services, which might indicate better networking 
that facilitated access to drug treatment for cannabis users though these channels.
Trends in treatment demand and prevalence of cannabis 
use in the population
Survey data indicate that the observed increase in treatment admissions for cannabis-
related disorders was accompanied by a constant increase in the prevalence of 
cannabis use in the general population. Between 1992 (15 %) and 2003 (33 %), lifetime 
prevalence of cannabis use was found to have significantly increased by a factor of two. 
In the same time, last year prevalence (4 % in 1992, 12 % in 2003) increased by a factor 
of three (Kraus, Augustin and Orth, 2005).
Population estimates of recent users (last 12 months) aged 18–29 years derived from 
cross-sectional surveys in 1990/92, 1995/97, 2000 and 2003 were compared with the 
estimated number of cannabis clients for the respective years. Survey data for 1990 
were taken as proxy for 1992. The number of recent cannabis users increased from 
935 000 in 1992 up to 2 105 000 in 2003. In the same period the number of clients 
treated for cannabis-related problems within a 1-year reporting period (admissions plus 
takeover from the year before) increased from 4 353 to 25 485 cases. The ratio of recent 
users in contact with outpatient treatment did not remain constant but increased at a 
disproportional rate. While, in 1992, 4.7 clients per 1 000 recent users were admitted 
for treatment, in 2003 12.1 users had entered treatment (Table 7).
Another way of comparing trends of recent cannabis use and treatment admissions 
is shown in Figure 2. Normalising the numbers of cannabis users and treatment 
Table 7: Estimated number of annual cannabis users and clients
1992 1995 2000 2003
Cannabis users (12-month 
prevalence, 18–29 years)a
935 000b 1 590 000 1 918 000 2 105 000
Cannabis clientsc 4 353 5 246 16 112 25 485
Number of clients per 1 000 users 4.7 3.3 8.4 12.1
aSource: Kraus, Augustin and Orth, 2005.
b1990 survey.
cSource: EBIS reports 1994–2001 (Türk and Welsch, 2000); German Addiction Aid Statistics (Welsch, 2001, 2002; 
Welsch and Sonntag, 2003, 2004).
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admissions for the year 1992 to an index value of 100, the changes for the consecutive 
years can be presented as percentages relative to the year 1992. While treatment 
admissions increased by 500 %, the prevalence of recent use increased by only 190 % 
(Figure 3).
Both analyses show that the number of clients with primary cannabis-related problems 
in treatment (CCs) grew faster than the prevalence of recent cannabis use in the 
population. A direct comparison, however, is too simple a model, since a delay of 8 
years on average between start of use and entering treatment needs to be considered 
(Strobl et al., 2007).
Conclusions
A clear increase in treatment admissions for primary cannabis-related disorders in 
outpatient treatment was found in Germany between 1992 and 2003. The number 
of cases increased roughly by 500 %. Three-quarters of persons with cannabis-related 
diagnoses in the treatment statistics were diagnosed appropriately as cannabis-related 
disorders fulfilling clinical criteria. The remaining cases may have had cannabis-related 
problems, but did not reach the level of clinical significance. In cases where multiple 
diagnoses exist, information on the diagnostic process as well as prevalence of such 
diagnoses showed no indication that cannabis was assigned as main drug incorrectly. 
For logical reasons there is also no reason to call into question cannabis as main 
diagnosis for the majority of cases.
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Other factors which might have influenced treatment admissions have not been analysed 
here. In particular, a change in the perception of risks linked to cannabis might have 
increased cannabis users’ willingness to enrol in treatment. This, and other, hypotheses 
might be evaluated by future research. While in Germany and other countries cannabis-
related problems were historically seen as minor and of limited relevance for public 
health, public debate in recent years has begun to take this topic more seriously. It will 
be necessary to find a new balance for a treatment system that was tailored in the past 
mainly to serve the needs of injecting users of heroin. In this respect, the outcome of the 
CARED study is in line with the results of a city-based evaluation of treatment services in 
Hamburg (FOGS, 2006) as well as a regional study on treatment provision in Munich 
(Perkonigg et al., 2004). Given the high and partly still rising prevalence of cannabis 
use in many European countries, this might become a problem for other countries as 
well (EMCDDA, 2005, 2007).
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Chapter 16
Risk factors for cannabis use
Keywords: cannabis – prevention – protective factors – risk factors – sociology
Setting the context
Lists of risk factors and protective factors are common features in the prevention and 
treatment literature on cannabis and other illicit drugs. Both groups of factors could 
relate to an individual’s genetic make-up and personality, or to their familial, social and 
physical environment. It is beneficial to understand the range of factors that have been 
identified for cannabis. Moreover, it is not always easy to judge which factors carry more 
weight for cannabis, or to exclude factors that may not be relevant to a specific group of 
users’ context. The diagram below (Figure 1), adapted from a UK Home Office report, 
offers a simplified overview of risk and protective factors.
This chapter explores the risk factors associated with cannabis use. In doing so, a 
distinction is drawn between cannabis use per se and the development of problematic 
cannabis use. The chapter reveals that many factors are linked with problematic 
cannabis use, including genetic vulnerability to certain psychological conditions, early 
use of tobacco and alcohol, dysfunctional family relationships, behavioural problems, 
peer associations, family substance use and early initiation.
Further reading
UK Home Office (2007), Identifying and exploring young people’s experiences of risk, protective 
factors and resilience to drug use, Home Office Development and Practice Report, Stationery 
Office, London.
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Risk factors for cannabis use
Niall Coggans
Introduction
Much effort has gone into researching the factors that increase the likelihood of using 
drugs (risk factors) and the factors that decrease the likelihood (protective factors) (e.g. 
Hawkins et al., 1992; Lloyd, 1998; Rhodes et al., 2003). The factors that influence 
individuals and groups to use cannabis are numerous and operate at all levels, from the 
individual to the social. Greater awareness of these various factors should lead to more 
effective and more precisely targeted educational and health promotion interventions. 
The purpose of this chapter is to highlight the risk factors for cannabis use.
There are two issues in relation to the title of this chapter, risk factors for cannabis use, 
that require clarification: (i) what is a risk factor and (ii) in what way or to what extent is 
cannabis use a problem? First, the nature of risk factors. The term risk factor is widely 
used in public health to identify and describe individual or social predictors of disease or 
undesirable conditions/behaviour. Of particular interest from a public health perspective 
are those factors which it is possible to reduce through prevention interventions. This 
is also true for drug-related health problems, including cannabis-related problems. 
However, do risk factors cause drug use and/or drug-related problems, or are risk 
factors predictive in that they are statistically associated with the behaviour in question?
A cause of a drug-related problem is something that exists prior to the drug-related 
problem (the effect) and the occurrence of a prior event or state of affairs would ensure, 
or increase the likelihood, of the drug-related problem happening. An association, on 
the other hand, is where there is a relationship between a drug-related problem and 
some other event or state of affairs. The key distinction between cause and association 
is that an association does not imply causation. It may be that there is a causal 
relationship between two associated phenomena or that the association is due to a 
third factor. Where an association between a risk factor and a drug-related problem 
has been found, a number of issues need to be investigated to assess the relationship 
for causality, including consistency with other studies, plausibility, temporal sequence, 
dose–response and strength of association (Campbell and Machin, 1999).
Taken individually, risk factors are unlikely to be causal in a direct ‘if A then B’ manner. 
Moreover, individual risk factors for drug use are unlikely to be either necessary or 
sufficient for the emergence of drug use and/or drug-related problems. Many of the 
risk factors for drug problems are mediated through individual development and social 
interaction. Problematic drug use is therefore the result of a complex of different risk 
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factors which cumulatively increase the likelihood of drug use and/or problems. In other 
words, risk factors do not cause, but are associated with problematic cannabis use.
Second, to what extent is cannabis use a problem? In this discussion of risk factors 
related to cannabis use a distinction is made between experimental or recreational use 
of cannabis and cannabis use that is problematic. Problematic cannabis use is usually 
defined in terms of diagnosed cannabis dependence or substance use disorders using 
standard diagnostic criteria (for more detail see Beck and Legleye, this monograph), and 
often includes people in treatment programmes for their cannabis-related problems. 
Experimental or recreational cannabis use, on the other hand, is often understood as 
use which is not bound up in adverse social, mental or physical health effects for the 
user (Coggans et al., 2004).
The extent to which drug use is actually or potentially harmful to individuals will depend 
on the nature and purity of the drug concerned, mode of ingestion, and the pattern of 
its use by the individual. Cannabis use will not necessarily continue once started, as 
many will stop after a period of recreational use. For example, in a longitudinal study 
of a sample of German cannabis users, half stopped of their own accord in their 20s 
(von Sydow et al., 2001). Moreover, the majority of young people who smoke cannabis 
do not experience cannabis-related problems (see Witton, this monograph, vol. 2). It 
could be argued that the term ‘risk factor’ is inappropriate in relation to this apparently 
non-problematic form of cannabis use. While it might devalue the concept of risk factors 
by referring to risk factors in relation to behaviour that is seen as undesirable by some 
people, rather than behaviour with clearly manifested problems, there remains the need 
to recognise that those who do develop cannabis-related problems will emerge from the 
wider population of cannabis users. From a prevention perspective, there is, therefore, a 
need to work with existing cannabis users who may not have developed cannabis-related 
problems in order to reduce the likelihood of their doing so. It is important to distinguish 
between predictive factors related to cannabis use that is non-problematic and factors 
that predict cannabis-related problems.
Those who use cannabis heavily and for a substantial period of their lives are 
considerably fewer than those who have ever used cannabis (House of Lords Select 
Committee on Science and Technology, 1998). While those who do use cannabis heavily 
over long periods of time in adulthood may develop cannabis-related problems, such as 
dependence, it is not the case that such use will necessarily be perceived as problematic 
by the users concerned (Coggans et al., 2004). Although it is a truism that there is no 
such thing as a safe drug, occasional ‘light’ use of cannabis will carry little risk for large 
numbers of people. Nonetheless, some people do experience problems with cannabis. 
Moreover, there is also concern over the potential for cannabis use among young 
people to compromise healthy development.
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This chapter is not intended to be an exhaustive review of the field, but to provide 
an overview of the nature and scope of the risk factors that predispose people to 
problematic cannabis use, including routes to cannabis use, early initiation, social 
environment (family and peers), psychological risk factors, and the growing evidence of 
genetic risk factors. When reviewing the relevant literature, however, a problem arises, 
as much research on risk factors shows little concern for distinguishing harmful drug 
use from drug use in its own right. Moreover, it is argued here that there is a need 
for a coherent view of the difference between risky or non-risky cannabis use, or what 
constitutes problematic or non-problematic cannabis use. Thus, this chapter includes 
risk factors for different types of cannabis use, and this is a limitation to which more 
attention should be paid in future research.
The term ‘problematic cannabis use’ is employed here to mean cannabis use that gives 
rise to psychological, physiological or behavioural problems. It is not meant here to 
reflect only specific diagnostic criteria such as ICD-10 or DSM-IV. Nor is the term used 
here to reflect frequency and intensity of use beyond arbitrary cut-off points. Here, 
problematic cannabis use refers to cannabis use which results in health problems with 
substantive impacts on the individual’s functioning. Potential problems include, for 
example, early school leaving (Lynskey et al., 2003a), mental health (Henquet et al., 
2004), depression (Bovasso, 2001), dependence (Swift et al., 1998), impairment of 
memory and attention (Solowij et al., 2002), and respiratory functioning (Taylor et al., 
2000).
Routes to cannabis use and cannabis dependence
Cannabis is often described as a ‘gateway’ drug to the use of other, more harmful 
drugs such as heroin and cocaine. While there is considerable debate over the nature of 
this gateway effect, if any (e.g. Morral et al., 2002), there are discernible associations 
between early use of tobacco, alcohol and cannabis.
Patterns of drug use progression
Kandel’s stage theory of drug use — that substance use initiation and progression, 
in those cases where progression occurs, follows predictable stages — has informed 
prevention efforts (Kandel and Faust, 1975; Kandel et al., 1992). However, such 
predictable progression, and with it the possibility of preventive interventions, may not 
be the case for those more at risk of developing problematic patterns of drug use. 
Contrary to the Kandel model, in some cases those at risk of developing problematic 
drug use are more likely to have used cannabis before using alcohol and more likely 
to have used other illicit drugs before using cannabis (Mackesy-Amiti et al., 1997). The 
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point here is that the typical pattern of progression described by Kandel and others may 
relate more to those for whom progression to problematic use is less likely. Moreover, 
routes into drug use may not be as one-way as per Kandel’s stage theory. For example, 
there is evidence that cannabis can lead to nicotine dependence (Patton et al., 2005; 
Amos et al., 2004).
The nature of the relationships between use of alcohol, tobacco and cannabis is the 
subject of ongoing debate. The Kandel stage model can be interpreted as implying 
a sequence of causal relationships, such that use of a prior substance is (somehow) 
causally related to the next substance in the sequence. More plausibly, the model is 
more of a description than an explanation of stages of drug use, with no implication 
of causality intended in its original formulation. What is less in doubt is that there are 
correlations between the use of cannabis and drug use progression (e.g. Blaze-Temple 
and Lo, 1992; Fergusson and Horwood, 2000; Lynskey et al., 2003b), and between the 
use of alcohol, tobacco and cannabis in adolescent populations (see also Monshouwer, 
Smit and Verdurmen, this monograph). Nonetheless, Lynskey et al. (2003b) noted that 
while there were associations between cannabis use and progression to other drugs and 
drug dependence, it was not possible to draw strong causal inferences about the role of 
cannabis.
What might explain these associations between cannabis use and use of other drugs? 
Lynskey et al. (1998) reported that the correlations between alcohol, tobacco and 
cannabis use could be explained by a general ‘vulnerability to substance use’ factor, 
based on connections with delinquent or substance-user peers, novelty seeking and 
parents’ drug use. More recently, Morral et al. (2002) concluded that users of any drug 
have a greater inclination to use other drugs and argued that this general propensity 
theory could adequately explain apparent gateway effects.
Alcohol and tobacco
In addition to correlations between use of cannabis and more harmful drugs, there are 
also associations between adolescent alcohol and tobacco use, on the one hand, and 
cannabis use on the other. In a sample of 11- to 16-year-olds, illicit drug use (primarily 
cannabis for the majority of regular users of drugs) and cigarette smoking were related 
to alcohol use. Those who had been drunk more often were more likely to smoke 
cigarettes and to use other drugs (Sutherland and Willner, 1998). The associations 
between number of episodes of drunkenness and either cigarette use or other drug use 
were not age dependent. Of those who had been drunk less often, from one to five 
times, 13 % reported other drug use, while of those who had been drunk more than 20 
times 58 % reported other drug use. Adolescents who drank more than three times in the 
previous week and who drank five or more units of alcohol were more likely to begin 
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cannabis use (Coffey et al., 2000). But another study found that there was no statistically 
significant relationship between drinking in adolescence and cannabis dependence in 
early adulthood, after possible confounding factors had been taken into account (Wells 
et al., 2004).
Adolescents who smoke tobacco are at greater risk of developing cannabis 
dependence by their mid-20s (Lewinsohn et al., 1999; Coffey et al., 2000). A recent 
longitudinal study in which data were gathered from participants at 11 years and 
20 years of age reported that ‘persistent’ tobacco smokers were more likely to use 
cannabis and to develop dependence on cannabis, as well as to use other drugs and 
develop dependence on other drugs (Vega and Gil, 2005). Coffey et al. (2000) also 
demonstrated that tobacco smoking and not alcohol was a risk factor for the transition 
from experimental cannabis use to a more established cannabis habit, with greater 
degree of tobacco smoking being predictive of subsequent greater cannabis use.
A fundamental issue with cannabis, alcohol and tobacco is whether the gateway 
theory is anything other than an artefact of patterns of typical drug use initiation and 
progression. It has been argued that the overriding trend in drug use over time is for 
young people to reduce their illicit drug use and that problematic drug use is best 
predicted by family, social and psychological deficits (Peele and Brodsky, 1997).
In many ways the numerous studies of drug initiation and progression provide 
descriptions of routes to drug use. For the more fundamental issue of explanation 
there is a need to consider the individual and social context in which these routes are 
recorded.
Age of initiation
Social, childhood and behavioural problems are associated with early onset of cannabis 
use, which in turn can lead to later association with substance users and educational 
disengagement. In turn, these latter risk factors can lead to development of a range 
of psychosocial risk factors that increase the likelihood of substance-related problems 
(Fergusson and Horwood, 1997). Comparison of recent-cannabis-onset adolescents 
and adults found that those who start to use cannabis in adolescence are more likely to 
develop cannabis dependence than adults who initiate cannabis use (Chen and Anthony, 
2003). Children who manifest behavioural disinhibition are at elevated risk of starting 
to drink alcohol at an early age (King et al., 2004). Moreover, early initiation of alcohol 
use is associated with increased risk of substance use disorders (McGue et al., 2001). 
Cannabis users who began using cannabis before late adolescence, and had used 
three or more other drugs before starting cannabis, were at higher risk of developing 
cannabis dependence within 2 years of onset (Chen et al., 2005).
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An investigation of the early onset cannabis users, who started using before they were 
17 years old, revealed an association with reduced measures of verbal IQ. One possible 
explanation for this is that cannabis adversely, and durably, affects cognitive faculties in 
younger people whose brains are still developing (Pope et al., 2003). It is also possible, 
however, that poorer verbal IQ is a consequence of disengagement from mainstream 
education, which is a risk factor for early cannabis use. Such disengagement from the 
educational mainstream may be reinforced by cannabis use. Indeed, Pope et al. (2003) 
speculate that the early onset users in this study had lower verbal IQs because they were 
less motivated to engage with education. Although far from conclusive, these data are 
consistent with other studies that show an association between poor educational status 
and early onset of cannabis use (Lynskey et al., 2003b).
Adolescents with substance use disorders and adults with substance use disorders who 
had initiated cannabis use in adolescence were quicker to develop dependence, have 
behavioural problems and major depression, than comparison groups who started 
cannabis use in early or later adulthood (Clark et al., 1998b).
Young people who are exposed to drug use may be more likely to initiate drug use 
themselves, at least on the basis of the argument that exposure provides both drug-using 
models (parents, siblings, peers) and availability of drugs. The younger children are 
when they experience such models and availability, the greater the risk of initiation at 
an early age, with a consequent elevated risk of developing problematic use in later 
years. One study of Scottish pre-adolescents (10–12 years of age) found that over a 
third had been exposed to drug use and one in seven had been offered drugs (McIntosh 
et al., 2003). McKeganey et al. (2004) found that those 10- to 12-year-olds who had 
initiated drug use (in most cases cannabis) were more likely to use tobacco and alcohol, 
and have problem behaviour and family difficulties. Pre-adolescents (defined as 10–12 
years of age) who used tobacco and had behavioural problems were at risk of early 
adolescent cannabis use (Clark et al., 1998a).
Evident from the research findings, which show an association between early onset and 
later problematic cannabis use, is that the association may not be causative. Indeed, 
as highlighted by Lloyd (1998), early onset use may only be an indicator of other risk 
factors that predict later problematic drug use. Thus, age itself might be less the issue 
than the interplay of other risk factors.
Other risk factors that have to be taken into account are the influences of family and 
peers, psychological risk factors and genetic factors.
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Social environment: family
The family and peer networks have received great attention in risk factor research 
(Rhodes et al., 2003). A study of 14- to 15-year-olds across five European cities 
concluded that ‘attachment to mothers’ inhibited drug use, an aspect of family 
relationships that appears to be more important for boys than girls. This protective factor 
was more important than living with both parents. However, this protective factor does 
not extend to antisocial young people (McArdle et al., 2002).
Kosterman et al. (2000) studied initiation of alcohol and cannabis use among 
adolescents and found that exposure to others who use drugs increases the risk of early 
initiation of cannabis use; as do parents who are not ‘proactive’ and/or parents who 
fail to set clear ‘family standards’. Chen et al. (2004) make the point that initiation to 
tobacco use is more likely to occur in a social environment that is tolerant of smoking.
Foxcroft and Lowe (1995) found relationships between adolescents’ perceptions of 
parent-centred authoritarian or neglectful family life and use of alcohol, tobacco and 
some illicit drugs. However, this was not observed for cannabis use. In other words, 
cannabis use per se was not related to pathological family relations in the way that 
other drug use was. In light of what is known about the risks of dysfunctional family 
relationships for elevation of risk for problematic use, it may be that cannabis use in this 
sample was non-problematic.
Young people exposed to stressors in the family, such as disrupted family structure and 
poor quality of family relationships, are more likely to use cannabis and to develop 
problematic patterns of cannabis use (Butters, 2002). Moreover, a compounding 
effect in terms of school problems was found in this study: family disruption elevated 
the likelihood of school problems, which in turn increased the chances of developing 
problematic cannabis use. The confounding nature of the risk factors delinquency and 
school problems with cannabis use was also highlighted in an American study of nearly 
14 000 11- to 21-year-olds (van den Bree and Pickworth, 2005). Children with social 
disadvantage, dysfunctional family life and behavioural problems are more likely to 
become adolescents who associate with delinquent or drug-using peers (Fergusson 
and Horwood, 2000). A recent study of a sample of adolescents in Turkey noted the 
significant statistical association between cannabis use and cannabis-using peers (Tot et 
al., 2004).
The extent of parental monitoring of children’s activities may influence likelihood of 
substance use, such that lower levels of monitoring increased the risk of initiation of 
drug use (Chilcoat et al., 1995; Bukstein, 1995; Kandel, 1996). Lack of closeness in 
parents’ relationships with their children, and inadequate time spent by parents with 
their children are risk factors (Bukstein, 1995; Hawkins et al., 1992; Kandel, 1996). To 
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some extent, this implies that the causal direction is one-way. It is likely that the process 
is more complex, with some degree of influence of children’s behaviour on their parents 
or carers.
There is much about the precise nature of the relationships within high-risk families 
that is not known, such as the characteristics of the parents and the ways in which 
they interact with their children. A study of the comorbidity of drug misuse and anxiety 
disorders in families found that young adolescents’ drug use was more strongly 
associated with parental drug misuse (diagnosed as having alcohol or drug disorders) 
than with diagnosed parental anxiety disorders. Children of drug misusers were, along 
with controls, less likely to manifest anxiety disorders than children of parents with 
anxiety disorders. Children of drug misusers were more likely to have behavioural 
problems, itself a risk factor for drug use and drug problems (Merikangas et al., 1998).
It is evident that the quality of relationships within the family is important in terms 
of emotional support, parenting style, control and family disruption. However, the 
relationship between these factors and cannabis use or problematic cannabis use is 
probably indirect in the sense that the presence of such factors increase the likelihood 
of young people developing emotional and behavioural problems in general. And it is 
the development of these problems that increase the chances of developing problematic 
patterns of drugs use.
As young people grow and develop, the influence of the family wanes in many cases as 
the influence of peers increases.
Social environment: peers
That cannabis users’ peers are more likely to smoke cannabis than the peers of non-
users is a commonplace of the literature. There is a need for considerable caution in 
going beyond the data when interpreting statistical associations between cannabis users 
and their peers’ cannabis use. In many cases it is not possible to specify the nature 
of the association: that is, does A cause B, vice versa, or neither? Yet, on the basis 
of such data it has often been asserted that drug-using peers somehow pressure or 
encourage drug use in their non-drug-using peers. Peer preference is a more plausible 
interpretation, such that those inclined to the use of cannabis deliberately associate 
with others who do so (Coggans and McKellar, 1994). For example, peers may in 
some instances encourage or even coerce others to take drugs, but there is a need to 
recognise that peer influences can take different forms, ranging from tolerance of drug 
use, through support of drug use to active encouragement of drug use. Often young 
people actively assort themselves to form groups which share similar interests and 
aspirations, which do not fit with (bad) pusher and (innocent) victim stereotypes.
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Changes of frequency in adolescent drug use have been found to precede changes in 
peer variables (Farrell and Danish, 1993). These researchers also analysed their data 
in different ways in order to compare three different hypothetical models, namely, a) 
drug use was a consequence of emotional restraint (ability to deal with negative affect) 
and peer variables (drug using peers and peer pressure); b) drug use was a cause 
of changes in emotional restraint and peer variables; and c) a reciprocal model that 
included both causes and consequences of drug use. While all three models ‘fit the data 
fairly well’, the reciprocal model was the best fit. Of particular note was their conclusion 
that ‘peer drug models and peer pressure were not related to subsequent changes in 
gateway drug use’ and ‘changes in peer drug models were … predicted by previous 
levels of gateway drug use’ (Farrell and Danish, 1993: 327). The authors also drew 
attention to the need for caution with data of this kind and emphasised the importance 
of studying dynamic models that address both the causes and the consequences of drug 
use.
Dobkin et al. (1995) examined the antecedents of early onset substance use in male 
adolescents and reported that individual characteristics were better predictors than 
association with deviant friends. They concluded that the argument that deviant youth 
seek out like-minded friends was plausible. Kandel (1996) suggested that the influence 
of peers on adolescent substance use has generally been overestimated, that this 
overestimate has tended to be at least double the actual effect, and that selection 
is at least as important as influence, if not more. Other researchers concluded from 
their review of the literature that selection ‘may make a substantial contribution to the 
association between drug behaviors of friends, and that failure to control for selection 
may overestimate the contribution of influence’ (Bauman and Ennett, 1996: 188). All of 
which emphasises the need to understand the factors that predispose young people to 
select drug-using associates.
A risk factor for cannabis users’ transition to problematic cannabis use is having more 
friends who use drugs and less perceived parental disapproval of cannabis, with the 
effects found to be greater for adolescent females than males (Butters, 2004). Not all 
cannabis users with cannabis-using peers will progress to problematic cannabis use. 
Progression to problematic cannabis use will depend on other risk factors and how these 
interact with the risks associated with cannabis-using peers.
Interactions within the school environment have been identified as important, although 
it can be difficult to disentangle the relative contribution of social relationships 
and educational experience as potential risk factors. For example, poor academic 
performance and classroom behaviour were found to be important risk factors for boys 
in particular (Hops et al., 1999). Lower attachment to school has been associated with 
higher levels of substance use (Ennett et al., 1997) and academic performance linked 
with subsequent academic and home self-esteem (Filozof et al., 1998). However, others 
Risk factors for cannabis use
336
have cautioned against too great an emphasis on self-esteem in prevention initiatives, 
due to uncertainty over the relationship between (low) self-esteem and substance use 
(Schroeder et al., 1993). Nonetheless, academic failure is a risk factor for adolescent 
drug use, as is low commitment to school (Hawkins et al., 1992).
The influence of peer pressure, especially when perceived as some form of coercion, has 
been overstated. More subtle forms of peer influence, such as attractive role models, 
are likely to have an influence. When young people with emotional or behavioural 
problems perceive cannabis-using others as attractive role models then they may be 
more likely to adopt similar behaviours. The difference between a young person who, 
with cannabis-using role models, becomes a cannabis user, on the one hand, and a 
problematic cannabis user, on the other hand, is explicable by presence of other risk 
factors described in earlier sections.
Psychological risk factors
Rhodes et al. (2003) point out that within the European literature, there is considerable 
agreement that there are correlations between problematic drug use and a variety of 
problematic behaviours. Conduct problems precede and influence early initiation of 
cannabis, the onset of which is greater where there is also early tobacco use (Pederson 
et al., 2001). There are also gender-specific influences of different aspects of problem 
behaviour prior to cannabis initiation. More serious conduct problems were an important 
predictor of cannabis initiation in boys, while aggressive and covert conduct problems 
predicted cannabis initiation in girls.
In a study of 15- to 16-year-olds, the heavier users of cannabis were characterised 
in three groups, according to a range of behavioural, relationship and psychological 
measures: namely, ‘antisocial’, ‘unhappy’ or ‘ordinary’ (Miller and Plant, 2002). While 
the antisocial and unhappy groups of young heavy cannabis users had already exhibited 
negative behaviours, including other substance use, the ordinary group were less likely 
to be heavy users of other substances. All of which is a reminder that cannabis use and 
even heavy cannabis use is not in itself sufficient to lead to problematic use of other 
drugs.
In a sample of 12- to 18-year-olds in treatment for cannabis abuse or dependence, 
most had a range of psychological and behavioural problems (Tims et al., 2002). 
Those with higher levels of drug misuse had problems with relationships, and with their 
psychological and physical health. The extent to which cannabis use, on the one hand, 
and individual and social circumstance (historical or present) on the other, are causal 
is difficult to specify. There is every likelihood that those with personal difficulties who 
subsequently use cannabis will exacerbate these problems.
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In a study of French 15- to 22-year-olds, ‘borderline symptomatology’ for a range of 
personality problems appeared to influence motivations for cannabis use, in particular 
expansion of awareness. However, mood enhancement for boys and expansion 
of awareness for girls were better predictors of cannabis use than psychological 
problems. While cannabis dependence in boys was related to psychological problems, 
it was related to motivation for expanded awareness in girls (Chabrol et al., 2005). 
‘Permissive’ beliefs about the nature and utility of cannabis is associated with cannabis 
use but not dependence, while beliefs that cannabis would ameliorate anxiety, boredom 
and ‘suffering’, and improve mood, were the only predictors of cannabis dependence 
(Chabrol et al., 2004).
In a similar vein, a study that related perceived functions of cannabis to cannabis use 
and to amount of use found that those who used for respite from negative moods 
were at risk of developing problems with cannabis. This contrasts with those who used 
cannabis for social functions, which was not related to degree of cannabis use (Boys and 
Marsden, 2003).
There is much current debate about the potential for cannabis to exacerbate or 
precipitate psychosis (see Witton, this monograph, vol. 2). However, psychotic symptoms 
can also precede cannabis use. While the debate over common vulnerability versus 
bidirectional causal pathways between cannabis and psychosis continues, psychotic 
symptoms were found to be a risk factor for subsequent cannabis use in a recent 
14-year follow-up study in the Netherlands (Ferdinand et al., 2005).
A recent study in Germany found that, in a sample of mid- to late adolescents, use 
of cannabis was predicted by a personality construct defined as ‘addiction’. However, 
cannabis use was more likely among young people who scored low on a measure of 
anxiety–depression and that those who had a positive self-image were more likely to 
use cannabis (Kirkcaldy et al., 2004). The cannabis use measure in these analyses was 
lifetime use.
Investigation of 13- to 19-year-olds with diagnosed major depression, conduct disorder 
and substance dependence found that adolescents with major depression were more 
likely to develop cannabis dependence than adolescents whose depression manifested at 
the same time as substance dependence or whose depression developed subsequent to 
cannabis substance use disorder (Libby et al., 2005).
There are associations between various psychological and behavioural problems and 
problematic drug use including problematic cannabis use. In such cases, problematic 
cannabis use is in part symptomatic of psychological and behavioural problems and in 
part likely to exacerbate psychological and behavioural problems.
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Genetic factors
The epidemiology of drug use is increasingly informed by research into genetic 
influences and it appears that the role of genetic influences is greater for drug problems 
than for drug use (Kendler et al., 2003). But this is a complex issue and the specific 
genes involved and the nature of their interactions with environmental factors are issues 
for further research. Nonetheless, the distinction between drug use and escalation 
to drug problems appears to be in terms of the relative influence of genetic and 
environmental factors. Genetic risk factors are vulnerabilities for conditions that in turn 
increase the likelihood of developing drug problems (Moss et al., 2002). Both genetic 
and environmental influences are non-specific in their influence in terms of drugs that 
are used or with which users develop problems (Kendler et al., 2003).
Genetic factors interacted with family environmental factors in the origins of disruptive 
behaviour in a study of sons of substance and non-substance misusing families 
(Majumnder et al., 1998). In substance-misusing families, sons with disruptive behaviour 
were influenced by parental dysfunction and family environment, while in non-
substance-misusing families sons with disruptive behaviour were influenced by family 
environment. Family and social factors were related to cannabis initiation, while genetic 
factors influenced progression to problematic cannabis use in a study of twin girls 
(Kendler and Prescott, 1998).
Genetic influences account more for cannabis dependence than they do for cannabis 
use, while common environmental influences explained more cannabis use than 
cannabis dependence, supporting an individual vulnerability perspective on development 
of cannabis problems (van den Bree et al., 1998). Miles et al. (2001) found broadly 
equivalent genetic and environmental influences on cannabis use.
The genetic influence on cannabis use may be in terms of a genetic basis for sensation-
seeking or problem behaviour, while genetic influence on problematic cannabis use may 
be in terms of a genetic basis for drug sensitivity and/or subjective reactions to cannabis 
(Agrawal and Lynskey, 2006). Genetic factors may explain in part why many cannabis 
users develop problematic cannabis use or escalation to drug problems of other kinds. 
While there will also be people with problematic cannabis use who are not at elevated 
genetic risk of substance-related problems, better understanding of how genetic factors 
are expressed and how they interact with environmental factors is a potentially valuable 
area of future research.
Implications for prevention
In order to be successful, prevention interventions should address risk factors, taking 
into account the distinctions between cannabis use and problematic cannabis use, with 
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recognition that different kinds of prevention interventions will be required depending 
on the risk factors being tackled. Universal (primary prevention) programmes will in all 
likelihood not work with young people whose risk factor load is greater. Such young 
people, whose backgrounds include family strife, behavioural difficulties, and so on, will 
not only be less likely to gain from universal programmes due to their nature, they will 
be less likely to participate in them by, for example, being less likely to attend school.
Prevention of cannabis initiation has been attempted for many years in the context 
of universal drug education programmes with little or no success. These universal 
prevention interventions typically target entire populations of school pupils of specific 
ages, usually in early adolescence and more recently in pre-adolescence. Evaluation 
of the success of such programmes is usually defined as prevention of onset (primary 
prevention). Even the most successful of universal primary prevention drug education 
programmes have notably poor outcomes, with, at best, small-scale success (Coggans 
and Watson, 1995; Coggans et al., 2002; Tobler and Stratton, 1997; Advisory Council 
on the Misuse of Drugs, 2006). The more successful of these interventions attempt 
to influence aspects of social competence and self-esteem as well as drug-related 
knowledge and attitudes. Such attempts to promote social competence (life skills) 
could, in theory, ameliorate the risks of cannabis and other drug use by equipping 
young people with the skills to cope with a social environment that facilitates drug use. 
However, this type of primary prevention may work best with those young people who 
are less likely to escalate cannabis use to problematic levels. Moreover, at least one 
such programme does not impact on mediating life skills as expected (Coggans et al., 
2002).
Given that the risk factors for experimental and recreational cannabis use are in many 
ways qualitatively different from the risk factors for problematic cannabis use, this lack 
of impact on cannabis initiation and on putative mediating factors is perhaps to be 
expected. However, those at risk of progression to problematic use may well benefit 
from interventions that aim to prevent escalation by addressing the psychological and 
behavioural factors that are risk factors for problematic use. However, such interventions 
require approaches targeted precisely at the individuals and groups at risk.
The recent report from the Advisory Council on the Misuse of Drugs (ACMD) (2006) 
concluded that the risk factors for hazardous drug use are early life experiences, family 
relationships and circumstances, and parental attitudes and behaviour. The ACMD 
also noted that it is not easy to predict who will develop serious problems. The role of 
parents is important, and many will not realise the extent of their potential role in the 
prevention of drug use problems and, most importantly, how to relate to their children 
in ways that maximise the influence of this central protective factor. While there is a 
growing awareness of the need for parent-oriented interventions, there have been 
few evaluations of drug education interventions aimed at parents. Positive impact 
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on mediating variables such as parent–child communication, normative beliefs and 
intentions to use has been reported, but there are also problems of low uptake and 
potential stigmatisation of higher-risk parents (Allot et al., 1999).
Summary and conclusions
There is a complex of potential risk factors that interact with each other to compound 
and increase the risk of cannabis- and other drug-related problems. The weight of 
evidence is that risk factors for problematic cannabis use are, in large part, to be 
found in the interactions between genetic factors, the early nurturing of people and 
their circumstances. In many ways these are risk factors for substance-related problems 
generally. The evidence is accumulating for individual vulnerability to drug-related 
problems. While most cannabis users restrict their preferred drug use and can do so 
presumably on the basis of the absence of risk factors/presence of protective factors, 
others develop problematic relationships with drugs. Such problematic relationships with 
drugs include drug effects as risk factors for intensifying or precipitating psychological or 
social problems in turn.
The influence of risk factors is cumulative, both in terms of interaction with each other 
and in terms of time. The more that multiple risk factors accumulate over time the more 
likely that developmental and behavioural problems will become evident (Loxley et al., 
2004). Behavioural problems, association with delinquent or deviant drug-using peers, 
dysfunctional family relationships, exposure to family substance misuse and genetic 
vulnerability to psychological conditions that increase the likelihood of drug problems all 
contribute to this complex of risk factors for problematic cannabis use. In the light of the 
varied, interactive and potentially confounding nature of risk factors for cannabis-related 
problems, prevention efforts need to be diverse. Universal programmes have a role to 
play in communicating key information and raising awareness of risks, but are unlikely 
to have any substantial impact on problematic cannabis users. Vulnerable groups and 
individuals require more precise targeting and delivery of programmes that will address 
their specific needs (see Burkhart, this monograph).
This chapter has drawn on a wide range of research literature assessing the role of 
various factors from the genetic to the social. Full justice will not have been done to 
the social and cultural differences across all the different settings in which the data 
were gathered for these research reports. To what extent are the conclusions justified 
without exploring these social and cultural contexts further? This is an empirical 
question. However, given the need to distinguish between recreational and problematic 
cannabis use in relation to the utility of the risk factors approach, it may be that there 
is a need to make the same distinction for other drugs as well. The potential for the risk 
factors approach to inform prevention efforts will depend in many respects on greater 
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understanding of the social norms and cultural factors related to recreational and 
problematic patterns of drug use.
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Approaching cannabis research — a quick guide
During the editing of this monograph, the EMCDDA soon realised that the publication 
was entering a crowded arena. Cannabis monographs appear several times a year in 
different languages. The core information they contain is being continuously revamped, 
revised, reworked, remixed or just repeated.
A concern for the Centre was to avoid the near-instant obsolescence of many cannabis 
monographs. This is why the publication takes a ‘reader’ approach, mapping current 
publication flows; sketching the history of cannabis monographs and identifying key 
sources for information. This appendix aims to (i) identify the main producers of 
literature on cannabis and (ii) illustrate the range in thematic focus of publications. In 
particular, it will help researchers who are new to the area or who are entering cannabis 
research from other disciplines (law, medicine, politics, sociology, etc.).
Information overload on cannabis, and the need for a 
trusted guide
Any researcher requiring definitive, accurate information on cannabis needs to be 
forearmed. In the age of the Internet, any taboos that may previously have hushed 
discussion on illicit drugs have vanished. On the contrary, researchers are overwhelmed 
with data (Table 1). Like drinking water from a firehose, it becomes impossible to 
manage the sheer volume of insider guides, reports and general punditry on cannabis. 
Cannabis has even evolved to have its own portal on Wikipedia, alongside such all-
encompassing subjects as science, history and medicine. A recent Spanish study on the 
use of the Internet for finding drugs over several months found that Spanish search 
engine registered 31 800 000 searches for the word ‘cannabis’, 481 000 for ‘marihuana 
efectos’ and 358 000 for ‘cultivo de marihuana’.
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Table 1: Basic internet search results (October 2006)
Internet search used Search terms Hits
Google ‘cannabis’, ‘marihuana’, ‘marijuana’ 18 400 000; 7 030 000; 26 900 000
Google Books ‘Cannabis’, ‘marihuana’, ‘marijuana’ 66 000; 46 400; 148 000
Google Books ‘Cannabis 2006’ 1 140
Google Scholar ‘Cannabis’, ‘marihuana’, ‘marijuana’ 94 500; 9 570; 112 000
PubMed ‘Cannabis’, ‘marihuana’, ‘marijuana’ 9 099; 6 000; 10 812
Bireme ‘Cannabis’ 3 723 (Medline); 462 (Cochrane); 
270 (LILACS); 23 (SciELO)
Amazon.com books ‘Cannabis’, ‘marihuana’, ‘marijuana’ 8 539 
Yahoo ‘Cannabis’, ‘marihuana/marijuana’ (1) 14 400 000; 30 500 000
(1) Yahoo tracks ‘marihuana’ and ‘marijuana’ as a single search term.
Information exchange among cannabis experts: journals, 
conferences and community
Faced with such a huge amount of information, where does one begin? The first 
step is to be able to identify the producers of quality scientific information. Scientific 
publications on cannabis are by-and-large the product of constant information exchange 
among academics and governments. In addition to standard forums for research (e.g. 
PubMed- and Medline-listed journals (1), HON-accredited websites) and annual cyclical 
publications (2), there exists a well-attended circuit of face-to-face meetings with a 
domestic, regional and international scope (3). An overview of websites focusing on drugs 
issues (NGOs, government campaigns) in Europe is provided by the Elisad Gateway. 
Some of these events focus purely on cannabis, but the majority discuss cannabis 
together with other illicit drugs, legal or healthcare topics. These cyclical meetings are 
increasingly bolstered by one-off conferences focusing on selected cannabis issues 
(legislation, treatment, medicinal cannabis, cannabinoid research). The result is a 
sizeable, yet close-knit network of global cannabis experts.
 (1) An invaluable tool for the preparation of this monograph has been the open source referencing 
tool, Jabref, which offers fast searches and abstracts of Medline literature.
 (2) Annual publications include: the UNODC’s World Drugs Report, EMCDDA’s Annual Report and 
Reitox national focal point reports, the ONDCP Annual report, SAMSHA’s National Survey on 
Drug Use and Health and the NDIC’s annual National Drug Threat Assessment in the USA.
 (3) A useful information source for meetings with a European focus is the events section of EMCDDA’s 
quarterly newsletter, DrugNet Europe.
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A hierarchy in expertise: the ‘cannabis research pyramid’
A three-tier pyramid can be created in terms of global expertise on the subject. On the 
bottom tier there are tens of thousands of practitioners: various healthcare and drugs 
professionals, together with employees of think tanks, charities and governments. To 
some extent, established lobbyist groups, for example NORML and EURAD, can be 
included in this tier. In the middle tier, there are some 2000 to 3000 cannabis experts 
working in research institutions. The majority of these are working directly with drugs 
issues. The top tier comprises around 200 to 300 leading authorities who are generally 
working at centres of excellence in cannabis research and playing an active role in 
informing government policy. The middle and top tiers are the typical publishers of 
general monographs on cannabis.
Top tier: several hundred experts
Centres of excellence in cannabis research.
National and international drugs coordination centres.
International cannabis research societies, e.g. National Drug and Alcohol Research 
Centre, Australia; National Addiction Centre, UK; Trimbos Institute, the Netherlands; 
National Institute of Drugs Dependence, China; Centre for Addictions Research, 
Canada; Addiction Research Centre, Canada; The Institute for Clinical Research, 
Germany; Sociedad Española De Investigación Sobre Cannaboides, Spain; International 
Association for Cannabis as Medicine; European Association of Addiction Therapy; 
National Institute on Drug Abuse, USA.
Middle tier: several thousand people worldwide
Drugs professionals specialising in cannabis: predominantly at national treatment 
centres and domestic centres of excellence.
Educational institutions involved in cannabis RCTs and testing.
Psychiatrists/treatment professionals working in a national advisory role on cannabis 
issues.
Commercial research laboratories involved in cannabis therapeutics.
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Government policymakers working specifically on drugs control and legislation.
Law enforcement professionals with experience in cannabis control, arrests and seizures.
Bottom tier: tens of thousands of people worldwide
Drugs professionals: local and regional treatment centres and clinics, prevention 
campaigns, drugs charities.
Healthcare practitioners: general practitioners, psychiatrists, psychologists.
Civil servants: working at government ministries, international organisations (UNODC, 
EMCDDA, WHO), healthcare providers.
Law enforcement: police, customs, international police organisations (Interpol, Europol), 
drug enforcement units (DEA).
Educational institutions: teaching centres, postgraduate and postdoctoral researchers.
Commercial research: medicinal cannabis and hemp industries.
Lobbyists: international think tanks (e.g. Pompidou Group, Senlis Council, RAND), 
domestic think tanks (e.g. Rowntree Foundation), legalisation lobbyists (NORML) and 
anti-legalisation lobbyists.
Core outputs of the pyramid: journals, commercial 
publishing, grey literature
Outputs from this research pyramid are dominated by the so-called ‘grey literature’ — 
that is, publications by government departments, NGOs and international organisations 
(this monograph being no exception). Other publications include special issues in 
academic journals, publications by lobbyists, as well as commercially oriented books. 
On a more passive level, the pyramid also helps to inform the several hundred 
journalistic articles on cannabis published each day in the world’s media by providing 
expert opinions, background information and quotes to the press. As such, the cannabis 
experts in the pyramid provide a useful calmative influence on a subject that is often 
discussed in alarmist, confrontational or heavily politicised tones. The outputs can 
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broadly be categorised into academic journals, commercial publications and grey 
literature.
Journals
Scholarly research into cannabis appears many times per month across a variety of 
academic journals, in particular journals focused on drugs, psychiatry, public health, 
science and medicine, and increasingly those focusing on sociology, law and media 
studies (Table 2). There occasionally appear ‘special focus’ editions on cannabis 
in journals. Examples include SWAPS — Spéciale Cannabis (Pialoux (ed.), 2003), 
Monográfico Cannabis — Revista Española de Drogodependencias Vol. 30 (AESED, 
2003). A useful list of scientific journals publishing on drugs issues can be found using 
the members list of the International Society of Addiction Journal Editors (http://www.
parint.org/isajewebsite/).
Table 2: A selection of academic journals regularly covering cannabis
Subject area Journal titles
Drugs and addiction Addiction, Addictive Behaviours, American Journal of Addictions, British 
Journal of Addiction, Bulletin on Narcotics, Drug and Alcohol Dependence, 
Drug and Alcohol Review, Drugs: education, prevention and policy; European 
Addiction Research, Harm Reduction Journal, International Journal of Drug 
Policy, Italian Journal on Drug Addiction and Alcoholism (Bollettino per 
le Farmacodipendenze e L’alcoolismo), The International Journal of the 
Addictions, International Journal of Mental Health & Addiction, Journal of 
Drug Issues, Prevention & Policy, Journal of Substance Abuse Treatment, 
SWAPS, Revista Española de Drogodependencias, Substance Use and Misuse, 
THS — La revue des addictions, The Cannabis Health Journal, Wiener 
Zeitschrift für Suchtforschung
Psychiatry British Journal of Psychiatry, The American Journal of Psychiatry, Psychotropes
Neurology Brain, Neurology, Neuropharmacology, Psychopharmacology
Science Nature, New Scientist
Medicine and 
pharmacology
Annales de toxicologie analytique, Annales pharmaceutiques françaises, 
Clinical Pharmacology and Therapeutics, Journal of the American Medical 
Association, Journal of Cannabis Therapeutics, Cannabinoids: The Journal 
of the International Association for Cannabis as Medicine (2001–2004), 
Journal of Pharmacy and Pharmacology, The Lancet, British Medical Journal, 
European Journal of Clinical Pharmacology
Sociology The Humanist, Journal of Sociology and Social Welfare
Law and 
criminology
The Cambridge Law Journal, European Journal on Criminal Policy and 
Research, Forensic Science International, International Journal of Drug Testing, 
Journal of Police Science and Management, European Review, Policy Review, 
Vanderbilt Journal of Transnational Law
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Commercial publishing
Outside academia, cannabis has sparked what can only be termed a publishing 
phenomenon in the past two decades, embracing all bookselling genres (Table 3). There 
have been novels and literary anthologies, political tracts, dedicated magazines such as 
The High Times, connoisseurship columns in mainstream magazines and newspapers, 
product and cultural histories, biographies (by traffickers, drugs detectives, musicians, 
actors), practical growguides, cannabis-oriented travel guides and cookbooks, not to 
mention a wealth of educational and harm reduction materials. While some of these are 
found only at headshops and specialised booksellers, others have entered bestseller lists. 
Cannabis, it seems, is a mainstream topic that attracts a commercially viable readership. 
Grey literature
As mentioned above, grey literature producers, such as NGOs and government 
agencies, are significant publishers of information on cannabis. The appendix to 
Volume 1 of this monograph provides a selection of key grey literature publications on 
cannabis published in recent years. Naturally, this list is non-exhaustive, yet it remains 
valuable for researchers. Just as this monograph is unlikely to be the last specialised 
publication on cannabis for the EMCDDA, so will peer organisations revisit the topic as 
issues of science, data and policy evolve.
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Table 3: A selection of recent books published on cannabis in three genres and 
three languages (genres: history, society/politics, health/medicine; languages: 
English (EN), French (FR), German (DE))
History Cannabis: a history (Booth, 2003) (EN)
Cannabis: from pariah to prescription (Russo (ed), 2003) (EN)
Cannabis. Hanf, Hemp, Chanvre, Canamo (Bröckers, 2002) (DE)
Cannabis Britannica: empire, trade, and prohibition (Mills, 2003) (EN)
Cannabis on the brain (Smith, 2002) (EN)
Marijuana for dopes: a pop culture history of cannabis (Romain, 2001) (EN)
Society/politics Cannabis (Green, 2002) (EN)
Cannabis: le dossier (Chollet-Przednowed, 2003) (FR)
Cannabis. Neue beiträge zu einer alten diskussion (Gaßmann, 2004) (EN)
Cannabis, ecstasy: du stigmate au déni. Les deux morales des usages récréatifs de 
drogues illicites (Peretti-Watel, 2005) (FR)
Cannabis ist immer anders (Kuntz, 2005) (DE)
Cannabis use and dependence: public health and public policy (Hall and Pacula, 
2002) (EN)
Le cannabis en question (Palazzolo, 2006) (FR)
Orgies of the hemp eaters: cuisine, slang, literature and ritual of cannabis culture 
(Bey and Zug (ed.), 2005) (EN)
Spliffs: a celebration of cannabis culture (Jones, 2004) (EN)
Spliffs 2: further adventures in cannabis culture (Pilcher, 2005) (EN)
The cannabis debate (Donnellan (ed.), 2004) (EN)
The complete illustrated guide to cannabis (Brownlee, 2003) (EN)
Un écran de fumée: le cannabis dans la famille (Bantman and Hefez, 2005) (FR)
Understanding marijuana: a new look at the scientific evidence (Earlywine, 2005) 
(EN)
Health/
medicine
Cannabinoids as therapeutics (Mechoulam (ed.), 2005) (EN)
Cannabis et santé (Raynaud, 2004) (FR)
Cannabis und cannabinoide. pharmakologie, toxikologie und therapeutisches 
potenzial (Grotenhermen, 2005) (DE)
Halte au cannabis (Costentin,2006) (FR)
Le cannabis: et les autres drogues (Benyamina and de Paillette, 2005) (FR)
Management of alcohol and drug problems (Hulse, White and Cape, 2002) (EN)
Marijuana and madness (Castle and Murray (eds), 2004) (EN)
Wenn cannabis der seele schadet: Hilfe bei Sucht und psychischen Störungen 
(Lindberg and Haasen, 2005) (DE)
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number in the index entry, e.g. ‘absorption’ can be found on p. 33 of Volume 1.
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